{"c9ac0a1d2dd861bfa590dc654ddadb324a993fa0": [["IntroductionAcute pancreatitis is a common disease and is associated with significant morbidity and mortality.", [["pancreatitis", "DISEASE", 18, 30], ["IntroductionAcute pancreatitis", "PROBLEM", 0, 30], ["a common disease", "PROBLEM", 34, 50], ["significant morbidity", "PROBLEM", 74, 95], ["pancreatitis", "OBSERVATION", 18, 30], ["common", "OBSERVATION_MODIFIER", 36, 42], ["disease", "OBSERVATION", 43, 50], ["associated with", "UNCERTAINTY", 58, 73], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["morbidity", "OBSERVATION", 86, 95]]], ["Although it has a mild and self-liming course, it can be severe and cause complications that carry a significant risk of death.", [["death", "DISEASE", 121, 126], ["a mild and self-liming course", "PROBLEM", 16, 45], ["complications", "PROBLEM", 74, 87], ["death", "PROBLEM", 121, 126], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["self-liming course", "OBSERVATION_MODIFIER", 27, 45], ["severe", "OBSERVATION_MODIFIER", 57, 63]]], ["In the United States, more than 3,00,000 patients are admitted with incident pancreatitis and about 20,000 die from the disease each year.", [["pancreatitis", "DISEASE", 77, 89], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["pancreatitis", "PROBLEM", 77, 89], ["pancreatitis", "OBSERVATION", 77, 89], ["disease", "OBSERVATION", 120, 127]]], ["[1] [2] [3] In Taiwan, the incidence rate of acute pancreatitis is 0.03% and the mortality rate among severe acute pancreatitis is 16.3%.", [["pancreatitis", "DISEASE", 51, 63], ["pancreatitis", "DISEASE", 115, 127], ["acute pancreatitis", "PROBLEM", 45, 63], ["the mortality rate", "TEST", 77, 95], ["severe acute pancreatitis", "PROBLEM", 102, 127], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["pancreatitis", "OBSERVATION", 51, 63], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["pancreatitis", "OBSERVATION", 115, 127]]], ["[4] The pancreas is a source of hormones, insulin, and glucagons that are important for regulating metabolism.", [["pancreas", "ANATOMY", 8, 16], ["pancreas", "ORGAN", 8, 16], ["insulin", "GENE_OR_GENE_PRODUCT", 42, 49], ["glucagons", "GENE_OR_GENE_PRODUCT", 55, 64], ["insulin", "TREATMENT", 42, 49], ["glucagons", "TREATMENT", 55, 64], ["pancreas", "ANATOMY", 8, 16]]], ["The key exocrine function of the pancreas is to produce pancreatic juices that contain water, bicarbonate, and various digestive enzymes.", [["exocrine", "ANATOMY", 8, 16], ["pancreas", "ANATOMY", 33, 41], ["pancreatic juices", "ANATOMY", 56, 73], ["bicarbonate", "CHEMICAL", 94, 105], ["bicarbonate", "CHEMICAL", 94, 105], ["exocrine", "ORGAN", 8, 16], ["pancreas", "ORGAN", 33, 41], ["pancreatic juices", "ORGANISM_SUBSTANCE", 56, 73], ["water", "SIMPLE_CHEMICAL", 87, 92], ["bicarbonate", "SIMPLE_CHEMICAL", 94, 105], ["digestive enzymes", "PROTEIN", 119, 136], ["pancreatic juices", "TREATMENT", 56, 73], ["bicarbonate", "TREATMENT", 94, 105], ["various digestive enzymes", "TEST", 111, 136], ["pancreas", "ANATOMY", 33, 41], ["pancreatic", "ANATOMY", 56, 66], ["juices", "OBSERVATION", 67, 73]]], ["[5] There are 2 types of acute pancreatitis, interstitial (about 80% of cases, with a 5%-10% mortality rate) and necrotizing (about 20% of cases, with a 50% mortality rate).", [["interstitial", "ANATOMY", 45, 57], ["pancreatitis", "DISEASE", 31, 43], ["acute pancreatitis", "PROBLEM", 25, 43], ["mortality rate", "TEST", 93, 107], ["necrotizing", "PROBLEM", 113, 124], ["acute", "OBSERVATION_MODIFIER", 25, 30], ["pancreatitis", "OBSERVATION", 31, 43], ["interstitial", "ANATOMY_MODIFIER", 45, 57], ["necrotizing", "OBSERVATION_MODIFIER", 113, 124]]], ["The leading causes of pancreatitis are gallstones, which are responsible for about 40% of cases, and alcoholism, which is responsible for about 35% of cases.", [["pancreatitis", "DISEASE", 22, 34], ["gallstones", "DISEASE", 39, 49], ["alcoholism", "DISEASE", 101, 111], ["pancreatitis", "PROBLEM", 22, 34], ["gallstones", "PROBLEM", 39, 49], ["alcoholism", "PROBLEM", 101, 111], ["pancreatitis", "OBSERVATION", 22, 34], ["gallstones", "OBSERVATION", 39, 49], ["alcoholism", "OBSERVATION", 101, 111]]], ["[6] [7] [8] [9] [10] It has been found that only 5% to 10% of patients with alcoholism develop acute pancreatitis, which argues that genetic or environmental cofactors are important in the development of alcoholic pancreatitis.", [["alcoholism", "DISEASE", 76, 86], ["pancreatitis", "DISEASE", 101, 113], ["alcoholic pancreatitis", "DISEASE", 204, 226], ["[6] [7] [8] [9] [10", "SIMPLE_CHEMICAL", 0, 19], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["alcoholism", "PROBLEM", 76, 86], ["acute pancreatitis", "PROBLEM", 95, 113], ["environmental cofactors", "PROBLEM", 144, 167], ["alcoholic pancreatitis", "PROBLEM", 204, 226], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["pancreatitis", "OBSERVATION", 101, 113], ["alcoholic", "OBSERVATION_MODIFIER", 204, 213], ["pancreatitis", "OBSERVATION", 214, 226]]], ["Smoking is another important cofactor.", [["Smoking", "DISEASE", 0, 7]]], ["[11] [12] [13] [14] [15] Patients who present with 2 of the following 3 manifestations are diagnosed as having acute pancreatitis: characteristic upper abdominal pain, elevated levels of pancreatic enzymes, and findings of ultrasonography (US), computed tomography (CT) or magnetic resonance imaging (MRI) suggesting acute pancreatitis.", [["abdominal", "ANATOMY", 152, 161], ["pancreatic", "ANATOMY", 187, 197], ["pancreatitis", "DISEASE", 117, 129], ["abdominal pain", "DISEASE", 152, 166], ["pancreatitis", "DISEASE", 323, 335], ["[11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 0, 24], ["Patients", "ORGANISM", 25, 33], ["upper abdominal", "ORGANISM_SUBDIVISION", 146, 161], ["pancreatic", "ORGAN", 187, 197], ["pancreatic enzymes", "PROTEIN", 187, 205], ["Patients", "SPECIES", 25, 33], ["acute pancreatitis", "PROBLEM", 111, 129], ["characteristic upper abdominal pain", "PROBLEM", 131, 166], ["elevated levels of pancreatic enzymes", "PROBLEM", 168, 205], ["ultrasonography", "TEST", 223, 238], ["US", "TEST", 240, 242], ["computed tomography", "TEST", 245, 264], ["CT", "TEST", 266, 268], ["magnetic resonance imaging", "TEST", 273, 299], ["MRI", "TEST", 301, 304], ["acute pancreatitis", "PROBLEM", 317, 335], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["pancreatitis", "OBSERVATION", 117, 129], ["upper", "ANATOMY_MODIFIER", 146, 151], ["abdominal", "ANATOMY", 152, 161], ["pain", "OBSERVATION", 162, 166], ["pancreatic", "ANATOMY", 187, 197], ["acute", "OBSERVATION_MODIFIER", 317, 322], ["pancreatitis", "OBSERVATION", 323, 335]]], ["Epigastric pain radiating to the back, nausea, and vomiting are the main symptoms of acute pancreatitis.", [["Epigastric", "ANATOMY", 0, 10], ["back", "ANATOMY", 33, 37], ["Epigastric pain", "DISEASE", 0, 15], ["nausea", "DISEASE", 39, 45], ["vomiting", "DISEASE", 51, 59], ["pancreatitis", "DISEASE", 91, 103], ["Epigastric pain", "PROBLEM", 0, 15], ["nausea", "PROBLEM", 39, 45], ["vomiting", "PROBLEM", 51, 59], ["the main symptoms", "PROBLEM", 64, 81], ["acute pancreatitis", "PROBLEM", 85, 103], ["pain", "OBSERVATION", 11, 15], ["back", "ANATOMY", 33, 37], ["nausea", "OBSERVATION", 39, 45], ["acute", "OBSERVATION_MODIFIER", 85, 90], ["pancreatitis", "OBSERVATION", 91, 103]]], ["Abdominal pain, which occurs in about 95% of cases, typically occurs acutely, and rapidly reaches maximum intensity.", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal pain", "DISEASE", 0, 14], ["Abdominal pain", "PROBLEM", 0, 14], ["pain", "OBSERVATION", 10, 14], ["maximum", "OBSERVATION_MODIFIER", 98, 105], ["intensity", "OBSERVATION_MODIFIER", 106, 115]]], ["[1, 16] Two key diagnostic tests for acute pancreatitis involve measuring the levels of serum amylase and serum lipase.", [["serum", "ANATOMY", 88, 93], ["serum", "ANATOMY", 106, 111], ["pancreatitis", "DISEASE", 43, 55], ["serum", "ORGANISM_SUBSTANCE", 88, 93], ["amylase", "GENE_OR_GENE_PRODUCT", 94, 101], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["lipase", "GENE_OR_GENE_PRODUCT", 112, 118], ["serum amylase", "PROTEIN", 88, 101], ["serum lipase", "PROTEIN", 106, 118], ["Two key diagnostic tests", "TEST", 8, 32], ["acute pancreatitis", "PROBLEM", 37, 55], ["serum amylase", "TEST", 88, 101], ["serum lipase", "TEST", 106, 118], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["pancreatitis", "OBSERVATION", 43, 55]]], ["Measurement of serum amylase is a very sensitive diagnostic test, but has low specificity.", [["serum", "ANATOMY", 15, 20], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["amylase", "GENE_OR_GENE_PRODUCT", 21, 28], ["serum amylase", "PROTEIN", 15, 28], ["Measurement of serum amylase", "TEST", 0, 28]]], ["[17] Measurement of serum lipase, however, has a much higher sensitivity (90%) and specificity (90%) for diagnosing acute pancreatitis.", [["serum", "ANATOMY", 20, 25], ["pancreatitis", "DISEASE", 122, 134], ["serum", "ORGANISM_SUBSTANCE", 20, 25], ["lipase", "GENE_OR_GENE_PRODUCT", 26, 32], ["serum lipase", "PROTEIN", 20, 32], ["Measurement of serum lipase", "TEST", 5, 32], ["specificity", "TEST", 83, 94], ["acute pancreatitis", "PROBLEM", 116, 134], ["acute", "OBSERVATION_MODIFIER", 116, 121], ["pancreatitis", "OBSERVATION", 122, 134]]], ["[18] Treatment for acute pancreatitis includes pain control, intravenous fluids, pancreatic rest, and monitoring for complications.", [["intravenous", "ANATOMY", 61, 72], ["pancreatic", "ANATOMY", 81, 91], ["pancreatitis", "DISEASE", 25, 37], ["pain", "DISEASE", 47, 51], ["pancreatic", "MULTI-TISSUE_STRUCTURE", 81, 91], ["Treatment", "TREATMENT", 5, 14], ["acute pancreatitis", "PROBLEM", 19, 37], ["pain control", "TREATMENT", 47, 59], ["intravenous fluids", "TREATMENT", 61, 79], ["pancreatic rest", "TREATMENT", 81, 96], ["complications", "PROBLEM", 117, 130], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["pancreatitis", "OBSERVATION", 25, 37], ["pancreatic", "ANATOMY", 81, 91]]], ["Aggressive surgical intervention may be necessary for patients who have signs of infected necrosis and whose disease is not controllable by conservative methods.", [["infected necrosis", "DISEASE", 81, 98], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["Aggressive surgical intervention", "TREATMENT", 0, 32], ["infected necrosis", "PROBLEM", 81, 98], ["whose disease", "PROBLEM", 103, 116], ["conservative methods", "TREATMENT", 140, 160], ["infected", "OBSERVATION_MODIFIER", 81, 89], ["necrosis", "OBSERVATION", 90, 98]]], ["[19] Nutrition should be instituted within a few days.IntroductionThe National Health Insurance (NHI) program is the backbone of the health care system in Taiwan.", [["Nutrition", "TREATMENT", 5, 14]]], ["In order to prevent unlimited and rapid growth of spending on health care, the Bureau of National Health Insurance (BNHI) implemented global budgeting to modify the FFS mechanism in 2002.", [["global budgeting", "TREATMENT", 134, 150], ["rapid", "OBSERVATION_MODIFIER", 34, 39], ["growth", "OBSERVATION_MODIFIER", 40, 46]]], ["Global budgeting in Taiwan is an overall spending target, designed to limit the volume of service and its total price.", [["its total price", "TREATMENT", 102, 117]]], ["[20] [21] [22] [23] [24] The global budgeting program adopted in Taiwan is an expenditure-cap system with a \"floating point value\" mechanism.", [["[20] [21] [22] [23", "SIMPLE_CHEMICAL", 0, 18], ["The global budgeting program", "TREATMENT", 25, 53], ["cap", "OBSERVATION", 90, 93]]], ["The aggregate level of expenditure in the previous year and age structure of the population determine the size of the national budget.", [["size", "OBSERVATION_MODIFIER", 106, 110]]], ["Reimbursement to providers is based on an existing FFS schedule, which lists a relative value or number of points for each item of service.", [["an existing FFS schedule", "TREATMENT", 39, 63]]], ["The degree of cuts in reimbursement was measured based on the quarterly monetary value of each point.IntroductionThe objectives of this study were to compare the health service utilization (length of hospital stay), health care expenditures (eg, total costs, drug costs, costs related to diagnoses, and costs pertaining to treatment), and the quality of care (eg, risk of readmission within 14 days and risk of revisiting the emergency department (ED) within 3 days) before and after adoption of the global budgeting system.Materials and methodsThis was a pre-post comparison study.", [["this study", "TEST", 131, 141], ["treatment", "TREATMENT", 323, 332], ["a pre-post comparison study", "TEST", 554, 581], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["cuts", "OBSERVATION_MODIFIER", 14, 18]]], ["The study was based in part on data from the National Health Insurance Research Database (NHIRD) provided by the BNHI, Department of Health and managed by the National Health Research Institutes.", [["The study", "TEST", 0, 9]]], ["The database contains registration files and original claims data for reimbursement.", [["registration files", "TEST", 22, 40]]], ["The NHIRD is provided to scientists in Taiwan for research purposes.", [["research purposes", "TEST", 50, 67]]], ["These data files are de-identified by scrambling the identification codes of both patients and medical facilities and then sent to the National Health Research Institutes to form the original files contained in the NHIRD.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90]]], ["[25] Based on the registration files and original claims data in the NHIRD, specific data subsets can be re-constructed for research purposes.", [["the registration files", "TEST", 14, 36], ["research purposes", "TEST", 124, 141]]], ["The registration datasets, systemic sampling inpatient expenditures by admissions (DD file) and systemic sampling ambulatory care expenditures by visits (CD file) were used in this study.", [["The registration datasets", "TEST", 0, 25], ["systemic sampling ambulatory care expenditures", "TREATMENT", 96, 142], ["this study", "TEST", 176, 186]]], ["Systemic sampling CD and DD files Approximately, 0.2% of the ambulatory care expenditures, by visit, CD file extracted by systematic sampling method on a monthly basis, together with the related records in details of ambulatory care orders form the systematic sampling CD file; 5% of the inpatient expenditures, by admission, DD file extracted by systematic sampling method on a monthly basis, together with the related records in details of inpatient orders form the systematic sampling DD file.", [["ambulatory care", "TREATMENT", 217, 232]]], ["[25] A total of 1 million cases of systemic sampling dataset were used in this study.Study populationSubjects in systemic sampling CD and systemic sampling DD files with a clinical diagnosis of acute pancreatitis, ICD-9 code 577.0, in 2000, 2001, 2004, and 2005 were recruited for comparison and analysis.", [["pancreatitis", "DISEASE", 200, 212], ["systemic sampling dataset", "TREATMENT", 35, 60], ["this study", "TEST", 74, 84], ["Study populationSubjects", "TEST", 85, 109], ["systemic sampling CD", "TEST", 113, 133], ["acute pancreatitis", "PROBLEM", 194, 212], ["ICD", "TEST", 214, 217], ["analysis", "TEST", 296, 304], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["pancreatitis", "OBSERVATION", 200, 212]]], ["ICD-9 577.0 was used to define the disease in both inpatient and ambulatory codes.", [["ICD-9 577.0", "CHEMICAL", 0, 11], ["ICD", "TEST", 0, 3], ["the disease", "PROBLEM", 31, 42], ["disease", "OBSERVATION", 35, 42]]], ["One time ICD-9 coding was used to be scrutinized before they can define the acute pancreatitis.", [["pancreatitis", "DISEASE", 82, 94], ["ICD-9 coding", "DNA", 9, 21], ["One time ICD", "TREATMENT", 0, 12], ["the acute pancreatitis", "PROBLEM", 72, 94], ["acute", "OBSERVATION_MODIFIER", 76, 81], ["pancreatitis", "OBSERVATION", 82, 94]]], ["The definition of readmission was that readmission event for the treatment of acute pancreatitis.", [["pancreatitis", "DISEASE", 84, 96], ["acute pancreatitis", "PROBLEM", 78, 96], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["pancreatitis", "OBSERVATION", 84, 96]]], ["The admission and readmission events need the same ICD-9 coding.", [["ICD-9 coding", "DNA", 51, 63], ["the same ICD", "TREATMENT", 42, 54]]], ["The global budget system in Taiwan It has been reported that SARS had an impact on health care utilization.", [["SARS", "DISEASE", 61, 65], ["Taiwan", "SPECIES", 28, 34], ["health care utilization", "TREATMENT", 83, 106], ["global", "OBSERVATION_MODIFIER", 4, 10], ["budget", "OBSERVATION", 11, 17]]], ["[26] Therefore, data from 2003 were not used in this study.Charlson comorbidity indexA score of 1 was added when the subjects had co-morbid myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, connective tissue disease, peptic ulcer disease, mild liver disease, or diabetes without end-organ damage.", [["myocardial", "ANATOMY", 140, 150], ["heart", "ANATOMY", 174, 179], ["peripheral vascular", "ANATOMY", 189, 208], ["cerebrovascular", "ANATOMY", 218, 233], ["pulmonary", "ANATOMY", 261, 270], ["connective tissue", "ANATOMY", 280, 297], ["peptic ulcer", "ANATOMY", 307, 319], ["liver", "ANATOMY", 334, 339], ["organ", "ANATOMY", 373, 378], ["myocardial infarction", "DISEASE", 140, 161], ["congestive heart failure", "DISEASE", 163, 187], ["peripheral vascular disease", "DISEASE", 189, 216], ["cerebrovascular disease", "DISEASE", 218, 241], ["dementia", "DISEASE", 243, 251], ["chronic pulmonary disease", "DISEASE", 253, 278], ["connective tissue disease", "DISEASE", 280, 305], ["peptic ulcer disease", "DISEASE", 307, 327], ["liver disease", "DISEASE", 334, 347], ["diabetes", "DISEASE", 352, 360], ["end-organ damage", "DISEASE", 369, 385], ["myocardial", "MULTI-TISSUE_STRUCTURE", 140, 150], ["heart", "ORGAN", 174, 179], ["peripheral vascular", "MULTI-TISSUE_STRUCTURE", 189, 208], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 218, 233], ["pulmonary", "ORGAN", 261, 270], ["connective tissue", "TISSUE", 280, 297], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 307, 319], ["liver", "ORGAN", 334, 339], ["organ", "ORGAN", 373, 378], ["this study", "TEST", 48, 58], ["Charlson comorbidity indexA score", "TEST", 59, 92], ["co-morbid myocardial infarction", "PROBLEM", 130, 161], ["congestive heart failure", "PROBLEM", 163, 187], ["peripheral vascular disease", "PROBLEM", 189, 216], ["cerebrovascular disease", "PROBLEM", 218, 241], ["dementia", "PROBLEM", 243, 251], ["chronic pulmonary disease", "PROBLEM", 253, 278], ["connective tissue disease", "PROBLEM", 280, 305], ["peptic ulcer disease", "PROBLEM", 307, 327], ["mild liver disease", "PROBLEM", 329, 347], ["diabetes", "PROBLEM", 352, 360], ["end-organ damage", "PROBLEM", 369, 385], ["myocardial", "ANATOMY", 140, 150], ["infarction", "OBSERVATION", 151, 161], ["congestive", "OBSERVATION_MODIFIER", 163, 173], ["heart", "ANATOMY", 174, 179], ["failure", "OBSERVATION", 180, 187], ["peripheral", "ANATOMY_MODIFIER", 189, 199], ["vascular", "ANATOMY", 200, 208], ["disease", "OBSERVATION", 209, 216], ["cerebrovascular", "ANATOMY", 218, 233], ["disease", "OBSERVATION", 234, 241], ["dementia", "OBSERVATION", 243, 251], ["chronic", "OBSERVATION_MODIFIER", 253, 260], ["pulmonary", "ANATOMY", 261, 270], ["disease", "OBSERVATION", 271, 278], ["connective tissue disease", "OBSERVATION", 280, 305], ["peptic", "OBSERVATION_MODIFIER", 307, 313], ["ulcer disease", "OBSERVATION", 314, 327], ["mild", "OBSERVATION_MODIFIER", 329, 333], ["liver", "ANATOMY", 334, 339], ["disease", "OBSERVATION", 340, 347], ["diabetes", "OBSERVATION", 352, 360], ["organ", "ANATOMY", 373, 378], ["damage", "OBSERVATION", 379, 385]]], ["A score of 2 was added when the subjects had co-morbid hemiplegia, moderate or severe renal disease, diabetes with end-organ damage, tumor without metastases, leukemia, or lymphoma.", [["renal", "ANATOMY", 86, 91], ["organ", "ANATOMY", 119, 124], ["tumor", "ANATOMY", 133, 138], ["metastases", "ANATOMY", 147, 157], ["leukemia", "ANATOMY", 159, 167], ["lymphoma", "ANATOMY", 172, 180], ["hemiplegia", "DISEASE", 55, 65], ["renal disease", "DISEASE", 86, 99], ["diabetes", "DISEASE", 101, 109], ["end-organ damage", "DISEASE", 115, 131], ["tumor", "DISEASE", 133, 138], ["metastases", "DISEASE", 147, 157], ["leukemia", "DISEASE", 159, 167], ["lymphoma", "DISEASE", 172, 180], ["renal", "ORGAN", 86, 91], ["organ", "ORGAN", 119, 124], ["tumor", "CANCER", 133, 138], ["leukemia", "CANCER", 159, 167], ["lymphoma", "CANCER", 172, 180], ["A score", "TEST", 0, 7], ["co-morbid hemiplegia", "PROBLEM", 45, 65], ["moderate or severe renal disease", "PROBLEM", 67, 99], ["diabetes", "PROBLEM", 101, 109], ["end-organ damage", "PROBLEM", 115, 131], ["tumor", "PROBLEM", 133, 138], ["metastases", "PROBLEM", 147, 157], ["leukemia", "PROBLEM", 159, 167], ["lymphoma", "PROBLEM", 172, 180], ["hemiplegia", "OBSERVATION", 55, 65], ["moderate", "OBSERVATION_MODIFIER", 67, 75], ["severe", "OBSERVATION_MODIFIER", 79, 85], ["renal", "ANATOMY", 86, 91], ["disease", "OBSERVATION", 92, 99], ["diabetes", "OBSERVATION", 101, 109], ["organ", "ANATOMY", 119, 124], ["damage", "OBSERVATION", 125, 131], ["tumor", "OBSERVATION", 133, 138], ["without", "UNCERTAINTY", 139, 146], ["metastases", "OBSERVATION", 147, 157], ["leukemia", "OBSERVATION", 159, 167], ["lymphoma", "OBSERVATION", 172, 180]]], ["A score of 3 was added when the subjects had co-morbid moderate or severe liver disease.", [["liver", "ANATOMY", 74, 79], ["liver disease", "DISEASE", 74, 87], ["liver", "ORGAN", 74, 79], ["A score", "TEST", 0, 7], ["co-morbid moderate or severe liver disease", "PROBLEM", 45, 87], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["liver", "ANATOMY", 74, 79], ["disease", "OBSERVATION", 80, 87]]], ["A score of 6 was added when the subjects had co-morbid metastatic solid tumors or acquired immunodeficiency syndrome (AIDS).", [["metastatic solid tumors", "ANATOMY", 55, 78], ["tumors", "DISEASE", 72, 78], ["acquired immunodeficiency syndrome", "DISEASE", 82, 116], ["AIDS", "DISEASE", 118, 122], ["solid tumors", "CANCER", 66, 78], ["A score", "TEST", 0, 7], ["co-morbid metastatic solid tumors", "PROBLEM", 45, 78], ["acquired immunodeficiency syndrome", "PROBLEM", 82, 116], ["metastatic", "OBSERVATION_MODIFIER", 55, 65], ["solid tumors", "OBSERVATION", 66, 78], ["immunodeficiency syndrome", "OBSERVATION", 91, 116]]], ["The total score was obtained by adding the relative weight of all co-morbidities.", [["The total score", "TEST", 0, 15]]], ["[27] [28] [29]Income state indexIn TaiwanEthics statementThe NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions.", [["patient", "ORGANISM", 76, 83], ["patient", "SPECIES", 76, 83]]], ["Patient consent is not required to access the NHIRD.", [["Patient", "SPECIES", 0, 7]]], ["This study was approved by the Institutional Review Board (IRB) of China Medical University (CMU-REC-101-012).", [["This study", "TEST", 0, 10]]], ["The IRB specifically waived the consent requirement.Data availability statementAll data and related metadata were deposited in an appropriate public repository.", [["All data", "TEST", 79, 87]]], ["The data on the study population that were obtained from the NHIRD (http://w3.nhri.org.tw/nhird//date_01. html) are maintained in the NHIRD (http://nhird.nhri.org.tw/).", [["the study population", "TEST", 12, 32]]], ["The NHRI is a nonprofit foundation established by the government.Statistical analysisData are described as mean \u00b1 standard deviation (SD).", [["Statistical analysisData", "TEST", 65, 89]]], ["The t-test was used to compare the differences in mean values of length of stay (LOS), diagnostic costs, drug costs, therapy costs, total costs, rate of revisiting the ED within 3 days, and 14-day re-admission rate before and after implementation of the global budget system.", [["The t-test", "TEST", 0, 10], ["drug costs", "TREATMENT", 105, 115], ["therapy costs", "TREATMENT", 117, 130]]], ["Multilevel and mixed-effects models were employed to determine the impact of several independent variables on LOS, diagnostic costs, drug costs, therapy costs, total costs, the risk of revisiting the ED within 3 days, and the risk of being readmitted within 14 days after discharge.", [["Multilevel and mixed-effects models", "PROBLEM", 0, 35], ["drug costs", "TREATMENT", 133, 143], ["therapy costs", "TREATMENT", 145, 158], ["mixed", "OBSERVATION_MODIFIER", 15, 20]]], ["Mixed-effects modeling is basically regression analysis that takes into account 2 kinds of effect sizes: fixed effects (intercepts and slopes that describe the population as a whole) and random effects (intercepts and slopes that can vary across subgroups of the sample).", [["basically regression analysis", "PROBLEM", 26, 55], ["effect sizes", "PROBLEM", 91, 103], ["fixed effects", "PROBLEM", 105, 118], ["random effects (intercepts and slopes", "PROBLEM", 187, 224], ["sizes", "OBSERVATION_MODIFIER", 98, 103], ["fixed effects", "OBSERVATION", 105, 118]]], ["[31] There were 2 nested levels in this study: hospital accreditation levels and regional levels.", [["this study", "TEST", 35, 45], ["hospital accreditation levels", "TEST", 47, 76], ["regional levels", "TEST", 81, 96]]], ["The independent variables evaluated in this study included pre-post global budgeting, age, gender, income state index, Charlson Comorbidity Index, the 3 hospital levels, and the 6 geographic areas in Taiwan.Statistical analysisAll statistical analyses were performed on a personal computer using the statistical package STATA for Windows (Version 11.0, College Station, TX).", [["this study", "TEST", 39, 49], ["pre-post global budgeting", "PROBLEM", 59, 84], ["Charlson Comorbidity Index", "TEST", 119, 145], ["Statistical analysis", "TEST", 207, 227], ["All statistical analyses", "TEST", 227, 251]]], ["A P-value of .05 was considered to represent statistical significance.ResultsA total of 2810 patients with acute pancreatitis (1108 pre-and 1702 post-global budget) were recruited in this study.", [["pancreatitis", "DISEASE", 113, 125], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["A P-value", "TEST", 0, 9], ["acute pancreatitis", "PROBLEM", 107, 125], ["this study", "TEST", 183, 193], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["pancreatitis", "OBSERVATION", 113, 125]]], ["In the pre-budget group, 74% of the subjects were men and in the post-budget group, 75% of the subjects were men.", [["subjects", "ORGANISM", 36, 44], ["men", "ORGANISM", 50, 53], ["subjects", "ORGANISM", 95, 103], ["men", "ORGANISM", 109, 112], ["men", "SPECIES", 50, 53], ["men", "SPECIES", 109, 112]]], ["The mean income state index before implementation of the global budgeting system was 1.79 \u00b1 0.05 and that after adoption of the system was 1.74 \u00b1 0.04.", [["the system", "TEST", 124, 134]]], ["The mean Charlson Comorbidity Index before global budgeting was 0.75 \u00b1 0.04 and that after introduction of the system was 1.00 \u00b1 0.03.", [["The mean Charlson Comorbidity Index", "TEST", 0, 35], ["global budgeting", "TEST", 43, 59], ["the system", "TEST", 107, 117]]], ["There were significant differences in age (P < .001), income state index (P = .04), and Charlson Comorbidity Index (P < .001) before and after the global budgeting system went into effect.", [["income state index", "TEST", 54, 72], ["P", "TEST", 74, 75], ["Charlson Comorbidity Index", "TEST", 88, 114], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34]]], ["There was no significant difference in male to female ratio before and after adoption of the global budget system (P = .10) ( Table 2) .ResultsThe mean LOS before implementation of the global budget system was 7.34 \u00b1 0.22 days and that after the system went into effect was 7.82 \u00b1 0.22 days.", [["the system", "TEST", 242, 252], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["The definitions of diagnostic cost, therapy costand drug cost were costs of laboratory diagnostic tests, treatment for acute pancreatitis, and medicines.", [["pancreatitis", "DISEASE", 125, 137], ["therapy costand drug cost", "TREATMENT", 36, 61], ["laboratory diagnostic tests", "TEST", 76, 103], ["treatment", "TREATMENT", 105, 114], ["acute pancreatitis", "PROBLEM", 119, 137], ["medicines", "TREATMENT", 143, 152], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["pancreatitis", "OBSERVATION", 125, 137]]], ["The mean diagnostic costs (in NT 2085.70 \u00b1 64.42 and NT$ 2875.96 \u00b1 86.96, respectively.", [["NT", "TEST", 30, 32], ["NT", "TEST", 53, 55]]], ["The mean drug costs before and after implementation of the global budget system were NT$ 6363.78 \u00b1 547.30 and NT$ 8723.39 \u00b1 665.60, respectively.", [["The mean drug costs", "TREATMENT", 0, 19], ["NT", "TEST", 110, 112]]], ["The mean therapy costs before and after the global budget were NT$ 1074.26 \u00b1 137.10 and NT$ 3412.97 \u00b1 320.40, respectively.", [["The mean therapy costs", "TREATMENT", 0, 22], ["NT", "TEST", 88, 90]]], ["The mean total costs before and after adoption of global budgeting were NT$ 28,290.66 \u00b1 1576.32 and NT$ 42,341.83 \u00b1 2285.23, respectively.", [["NT", "TEST", 100, 102]]], ["The mean 14-day re-admission rates before and after the global budget went into effect were 11.6 \u00b1 1.0% and 7.9 \u00b1 0.7%.", [["the global budget", "TEST", 52, 69]]], ["Table 1 National health insurance premium level.Income levelMonthly salary (NT$) There were significant differences in LOS, diagnostic costs, drug costs, therapy total costs, 3-day ED revisit rate, and 14-day readmission rate before and after adoption of global budgeting (P = .001 for LOS and P < .001 for others) ( Table 3) .LOSA mixed-effects Poisson model was used for clustered count data analysis.", [["drug costs", "TREATMENT", 142, 152], ["therapy total costs", "TREATMENT", 154, 173], ["rate", "TEST", 192, 196], ["global budgeting", "TREATMENT", 255, 271], ["LOS", "TEST", 286, 289], ["Poisson model", "TEST", 346, 359], ["clustered count data analysis", "TEST", 373, 402], ["significant", "OBSERVATION_MODIFIER", 92, 103], ["differences", "OBSERVATION_MODIFIER", 104, 115]]], ["[32] The Poisson regression model was fitted using option IRR (incidence-rate ratio) to obtain exponential estimates.", [["The Poisson regression model", "TREATMENT", 5, 33], ["option IRR", "TEST", 51, 61]]], ["Global budgeting did not have a significant impact on LOS (IRR = 0.99, P = .51).", [["LOS", "TEST", 54, 57], ["IRR", "TEST", 59, 62], ["P", "TEST", 71, 72], ["significant", "OBSERVATION_MODIFIER", 32, 43]]], ["Male gender was associated with a significantly shorter LOS than female gender (IRR = 0.96, P = .016).", [["a significantly shorter LOS", "PROBLEM", 32, 59], ["IRR", "TEST", 80, 83], ["P", "TEST", 92, 93]]], ["In addition, LOS was positively correlated with age and Charlson Comorbidity Index (IRR = 1.003, P = .002; IRR = 1.11, P < .001).", [["LOS", "TEST", 13, 16], ["Charlson Comorbidity Index", "TEST", 56, 82], ["IRR", "TEST", 84, 87], ["P", "TEST", 97, 98], ["IRR", "TEST", 107, 110], ["P", "TEST", 119, 120]]], ["There was a significantly negative correlation between income state index and LOS (IRR = 0.97, P < .001).", [["LOS", "TEST", 78, 81], ["IRR", "TEST", 83, 86], ["P", "TEST", 95, 96]]], ["Compared with medical centers, there was no significant difference in LOS between regional hospitals or local hospitals (IRR = 1.04, P= .55; IRR = 1.05, P = .49).", [["IRR", "TEST", 121, 124], ["P", "TEST", 133, 134], ["IRR", "TEST", 141, 144], ["P", "TEST", 153, 154], ["no", "UNCERTAINTY", 41, 43], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["difference", "OBSERVATION_MODIFIER", 56, 66], ["LOS", "OBSERVATION_MODIFIER", 70, 73]]], ["Compared with hospitals in Taipei city, LOS differed significantly among hospitals in northern Taiwan, central Taiwan, southern Taiwan, Kaoshiung city, and eastern Taiwan (IRR = 1.15, P = .14; b = 0.99, P = .91; b = 1.10, P = .32; b = 0.92, P = .38; b = 0.83, P = .14) ( Table 4 ).Diagnostic costsA mixed-effects linear model was used for analysis.", [["IRR", "TEST", 172, 175], ["P", "TEST", 184, 185], ["b", "TEST", 193, 194], ["P", "TEST", 203, 204], ["b", "TEST", 212, 213], ["P", "TEST", 222, 223], ["b", "TEST", 231, 232], ["P", "TEST", 241, 242], ["b", "TEST", 250, 251], ["P", "TEST", 260, 261], ["Diagnostic costsA mixed-effects linear model", "TREATMENT", 281, 325], ["analysis", "TEST", 339, 347]]], ["Because diagnostic costs were skewed to the right, data were converted to natural logarithm for statistical analysis.", [["statistical analysis", "TEST", 96, 116], ["right", "ANATOMY_MODIFIER", 44, 49]]], ["Global budgeting had a significantly positive impact on diagnostic costs (b = 0.19, P < .001).", [["Global budgeting", "PROBLEM", 0, 16], ["diagnostic costs", "TEST", 56, 72]]], ["Male gender was associated with significantly lower diagnostic costs than female gender (b = \u00c00.08, P = .01).", [["significantly lower diagnostic costs", "PROBLEM", 32, 68]]], ["There was no significant correlation between age and diagnostic costs (b = 0.003, P = .19).", [["diagnostic costs", "TEST", 53, 69], ["P", "TEST", 82, 83], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24]]], ["There was, however, a significantly negative correlation between income state index and diagnostic costs (b = \u00c00.02, P = .01).", [["diagnostic costs", "TEST", 88, 104], ["P", "TEST", 117, 118]]], ["Furthermore, there was a significantly positive correlation between Charlson Comorbidity Index and diagnostic costs (b = 0.08, P = .003).", [["diagnostic costs", "TEST", 99, 115], ["P", "TEST", 127, 128]]], ["Compared with medical centers, there was no significant difference in diagnostic costs between regional hospitals and local hospitals (b = 0.001, P = .98; b = 0.03, P = .76).", [["P", "TEST", 146, 147], ["b", "TEST", 155, 156], ["P", "TEST", 165, 166], ["no", "UNCERTAINTY", 41, 43], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["difference", "OBSERVATION_MODIFIER", 56, 66]]], ["Compared with diagnostic costs incurred in hospitals in Taipei city, there were no significant differences in diagnostic costs among hospitals in northern Taiwan, central Taiwan, southern Taiwan, Kaoshiung city, and eastern Taiwan (b = 0.05, P = .43; b = 0.02, P = .80; b = 0.08, P = .24; b = \u00c00.02, P = .82; b = \u00c00.16, P = .20) (Table 5 ).Drug costsA mixed-effects linear model was used for analysis.", [["P", "TEST", 242, 243], ["b", "TEST", 251, 252], ["P", "TEST", 261, 262], ["b", "TEST", 270, 271], ["P", "TEST", 280, 281], ["b", "TEST", 289, 290], ["P", "TEST", 300, 301], ["b", "TEST", 309, 310], ["P", "TEST", 320, 321], ["Drug costsA mixed-effects linear model", "TREATMENT", 340, 378], ["analysis", "TEST", 392, 400], ["no", "UNCERTAINTY", 80, 82], ["significant", "OBSERVATION_MODIFIER", 83, 94], ["differences", "OBSERVATION_MODIFIER", 95, 106]]], ["Because drug costs were skewed to the right, data were converted to natural logarithm for statistical analysis.", [["drug costs", "PROBLEM", 8, 18], ["statistical analysis", "TEST", 90, 110], ["right", "ANATOMY_MODIFIER", 38, 43]]], ["Global budgeting did not have a significant impact on drug costs (b = 0.03, P = .71).", [["P", "TEST", 76, 77], ["significant", "OBSERVATION_MODIFIER", 32, 43]]], ["Male gender was associated with significantly lower drug costs than female gender (b = \u00c00.13, P = .03).", [["significantly lower drug costs", "PROBLEM", 32, 62], ["P", "TEST", 94, 95]]], ["There was a significantly positive correlation between age and drug costs (b = 0.01, P = .003).", [["drug costs", "TEST", 63, 73], ["P", "TEST", 85, 86]]], ["There was, however, no significant correlation between income state index or Charlson Comorbidity Index and drug costs (b = \u00c0 0.01, P = .42; b = 0.08, P = .14).", [["Charlson Comorbidity Index", "TEST", 77, 103], ["drug costs", "TEST", 108, 118], ["b", "TEST", 120, 121], ["P", "TEST", 132, 133], ["b", "TEST", 141, 142], ["P", "TEST", 151, 152]]], ["Compared with medical centers, there was no significant difference in drug costs between regional hospitals and local hospitals (b = \u00c00.04, P = .83; b = 0.003, P = .99).", [["P", "TEST", 140, 141], ["P", "TEST", 160, 161], ["no", "UNCERTAINTY", 41, 43], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["difference", "OBSERVATION_MODIFIER", 56, 66], ["drug costs", "OBSERVATION", 70, 80]]], ["Compared with hospitals in Taipei city, there was no significant difference in drug costs among hospitals in northern Taiwan, central Taiwan, southern Taiwan, Kaoshiung city, and eastern Taiwan (b = \u00c00.06, P = .57; b = \u00c00.13, P = .18; b = 0.01, P = .90; b = \u00c00.12, P = .27; b = \u00c00.37, P = .09).", [["P", "TEST", 206, 207], ["b", "TEST", 215, 216], ["P", "TEST", 226, 227], ["b", "TEST", 235, 236], ["P", "TEST", 245, 246], ["b", "TEST", 254, 255], ["P", "TEST", 265, 266], ["b", "TEST", 274, 275], ["P", "TEST", 285, 286], ["no", "UNCERTAINTY", 50, 52], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["difference", "OBSERVATION_MODIFIER", 65, 75]]], ["Compare the differences in mean values ofLOS, diagnostic costs, drug costs, therapy costs, total costs, rate of revisiting the ED within 3 days, and 14-day re-admission rate before and after implementation of the global budget system.Therapy costsA mixed-effects linear model was used for analysis.", [["therapy costs", "TREATMENT", 76, 89], ["Therapy costsA mixed-effects linear model", "TREATMENT", 234, 275], ["analysis", "TEST", 289, 297]]], ["Because therapy costs were skewed to the right, data were converted to natural logarithm for statistical analysis.", [["therapy costs", "TREATMENT", 8, 21], ["statistical analysis", "TEST", 93, 113], ["right", "ANATOMY_MODIFIER", 41, 46]]], ["Global budgeting had a significantly positive impact on therapy costs (b = 0.38, P = .01).", [["Global budgeting", "PROBLEM", 0, 16], ["therapy costs", "TREATMENT", 56, 69], ["P", "TEST", 81, 82]]], ["There was no significant correlation between gender, age, or income state index and therapy costs (b = 0.06, P = .63; b = 0.002, P = .76; b = 0.009, P = .81).", [["therapy costs", "TREATMENT", 84, 97], ["P", "TEST", 109, 110], ["b", "TEST", 118, 119], ["P", "TEST", 129, 130], ["b", "TEST", 138, 139], ["P", "TEST", 149, 150], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24]]], ["There was, however, a significantly positive correlation between Charlson Comorbidity Index and therapy costs (b = 0.27, P = .006).", [["therapy costs", "TREATMENT", 96, 109], ["P", "TEST", 121, 122]]], ["Compared with medical centers, there was no significant difference in therapy costs between regional hospitals and local hospitals (b = \u00c00.08, P = .82; b = 0.03, P = .93).", [["P", "TEST", 143, 144], ["b", "TEST", 152, 153], ["P", "TEST", 162, 163], ["no", "UNCERTAINTY", 41, 43], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["difference", "OBSERVATION_MODIFIER", 56, 66]]], ["Compared with hospitals in Taipei city, there were no significant differences in therapy costs among hospitals in northern Taiwan, central Taiwan, southern Taiwan, Kaoshiung city, and eastern Taiwan (b = \u00c00.09, P = .74; b = \u00c0 0.06, P = .79; b = 0.26, P = .29; b = 0.32, P = .25; b = \u00c00.14, P = .75) ( Table 6 ).Total costsA mixed-effects linear model was used for analysis.", [["P", "TEST", 211, 212], ["b", "TEST", 220, 221], ["P", "TEST", 232, 233], ["b", "TEST", 241, 242], ["P", "TEST", 251, 252], ["b", "TEST", 260, 261], ["P", "TEST", 270, 271], ["b", "TEST", 279, 280], ["P", "TEST", 290, 291], ["Total costsA mixed-effects linear model", "TREATMENT", 311, 350], ["analysis", "TEST", 364, 372], ["no", "UNCERTAINTY", 51, 53], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["differences", "OBSERVATION_MODIFIER", 66, 77]]], ["Because total costs were skewed to the right, data were converted to natural logarithm for statistical analysis.", [["total costs", "PROBLEM", 8, 19], ["statistical analysis", "TEST", 91, 111], ["right", "ANATOMY_MODIFIER", 39, 44]]], ["Global budgeting had a significantly positive impact on total costs (b = 0.17, P = .02).Total costsMale gender was associated with significantly lower total costs (b = \u00c00.15, P = .001).", [["Global budgeting", "PROBLEM", 0, 16], ["a significantly positive impact", "PROBLEM", 21, 52], ["total costs", "TEST", 56, 67], ["P", "TEST", 79, 80], ["significantly lower total costs", "PROBLEM", 131, 162], ["P", "TEST", 175, 176]]], ["There was a significantly positive correlation between age and total costs (b = 0.008, P = .007).", [["total costs", "TEST", 63, 74], ["P", "TEST", 87, 88]]], ["There was, however, no significant correlation between income state index and total costs (b = \u00c00.02, P = .09).", [["total costs", "TEST", 78, 89], ["P", "TEST", 102, 103]]], ["There was a significantly positive correlation between Charlson Comorbidity Index and total costs (b = 0.12, P = .002).", [["Charlson Comorbidity Index", "TEST", 55, 81], ["total costs", "TEST", 86, 97], ["b", "TEST", 99, 100], ["P", "TEST", 109, 110]]], ["Compared with medical centers, there was no significant difference in total costs between regional hospitals and local hospitals (b = \u00c00.01, P = .94; b = 0.06, P = .66).", [["P", "TEST", 141, 142], ["b", "TEST", 150, 151], ["P", "TEST", 160, 161], ["no", "UNCERTAINTY", 41, 43], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["difference", "OBSERVATION_MODIFIER", 56, 66], ["total", "OBSERVATION_MODIFIER", 70, 75]]], ["Compared with hospitals in Taipei city, there was no significant difference in total costs among hospitals in northern Taiwan, central Taiwan, southern Taiwan, Kaoshiung city, or eastern Taiwan (b = 0.02, P = .85; b = 0.004, P = .96; b = 0.07, P = .38; b = \u00c00.05, P = .58; b = \u00c00.22, P = .17) ( Table 7) .", [["P", "TEST", 205, 206], ["b", "TEST", 214, 215], ["P", "TEST", 225, 226], ["b", "TEST", 234, 235], ["P", "TEST", 244, 245], ["b", "TEST", 253, 254], ["P", "TEST", 264, 265], ["b", "TEST", 273, 274], ["P", "TEST", 284, 285], ["no", "UNCERTAINTY", 50, 52], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["difference", "OBSERVATION_MODIFIER", 65, 75]]], ["Table 5 The impact of several independent variables on diagnostic costs, drug costs, therapy costs, and total costs in acute pancreatitis (mixed-effects linear model).", [["pancreatitis", "DISEASE", 125, 137], ["diagnostic costs", "TREATMENT", 55, 71], ["drug costs", "TREATMENT", 73, 83], ["therapy costs", "TREATMENT", 85, 98], ["acute pancreatitis", "PROBLEM", 119, 137], ["mixed-effects linear model", "TREATMENT", 139, 165], ["acute", "OBSERVATION_MODIFIER", 119, 124], ["pancreatitis", "OBSERVATION", 125, 137]]], ["The impact of GB, age, sex, income index, Charlson Comorbidity Index, accreditation hospital level, and regional level on therapy costs (log e ) using mixed-effects linear model.", [["therapy costs (log e )", "TREATMENT", 122, 144], ["mixed-effects linear model", "TREATMENT", 151, 177], ["GB", "ANATOMY", 14, 16]]], ["Table 7 The impact of GB, age, sex, income index, Charlson Comorbidity Index, accreditation hospital level, and regional level on total costs (log e ) using mixed-effects linear model.Risk of revisiting the ED within 3 daysA generalized linear binary regression model was used for analysis.", [["total costs (log e )", "TREATMENT", 130, 150], ["mixed-effects linear model", "TREATMENT", 157, 183], ["analysis", "TEST", 281, 289], ["GB", "ANATOMY", 22, 24]]], ["Global budgeting did not have a significant impact on the risk of revisiting the ED within 3 days (odds ratio, OR = 0.78; P = .21).", [["odds ratio", "TEST", 99, 109], ["P", "TEST", 122, 123]]], ["In addition, there was no significant correlation between age, gender or income state index, and risk of revisiting the ED within 3 days (OR = 1.01, P = .27; OR = 0.90, P = .53; OR = 0.92, P = .12).", [["P", "TEST", 149, 150], ["OR", "TEST", 158, 160], ["P", "TEST", 169, 170], ["OR", "TEST", 178, 180], ["P", "TEST", 189, 190], ["no", "UNCERTAINTY", 23, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37]]], ["There was, however, a significantly negative correlation between Charlson Comorbidity Index and risk of revisiting the ED (OR = 0.74, P = .04).", [["P", "TEST", 134, 135]]], ["Compared with medical centers, there was no significant difference in the risk of revisiting the ED within 3 days between regional hospitals and local hospitals (OR = 1.20, P = .27; OR = 0.74, P = .14).", [["P", "TEST", 173, 174], ["no", "UNCERTAINTY", 41, 43], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["difference", "OBSERVATION_MODIFIER", 56, 66]]], ["Compared with hospitals in Taipei city, there was no significant difference in the risk of revisiting the ED within 3 days among hospitals in northern Taiwan, central Taiwan, southern Taiwan, Kaoshiung city, or eastern Taiwan (OR = 0.78, P = .38; OR = 1.03, P = .86; OR = 1.26, P = .27; OR = 1.35, P = .27; OR = 4.21E-08, P = .99) ( Table 8) .Risk of readmission within 14 daysA generalized linear binary regression model was used for analysis.", [["P", "TEST", 238, 239], ["OR", "TEST", 247, 249], ["P", "TEST", 258, 259], ["OR", "TEST", 267, 269], ["P", "TEST", 278, 279], ["OR", "TEST", 287, 289], ["P", "TEST", 298, 299], ["OR", "TEST", 307, 309], ["P", "TEST", 322, 323], ["14 daysA generalized linear binary regression model", "TREATMENT", 370, 421], ["analysis", "TEST", 435, 443], ["no", "UNCERTAINTY", 50, 52], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["difference", "OBSERVATION", 65, 75]]], ["Global budgeting had a significantly negative impact on the risk of being readmitted within 14 days (OR = 0.65; P = .02).", [["Global budgeting", "PROBLEM", 0, 16]]], ["There were no significant correlations between age, gender, income state index, or Charlson Comorbidity Index and the risk of readmission within 14 days (OR = 1.02, P = .12; OR = 0.81, P = .17; OR = 0.97, P = .50; OR = 0.81, P = .14).", [["P", "TEST", 165, 166], ["OR", "TEST", 174, 176], ["P", "TEST", 185, 186], ["OR", "TEST", 194, 196], ["P", "TEST", 205, 206], ["OR", "TEST", 214, 216], ["P", "TEST", 225, 226], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["In addition, there was no significant difference in the risk of being readmitted within 14 days between medical centers and regional hospitals (OR = 0.86, P = .33).", [["no", "UNCERTAINTY", 23, 25], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["difference", "OBSERVATION_MODIFIER", 38, 48]]], ["However, patients treated in local hospitals were at significantly lower risk of readmission within 14 days than patients treated in medical centers (OR = 0.65, P = .02).", [["patients", "ORGANISM", 9, 17], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 9, 17], ["patients", "SPECIES", 113, 121]]], ["Compared with hospitals in Taipei city, there was no significant difference in the risk of readmission within 14 days among hospitals in northern Taiwan, central Taiwan, southern Taiwan, Kaoshiung city, and eastern Taiwan (OR = 1.13, P = .63; OR = 1.33, P = .18; OR = 1.41, P = .10; OR = 1.22, P = .47; OR = 4347E-08, P = .99) ( Table 9 ).DiscussionThe number of patients with acute pancreatitis increased by 53.6% after implementation of global budgeting.", [["pancreatitis", "DISEASE", 383, 395], ["patients", "ORGANISM", 363, 371], ["patients", "SPECIES", 363, 371], ["P", "TEST", 234, 235], ["OR", "TEST", 243, 245], ["P", "TEST", 254, 255], ["OR", "TEST", 263, 265], ["P", "TEST", 274, 275], ["OR", "TEST", 283, 285], ["P", "TEST", 294, 295], ["P", "TEST", 318, 319], ["acute pancreatitis", "PROBLEM", 377, 395], ["global budgeting", "TREATMENT", 439, 455], ["no", "UNCERTAINTY", 50, 52], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["difference", "OBSERVATION", 65, 75], ["acute", "OBSERVATION_MODIFIER", 377, 382], ["pancreatitis", "OBSERVATION", 383, 395]]], ["Alcohol is one of the leading causes of acute pancreatitis.", [["Alcohol", "CHEMICAL", 0, 7], ["pancreatitis", "DISEASE", 46, 58], ["acute pancreatitis", "PROBLEM", 40, 58], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["pancreatitis", "OBSERVATION", 46, 58]]], ["The prevalence of alcoholism increased in Taiwan.", [["alcoholism", "DISEASE", 18, 28], ["alcoholism", "PROBLEM", 18, 28], ["alcoholism", "OBSERVATION", 18, 28], ["increased", "OBSERVATION_MODIFIER", 29, 38]]], ["This might partially explain why the number of cases of pancreatitis increased after adoption of the global budgeting system.", [["pancreatitis", "DISEASE", 56, 68], ["pancreatitis", "PROBLEM", 56, 68], ["pancreatitis", "OBSERVATION", 56, 68]]], ["[33] The LOS was significantly longer after global budgeting took effect.", [["The LOS", "TEST", 5, 12]]], ["Aging and more severe forms of morbidity may have contributed to longer hospital stays in patients with acute pancreatitis.", [["pancreatitis", "DISEASE", 110, 122], ["patients", "ORGANISM", 90, 98], ["patients", "SPECIES", 90, 98], ["morbidity", "PROBLEM", 31, 40], ["acute pancreatitis", "PROBLEM", 104, 122], ["more severe", "OBSERVATION_MODIFIER", 10, 21], ["morbidity", "OBSERVATION", 31, 40], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["pancreatitis", "OBSERVATION", 110, 122]]], ["Diagnostic costs, drug costs, therapy costs, and total costs all significantly increased after implementation of the global budget system.", [["drug costs", "TREATMENT", 18, 28], ["therapy costs", "TREATMENT", 30, 43], ["total costs", "TREATMENT", 49, 60], ["significantly", "OBSERVATION_MODIFIER", 65, 78], ["increased", "OBSERVATION_MODIFIER", 79, 88]]], ["This represents the increases of 37.1% to 217.7%, significantly exceeding Taiwan's 2.2% growth in consumer price index (CPI) for the same period (Appendix 1).", [["Taiwan's", "TEST", 74, 82], ["CPI", "TEST", 120, 123], ["increases", "OBSERVATION_MODIFIER", 20, 29]]], ["Possible reasons for the incremental increases in health care expenditures during the study period include longer LOS, older age, and the presence of more comorbidities in the study population.", [["the incremental increases in health care expenditures", "PROBLEM", 21, 74], ["the study", "TEST", 82, 91], ["increases", "OBSERVATION_MODIFIER", 37, 46]]], ["Another possible cause is that the in an expenditure cap system, the budget is fixed ex ante but the reimbursement prices are determined ex poste.", [["the reimbursement prices", "TREATMENT", 97, 121], ["possible", "UNCERTAINTY", 8, 16]]], ["Once the services have been provided, the prices of those services are adjusted so that the fixed budget will cover them.", [["those services", "TREATMENT", 52, 66], ["the fixed budget", "TREATMENT", 88, 104]]], ["Each provider will have an incentive to increase their supply and result in a rise in the total costs post global budgeting.DiscussionPossible cause of significant incremental mean costs is the extreme values of costs, because the mean values will be affected by extreme values.", [["global budgeting", "TREATMENT", 107, 123], ["significant incremental mean costs", "PROBLEM", 152, 186], ["the mean values", "TEST", 227, 242], ["extreme values", "PROBLEM", 263, 277], ["significant", "OBSERVATION_MODIFIER", 152, 163], ["incremental", "OBSERVATION_MODIFIER", 164, 175], ["mean costs", "OBSERVATION", 176, 186]]], ["The incremental rates in mean diagnostic costs, drug costs, therapy costs and total costs were 0.38, 0.37, 2.18, and 0.50.", [["The incremental rates", "TEST", 0, 21], ["drug costs", "TREATMENT", 48, 58], ["therapy costs", "TREATMENT", 60, 73], ["total costs", "TEST", 78, 89]]], ["The different rates in median diagnostic costs, drug costs, therapy costs and total costs were 0.23, \u00c00.08, 0, and 0.21.", [["drug costs", "TREATMENT", 48, 58], ["therapy costs", "TREATMENT", 60, 73], ["total costs", "TEST", 78, 89], ["different", "OBSERVATION_MODIFIER", 4, 13], ["rates", "OBSERVATION_MODIFIER", 14, 19]]], ["Differences in median costs were much smaller than the mean costs.", [["median costs", "OBSERVATION", 15, 27], ["smaller", "OBSERVATION_MODIFIER", 38, 45]]], ["There was no difference in median therapy costs before and after global budgeting.", [["median therapy costs", "TREATMENT", 27, 47], ["global budgeting", "TREATMENT", 65, 81], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["median therapy", "OBSERVATION", 27, 41]]], ["The median drug cost after global budgeting was even lower than that before global Table 8 The impact of several independent variables on the risk of revisiting ED within 3 days and the risk of re-admission within 14 days among patients with acute pancreatitis (mixed-effects linear binary regression model).", [["pancreatitis", "DISEASE", 248, 260], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["The median drug cost", "TREATMENT", 0, 20], ["global budgeting", "TREATMENT", 27, 43], ["acute pancreatitis", "PROBLEM", 242, 260], ["acute", "OBSERVATION_MODIFIER", 242, 247], ["pancreatitis", "OBSERVATION", 248, 260]]], ["The impact of GB, age, sex, income index, Charlson Comorbidity Index, accreditation hospital level, and regional level on the risk of re-admission within 14 days using generalized linear binary regression model. budgeting.", [["generalized linear binary regression model", "TREATMENT", 168, 210], ["GB", "ANATOMY", 14, 16]]], ["There was no significant difference in health care expenditures for acute pancreatitis between hospitals with different accreditation levels or between different geographic areas in Taiwan.", [["pancreatitis", "DISEASE", 74, 86], ["significant difference in health care expenditures", "PROBLEM", 13, 63], ["acute pancreatitis", "PROBLEM", 68, 86], ["different accreditation levels", "PROBLEM", 110, 140], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["pancreatitis", "OBSERVATION", 74, 86]]], ["The risk of revisiting the ED within 3 days and the risk of being readmitted within 14 days were significantly lower after global budgeting went into effect.", [["global budgeting", "TREATMENT", 123, 139]]], ["Those findings indicate that the quality of care of patients with acute pancreatitis improved after adoption of the global budgeting system.", [["pancreatitis", "DISEASE", 72, 84], ["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["acute pancreatitis", "PROBLEM", 66, 84], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["pancreatitis", "OBSERVATION", 72, 84]]], ["Improvements in care may be attributed to the use of more effective antibiotics, advances in standard operative procedures, and better-trained medical providers.", [["more effective antibiotics", "TREATMENT", 53, 79], ["standard operative procedures", "TREATMENT", 93, 122]]], ["The impact of global budgeting on the risk of revisiting the ED within 3 days, however, was not significant.", [["global", "OBSERVATION_MODIFIER", 14, 20]]], ["Nevertheless, patients treated at local hospitals were at significantly lower risk of readmission within 14 days than patients treated at medical centers.", [["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 118, 126]]], ["Risk factors for early readmission in patients with acute pancreatitis include moderate to heavy alcohol use, persistent gastrointestinal symptoms (nausea, vomiting, or diarrhea), and diet at the time of discharge.", [["gastrointestinal", "ANATOMY", 121, 137], ["pancreatitis", "DISEASE", 58, 70], ["alcohol", "CHEMICAL", 97, 104], ["gastrointestinal symptoms", "DISEASE", 121, 146], ["nausea", "DISEASE", 148, 154], ["vomiting", "DISEASE", 156, 164], ["diarrhea", "DISEASE", 169, 177], ["alcohol", "CHEMICAL", 97, 104], ["patients", "ORGANISM", 38, 46], ["gastrointestinal", "ORGANISM_SUBDIVISION", 121, 137], ["patients", "SPECIES", 38, 46], ["Risk factors", "PROBLEM", 0, 12], ["early readmission", "PROBLEM", 17, 34], ["acute pancreatitis", "PROBLEM", 52, 70], ["persistent gastrointestinal symptoms", "PROBLEM", 110, 146], ["nausea", "PROBLEM", 148, 154], ["vomiting", "PROBLEM", 156, 164], ["diarrhea", "PROBLEM", 169, 177], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["pancreatitis", "OBSERVATION", 58, 70], ["moderate", "OBSERVATION_MODIFIER", 79, 87], ["persistent", "OBSERVATION_MODIFIER", 110, 120], ["gastrointestinal", "ANATOMY", 121, 137]]], ["[34] Those patient characteristics were not available from the database; it is, therefore, not clear whether those factors played a role in early readmission in this study.", [["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["this study", "TEST", 161, 171]]], ["The reasons why patients treated in local hospitals were at a lower risk of readmission within 14 days than patients in medical centers is also not clear.", [["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 108, 116], ["clear", "OBSERVATION", 148, 153]]], ["Whether patients with acute pancreatitis in local hospitals received better quality care than patients in medical centers or whether patients in medical centers had more risk factors for early re-admission needs to be investigated.Risk of revising EDIn Taiwan's market-driven health-care system, 65% of hospitals are private (department of Health, 2001).", [["pancreatitis", "DISEASE", 28, 40], ["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 133, 141], ["acute pancreatitis", "PROBLEM", 22, 40], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["pancreatitis", "OBSERVATION", 28, 40]]], ["Sixty-three percent of physicians are salaried employees of hospitals, some receiving bonus payments based on productivity.", [["bonus payments", "TREATMENT", 86, 100]]], ["In response to an expenditure cap, physicians increased their activity levels including do more tests, provide more complex and high-priced procedures which make diagnostic costs, therapy costs, and total costs significantly increased after global budgeting.", [["an expenditure cap", "TREATMENT", 15, 33], ["high-priced procedures", "TREATMENT", 128, 150], ["therapy costs", "TREATMENT", 180, 193], ["global budgeting", "TREATMENT", 241, 257]]], ["The major treatment for acute pancreatitis includes supportive care, fluid resuscitation, transfer to intensive care unit and enteral feeding.", [["fluid", "ANATOMY", 69, 74], ["pancreatitis", "DISEASE", 30, 42], ["acute pancreatitis", "PROBLEM", 24, 42], ["supportive care", "TREATMENT", 52, 67], ["fluid resuscitation", "TREATMENT", 69, 88], ["enteral feeding", "TREATMENT", 126, 141], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["pancreatitis", "OBSERVATION", 30, 42], ["fluid resuscitation", "OBSERVATION", 69, 88]]], ["Since routine use of prophylactic antibiotics in patients with severe acute pancreatitis and/or sterile necrosis is not recommended; drug costs after global budget were not affected significantly.", [["pancreatitis", "DISEASE", 76, 88], ["necrosis", "DISEASE", 104, 112], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["prophylactic antibiotics", "TREATMENT", 21, 45], ["severe acute pancreatitis", "PROBLEM", 63, 88], ["sterile necrosis", "PROBLEM", 96, 112], ["global budget", "TREATMENT", 150, 163], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["pancreatitis", "OBSERVATION", 76, 88], ["necrosis", "OBSERVATION", 104, 112]]], ["It has been reported that the launch of global budgets leads to an increase in the quantity of medical services supply to maximize profits.", [["medical services supply", "TREATMENT", 95, 118], ["global", "OBSERVATION_MODIFIER", 40, 46], ["budgets", "OBSERVATION_MODIFIER", 47, 54], ["increase", "OBSERVATION_MODIFIER", 67, 75]]], ["In order to maximize revenue, the medical providers in Taiwan present incentives to increase medical care utilization and result in significantly longer length of stay after global budgeting.", [["medical care utilization", "TREATMENT", 93, 117], ["global budgeting", "TREATMENT", 174, 190]]], ["Market competition between hospitals continues to increase in the health-care industry.", [["increase", "OBSERVATION_MODIFIER", 50, 58]]], ["Furthermore, if the hospital has the plans to improve its service quality, there is more room for a hospital to negotiate the expenditure cap with the BNHI.", [["the expenditure cap", "TREATMENT", 122, 141]]], ["Thus quality of care significantly improved after global budgeting in Taiwan.Risk of revising EDThis study was subject to limitations.", [["EDThis study", "TEST", 94, 106]]], ["First, the NHIRD provides no detailed information on patients regarding factors such as their lifestyle, habits, body mass index, physical activity, socioeconomic status, or family history; all of which are possible confounding factors in this study.", [["body", "ANATOMY", 113, 117], ["patients", "ORGANISM", 53, 61], ["body", "ORGANISM_SUBDIVISION", 113, 117], ["patients", "SPECIES", 53, 61], ["body mass index", "PROBLEM", 113, 128], ["confounding factors", "PROBLEM", 216, 235], ["this study", "TEST", 239, 249]]], ["Second, the evidence derived from a cohort study is generally of lower methodological quality than that from randomized trials because a cohort study is subject to many biases related to the necessary adjustments for confounding factors.", [["a cohort study", "TEST", 34, 48], ["a cohort study", "TEST", 135, 149], ["confounding factors", "PROBLEM", 217, 236]]], ["Despite the meticulous design of this study and its adequate control of confounding factors, biases could remain because of possibly unmeasured or unknown confounding factors.", [["this study", "TEST", 33, 43], ["unknown confounding factors", "PROBLEM", 147, 174]]], ["Because of the anonymity of the identification numbers, obtaining additional information by directly contacting the patients was not possible.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124]]], ["The insurance system has mechanisms to monitor the insurance claims.ConclusionThe global budget system was associated with significantly longer length of stay, higher health care expenditures, and better quality of care in patients treated for acute pancreatitis.", [["pancreatitis", "DISEASE", 250, 262], ["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["acute pancreatitis", "PROBLEM", 244, 262], ["acute", "OBSERVATION_MODIFIER", 244, 249], ["pancreatitis", "OBSERVATION", 250, 262]]]], "12b74658dd1b4a98a8b3edd4f75602d8afec993b": [["IntroductionInfectious bronchitis is one of the most significant diseases of chickens in the commercial poultry industry.", [["Infectious bronchitis", "DISEASE", 12, 33], ["chickens", "ORGANISM", 77, 85], ["chickens", "SPECIES", 77, 85], ["chickens", "SPECIES", 77, 85], ["Infectious bronchitis", "PROBLEM", 12, 33], ["Infectious", "OBSERVATION_MODIFIER", 12, 22], ["bronchitis", "OBSERVATION", 23, 33], ["one of the most", "OBSERVATION_MODIFIER", 37, 52], ["significant", "OBSERVATION_MODIFIER", 53, 64], ["diseases", "OBSERVATION", 65, 73], ["chickens", "OBSERVATION", 77, 85]]], ["The etiologic agent is Infectious bronchitis virus (IBV), a member of the family Coronaviridae [1] .", [["Infectious bronchitis virus (IBV)", "DISEASE", 23, 56], ["Infectious bronchitis virus", "ORGANISM", 23, 50], ["IBV", "ORGANISM", 52, 55], ["Infectious bronchitis virus", "SPECIES", 23, 50], ["IBV", "SPECIES", 52, 55], ["Infectious bronchitis virus", "PROBLEM", 23, 50], ["Infectious", "OBSERVATION_MODIFIER", 23, 33]]], ["The pathology of the disease associated with IBV infection can show different characteristics depending on the tissue where virus replication occurs.", [["tissue", "ANATOMY", 111, 117], ["IBV infection", "DISEASE", 45, 58], ["IBV", "ORGANISM", 45, 48], ["tissue", "TISSUE", 111, 117], ["IBV", "SPECIES", 45, 48], ["the disease", "PROBLEM", 17, 28], ["IBV infection", "PROBLEM", 45, 58], ["virus replication", "TREATMENT", 124, 141], ["disease", "OBSERVATION", 21, 28], ["IBV", "OBSERVATION_MODIFIER", 45, 48], ["infection", "OBSERVATION", 49, 58]]], ["IBV enters its host via the oro/oculo-nasal route and the first site of replication is the respiratory epithelium.", [["oro", "ANATOMY", 28, 31], ["nasal", "ANATOMY", 38, 43], ["respiratory epithelium", "ANATOMY", 91, 113], ["IBV", "ORGANISM", 0, 3], ["respiratory epithelium", "TISSUE", 91, 113], ["IBV", "SPECIES", 0, 3], ["IBV", "TREATMENT", 0, 3], ["the oro/oculo-nasal route", "TREATMENT", 24, 49], ["the respiratory epithelium", "PROBLEM", 87, 113], ["nasal", "ANATOMY", 38, 43], ["replication", "OBSERVATION", 72, 83], ["respiratory epithelium", "OBSERVATION", 91, 113]]], ["From there the virus infection can spread to several organs, including kidney and reproductive tract (reviewed in [2] ).", [["organs", "ANATOMY", 53, 59], ["kidney", "ANATOMY", 71, 77], ["reproductive tract", "ANATOMY", 82, 100], ["infection", "DISEASE", 21, 30], ["kidney and reproductive tract", "DISEASE", 71, 100], ["organs", "ORGAN", 53, 59], ["kidney", "ORGAN", 71, 77], ["reproductive tract", "ORGANISM_SUBDIVISION", 82, 100], ["the virus infection", "PROBLEM", 11, 30], ["kidney and reproductive tract", "PROBLEM", 71, 100], ["virus", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["kidney", "ANATOMY", 71, 77], ["reproductive tract", "ANATOMY", 82, 100]]], ["Secondary pathogens can complicate the disease resulting in increased morbidity and mortality.IntroductionThe tissue tropism of viruses may be determined by several factors including the distribution of the cellular receptor for the virus.", [["tissue", "ANATOMY", 110, 116], ["cellular", "ANATOMY", 207, 215], ["tissue", "TISSUE", 110, 116], ["cellular", "CELL", 207, 215], ["cellular receptor", "PROTEIN", 207, 224], ["Secondary pathogens", "PROBLEM", 0, 19], ["the disease", "PROBLEM", 35, 46], ["increased morbidity", "PROBLEM", 60, 79], ["The tissue tropism of viruses", "PROBLEM", 106, 135], ["the cellular receptor", "TREATMENT", 203, 224], ["the virus", "PROBLEM", 229, 238], ["disease", "OBSERVATION", 39, 46], ["increased", "OBSERVATION_MODIFIER", 60, 69], ["morbidity", "OBSERVATION", 70, 79], ["tissue tropism", "OBSERVATION", 110, 124], ["viruses", "OBSERVATION", 128, 135]]], ["In the case of coronaviruses, the surface protein S is responsible for attachment to cells.", [["surface", "ANATOMY", 34, 41], ["cells", "ANATOMY", 85, 90], ["coronaviruses", "ORGANISM", 15, 28], ["cells", "CELL", 85, 90], ["surface protein S", "PROTEIN", 34, 51], ["coronaviruses", "PROBLEM", 15, 28], ["the surface protein S", "TEST", 30, 51], ["attachment to cells", "PROBLEM", 71, 90], ["coronaviruses", "OBSERVATION", 15, 28]]], ["The S protein has not only receptor-binding activity, it also mediates the fusion of the viral lipid envelope with the cellular membrane.", [["cellular membrane", "ANATOMY", 119, 136], ["cellular membrane", "CELLULAR_COMPONENT", 119, 136], ["S protein", "PROTEIN", 4, 13], ["The S protein", "TEST", 0, 13], ["binding activity", "OBSERVATION", 36, 52], ["fusion", "OBSERVATION", 75, 81], ["viral lipid envelope", "OBSERVATION", 89, 109], ["cellular membrane", "OBSERVATION", 119, 136]]], ["For several coronaviruses specific proteins have been described that serve as cellular receptors for the initiation of infection.", [["cellular", "ANATOMY", 78, 86], ["infection", "DISEASE", 119, 128], ["cellular", "CELL", 78, 86], ["cellular receptors", "PROTEIN", 78, 96], ["several coronaviruses specific proteins", "PROBLEM", 4, 43], ["cellular receptors", "TREATMENT", 78, 96], ["infection", "PROBLEM", 119, 128], ["infection", "OBSERVATION", 119, 128]]], ["Angiotensin-converting enzyme 2 has been identified as a receptor for SARS coronavirus [3, 4] and several group 1 coronaviruses including transmissible gastroenteritis virus require aminopeptidase N to enter their host cells [5, 6] .", [["cells", "ANATOMY", 219, 224], ["Angiotensin", "CHEMICAL", 0, 11], ["SARS coronavirus", "DISEASE", 70, 86], ["transmissible gastroenteritis", "DISEASE", 138, 167], ["Angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 0, 31], ["SARS coronavirus", "ORGANISM", 70, 86], ["1 coronaviruses", "ORGANISM", 112, 127], ["transmissible gastroenteritis virus", "ORGANISM", 138, 173], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 182, 198], ["cells", "CELL", 219, 224], ["Angiotensin-converting enzyme 2", "PROTEIN", 0, 31], ["aminopeptidase N", "PROTEIN", 182, 198], ["host cells", "CELL_TYPE", 214, 224], ["transmissible gastroenteritis virus", "SPECIES", 138, 173], ["SARS coronavirus", "SPECIES", 70, 86], ["transmissible gastroenteritis virus", "SPECIES", 138, 173], ["Angiotensin", "TREATMENT", 0, 11], ["converting enzyme", "TEST", 12, 29], ["SARS coronavirus", "PROBLEM", 70, 86], ["several group 1 coronaviruses", "PROBLEM", 98, 127], ["transmissible gastroenteritis virus", "PROBLEM", 138, 173], ["aminopeptidase N", "TREATMENT", 182, 198]]], ["A protein receptor has not been identified so far for IBV.", [["IBV", "ORGANISM", 54, 57], ["protein receptor", "PROTEIN", 2, 18], ["IBV", "SPECIES", 54, 57], ["A protein receptor", "TREATMENT", 0, 18], ["IBV", "PROBLEM", 54, 57]]], ["Recently we demonstrated that a2,3-linked sialic acids serve as receptor determinants on Vero-cells and primary chicken embryo kidney cells [7] .", [["Vero-cells", "ANATOMY", 89, 99], ["embryo kidney cells", "ANATOMY", 120, 139], ["sialic acids", "CHEMICAL", 42, 54], ["sialic acids", "CHEMICAL", 42, 54], ["a2,3-linked sialic acids", "SIMPLE_CHEMICAL", 30, 54], ["Vero-cells", "CELL", 89, 99], ["chicken", "ORGANISM", 112, 119], ["embryo kidney cells", "CELL", 120, 139], ["a2,3", "PROTEIN", 30, 34], ["Vero-cells", "CELL_LINE", 89, 99], ["primary chicken embryo kidney cells", "CELL_TYPE", 104, 139], ["chicken", "SPECIES", 112, 119], ["chicken", "SPECIES", 112, 119], ["linked sialic acids", "PROBLEM", 35, 54], ["Vero-cells", "TREATMENT", 89, 99], ["primary chicken embryo kidney cells", "PROBLEM", 104, 139], ["embryo kidney cells", "OBSERVATION", 120, 139]]], ["Here we show that sialic acids also play a role in the infection of the avian respiratory epithelium by IBV.Preparation of TOCsTracheas were prepared from 20-day-old SPF chicken embryos (Lohmann, Cuxhaven, Germany) and, after removing connective tissue, were cut manually into approximately 1 mm thick rings by using a microtome blade.", [["respiratory epithelium", "ANATOMY", 78, 100], ["embryos", "ANATOMY", 178, 185], ["connective tissue", "ANATOMY", 235, 252], ["sialic acids", "CHEMICAL", 18, 30], ["infection", "DISEASE", 55, 64], ["sialic acids", "CHEMICAL", 18, 30], ["sialic acids", "SIMPLE_CHEMICAL", 18, 30], ["avian", "ORGANISM", 72, 77], ["respiratory epithelium", "TISSUE", 78, 100], ["IBV", "ORGANISM", 104, 107], ["TOCsTracheas", "SIMPLE_CHEMICAL", 123, 135], ["SPF", "ORGANISM", 166, 169], ["chicken", "ORGANISM", 170, 177], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 178, 185], ["connective tissue", "TISSUE", 235, 252], ["chicken", "SPECIES", 170, 177], ["IBV", "SPECIES", 104, 107], ["chicken", "SPECIES", 170, 177], ["sialic acids", "TREATMENT", 18, 30], ["the infection", "PROBLEM", 51, 64], ["the avian respiratory epithelium", "PROBLEM", 68, 100], ["TOCsTracheas", "TREATMENT", 123, 135], ["connective tissue", "TREATMENT", 235, 252], ["a microtome blade", "TREATMENT", 317, 334], ["infection", "OBSERVATION", 55, 64], ["respiratory epithelium", "OBSERVATION", 78, 100], ["connective tissue", "ANATOMY", 235, 252]]], ["Individual rings were transferred into 5 ml tubes (Sarstedt, N\u00fcmbrecht, Germany) containing 0.5 ml of Medium 199 with Hanks salts (Biochrom, Berlin, Germany) and incubated at 37 C on a rotator.", [["Hanks salts", "CHEMICAL", 118, 129], ["Individual rings", "TREATMENT", 0, 16], ["5 ml tubes", "TREATMENT", 39, 49], ["rotator", "ANATOMY", 185, 192]]], ["The next day, TOCs were screened for 100% ciliary activity (see Section 2.5).VirusesStock virus of the IBV strains M41 and B1648 were obtained by inoculating embryonated SPF chicken eggs.", [["ciliary", "ANATOMY", 42, 49], ["eggs", "ANATOMY", 182, 186], ["ciliary", "MULTI-TISSUE_STRUCTURE", 42, 49], ["VirusesStock virus", "ORGANISM", 77, 95], ["IBV strains M41", "ORGANISM", 103, 118], ["B1648", "CELL", 123, 128], ["chicken", "ORGANISM", 174, 181], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 182, 186], ["IBV", "SPECIES", 103, 106], ["chicken", "SPECIES", 174, 181], ["VirusesStock virus", "SPECIES", 77, 95], ["IBV strains M41", "SPECIES", 103, 118], ["SPF", "SPECIES", 170, 173], ["chicken", "SPECIES", 174, 181], ["TOCs", "TEST", 14, 18], ["VirusesStock virus", "PROBLEM", 77, 95], ["the IBV strains M41", "TEST", 99, 118]]], ["Following incubation at 37 C, the allantoic fluid was collected, clarified by low speed centrifugation and stored at \u00c080 C. Strain Beaudette of IBV was propagated in Vero cells.", [["allantoic fluid", "ANATOMY", 34, 49], ["Vero cells", "ANATOMY", 166, 176], ["allantoic fluid", "ORGANISM_SUBSTANCE", 34, 49], ["IBV", "ORGANISM", 144, 147], ["Vero cells", "CELL", 166, 176], ["Vero cells", "CELL_LINE", 166, 176], ["IBV", "SPECIES", 144, 147], ["the allantoic fluid", "TEST", 30, 49], ["IBV", "PROBLEM", 144, 147], ["Vero cells", "OBSERVATION", 166, 176]]], ["Supernatants of infected cell cultures were harvested, clarified by low speed centrifugation and stored at \u00c080 C. All IBV strains were kindly provided by Dave Cavanagh, Institute for Animal Health, Compton, UK.", [["Supernatants", "ANATOMY", 0, 12], ["cell cultures", "ANATOMY", 25, 38], ["cell cultures", "CELL", 25, 38], ["IBV", "ORGANISM", 118, 121], ["infected cell cultures", "CELL_LINE", 16, 38], ["IBV", "SPECIES", 118, 121], ["infected cell cultures", "PROBLEM", 16, 38], ["infected cell cultures", "OBSERVATION", 16, 38], ["low speed", "OBSERVATION_MODIFIER", 68, 77]]], ["Avian metapneumovirus subtype A, employed as a control virus, was kindly provided by Silke Rautenschlein, University of Veterinary Medicine, Hannover, Germany.Neuraminidase treatment and virus infection of TOCsTOCs were washed with PBS prior to addition of neuraminidase from Clostridium perfringens (Type 6) or Streptococcus pneumoniae (SigmaeAldrich, St. Louis, MO, USA) using MES (2[N-morpholino]ethanesulfonic acid) buffer as a diluant.", [["Avian metapneumovirus subtype A", "DISEASE", 0, 31], ["Neuraminidase", "CHEMICAL", 159, 172], ["infection", "DISEASE", 193, 202], ["Clostridium perfringens", "DISEASE", 276, 299], ["MES", "CHEMICAL", 379, 382], ["2[N-morpholino]ethanesulfonic acid", "CHEMICAL", 384, 418], ["2[N-morpholino]ethanesulfonic acid", "CHEMICAL", 384, 418], ["Avian metapneumovirus", "ORGANISM", 0, 21], ["Neuraminidase", "SIMPLE_CHEMICAL", 159, 172], ["TOCsTOCs", "SIMPLE_CHEMICAL", 206, 214], ["Clostridium perfringens", "ORGANISM", 276, 299], ["Type 6", "ORGANISM", 301, 307], ["Streptococcus pneumoniae", "ORGANISM", 312, 336], ["St. Louis", "ORGANISM", 353, 362], ["2[N-morpholino]ethanesulfonic acid", "SIMPLE_CHEMICAL", 384, 418], ["neuraminidase", "PROTEIN", 257, 270], ["Avian metapneumovirus", "SPECIES", 0, 21], ["Clostridium perfringens", "SPECIES", 276, 299], ["Streptococcus pneumoniae", "SPECIES", 312, 336], ["Avian metapneumovirus subtype A", "SPECIES", 0, 31], ["Clostridium perfringens", "SPECIES", 276, 299], ["Streptococcus pneumoniae", "SPECIES", 312, 336], ["Avian metapneumovirus subtype A", "PROBLEM", 0, 31], ["Neuraminidase treatment", "TREATMENT", 159, 182], ["virus infection of TOCsTOCs", "PROBLEM", 187, 214], ["PBS", "TREATMENT", 232, 235], ["neuraminidase", "TREATMENT", 257, 270], ["Clostridium perfringens", "PROBLEM", 276, 299], ["Streptococcus pneumoniae", "PROBLEM", 312, 336], ["MES (2[N-morpholino]ethanesulfonic acid)", "TREATMENT", 379, 419], ["metapneumovirus", "OBSERVATION", 6, 21], ["Clostridium perfringens", "OBSERVATION", 276, 299], ["Streptococcus pneumoniae", "OBSERVATION", 312, 336]]], ["If not otherwise indicated TOCs were incubated with 50 mU neuraminidase per ring.", [["TOCs", "SIMPLE_CHEMICAL", 27, 31], ["TOCs", "PROTEIN", 27, 31], ["50 mU neuraminidase per ring", "TREATMENT", 52, 80]]], ["After incubation at 37 C for 1 h, the TOCs were washed three times with PBS and infected by IBV-Beaudette (10 4 pfu/ring) or any of the other viruses for 1 h at 37 C. Following three washes with PBS, the TOCs were incubated with medium at 37 C on a rotator.", [["TOCs", "ANATOMY", 38, 42], ["TOCs", "ANATOMY", 204, 208], ["IBV-Beaudette", "CHEMICAL", 92, 105], ["TOCs", "SIMPLE_CHEMICAL", 38, 42], ["IBV-Beaudette", "ORGANISM", 92, 105], ["TOCs", "SIMPLE_CHEMICAL", 204, 208], ["IBV", "SPECIES", 92, 95], ["PBS", "TREATMENT", 72, 75], ["the other viruses", "PROBLEM", 132, 149], ["PBS", "TREATMENT", 195, 198], ["a rotator", "TREATMENT", 247, 256]]], ["For all experiments groups of four TOCs were used to estimate the mean ciliary activity.", [["ciliary", "ANATOMY", 71, 78], ["ciliary", "MULTI-TISSUE_STRUCTURE", 71, 78], ["four TOCs", "TREATMENT", 30, 39], ["ciliary activity", "OBSERVATION", 71, 87]]], ["All experiments were performed in triplicate.Neuraminidase treatmentEach ring of TOC was suspended in 100 ml medium 199 containing 50 mU neuraminidase of Clostridium perfringens and in some cases 2.5 mg of the neuraminidase inhibitor DANA (2,3-didehydro-2-deoxyneuraminic acid).", [["TOC", "CHEMICAL", 81, 84], ["Clostridium perfringens", "DISEASE", 154, 177], ["DANA", "CHEMICAL", 234, 238], ["2,3-didehydro-2-deoxyneuraminic acid", "CHEMICAL", 240, 276], ["TOC", "CHEMICAL", 81, 84], ["DANA", "CHEMICAL", 234, 238], ["2,3-didehydro-2-deoxyneuraminic acid", "CHEMICAL", 240, 276], ["Neuraminidase", "SIMPLE_CHEMICAL", 45, 58], ["TOC", "SIMPLE_CHEMICAL", 81, 84], ["Clostridium perfringens", "ORGANISM", 154, 177], ["DANA", "SIMPLE_CHEMICAL", 234, 238], ["2,3-didehydro-2-deoxyneuraminic acid", "SIMPLE_CHEMICAL", 240, 276], ["Clostridium perfringens", "SPECIES", 154, 177], ["Clostridium perfringens", "SPECIES", 154, 177], ["Neuraminidase treatment", "TREATMENT", 45, 68], ["Each ring of TOC", "TREATMENT", 68, 84], ["Clostridium perfringens", "PROBLEM", 154, 177], ["the neuraminidase inhibitor DANA", "TREATMENT", 206, 238], ["didehydro", "TREATMENT", 244, 253], ["deoxyneuraminic acid", "TREATMENT", 256, 276]]], ["After incubation for 1 h at 37 C TOCs were washed and infected by the Beaudette strain with 10 4 pfu/ring.Ciliary activity assayTOCs were analyzed daily with a microscope to estimate the ciliary activity.", [["Ciliary", "ANATOMY", 106, 113], ["ciliary", "ANATOMY", 187, 194], ["ciliary", "MULTI-TISSUE_STRUCTURE", 187, 194], ["Ciliary activity assayTOCs", "TREATMENT", 106, 132], ["a microscope", "TEST", 158, 170], ["ciliary activity", "OBSERVATION", 187, 203]]], ["Rings were virtually divided into 10 parts and each part was monitored for ciliary movement.", [["ciliary", "ANATOMY", 75, 82], ["Rings", "GENE_OR_GENE_PRODUCT", 0, 5], ["ciliary", "MULTI-TISSUE_STRUCTURE", 75, 82], ["Rings", "TREATMENT", 0, 5]]], ["Only rings with a starting ciliary activity of 100% were used for the experiments.InfectivityGroups of five TOCs were infected in triplicate by 2 \u00c2 10 4 pfu of IBV.", [["ciliary", "ANATOMY", 27, 34], ["TOCs", "ANATOMY", 108, 112], ["rings", "MULTI-TISSUE_STRUCTURE", 5, 10], ["ciliary", "MULTI-TISSUE_STRUCTURE", 27, 34], ["TOCs", "CANCER", 108, 112], ["IBV", "ORGANISM", 160, 163], ["IBV", "SPECIES", 160, 163], ["a starting ciliary activity", "TREATMENT", 16, 43], ["IBV", "TREATMENT", 160, 163], ["infected", "OBSERVATION", 118, 126]]], ["At 24 h post infection, the supernatants were collected and titrated on primary chick kidney cells as described previously [7] .", [["supernatants", "ANATOMY", 28, 40], ["kidney cells", "ANATOMY", 86, 98], ["chick", "ORGANISM", 80, 85], ["kidney cells", "CELL", 86, 98], ["primary chick kidney cells", "CELL_TYPE", 72, 98], ["infection", "PROBLEM", 13, 22], ["the supernatants", "TEST", 24, 40], ["primary chick kidney cells", "TREATMENT", 72, 98], ["infection", "OBSERVATION", 13, 22], ["kidney", "ANATOMY", 86, 92]]], ["Plaques were visualized by immunofluorescence using a polyclonal anti-IBV serum raised in rabbits.Preparation of cryosectionsTracheas were prepared from three-week old SPF chickens (Lohmann, Cuxhaven, Germany).", [["Plaques", "ANATOMY", 0, 7], ["serum", "ANATOMY", 74, 79], ["cryosections", "ANATOMY", 113, 125], ["Tracheas", "ANATOMY", 125, 133], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["rabbits", "ORGANISM", 90, 97], ["Tracheas", "CELL", 125, 133], ["chickens", "ORGANISM", 172, 180], ["rabbits", "SPECIES", 90, 97], ["chickens", "SPECIES", 172, 180], ["anti-IBV", "SPECIES", 65, 73], ["rabbits", "SPECIES", 90, 97], ["chickens", "SPECIES", 172, 180], ["Plaques", "PROBLEM", 0, 7], ["immunofluorescence", "TEST", 27, 45], ["a polyclonal anti-IBV serum", "TEST", 52, 79], ["cryosections", "TEST", 113, 125], ["Tracheas", "TREATMENT", 125, 133]]], ["They were cut into rings approximately 1 cm thick.", [["rings", "OBSERVATION_MODIFIER", 19, 24], ["approximately", "OBSERVATION_MODIFIER", 25, 38], ["1 cm", "OBSERVATION_MODIFIER", 39, 43]]], ["The rings were washed with PBS and either infected by IBV-Beaudette (1 \u00c2 10 5 pfu/ring) for 1 h at 37 C. or subjected to neuraminidase treatment and lectin staining.", [["rings", "ANATOMY", 4, 9], ["IBV-Beaudette", "CHEMICAL", 54, 67], ["IBV", "ORGANISM", 54, 57], ["lectin", "GENE_OR_GENE_PRODUCT", 149, 155], ["neuraminidase", "PROTEIN", 121, 134], ["lectin", "PROTEIN", 149, 155], ["IBV", "SPECIES", 54, 57], ["The rings", "TREATMENT", 0, 9], ["PBS", "TREATMENT", 27, 30], ["neuraminidase treatment", "TREATMENT", 121, 144], ["lectin staining", "PROBLEM", 149, 164], ["rings", "OBSERVATION_MODIFIER", 4, 9]]], ["Infected TOCs were incubated in Medium 199 (Biochrom, Berlin, Germany) at 37 C. After 24 h, they were mounted on small filter papers with tissue freezing medium (Jung, Heidelberg, Germany) and frozen in liquid nitrogen.", [["TOCs", "ANATOMY", 9, 13], ["tissue", "ANATOMY", 138, 144], ["nitrogen", "CHEMICAL", 210, 218], ["TOCs", "CELL", 9, 13], ["Biochrom", "ORGANISM_SUBSTANCE", 44, 52], ["tissue", "TISSUE", 138, 144], ["TOCs", "CELL_TYPE", 9, 13], ["Infected TOCs", "PROBLEM", 0, 13], ["tissue freezing medium", "TREATMENT", 138, 160], ["frozen in liquid nitrogen", "TREATMENT", 193, 218], ["small", "OBSERVATION_MODIFIER", 113, 118], ["filter", "OBSERVATION", 119, 125]]], ["Neuraminidase treatment was performed by incubation with 500 ml Medium199 containing 200 mU neuraminidase from Clostridium perfringens for 1 h at 37 C, before freezing in liquid nitrogen.", [["nitrogen", "CHEMICAL", 178, 186], ["Neuraminidase", "SIMPLE_CHEMICAL", 0, 13], ["Clostridium perfringens", "ORGANISM", 111, 134], ["Clostridium perfringens", "SPECIES", 111, 134], ["Clostridium perfringens", "SPECIES", 111, 134], ["Neuraminidase treatment", "TREATMENT", 0, 23], ["Clostridium perfringens", "PROBLEM", 111, 134], ["freezing in liquid nitrogen", "TREATMENT", 159, 186]]], ["The frozen organs were stored at \u00c020 C until they were cut with a cryostat.Immunofluorescence analysisCryosections were fixed with ice-cold acetone for 10 min followed by air drying for another 10 min.", [["organs", "ANATOMY", 11, 17], ["ice-cold acetone", "CHEMICAL", 131, 147], ["acetone", "CHEMICAL", 140, 147], ["organs", "ORGAN", 11, 17], ["a cryostat", "TREATMENT", 64, 74], ["Immunofluorescence analysisCryosections", "TEST", 75, 114], ["ice-cold acetone", "TREATMENT", 131, 147]]], ["The antibodies or lectins were diluted in 1% bovine serum albumin and sections were incubated with antibodies or lectins for 1 h at room temperature in an incubation chamber.", [["serum", "ANATOMY", 52, 57], ["sections", "ANATOMY", 70, 78], ["bovine", "ORGANISM", 45, 51], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["albumin", "GENE_OR_GENE_PRODUCT", 58, 65], ["sections", "MULTI-TISSUE_STRUCTURE", 70, 78], ["antibodies", "PROTEIN", 4, 14], ["lectins", "PROTEIN", 18, 25], ["antibodies", "PROTEIN", 99, 109], ["bovine", "SPECIES", 45, 51], ["bovine", "SPECIES", 45, 51], ["The antibodies", "TREATMENT", 0, 14], ["lectins", "TREATMENT", 18, 25], ["1% bovine serum albumin", "TREATMENT", 42, 65], ["antibodies", "TREATMENT", 99, 109]]], ["After three washing steps with PBS, the sections were incubated with appropriate second antibodies for 1 h at room temperature in the dark.", [["sections", "ANATOMY", 40, 48], ["PBS", "TREATMENT", 31, 34], ["the sections", "TEST", 36, 48]]], ["Virus antigen was stained with polyclonal anti-IBV Beaudette serum raised in rabbits.", [["serum", "ANATOMY", 61, 66], ["Virus", "ORGANISM", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["rabbits", "ORGANISM", 77, 84], ["Virus antigen", "PROTEIN", 0, 13], ["rabbits", "SPECIES", 77, 84], ["anti-IBV", "SPECIES", 42, 50], ["rabbits", "SPECIES", 77, 84], ["Virus antigen", "TEST", 0, 13], ["polyclonal anti-IBV Beaudette serum", "TEST", 31, 66]]], ["Sialic acids were detected with lectins from Maackia amurensis (binding to a2,3 linked sialic acids) or Sambucus nigra agglutinin (binding to a2,6 linked sialic acids) labeled with digoxigenin (DIG Glycan Differentiation kit, Roche, Basel, Switzerland).", [["Sialic acids", "CHEMICAL", 0, 12], ["sialic acids", "CHEMICAL", 87, 99], ["sialic acids", "CHEMICAL", 154, 166], ["Sialic acids", "CHEMICAL", 0, 12], ["sialic acids", "CHEMICAL", 87, 99], ["sialic acids", "CHEMICAL", 154, 166], ["digoxigenin", "CHEMICAL", 181, 192], ["Sialic acids", "SIMPLE_CHEMICAL", 0, 12], ["Maackia amurensis", "ORGANISM", 45, 62], ["a2,3 linked sialic acids", "SIMPLE_CHEMICAL", 75, 99], ["Sambucus nigra agglutinin", "ORGANISM", 104, 129], ["a2,6 linked sialic acids", "SIMPLE_CHEMICAL", 142, 166], ["digoxigenin", "SIMPLE_CHEMICAL", 181, 192], ["lectins", "PROTEIN", 32, 39], ["Sambucus nigra agglutinin", "PROTEIN", 104, 129], ["binding to a2,6 linked sialic acids", "PROTEIN", 131, 166], ["Maackia amurensis", "SPECIES", 45, 62], ["Sambucus nigra", "SPECIES", 104, 118], ["Maackia amurensis", "SPECIES", 45, 62], ["Sambucus nigra", "SPECIES", 104, 118], ["Sialic acids", "TREATMENT", 0, 12], ["lectins from Maackia amurensis", "PROBLEM", 32, 62], ["sialic acids", "TEST", 87, 99], ["Sambucus nigra agglutinin", "PROBLEM", 104, 129], ["sialic acids", "TEST", 154, 166], ["digoxigenin", "TREATMENT", 181, 192]]], ["Mucus producing goblet cells were stained with anti MUC-5AC antibody (Acris, Hiddenhausen, Germany).", [["Mucus", "ANATOMY", 0, 5], ["goblet cells", "ANATOMY", 16, 28], ["Mucus", "ORGANISM_SUBSTANCE", 0, 5], ["goblet cells", "CELL", 16, 28], ["MUC-5AC", "GENE_OR_GENE_PRODUCT", 52, 59], ["Mucus producing goblet cells", "CELL_TYPE", 0, 28], ["anti MUC-5AC antibody", "PROTEIN", 47, 68], ["Mucus producing goblet cells", "PROBLEM", 0, 28], ["anti MUC", "TEST", 47, 55], ["goblet cells", "OBSERVATION", 16, 28]]], ["Bound antibodies or lectins were visualized by FITC-and Cy3-labeled anti-rabbit (SigmaeAldrich), anti-mouse (Acris) or anti-digoxigenin antibodies (Roche).", [["FITC", "CHEMICAL", 47, 51], ["FITC", "SIMPLE_CHEMICAL", 47, 51], ["Cy3", "SIMPLE_CHEMICAL", 56, 59], ["SigmaeAldrich", "SIMPLE_CHEMICAL", 81, 94], ["Acris", "SIMPLE_CHEMICAL", 109, 114], ["anti-digoxigenin antibodies", "SIMPLE_CHEMICAL", 119, 146], ["Bound antibodies", "PROTEIN", 0, 16], ["lectins", "PROTEIN", 20, 27], ["FITC-and Cy3-labeled anti-rabbit (SigmaeAldrich), anti-mouse", "PROTEIN", 47, 107], ["Acris", "PROTEIN", 109, 114], ["anti-digoxigenin antibodies", "PROTEIN", 119, 146], ["anti-rabbit", "SPECIES", 68, 79], ["anti-mouse", "SPECIES", 97, 107], ["Bound antibodies", "TEST", 0, 16], ["lectins", "TEST", 20, 27], ["FITC", "TEST", 47, 51], ["Cy3-labeled anti-rabbit (SigmaeAldrich)", "TREATMENT", 56, 95], ["anti-mouse (Acris", "TREATMENT", 97, 114], ["anti-digoxigenin antibodies", "PROBLEM", 119, 146]]], ["Cilia were detected by CY3 labeled anti-b-tubulin antibody (SigmaeAldrich).", [["Cilia", "ANATOMY", 0, 5], ["Cilia", "MULTI-TISSUE_STRUCTURE", 0, 5], ["CY3", "SIMPLE_CHEMICAL", 23, 26], ["anti-b-tubulin antibody", "GENE_OR_GENE_PRODUCT", 35, 58], ["CY3", "PROTEIN", 23, 26], ["anti-b-tubulin antibody", "PROTEIN", 35, 58], ["SigmaeAldrich", "PROTEIN", 60, 73]]], ["Fluorescence microscopy was performed with a Leica inverted-2 confocal microscope.Effect of neuraminidase treatment on the infection of tracheal organ cultures (TOCs) by IBVAfter having shown recently that sialic acid serves as a receptor determinant for IBV on cultured cells, we were interested to find out whether this type of sugar is also important for an infection in vivo.", [["tracheal organ cultures", "ANATOMY", 136, 159], ["TOCs", "ANATOMY", 161, 165], ["cells", "ANATOMY", 271, 276], ["infection", "DISEASE", 123, 132], ["sialic acid", "CHEMICAL", 206, 217], ["infection", "DISEASE", 361, 370], ["sialic acid", "CHEMICAL", 206, 217], ["sugar", "CHEMICAL", 330, 335], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 92, 105], ["tracheal organ cultures", "CELL", 136, 159], ["sialic acid", "SIMPLE_CHEMICAL", 206, 217], ["IBV", "ORGANISM", 255, 258], ["cells", "CELL", 271, 276], ["sugar", "SIMPLE_CHEMICAL", 330, 335], ["neuraminidase", "PROTEIN", 92, 105], ["tracheal organ cultures", "CELL_LINE", 136, 159], ["cultured cells", "CELL_LINE", 262, 276], ["IBV", "SPECIES", 255, 258], ["Fluorescence microscopy", "TEST", 0, 23], ["a Leica inverted", "TREATMENT", 43, 59], ["neuraminidase treatment", "TREATMENT", 92, 115], ["the infection", "PROBLEM", 119, 132], ["tracheal organ cultures", "TEST", 136, 159], ["sialic acid serves", "TREATMENT", 206, 224], ["IBV on cultured cells", "TREATMENT", 255, 276], ["this type of sugar", "PROBLEM", 317, 335], ["an infection in vivo", "PROBLEM", 358, 378], ["tracheal organ", "ANATOMY", 136, 150], ["infection", "OBSERVATION", 361, 370]]], ["To address this question we chose TOCs as a model for the upper respiratory epithelium.", [["upper respiratory epithelium", "ANATOMY", 58, 86], ["TOCs", "GENE_OR_GENE_PRODUCT", 34, 38], ["upper respiratory epithelium", "TISSUE", 58, 86], ["the upper respiratory epithelium", "PROBLEM", 54, 86], ["upper", "ANATOMY_MODIFIER", 58, 63], ["respiratory epithelium", "ANATOMY", 64, 86]]], ["The trachea of chicken embryos was cut into pieces about 1 mm thick.", [["trachea", "ANATOMY", 4, 11], ["embryos", "ANATOMY", 23, 30], ["trachea", "MULTI-TISSUE_STRUCTURE", 4, 11], ["chicken", "ORGANISM", 15, 22], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 23, 30], ["chicken", "SPECIES", 15, 22], ["chicken", "SPECIES", 15, 22], ["trachea", "ANATOMY", 4, 11], ["chicken embryos", "OBSERVATION", 15, 30]]], ["Tracheal rings chosen for this analysis showed ciliary activity along the whole contact area of the epithelium with the lumen of the trachea, i.e. 360 of the tracheal ring.", [["Tracheal rings", "ANATOMY", 0, 14], ["ciliary", "ANATOMY", 47, 54], ["epithelium", "ANATOMY", 100, 110], ["lumen", "ANATOMY", 120, 125], ["trachea", "ANATOMY", 133, 140], ["tracheal ring", "ANATOMY", 158, 171], ["Tracheal rings", "MULTI-TISSUE_STRUCTURE", 0, 14], ["ciliary", "MULTI-TISSUE_STRUCTURE", 47, 54], ["epithelium", "TISSUE", 100, 110], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 120, 125], ["trachea", "ORGAN", 133, 140], ["tracheal ring", "MULTI-TISSUE_STRUCTURE", 158, 171], ["Tracheal rings", "TREATMENT", 0, 14], ["this analysis", "TEST", 26, 39], ["ciliary activity", "PROBLEM", 47, 63], ["the tracheal ring", "TREATMENT", 154, 171], ["rings", "OBSERVATION", 9, 14], ["ciliary activity", "OBSERVATION", 47, 63], ["epithelium", "ANATOMY_MODIFIER", 100, 110], ["lumen", "ANATOMY_MODIFIER", 120, 125], ["trachea", "ANATOMY", 133, 140], ["tracheal", "ANATOMY", 158, 166], ["ring", "ANATOMY_MODIFIER", 167, 171]]], ["Infection of TOCs by IBV results in ciliostasis that can easily be detected microscopically.", [["TOCs", "ANATOMY", 13, 17], ["TOCs", "GENE_OR_GENE_PRODUCT", 13, 17], ["IBV", "ORGANISM", 21, 24], ["IBV", "SPECIES", 21, 24], ["Infection of TOCs", "PROBLEM", 0, 17], ["IBV", "PROBLEM", 21, 24], ["ciliostasis", "PROBLEM", 36, 47]]], ["As shown in Fig. 1 , infection by IBV-Beaudette reduced the portion of the epithelium with ciliary activity.", [["epithelium", "ANATOMY", 75, 85], ["ciliary", "ANATOMY", 91, 98], ["infection", "DISEASE", 21, 30], ["IBV-Beaudette", "ORGANISM", 34, 47], ["epithelium", "TISSUE", 75, 85], ["ciliary", "MULTI-TISSUE_STRUCTURE", 91, 98], ["IBV", "SPECIES", 34, 37], ["infection", "PROBLEM", 21, 30], ["IBV", "PROBLEM", 34, 37], ["Fig", "OBSERVATION", 12, 15], ["infection", "OBSERVATION", 21, 30], ["portion", "ANATOMY_MODIFIER", 60, 67], ["epithelium", "ANATOMY_MODIFIER", 75, 85], ["ciliary activity", "OBSERVATION", 91, 107]]], ["At 2 days post infection (d.p.i.), complete ciliostasis was observed at this experimental setting.", [["infection", "DISEASE", 15, 24], ["infection", "PROBLEM", 15, 24], ["complete ciliostasis", "PROBLEM", 35, 55], ["infection", "OBSERVATION", 15, 24]]], ["To analyze the importance of sialic acids we treated TOCs with neuraminidase from Clostridium perfringens, which releases the sialic acids from the cell surface.", [["cell surface", "ANATOMY", 148, 160], ["sialic acids", "CHEMICAL", 29, 41], ["TOCs", "CHEMICAL", 53, 57], ["sialic acids", "CHEMICAL", 126, 138], ["sialic acids", "CHEMICAL", 29, 41], ["sialic acids", "CHEMICAL", 126, 138], ["sialic acids", "SIMPLE_CHEMICAL", 29, 41], ["TOCs", "SIMPLE_CHEMICAL", 53, 57], ["Clostridium perfringens", "ORGANISM", 82, 105], ["sialic acids", "SIMPLE_CHEMICAL", 126, 138], ["cell surface", "CELLULAR_COMPONENT", 148, 160], ["neuraminidase", "PROTEIN", 63, 76], ["Clostridium perfringens", "SPECIES", 82, 105], ["Clostridium perfringens", "SPECIES", 82, 105], ["sialic acids", "TREATMENT", 29, 41], ["neuraminidase", "TREATMENT", 63, 76], ["Clostridium perfringens", "PROBLEM", 82, 105], ["the sialic acids", "TEST", 122, 138], ["cell surface", "OBSERVATION", 148, 160]]], ["As a result desialylated TOCs were less sensitive to the ciliostatic effect of the IBV infection.", [["IBV infection", "DISEASE", 83, 96], ["TOCs", "SIMPLE_CHEMICAL", 25, 29], ["IBV", "ORGANISM", 83, 86], ["IBV", "SPECIES", 83, 86], ["a result desialylated TOCs", "PROBLEM", 3, 29], ["the IBV infection", "PROBLEM", 79, 96], ["IBV", "ANATOMY", 83, 86], ["infection", "OBSERVATION", 87, 96]]], ["At 5 d.p.i., about 25% of the epithelium still showed ciliary activity.", [["epithelium", "ANATOMY", 30, 40], ["ciliary", "ANATOMY", 54, 61], ["epithelium", "TISSUE", 30, 40], ["ciliary", "MULTI-TISSUE_STRUCTURE", 54, 61], ["ciliary activity", "PROBLEM", 54, 70], ["ciliary activity", "OBSERVATION", 54, 70]]], ["This effect is accounted for by the neuraminidase itself rather than by a contaminant enzyme, because in the presence of a neuraminidase inhibitor the enzyme was unable to protect the tracheal epithelium from the ciliostatic effect of the IBV infection (Fig. 1) .Effect of neuraminidase treatment on the infection of tracheal organ cultures (TOCs) by IBVThe infection of cultured cells by IBV was found to be dependent on a2,3-linked sialic acid.", [["tracheal epithelium", "ANATOMY", 184, 203], ["tracheal organ cultures", "ANATOMY", 317, 340], ["TOCs", "ANATOMY", 342, 346], ["cells", "ANATOMY", 380, 385], ["IBV infection", "DISEASE", 239, 252], ["infection", "DISEASE", 304, 313], ["infection", "DISEASE", 358, 367], ["sialic acid", "CHEMICAL", 434, 445], ["sialic acid", "CHEMICAL", 434, 445], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 36, 49], ["tracheal epithelium", "TISSUE", 184, 203], ["IBV", "ORGANISM", 239, 242], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 273, 286], ["tracheal organ cultures", "CELL", 317, 340], ["cells", "CELL", 380, 385], ["IBV", "ORGANISM", 389, 392], ["a2,3-linked sialic acid", "SIMPLE_CHEMICAL", 422, 445], ["neuraminidase", "PROTEIN", 36, 49], ["neuraminidase", "PROTEIN", 273, 286], ["tracheal organ cultures", "CELL_LINE", 317, 340], ["cultured cells", "CELL_LINE", 371, 385], ["IBV", "SPECIES", 239, 242], ["IBV", "SPECIES", 389, 392], ["the neuraminidase itself", "PROBLEM", 32, 56], ["a contaminant enzyme", "TEST", 72, 92], ["a neuraminidase inhibitor", "TREATMENT", 121, 146], ["the enzyme", "TEST", 147, 157], ["the tracheal epithelium", "PROBLEM", 180, 203], ["the IBV infection", "PROBLEM", 235, 252], ["neuraminidase treatment", "TREATMENT", 273, 296], ["the infection", "PROBLEM", 300, 313], ["tracheal organ cultures", "TEST", 317, 340], ["IBVThe infection of cultured cells", "PROBLEM", 351, 385], ["IBV", "PROBLEM", 389, 392], ["a2,3", "TEST", 422, 426], ["sialic acid", "TEST", 434, 445], ["tracheal", "ANATOMY", 184, 192], ["epithelium", "ANATOMY_MODIFIER", 193, 203], ["IBV", "OBSERVATION_MODIFIER", 239, 242], ["infection", "OBSERVATION", 243, 252], ["neuraminidase", "OBSERVATION", 273, 286], ["tracheal organ", "ANATOMY", 317, 331]]], ["To find out whether there is also a linkage specificity in the infection of the tracheal epithelium, TOCs were treated with neuraminidase from Streptococcus pneumoniae, which has a high preference for cleaving a2,3-linked sialic acid.", [["tracheal epithelium", "ANATOMY", 80, 99], ["TOCs", "ANATOMY", 101, 105], ["infection", "DISEASE", 63, 72], ["sialic acid", "CHEMICAL", 222, 233], ["sialic acid", "CHEMICAL", 222, 233], ["tracheal epithelium", "TISSUE", 80, 99], ["TOCs", "SIMPLE_CHEMICAL", 101, 105], ["Streptococcus pneumoniae", "ORGANISM", 143, 167], ["a2,3-linked sialic acid", "SIMPLE_CHEMICAL", 210, 233], ["TOCs", "CELL_TYPE", 101, 105], ["neuraminidase", "PROTEIN", 124, 137], ["a2,3", "PROTEIN", 210, 214], ["Streptococcus pneumoniae", "SPECIES", 143, 167], ["Streptococcus pneumoniae", "SPECIES", 143, 167], ["a linkage specificity", "PROBLEM", 34, 55], ["the infection of the tracheal epithelium", "PROBLEM", 59, 99], ["neuraminidase", "TREATMENT", 124, 137], ["Streptococcus pneumoniae", "PROBLEM", 143, 167], ["infection", "OBSERVATION", 63, 72], ["tracheal epithelium", "ANATOMY", 80, 99], ["Streptococcus pneumoniae", "OBSERVATION", 143, 167]]], ["As shown in Fig. 2 , incubation with this enzyme protected the epithelial cells from the ciliostatic effect of the IBV infection in the same way as was observed with the neuraminidase from Clostridium perfringens (Fig. 1) .", [["epithelial cells", "ANATOMY", 63, 79], ["IBV infection", "DISEASE", 115, 128], ["epithelial cells", "CELL", 63, 79], ["IBV", "ORGANISM", 115, 118], ["Clostridium perfringens", "ORGANISM", 189, 212], ["epithelial cells", "CELL_TYPE", 63, 79], ["neuraminidase", "PROTEIN", 170, 183], ["Clostridium perfringens", "SPECIES", 189, 212], ["IBV", "SPECIES", 115, 118], ["Clostridium perfringens", "SPECIES", 189, 212], ["this enzyme", "TEST", 37, 48], ["the epithelial cells", "PROBLEM", 59, 79], ["the IBV infection", "PROBLEM", 111, 128], ["the neuraminidase", "TREATMENT", 166, 183], ["Clostridium perfringens", "PROBLEM", 189, 212], ["Fig", "OBSERVATION", 12, 15], ["epithelial cells", "OBSERVATION", 63, 79], ["IBV", "OBSERVATION_MODIFIER", 115, 118], ["infection", "OBSERVATION", 119, 128]]], ["From this result we conclude that a2,3-linked sialic acid serves as a receptor determinant for the infection of avian tracheal epithelial cells by the Beaudette strain of IBV.Strain-dependent differencesThe Beaudette strain of IBV has been adapted to grow in cultured cells of non-avian origin, such as Vero cells.", [["tracheal epithelial cells", "ANATOMY", 118, 143], ["cells", "ANATOMY", 268, 273], ["Vero cells", "ANATOMY", 303, 313], ["a2,3-linked sialic acid", "CHEMICAL", 34, 57], ["infection", "DISEASE", 99, 108], ["sialic acid", "CHEMICAL", 46, 57], ["a2,3-linked sialic acid", "SIMPLE_CHEMICAL", 34, 57], ["avian", "ORGANISM", 112, 117], ["tracheal epithelial cells", "CELL", 118, 143], ["IBV", "ORGANISM", 171, 174], ["IBV", "ORGANISM", 227, 230], ["cells", "CELL", 268, 273], ["Vero cells", "CELL", 303, 313], ["avian tracheal epithelial cells", "CELL_TYPE", 112, 143], ["cultured cells", "CELL_LINE", 259, 273], ["Vero cells", "CELL_LINE", 303, 313], ["IBV", "SPECIES", 171, 174], ["IBV", "SPECIES", 227, 230], ["linked sialic acid serves", "PROBLEM", 39, 64], ["the infection of avian tracheal epithelial cells", "PROBLEM", 95, 143], ["IBV", "PROBLEM", 171, 174], ["Strain-dependent differences", "PROBLEM", 175, 203], ["The Beaudette strain of IBV", "PROBLEM", 203, 230], ["Vero cells", "PROBLEM", 303, 313], ["infection", "OBSERVATION", 99, 108], ["tracheal", "ANATOMY", 118, 126], ["epithelial cells", "OBSERVATION", 127, 143], ["dependent", "OBSERVATION_MODIFIER", 182, 191], ["differences", "OBSERVATION_MODIFIER", 192, 203], ["IBV", "OBSERVATION", 227, 230], ["Vero cells", "OBSERVATION", 303, 313]]], ["To demonstrate that the sialic acid-dependent infection of tracheal epithelial cells is a general feature of IBV, we included two other strains.", [["tracheal epithelial cells", "ANATOMY", 59, 84], ["infection", "DISEASE", 46, 55], ["sialic acid-dependent", "SIMPLE_CHEMICAL", 24, 45], ["tracheal epithelial cells", "CELL", 59, 84], ["IBV", "ORGANISM", 109, 112], ["tracheal epithelial cells", "CELL_TYPE", 59, 84], ["IBV", "SPECIES", 109, 112], ["the sialic acid-dependent infection of tracheal epithelial cells", "PROBLEM", 20, 84], ["IBV", "PROBLEM", 109, 112], ["two other strains", "PROBLEM", 126, 143], ["sialic", "OBSERVATION_MODIFIER", 24, 30], ["acid-dependent", "OBSERVATION_MODIFIER", 31, 45], ["infection", "OBSERVATION", 46, 55], ["tracheal epithelial cells", "OBSERVATION", 59, 84]]], ["The M41 strain causes respiratory disease, whereas the B1648 strain has a nephropathogenic potential [8] .", [["respiratory", "ANATOMY", 22, 33], ["respiratory disease", "DISEASE", 22, 41], ["M41 strain", "ORGANISM", 4, 14], ["respiratory disease", "PROBLEM", 22, 41], ["respiratory disease", "OBSERVATION", 22, 41]]], ["After application of an infectious dose of 10 4 pfu per tracheal ring, the IBV strains caused ciliostasis by day 3 (M41), 4 (B1648) or 5 (Beaudette) after infection (Fig. 3AeC) .", [["tracheal ring", "ANATOMY", 56, 69], ["ciliostasis", "DISEASE", 94, 105], ["infection", "DISEASE", 155, 164], ["tracheal ring", "MULTI-TISSUE_STRUCTURE", 56, 69], ["IBV", "ORGANISM", 75, 78], ["IBV", "SPECIES", 75, 78], ["an infectious dose", "TREATMENT", 21, 39], ["tracheal ring", "TREATMENT", 56, 69], ["the IBV strains", "PROBLEM", 71, 86], ["ciliostasis", "PROBLEM", 94, 105], ["infection", "PROBLEM", 155, 164], ["infectious", "OBSERVATION", 24, 34], ["tracheal ring", "ANATOMY", 56, 69], ["infection", "OBSERVATION", 155, 164]]], ["Strain M41 was more pathogenic than the other two strains resulting in a loss of ciliary activity at 2 d.p.i. on 80% of the epithelium in the microscopic field (Fig. 3C) .", [["ciliary", "ANATOMY", 81, 88], ["epithelium", "ANATOMY", 124, 134], ["loss of ciliary activity", "DISEASE", 73, 97], ["ciliary", "MULTI-TISSUE_STRUCTURE", 81, 88], ["epithelium", "TISSUE", 124, 134], ["the other two strains", "PROBLEM", 36, 57], ["a loss of ciliary activity", "PROBLEM", 71, 97], ["more pathogenic", "OBSERVATION_MODIFIER", 15, 30], ["loss", "OBSERVATION_MODIFIER", 73, 77], ["ciliary activity", "OBSERVATION", 81, 97], ["epithelium", "ANATOMY_MODIFIER", 124, 134]]], ["A comparable reduction was observed with the two other strains only 3 days following infection of TOCs (Fig. 3A and B) .", [["infection", "DISEASE", 85, 94], ["B", "CELL", 116, 117], ["A comparable reduction", "TREATMENT", 0, 22], ["infection of TOCs", "PROBLEM", 85, 102], ["reduction", "OBSERVATION", 13, 22]]], ["For all three strains, a protective effect of neuraminidase treatment was found.", [["neuraminidase", "CHEMICAL", 46, 59], ["neuraminidase", "SIMPLE_CHEMICAL", 46, 59], ["neuraminidase", "PROTEIN", 46, 59], ["all three strains", "PROBLEM", 4, 21], ["neuraminidase treatment", "TREATMENT", 46, 69]]], ["In the case of M41, ciliostasis was delayed for 1 day; in the case of the other two strains, the ciliary activity was retained in about 60% of the desialylated epithelium even on day 5 following infection.", [["ciliary", "ANATOMY", 97, 104], ["epithelium", "ANATOMY", 160, 170], ["ciliostasis", "DISEASE", 20, 31], ["infection", "DISEASE", 195, 204], ["ciliary", "MULTI-TISSUE_STRUCTURE", 97, 104], ["epithelium", "TISSUE", 160, 170], ["the other two strains", "PROBLEM", 70, 91], ["infection", "PROBLEM", 195, 204], ["ciliary activity", "OBSERVATION", 97, 113], ["infection", "OBSERVATION", 195, 204]]], ["Ciliostasis was also found after infection by Avian metapneumovirus.", [["Ciliostasis", "DISEASE", 0, 11], ["infection", "DISEASE", 33, 42], ["Avian metapneumovirus", "DISEASE", 46, 67], ["Avian metapneumovirus", "ORGANISM", 46, 67], ["Avian metapneumovirus", "SPECIES", 46, 67], ["Avian metapneumovirus", "SPECIES", 46, 67], ["Ciliostasis", "PROBLEM", 0, 11], ["infection", "PROBLEM", 33, 42], ["Avian metapneumovirus", "PROBLEM", 46, 67], ["infection", "OBSERVATION", 33, 42], ["metapneumovirus", "OBSERVATION", 52, 67]]], ["However, in contrast to IBV infection, neuraminidase treatment did not prevent the ciliostatic effect of the metapneumovirus infection.", [["IBV infection", "DISEASE", 24, 37], ["metapneumovirus infection", "DISEASE", 109, 134], ["IBV", "ORGANISM", 24, 27], ["neuraminidase", "SIMPLE_CHEMICAL", 39, 52], ["metapneumovirus", "ORGANISM", 109, 124], ["IBV", "SPECIES", 24, 27], ["IBV infection", "PROBLEM", 24, 37], ["neuraminidase treatment", "TREATMENT", 39, 62], ["the metapneumovirus infection", "PROBLEM", 105, 134], ["infection", "OBSERVATION", 28, 37], ["metapneumovirus infection", "OBSERVATION", 109, 134]]], ["This result confirms that the sialic acid dependence of the TOC infection is a characteristic feature of IBV.Strain-dependent differencesIn the experiments described above, the ciliary activity was used to monitor the course of infection.", [["ciliary", "ANATOMY", 177, 184], ["sialic acid", "CHEMICAL", 30, 41], ["TOC", "CHEMICAL", 60, 63], ["infection", "DISEASE", 64, 73], ["infection", "DISEASE", 228, 237], ["sialic acid", "CHEMICAL", 30, 41], ["TOC", "CHEMICAL", 60, 63], ["sialic acid", "SIMPLE_CHEMICAL", 30, 41], ["TOC", "SIMPLE_CHEMICAL", 60, 63], ["IBV", "ORGANISM", 105, 108], ["ciliary", "MULTI-TISSUE_STRUCTURE", 177, 184], ["IBV", "SPECIES", 105, 108], ["the sialic acid dependence", "PROBLEM", 26, 52], ["the TOC infection", "PROBLEM", 56, 73], ["IBV", "PROBLEM", 105, 108], ["Strain-dependent differences", "PROBLEM", 109, 137], ["infection", "PROBLEM", 228, 237], ["TOC", "OBSERVATION_MODIFIER", 60, 63], ["infection", "OBSERVATION", 64, 73], ["IBV", "OBSERVATION", 105, 108], ["dependent", "OBSERVATION_MODIFIER", 116, 125], ["differences", "OBSERVATION_MODIFIER", 126, 137], ["ciliary", "ANATOMY", 177, 184], ["infection", "OBSERVATION", 228, 237]]], ["To determine the effect of neuraminidase treatment on virus production, the amount of infectious virus released from the epithelial cells was measured.", [["epithelial cells", "ANATOMY", 121, 137], ["neuraminidase", "SIMPLE_CHEMICAL", 27, 40], ["epithelial cells", "CELL", 121, 137], ["neuraminidase", "PROTEIN", 27, 40], ["epithelial cells", "CELL_TYPE", 121, 137], ["neuraminidase treatment", "TREATMENT", 27, 50], ["virus production", "TREATMENT", 54, 70], ["infectious virus", "PROBLEM", 86, 102], ["the epithelial cells", "TEST", 117, 137], ["amount", "OBSERVATION_MODIFIER", 76, 82], ["infectious virus", "OBSERVATION", 86, 102], ["epithelial cells", "OBSERVATION", 121, 137]]], ["Groups of five TOC rings were treated with neuraminidase prior to infection by either of the IBV strains, Beaudette and M41.", [["TOC rings", "ANATOMY", 15, 24], ["infection", "DISEASE", 66, 75], ["TOC", "CHEMICAL", 15, 18], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 43, 56], ["IBV", "ORGANISM", 93, 96], ["neuraminidase", "PROTEIN", 43, 56], ["IBV", "SPECIES", 93, 96], ["five TOC rings", "TREATMENT", 10, 24], ["neuraminidase", "TREATMENT", 43, 56], ["infection", "PROBLEM", 66, 75], ["the IBV strains", "PROBLEM", 89, 104], ["infection", "OBSERVATION", 66, 75]]], ["In parallel, TOC were infected that had been incubated in the absence of neuraminidase.", [["TOC", "CHEMICAL", 13, 16], ["TOC", "CHEMICAL", 13, 16], ["TOC", "SIMPLE_CHEMICAL", 13, 16], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 73, 86], ["neuraminidase", "PROTEIN", 73, 86], ["neuraminidase", "PROBLEM", 73, 86], ["infected", "OBSERVATION", 22, 30], ["neuraminidase", "OBSERVATION", 73, 86]]], ["At 24 h p.i. the supernatants were collected and titrated on primary chicken kidney cells.", [["supernatants", "ANATOMY", 17, 29], ["kidney cells", "ANATOMY", 77, 89], ["chicken", "ORGANISM", 69, 76], ["kidney cells", "CELL", 77, 89], ["primary chicken kidney cells", "CELL_TYPE", 61, 89], ["chicken", "SPECIES", 69, 76], ["chicken", "SPECIES", 69, 76], ["primary chicken kidney cells", "TREATMENT", 61, 89], ["kidney", "ANATOMY", 77, 83], ["cells", "OBSERVATION", 84, 89]]], ["With both virus strains, desialylation resulted in a decrease of the virus titer by about 60% (Fig. 4) .", [["both virus strains", "PROBLEM", 5, 23], ["desialylation", "TREATMENT", 25, 38], ["a decrease of the virus titer", "PROBLEM", 51, 80], ["virus strains", "OBSERVATION", 10, 23], ["decrease", "OBSERVATION_MODIFIER", 53, 61]]], ["There was a clear difference in the amount of virus released from infected TOCs.", [["TOCs", "ANATOMY", 75, 79], ["TOCs", "CELL", 75, 79], ["virus", "PROBLEM", 46, 51], ["infected TOCs", "PROBLEM", 66, 79], ["clear", "OBSERVATION_MODIFIER", 12, 17], ["difference", "OBSERVATION_MODIFIER", 18, 28], ["amount", "OBSERVATION_MODIFIER", 36, 42], ["virus", "OBSERVATION", 46, 51], ["infected", "OBSERVATION_MODIFIER", 66, 74]]], ["For the Beaudette strain, the titer of infectious virus in the supernatant was 50e100 fold higher than that determined for strain M41.Infection of different cell types in the chicken tracheal epitheliumThe respiratory epithelium is the primary target for an IBV infection.", [["supernatant", "ANATOMY", 63, 74], ["cell", "ANATOMY", 157, 161], ["tracheal epithelium", "ANATOMY", 183, 202], ["respiratory epithelium", "ANATOMY", 206, 228], ["IBV infection", "DISEASE", 258, 271], ["infectious virus", "ORGANISM", 39, 55], ["cell", "CELL", 157, 161], ["chicken", "ORGANISM", 175, 182], ["tracheal epithelium", "TISSUE", 183, 202], ["respiratory epithelium", "TISSUE", 206, 228], ["IBV", "ORGANISM", 258, 261], ["chicken", "SPECIES", 175, 182], ["chicken", "SPECIES", 175, 182], ["IBV", "SPECIES", 258, 261], ["the Beaudette strain", "PROBLEM", 4, 24], ["infectious virus", "PROBLEM", 39, 55], ["Infection of different cell types", "PROBLEM", 134, 167], ["the chicken tracheal epithelium", "PROBLEM", 171, 202], ["an IBV infection", "PROBLEM", 255, 271], ["infectious", "OBSERVATION_MODIFIER", 39, 49], ["different cell types", "OBSERVATION", 147, 167], ["tracheal epithelium", "ANATOMY", 183, 202], ["respiratory epithelium", "OBSERVATION", 206, 228], ["IBV", "OBSERVATION_MODIFIER", 258, 261], ["infection", "OBSERVATION", 262, 271]]], ["Cryosections of TOC were prepared and ciliated cells were visualized by staining with antibodies directed against btubulin.", [["Cryosections", "ANATOMY", 0, 12], ["ciliated cells", "ANATOMY", 38, 52], ["TOC", "CHEMICAL", 16, 19], ["TOC", "CHEMICAL", 16, 19], ["TOC", "SIMPLE_CHEMICAL", 16, 19], ["ciliated cells", "CELL", 38, 52], ["btubulin", "GENE_OR_GENE_PRODUCT", 114, 122], ["TOC", "CELL_TYPE", 16, 19], ["ciliated cells", "CELL_TYPE", 38, 52], ["antibodies", "PROTEIN", 86, 96], ["btubulin", "PROTEIN", 114, 122], ["Cryosections of TOC", "PROBLEM", 0, 19], ["ciliated cells", "PROBLEM", 38, 52], ["antibodies", "TREATMENT", 86, 96], ["btubulin", "TREATMENT", 114, 122]]], ["Mucus-producing goblet cells were stained with an antibody recognizing MUC5AC.", [["Mucus", "ANATOMY", 0, 5], ["goblet cells", "ANATOMY", 16, 28], ["Mucus", "GENE_OR_GENE_PRODUCT", 0, 5], ["goblet cells", "CELL", 16, 28], ["MUC5AC", "GENE_OR_GENE_PRODUCT", 71, 77], ["Mucus-producing goblet cells", "CELL_TYPE", 0, 28], ["MUC5AC", "PROTEIN", 71, 77], ["goblet cells", "PROBLEM", 16, 28], ["an antibody", "TEST", 47, 58], ["goblet cells", "OBSERVATION", 16, 28]]], ["As shown in Fig. 5 (top two rows), both ciliated and mucus-producing cells are infected by IBV.", [["ciliated", "ANATOMY", 40, 48], ["mucus", "ANATOMY", 53, 58], ["cells", "ANATOMY", 69, 74], ["mucus", "CELL", 53, 58], ["cells", "CELL", 69, 74], ["IBV", "ORGANISM", 91, 94], ["ciliated and mucus-producing cells", "CELL_TYPE", 40, 74], ["IBV", "SPECIES", 91, 94], ["IBV", "PROBLEM", 91, 94], ["Fig", "OBSERVATION", 12, 15], ["mucus", "ANATOMY", 53, 58]]], ["Cryosections were also stained for sialic acid expression using the lectin MAA which binds to a2,3-linked sialic acids and SNA which recognizes a2,6-linked sialic acids.", [["Cryosections", "ANATOMY", 0, 12], ["sialic acid", "CHEMICAL", 35, 46], ["MAA", "CHEMICAL", 75, 78], ["a2,3-linked sialic acids", "CHEMICAL", 94, 118], ["a2,6-linked sialic acids", "CHEMICAL", 144, 168], ["sialic acid", "CHEMICAL", 35, 46], ["sialic acids", "CHEMICAL", 106, 118], ["sialic acids", "CHEMICAL", 156, 168], ["Cryosections", "ORGANISM_SUBSTANCE", 0, 12], ["sialic acid", "SIMPLE_CHEMICAL", 35, 46], ["lectin", "GENE_OR_GENE_PRODUCT", 68, 74], ["MAA", "SIMPLE_CHEMICAL", 75, 78], ["a2,3-linked sialic acids", "SIMPLE_CHEMICAL", 94, 118], ["SNA", "SIMPLE_CHEMICAL", 123, 126], ["a2,6-linked sialic acids", "SIMPLE_CHEMICAL", 144, 168], ["lectin MAA", "PROTEIN", 68, 78], ["a2,3", "PROTEIN", 94, 98], ["SNA", "PROTEIN", 123, 126], ["a2,6", "PROTEIN", 144, 148], ["Cryosections", "TEST", 0, 12], ["sialic acid expression", "PROBLEM", 35, 57], ["the lectin MAA", "TREATMENT", 64, 78], ["sialic acids", "OBSERVATION", 156, 168]]], ["The epithelial cell layer lining the surface of the trachea shows bright fluorescence after staining with MAA, indicating that these cells abundantly express a2,3-linked sialic acid.", [["epithelial cell layer", "ANATOMY", 4, 25], ["surface", "ANATOMY", 37, 44], ["trachea", "ANATOMY", 52, 59], ["cells", "ANATOMY", 133, 138], ["MAA", "CHEMICAL", 106, 109], ["a2,3-linked sialic acid", "CHEMICAL", 158, 181], ["MAA", "CHEMICAL", 106, 109], ["sialic acid", "CHEMICAL", 170, 181], ["epithelial cell layer", "TISSUE", 4, 25], ["surface", "CELLULAR_COMPONENT", 37, 44], ["trachea", "ORGAN", 52, 59], ["MAA", "SIMPLE_CHEMICAL", 106, 109], ["cells", "CELL", 133, 138], ["a2,3-linked sialic acid", "SIMPLE_CHEMICAL", 158, 181], ["a2,3", "PROTEIN", 158, 162], ["bright fluorescence", "PROBLEM", 66, 85], ["epithelial cell", "OBSERVATION", 4, 19], ["layer", "OBSERVATION_MODIFIER", 20, 25], ["lining", "OBSERVATION_MODIFIER", 26, 32], ["surface", "OBSERVATION_MODIFIER", 37, 44], ["trachea", "ANATOMY", 52, 59], ["bright fluorescence", "OBSERVATION", 66, 85], ["sialic acid", "OBSERVATION", 170, 181]]], ["They colocalize with IBV-infected cells (Fig 5, third row) .", [["cells", "ANATOMY", 34, 39], ["IBV-infected", "DISEASE", 21, 33], ["IBV", "ORGANISM", 21, 24], ["cells", "CELL", 34, 39], ["IBV-infected cells", "CELL_TYPE", 21, 39], ["IBV", "SPECIES", 21, 24], ["IBV", "PROBLEM", 21, 24], ["infected cells", "PROBLEM", 25, 39], ["infected cells", "OBSERVATION", 25, 39]]], ["This result is consistent with a role of a2,3-linked sialic acid as a receptor determinant for IBV.", [["sialic acid", "CHEMICAL", 53, 64], ["sialic acid", "CHEMICAL", 53, 64], ["a2,3-linked sialic acid", "SIMPLE_CHEMICAL", 41, 64], ["IBV", "ORGANISM", 95, 98], ["a2,3", "PROTEIN", 41, 45], ["IBV", "SPECIES", 95, 98], ["sialic acid", "TREATMENT", 53, 64], ["IBV", "PROBLEM", 95, 98], ["consistent with", "UNCERTAINTY", 15, 30]]], ["Staining with SNA indicates that basal cell layers of the tracheal epithelium express a2,6-linked sialic acid.", [["basal cell layers", "ANATOMY", 33, 50], ["tracheal epithelium", "ANATOMY", 58, 77], ["a2,6-linked sialic acid", "CHEMICAL", 86, 109], ["sialic acid", "CHEMICAL", 98, 109], ["SNA", "GENE_OR_GENE_PRODUCT", 14, 17], ["basal cell layers", "TISSUE", 33, 50], ["tracheal epithelium", "TISSUE", 58, 77], ["a2,6-linked sialic acid", "SIMPLE_CHEMICAL", 86, 109], ["SNA", "PROTEIN", 14, 17], ["a2,6", "PROTEIN", 86, 90], ["basal cell layers of the tracheal epithelium", "PROBLEM", 33, 77], ["SNA", "ANATOMY", 14, 17], ["basal cell layers", "OBSERVATION", 33, 50], ["tracheal", "ANATOMY", 58, 66], ["epithelium", "ANATOMY_MODIFIER", 67, 77], ["sialic acid", "OBSERVATION", 98, 109]]], ["These cells are not infected by IBV (Fig. 5, bottom row) .Effect of neuraminidase treatment on the staining by the lectin MAATo visualize the effect of neuraminidase treatment, we prepared cryosections of neuraminidase-treated tracheal rings and stained the sections with the MAA lectin.", [["cells", "ANATOMY", 6, 11], ["cryosections", "ANATOMY", 189, 201], ["tracheal rings", "ANATOMY", 227, 241], ["sections", "ANATOMY", 258, 266], ["cells", "CELL", 6, 11], ["IBV", "ORGANISM", 32, 35], ["neuraminidase", "SIMPLE_CHEMICAL", 68, 81], ["lectin", "GENE_OR_GENE_PRODUCT", 115, 121], ["neuraminidase", "SIMPLE_CHEMICAL", 152, 165], ["neuraminidase", "SIMPLE_CHEMICAL", 205, 218], ["tracheal rings", "MULTI-TISSUE_STRUCTURE", 227, 241], ["MAA lectin", "GENE_OR_GENE_PRODUCT", 276, 286], ["neuraminidase", "PROTEIN", 68, 81], ["lectin MAATo", "PROTEIN", 115, 127], ["neuraminidase", "PROTEIN", 205, 218], ["MAA lectin", "PROTEIN", 276, 286], ["IBV", "SPECIES", 32, 35], ["neuraminidase treatment", "TREATMENT", 68, 91], ["the staining", "TEST", 95, 107], ["neuraminidase treatment", "TREATMENT", 152, 175], ["neuraminidase", "TREATMENT", 205, 218], ["tracheal rings", "TREATMENT", 227, 241], ["the MAA lectin", "TREATMENT", 272, 286], ["not", "UNCERTAINTY", 16, 19], ["infected", "OBSERVATION", 20, 28], ["neuraminidase", "OBSERVATION", 68, 81], ["tracheal rings", "ANATOMY", 227, 241]]], ["As shown in Fig. 6 , neuraminidase treatment resulted in a reduced reactivity of MAA with the apical membrane of the epithelial cells.", [["apical membrane", "ANATOMY", 94, 109], ["epithelial cells", "ANATOMY", 117, 133], ["MAA", "CHEMICAL", 81, 84], ["MAA", "CHEMICAL", 81, 84], ["neuraminidase", "SIMPLE_CHEMICAL", 21, 34], ["MAA", "SIMPLE_CHEMICAL", 81, 84], ["apical membrane", "CELLULAR_COMPONENT", 94, 109], ["epithelial cells", "CELL", 117, 133], ["neuraminidase", "PROTEIN", 21, 34], ["epithelial cells", "CELL_TYPE", 117, 133], ["neuraminidase treatment", "TREATMENT", 21, 44], ["a reduced reactivity of MAA", "PROBLEM", 57, 84], ["reduced", "OBSERVATION_MODIFIER", 59, 66], ["reactivity", "OBSERVATION", 67, 77], ["apical", "ANATOMY_MODIFIER", 94, 100], ["membrane", "ANATOMY_MODIFIER", 101, 109], ["epithelial cells", "OBSERVATION", 117, 133]]], ["The residual fluorescent signal indicates that the neuraminidase did not release all sialic acids from the epithelial cells.DiscussionThe binding to receptors on the cell surface is an important determinant of cell tropism and viral pathogenesis.", [["epithelial cells", "ANATOMY", 107, 123], ["cell surface", "ANATOMY", 166, 178], ["cell", "ANATOMY", 210, 214], ["sialic acids", "CHEMICAL", 85, 97], ["sialic acids", "CHEMICAL", 85, 97], ["sialic acids", "SIMPLE_CHEMICAL", 85, 97], ["epithelial cells", "CELL", 107, 123], ["cell surface", "CELLULAR_COMPONENT", 166, 178], ["cell", "CELL", 210, 214], ["neuraminidase", "PROTEIN", 51, 64], ["epithelial cells", "CELL_TYPE", 107, 123], ["The residual fluorescent signal", "TEST", 0, 31], ["the neuraminidase", "PROBLEM", 47, 64], ["all sialic acids", "TEST", 81, 97], ["cell tropism", "PROBLEM", 210, 222], ["viral pathogenesis", "PROBLEM", 227, 245], ["residual", "OBSERVATION_MODIFIER", 4, 12], ["fluorescent signal", "OBSERVATION", 13, 31], ["epithelial cells", "OBSERVATION", 107, 123], ["important determinant of", "UNCERTAINTY", 185, 209], ["cell tropism", "OBSERVATION", 210, 222]]], ["Recently we demonstrated that a2,3-linked sialic acid serves as a receptor determinant for IBV on cultured cells [7] .", [["cells", "ANATOMY", 107, 112], ["a2,3-linked sialic acid", "CHEMICAL", 30, 53], ["sialic acid", "CHEMICAL", 42, 53], ["a2,3-linked sialic acid", "SIMPLE_CHEMICAL", 30, 53], ["IBV", "ORGANISM", 91, 94], ["cells", "CELL", 107, 112], ["a2,3", "PROTEIN", 30, 34], ["cultured cells", "CELL_LINE", 98, 112], ["IBV", "SPECIES", 91, 94], ["a2,3-linked sialic acid serves", "PROBLEM", 30, 60], ["IBV on cultured cells", "TREATMENT", 91, 112]]], ["This binding activity of IBV has been shown for strains that only grow in avian cells as well as for the Beaudette strain that has been adapted to grow also in cultured cells of mammalian origin.", [["cells", "ANATOMY", 80, 85], ["cells", "ANATOMY", 169, 174], ["IBV", "ORGANISM", 25, 28], ["cells", "CELL", 80, 85], ["Beaudette strain", "ORGANISM", 105, 121], ["cells", "CELL", 169, 174], ["avian cells", "CELL_TYPE", 74, 85], ["cultured cells", "CELL_LINE", 160, 174], ["IBV", "SPECIES", 25, 28], ["IBV", "PROBLEM", 25, 28], ["strains", "PROBLEM", 48, 55], ["avian cells", "PROBLEM", 74, 85], ["the Beaudette strain", "PROBLEM", 101, 121], ["mammalian origin", "OBSERVATION", 178, 194]]], ["For the latter strain it has been recently reported that it also recognizes glycosaminoglycans of the heparan sulfate type [9] .", [["heparan sulfate", "CHEMICAL", 102, 117], ["sulfate", "CHEMICAL", 110, 117], ["glycosaminoglycans", "GENE_OR_GENE_PRODUCT", 76, 94], ["the latter strain", "PROBLEM", 4, 21], ["the heparan sulfate type", "TREATMENT", 98, 122]]], ["The acquisition of this additional binding activity may have allowed the adaptation to new host cells as has been shown for other viruses, e.g. foot and mouth disease virus [10] and tick-borne encephalitis virus [11] .", [["cells", "ANATOMY", 96, 101], ["foot and mouth disease", "DISEASE", 144, 166], ["tick-borne encephalitis", "DISEASE", 182, 205], ["host cells", "CELL", 91, 101], ["foot and mouth disease virus", "ORGANISM", 144, 172], ["tick-borne encephalitis virus", "ORGANISM", 182, 211], ["host cells", "CELL_TYPE", 91, 101], ["foot and mouth disease virus", "SPECIES", 144, 172], ["tick-borne encephalitis virus", "SPECIES", 182, 211], ["foot and mouth disease virus", "SPECIES", 144, 172], ["tick-borne encephalitis virus", "SPECIES", 182, 211], ["new host cells", "TREATMENT", 87, 101], ["other viruses", "PROBLEM", 124, 137], ["foot and mouth disease virus", "PROBLEM", 144, 172], ["tick-borne encephalitis virus", "PROBLEM", 182, 211], ["foot", "ANATOMY", 144, 148], ["mouth", "ANATOMY", 153, 158]]], ["By contrast, the sialic acid binding activity has been detected on all IBV strains analyzed including respiratory and nephropathogenic variants.", [["respiratory", "ANATOMY", 102, 113], ["sialic acid", "CHEMICAL", 17, 28], ["sialic acid", "CHEMICAL", 17, 28], ["sialic acid", "SIMPLE_CHEMICAL", 17, 28], ["IBV", "ORGANISM", 71, 74], ["IBV", "SPECIES", 71, 74], ["the sialic acid binding activity", "PROBLEM", 13, 45], ["all IBV strains", "TEST", 67, 82], ["respiratory and nephropathogenic variants", "PROBLEM", 102, 143], ["nephropathogenic variants", "OBSERVATION", 118, 143]]], ["Here we have demonstrated that this also holds true for epithelial cells of the trachea, which are among the primary target cells for this virus.DiscussionThe importance of sialic acid for IBV infection was evident from the delayed appearance of ciliostasis on desialylated TOCs.", [["epithelial cells", "ANATOMY", 56, 72], ["trachea", "ANATOMY", 80, 87], ["cells", "ANATOMY", 124, 129], ["sialic acid", "CHEMICAL", 173, 184], ["IBV infection", "DISEASE", 189, 202], ["ciliostasis", "DISEASE", 246, 257], ["sialic acid", "CHEMICAL", 173, 184], ["epithelial cells", "CELL", 56, 72], ["trachea", "ORGAN", 80, 87], ["cells", "CELL", 124, 129], ["sialic acid", "SIMPLE_CHEMICAL", 173, 184], ["IBV", "ORGANISM", 189, 192], ["TOCs", "GENE_OR_GENE_PRODUCT", 274, 278], ["epithelial cells", "CELL_TYPE", 56, 72], ["primary target cells", "CELL_TYPE", 109, 129], ["desialylated TOCs", "PROTEIN", 261, 278], ["IBV", "SPECIES", 189, 192], ["epithelial cells of the trachea", "PROBLEM", 56, 87], ["this virus", "PROBLEM", 134, 144], ["sialic acid", "TREATMENT", 173, 184], ["IBV infection", "PROBLEM", 189, 202], ["the delayed appearance of ciliostasis", "PROBLEM", 220, 257], ["desialylated TOCs", "TREATMENT", 261, 278], ["epithelial cells", "OBSERVATION", 56, 72], ["trachea", "ANATOMY", 80, 87], ["target cells", "OBSERVATION", 117, 129], ["infection", "OBSERVATION", 193, 202]]], ["For the M41 strain, the ciliostatic effect was delayed only by 1 day, whereas for the two other strains analyzed, some ciliary activity was retained even 5 days after infection.", [["ciliary", "ANATOMY", 119, 126], ["infection", "DISEASE", 167, 176], ["ciliary", "MULTI-TISSUE_STRUCTURE", 119, 126], ["the M41 strain", "PROBLEM", 4, 18], ["the two other strains", "PROBLEM", 82, 103], ["infection", "PROBLEM", 167, 176], ["ciliary activity", "OBSERVATION", 119, 135]]], ["This difference in the protective effect of neuraminidase treatment is probably accounted for by the difference in the cytopathogenicity of these viruses.", [["neuraminidase", "CHEMICAL", 44, 57], ["neuraminidase", "SIMPLE_CHEMICAL", 44, 57], ["neuraminidase", "PROTEIN", 44, 57], ["neuraminidase treatment", "TREATMENT", 44, 67], ["protective effect", "OBSERVATION_MODIFIER", 23, 40], ["neuraminidase", "OBSERVATION", 44, 57], ["probably accounted for", "UNCERTAINTY", 71, 93], ["viruses", "OBSERVATION", 146, 153]]], ["This may also explain the larger amount of virus that is released from TOCs infected by IBV-Beaudette compared to M41-infected tracheal rings.", [["tracheal rings", "ANATOMY", 127, 141], ["IBV-Beaudette", "CHEMICAL", 88, 101], ["TOCs", "GENE_OR_GENE_PRODUCT", 71, 75], ["IBV-Beaudette", "ORGANISM", 88, 101], ["M41", "CELL", 114, 117], ["tracheal rings", "MULTI-TISSUE_STRUCTURE", 127, 141], ["IBV", "SPECIES", 88, 91], ["the larger amount of virus", "PROBLEM", 22, 48], ["M41", "TEST", 114, 117], ["infected tracheal rings", "TREATMENT", 118, 141], ["may also explain", "UNCERTAINTY", 5, 21], ["larger", "OBSERVATION_MODIFIER", 26, 32], ["amount", "OBSERVATION_MODIFIER", 33, 39], ["virus", "OBSERVATION", 43, 48], ["infected", "OBSERVATION_MODIFIER", 76, 84], ["infected", "OBSERVATION", 118, 126], ["tracheal rings", "ANATOMY", 127, 141]]], ["Despite these differences, the relative effect of desialylation was similar, i.e. the amount of released virus was reduced by about 60%.", [["desialylation", "PROBLEM", 50, 63], ["released virus", "PROBLEM", 96, 110], ["effect", "OBSERVATION_MODIFIER", 40, 46], ["amount", "OBSERVATION_MODIFIER", 86, 92], ["virus", "OBSERVATION", 105, 110]]], ["The partial protection of TOCs from IBV infection may be attributable to the difficulties in removing all sialic acid residues from the cell surface of the tracheal epithelium.", [["cell surface", "ANATOMY", 136, 148], ["tracheal epithelium", "ANATOMY", 156, 175], ["IBV infection", "DISEASE", 36, 49], ["sialic acid", "CHEMICAL", 106, 117], ["sialic acid", "CHEMICAL", 106, 117], ["TOCs", "CANCER", 26, 30], ["IBV", "ORGANISM", 36, 39], ["sialic acid", "SIMPLE_CHEMICAL", 106, 117], ["cell surface", "CELLULAR_COMPONENT", 136, 148], ["tracheal epithelium", "TISSUE", 156, 175], ["IBV", "SPECIES", 36, 39], ["TOCs", "PROBLEM", 26, 30], ["IBV infection", "PROBLEM", 36, 49], ["all sialic acid residues", "TREATMENT", 102, 126], ["partial", "OBSERVATION_MODIFIER", 4, 11], ["IBV", "OBSERVATION_MODIFIER", 36, 39], ["infection", "OBSERVATION", 40, 49], ["may be attributable to", "UNCERTAINTY", 50, 72], ["cell surface", "OBSERVATION", 136, 148], ["tracheal epithelium", "ANATOMY", 156, 175]]], ["Staining by MAA revealed that some sialic acids are still present on the apical membrane of the epithelial cells after neuraminidase treatment.", [["apical membrane", "ANATOMY", 73, 88], ["epithelial cells", "ANATOMY", 96, 112], ["MAA", "CHEMICAL", 12, 15], ["sialic acids", "CHEMICAL", 35, 47], ["MAA", "CHEMICAL", 12, 15], ["sialic acids", "CHEMICAL", 35, 47], ["MAA", "SIMPLE_CHEMICAL", 12, 15], ["sialic acids", "SIMPLE_CHEMICAL", 35, 47], ["apical membrane", "CELLULAR_COMPONENT", 73, 88], ["epithelial cells", "CELL", 96, 112], ["neuraminidase", "SIMPLE_CHEMICAL", 119, 132], ["epithelial cells", "CELL_TYPE", 96, 112], ["neuraminidase", "PROTEIN", 119, 132], ["some sialic acids", "PROBLEM", 30, 47], ["neuraminidase treatment", "TREATMENT", 119, 142], ["some", "OBSERVATION_MODIFIER", 30, 34], ["sialic acids", "OBSERVATION", 35, 47], ["apical", "ANATOMY_MODIFIER", 73, 79], ["membrane", "ANATOMY_MODIFIER", 80, 88], ["epithelial cells", "ANATOMY", 96, 112], ["neuraminidase treatment", "OBSERVATION", 119, 142]]], ["Whether this low level of sialic acid by itself is sufficient for a low level of infection is not known.", [["sialic acid", "CHEMICAL", 26, 37], ["infection", "DISEASE", 81, 90], ["sialic acid", "CHEMICAL", 26, 37], ["sialic acid", "SIMPLE_CHEMICAL", 26, 37], ["this low level of sialic acid", "PROBLEM", 8, 37], ["a low level of infection", "PROBLEM", 66, 90], ["low level", "OBSERVATION_MODIFIER", 68, 77], ["infection", "OBSERVATION", 81, 90]]], ["An alternative explanation is that binding to surfacebound sialic acids is only a first attachment step in the infection cycle that precedes the binding to a second receptor, though such a receptor has not been identified for IBV so far.", [["sialic acids", "CHEMICAL", 59, 71], ["infection", "DISEASE", 111, 120], ["sialic acids", "CHEMICAL", 59, 71], ["surfacebound sialic acids", "SIMPLE_CHEMICAL", 46, 71], ["IBV", "ORGANISM", 226, 229], ["IBV", "SPECIES", 226, 229], ["binding to surfacebound sialic acids", "PROBLEM", 35, 71], ["the infection cycle", "PROBLEM", 107, 126], ["a second receptor", "TREATMENT", 156, 173], ["IBV", "PROBLEM", 226, 229], ["infection", "OBSERVATION", 111, 120]]], ["In favor of the latter explanation is the fact that IBV recognizes sialic acid with lower affinity when compared to influenza virus and Sendai virus [7] .", [["sialic acid", "CHEMICAL", 67, 78], ["sialic acid", "CHEMICAL", 67, 78], ["IBV", "ORGANISM", 52, 55], ["sialic acid", "SIMPLE_CHEMICAL", 67, 78], ["influenza virus", "ORGANISM", 116, 131], ["Sendai virus", "ORGANISM", 136, 148], ["influenza virus", "SPECIES", 116, 131], ["Sendai virus", "SPECIES", 136, 148], ["IBV", "SPECIES", 52, 55], ["influenza virus", "SPECIES", 116, 131], ["Sendai virus", "SPECIES", 136, 148], ["IBV", "PROBLEM", 52, 55], ["sialic acid", "TEST", 67, 78], ["lower affinity", "PROBLEM", 84, 98], ["influenza virus", "PROBLEM", 116, 131], ["Sendai virus", "PROBLEM", 136, 148]]], ["Because of the higher affinity for sialic acids, a second receptor may be dispensable for influenza viruses; however, it may require the presence of a neuraminidase (receptor-destroying enzyme) to allow passage through the mucus layer covering the respiratory epithelium [12] and to enable virus release from infected cells [13] .", [["mucus layer", "ANATOMY", 223, 234], ["respiratory epithelium", "ANATOMY", 248, 270], ["cells", "ANATOMY", 318, 323], ["sialic acids", "CHEMICAL", 35, 47], ["influenza viruses", "DISEASE", 90, 107], ["sialic acids", "CHEMICAL", 35, 47], ["sialic acids", "SIMPLE_CHEMICAL", 35, 47], ["influenza viruses", "ORGANISM", 90, 107], ["mucus layer", "TISSUE", 223, 234], ["epithelium", "TISSUE", 260, 270], ["cells", "CELL", 318, 323], ["neuraminidase (receptor-destroying enzyme", "PROTEIN", 151, 192], ["infected cells", "CELL_TYPE", 309, 323], ["sialic acids", "TREATMENT", 35, 47], ["a second receptor", "TREATMENT", 49, 66], ["influenza viruses", "PROBLEM", 90, 107], ["a neuraminidase (receptor-destroying enzyme", "TREATMENT", 149, 192], ["the mucus layer", "PROBLEM", 219, 234], ["the respiratory epithelium", "PROBLEM", 244, 270], ["infected cells", "PROBLEM", 309, 323], ["respiratory epithelium", "ANATOMY", 248, 270]]], ["On the other hand, a receptor-destroying enzyme may be dispensable for IBV because of the lower affinity for sialic acids.DiscussionSo far, two groups of coronaviruses with sialic acid binding activity have been described.", [["sialic acids", "CHEMICAL", 109, 121], ["sialic acid", "CHEMICAL", 173, 184], ["sialic acids", "CHEMICAL", 109, 121], ["sialic acid", "CHEMICAL", 173, 184], ["IBV", "ORGANISM", 71, 74], ["sialic acids", "SIMPLE_CHEMICAL", 109, 121], ["coronaviruses", "ORGANISM", 154, 167], ["sialic acid", "SIMPLE_CHEMICAL", 173, 184], ["IBV", "SPECIES", 71, 74], ["a receptor-destroying enzyme", "TEST", 19, 47], ["IBV", "PROBLEM", 71, 74], ["sialic acids", "TREATMENT", 109, 121], ["coronaviruses", "PROBLEM", 154, 167], ["sialic acid binding activity", "TREATMENT", 173, 201]]], ["On one hand, there is bovine coronavirus and related viruses that resemble influenza C virus, because they recognize N-acetyl-9-O-acetylneuraminic acid and contain an acetylesterase that acts as a receptor-destroying enzyme comparable to the neuraminidase of influenza A and B viruses [14, 15] .", [["influenza C virus", "DISEASE", 75, 92], ["N-acetyl-9-O-acetylneuraminic acid", "CHEMICAL", 117, 151], ["N-acetyl-9-O-acetylneuraminic acid", "CHEMICAL", 117, 151], ["bovine coronavirus", "ORGANISM", 22, 40], ["influenza C virus", "ORGANISM", 75, 92], ["N-acetyl-9-O-acetylneuraminic acid", "SIMPLE_CHEMICAL", 117, 151], ["acetylesterase", "SIMPLE_CHEMICAL", 167, 181], ["influenza A and B viruses", "ORGANISM", 259, 284], ["acetylesterase", "PROTEIN", 167, 181], ["neuraminidase", "PROTEIN", 242, 255], ["bovine", "SPECIES", 22, 28], ["influenza C virus", "SPECIES", 75, 92], ["bovine coronavirus", "SPECIES", 22, 40], ["influenza C virus", "SPECIES", 75, 92], ["bovine coronavirus", "PROBLEM", 22, 40], ["related viruses", "PROBLEM", 45, 60], ["influenza C virus", "PROBLEM", 75, 92], ["N-acetyl", "TEST", 117, 125], ["O-acetylneuraminic acid", "TREATMENT", 128, 151], ["an acetylesterase", "TREATMENT", 164, 181], ["a receptor-destroying enzyme", "TREATMENT", 195, 223], ["influenza A and B viruses", "PROBLEM", 259, 284], ["bovine coronavirus", "OBSERVATION", 22, 40], ["viruses", "OBSERVATION", 53, 60]]], ["These viruses depend on sialic acid for infection of cells.", [["cells", "ANATOMY", 53, 58], ["sialic acid", "CHEMICAL", 24, 35], ["infection", "DISEASE", 40, 49], ["sialic acid", "CHEMICAL", 24, 35], ["sialic acid", "SIMPLE_CHEMICAL", 24, 35], ["cells", "CELL", 53, 58], ["These viruses", "PROBLEM", 0, 13], ["sialic acid", "TEST", 24, 35], ["infection of cells", "PROBLEM", 40, 58], ["viruses", "OBSERVATION", 6, 13]]], ["On the other hand, there is transmissible gastroenteritis virus, a porcine coronavirus.", [["transmissible gastroenteritis virus", "DISEASE", 28, 63], ["porcine coronavirus", "DISEASE", 67, 86], ["transmissible gastroenteritis virus", "ORGANISM", 28, 63], ["porcine coronavirus", "ORGANISM", 67, 86], ["porcine coronavirus", "SPECIES", 67, 86], ["transmissible gastroenteritis virus", "SPECIES", 28, 63], ["porcine coronavirus", "SPECIES", 67, 86], ["transmissible gastroenteritis virus", "PROBLEM", 28, 63], ["a porcine coronavirus", "PROBLEM", 65, 86], ["transmissible", "OBSERVATION_MODIFIER", 28, 41], ["gastroenteritis virus", "OBSERVATION", 42, 63], ["porcine coronavirus", "OBSERVATION", 67, 86]]], ["This virus uses aminopeptidase N as a cellular receptor and it does not require sialic acid for successful infection of cultured cells.", [["cellular", "ANATOMY", 38, 46], ["cells", "ANATOMY", 129, 134], ["sialic acid", "CHEMICAL", 80, 91], ["infection", "DISEASE", 107, 116], ["sialic acid", "CHEMICAL", 80, 91], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 16, 32], ["cellular", "CELL", 38, 46], ["sialic acid", "SIMPLE_CHEMICAL", 80, 91], ["cells", "CELL", 129, 134], ["aminopeptidase N", "PROTEIN", 16, 32], ["cellular receptor", "PROTEIN", 38, 55], ["cultured cells", "CELL_LINE", 120, 134], ["This virus", "PROBLEM", 0, 10], ["aminopeptidase N", "TREATMENT", 16, 32], ["a cellular receptor", "TREATMENT", 36, 55], ["sialic acid", "TREATMENT", 80, 91], ["successful infection of cultured cells", "PROBLEM", 96, 134], ["infection", "OBSERVATION", 107, 116]]], ["However, binding to sialylated surface components may increase the efficiency of infection, because mutants lacking the sialic acid binding activity have lost the enteropathogenicity [16, 17] .", [["surface", "ANATOMY", 31, 38], ["infection", "DISEASE", 81, 90], ["sialic acid", "CHEMICAL", 120, 131], ["sialic acid", "CHEMICAL", 120, 131], ["sialic acid", "SIMPLE_CHEMICAL", 120, 131], ["sialylated surface components", "TREATMENT", 20, 49], ["infection", "PROBLEM", 81, 90], ["mutants lacking the sialic acid binding activity", "PROBLEM", 100, 148], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["efficiency", "OBSERVATION_MODIFIER", 67, 77], ["infection", "OBSERVATION", 81, 90]]], ["IBV takes an intermediate position; sialic acid is important for infection of cultured cells but it lacks a receptor-destroying enzyme.", [["cells", "ANATOMY", 87, 92], ["sialic acid", "CHEMICAL", 36, 47], ["infection", "DISEASE", 65, 74], ["sialic acid", "CHEMICAL", 36, 47], ["IBV", "ORGANISM", 0, 3], ["sialic acid", "SIMPLE_CHEMICAL", 36, 47], ["cells", "CELL", 87, 92], ["cultured cells", "CELL_LINE", 78, 92], ["receptor-destroying enzyme", "PROTEIN", 108, 134], ["IBV", "SPECIES", 0, 3], ["IBV", "TREATMENT", 0, 3], ["sialic acid", "TREATMENT", 36, 47], ["infection of cultured cells", "PROBLEM", 65, 92], ["intermediate position", "OBSERVATION_MODIFIER", 13, 34]]], ["As mentioned above, IBV maydin addition to sialylated surface moleculesdbind to a specific receptor similar to the interaction of TGEV with aminopeptidase N. Though it Fig. 6 .", [["surface", "ANATOMY", 54, 61], ["maydin", "CHEMICAL", 24, 30], ["IBV", "ORGANISM", 20, 23], ["maydin", "GENE_OR_GENE_PRODUCT", 24, 30], ["TGEV", "ORGANISM", 130, 134], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 140, 154], ["aminopeptidase", "PROTEIN", 140, 154], ["IBV", "SPECIES", 20, 23], ["TGEV", "SPECIES", 130, 134], ["IBV", "TREATMENT", 20, 23], ["sialylated surface moleculesdbind", "TREATMENT", 43, 76], ["aminopeptidase N.", "TREATMENT", 140, 157]]], ["Effect of neuraminidase treatment on the staining of the tracheal epithelium by the lectin MAA.", [["tracheal epithelium", "ANATOMY", 57, 76], ["MAA", "CHEMICAL", 91, 94], ["neuraminidase", "SIMPLE_CHEMICAL", 10, 23], ["tracheal epithelium", "TISSUE", 57, 76], ["lectin MAA", "GENE_OR_GENE_PRODUCT", 84, 94], ["neuraminidase", "PROTEIN", 10, 23], ["lectin MAA", "PROTEIN", 84, 94], ["neuraminidase treatment", "TREATMENT", 10, 33], ["neuraminidase", "OBSERVATION", 10, 23], ["tracheal", "ANATOMY", 57, 65], ["epithelium", "ANATOMY_MODIFIER", 66, 76], ["lectin MAA", "OBSERVATION", 84, 94]]], ["TOCs were incubated in the presence (\u00feNA) or absence (\u00c0NA) of neuraminidase.", [["TOCs", "SIMPLE_CHEMICAL", 0, 4], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 62, 75], ["TOCs", "CELL_TYPE", 0, 4], ["neuraminidase", "PROTEIN", 62, 75], ["neuraminidase", "PROBLEM", 62, 75]]], ["After incubation, cryosections were prepared and subjected to MAA staining.", [["cryosections", "ANATOMY", 18, 30], ["MAA", "CHEMICAL", 62, 65], ["MAA", "SIMPLE_CHEMICAL", 62, 65], ["cryosections", "TEST", 18, 30], ["MAA staining", "PROBLEM", 62, 74]]], ["Arrows point to the apical membrane of the tracheal epithelium.", [["apical membrane", "ANATOMY", 20, 35], ["tracheal epithelium", "ANATOMY", 43, 62], ["apical membrane", "CELLULAR_COMPONENT", 20, 35], ["tracheal epithelium", "TISSUE", 43, 62], ["apical", "ANATOMY_MODIFIER", 20, 26], ["membrane", "ANATOMY_MODIFIER", 27, 35], ["tracheal epithelium", "ANATOMY", 43, 62]]], ["It should be noted that the enzyme had access only to the apical side of the epithelium. has been suggested that feline aminopeptidase N may be used by IBV to infect cells [18] , recently it has been shown that aminopeptidase N does not serve as a receptor for IBV [19] .DiscussionOur analysis of TOC revealed that both ciliated and mucusproducing cells are susceptible to infection.", [["apical", "ANATOMY", 58, 64], ["epithelium", "ANATOMY", 77, 87], ["cells", "ANATOMY", 166, 171], ["ciliated", "ANATOMY", 320, 328], ["mucusproducing cells", "ANATOMY", 333, 353], ["TOC", "CHEMICAL", 297, 300], ["infection", "DISEASE", 373, 382], ["epithelium", "TISSUE", 77, 87], ["feline", "ORGANISM", 113, 119], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 120, 136], ["IBV", "ORGANISM", 152, 155], ["cells", "CELL", 166, 171], ["aminopeptidase N", "GENE_OR_GENE_PRODUCT", 211, 227], ["IBV", "ORGANISM", 261, 264], ["mucusproducing cells", "CELL", 333, 353], ["feline aminopeptidase N", "PROTEIN", 113, 136], ["aminopeptidase N", "PROTEIN", 211, 227], ["ciliated and mucusproducing cells", "CELL_TYPE", 320, 353], ["IBV", "SPECIES", 152, 155], ["IBV", "SPECIES", 261, 264], ["the enzyme", "TEST", 24, 34], ["feline aminopeptidase N", "TREATMENT", 113, 136], ["aminopeptidase N", "TREATMENT", 211, 227], ["DiscussionOur analysis of TOC", "TEST", 271, 300], ["both ciliated and mucusproducing cells", "PROBLEM", 315, 353], ["infection", "PROBLEM", 373, 382], ["apical", "ANATOMY_MODIFIER", 58, 64], ["epithelium", "ANATOMY_MODIFIER", 77, 87], ["mucusproducing cells", "OBSERVATION", 333, 353], ["infection", "OBSERVATION", 373, 382]]], ["From this result we conclude that in vivo both cell types can act as primary target cells for IBV.", [["cell", "ANATOMY", 47, 51], ["cells", "ANATOMY", 84, 89], ["cell", "CELL", 47, 51], ["cells", "CELL", 84, 89], ["IBV", "ORGANISM", 94, 97], ["primary target cells", "CELL_TYPE", 69, 89], ["IBV", "SPECIES", 94, 97], ["IBV", "PROBLEM", 94, 97]]], ["The expression of a2,3-linked sialic acids and the absence of a2,6-linked sialic acids is consistent with the preference of IBV for the former linkage type ( [7] and this report).", [["sialic acids", "CHEMICAL", 30, 42], ["sialic acids", "CHEMICAL", 74, 86], ["sialic acids", "CHEMICAL", 30, 42], ["sialic acids", "CHEMICAL", 74, 86], ["a2,3-linked sialic acids", "SIMPLE_CHEMICAL", 18, 42], ["a2,6-linked sialic acids", "SIMPLE_CHEMICAL", 62, 86], ["IBV", "ORGANISM", 124, 127], ["a2,3", "PROTEIN", 18, 22], ["a2,6", "PROTEIN", 62, 66], ["IBV", "SPECIES", 124, 127], ["a2,3-linked sialic acids", "PROBLEM", 18, 42], ["a2,6-linked sialic acids", "PROBLEM", 62, 86], ["consistent with", "UNCERTAINTY", 90, 105]]], ["In this respect IBV appears to have developed a similar strategy to avian influenza viruses which also use a2,3-linked sialic on the cell surface to initiate an infection.", [["cell surface", "ANATOMY", 133, 145], ["influenza viruses", "DISEASE", 74, 91], ["infection", "DISEASE", 161, 170], ["IBV", "ORGANISM", 16, 19], ["avian", "ORGANISM", 68, 73], ["influenza viruses", "ORGANISM", 74, 91], ["cell surface", "CELLULAR_COMPONENT", 133, 145], ["avian influenza", "SPECIES", 68, 83], ["IBV", "SPECIES", 16, 19], ["avian influenza viruses", "PROBLEM", 68, 91], ["the cell surface", "TREATMENT", 129, 145], ["an infection", "PROBLEM", 158, 170], ["influenza viruses", "OBSERVATION", 74, 91], ["infection", "OBSERVATION", 161, 170]]], ["However, there are also major differences between avian influenza and avian coronaviruses.", [["avian influenza", "DISEASE", 50, 65], ["avian coronaviruses", "DISEASE", 70, 89], ["avian influenza", "ORGANISM", 50, 65], ["avian coronaviruses", "ORGANISM", 70, 89], ["avian influenza", "SPECIES", 50, 65], ["avian", "SPECIES", 70, 75], ["avian coronaviruses", "SPECIES", 70, 89], ["avian influenza and avian coronaviruses", "PROBLEM", 50, 89], ["major", "OBSERVATION_MODIFIER", 24, 29], ["influenza", "OBSERVATION", 56, 65]]], ["A major determinant of the pathogenicity of influenza viruses is the proteolytic cleavage of the hemagglutinin.", [["influenza viruses", "DISEASE", 44, 61], ["influenza viruses", "ORGANISM", 44, 61], ["hemagglutinin", "PROTEIN", 97, 110], ["influenza viruses", "PROBLEM", 44, 61], ["the proteolytic cleavage", "TREATMENT", 65, 89], ["the hemagglutinin", "TREATMENT", 93, 110], ["influenza viruses", "OBSERVATION", 44, 61]]], ["The hemagglutinins of highly pathogenic viruses have a multibasic cleavage site that is susceptible to furin-like enzymes present in many cell types.", [["cell", "ANATOMY", 138, 142], ["furin", "GENE_OR_GENE_PRODUCT", 103, 108], ["cell", "CELL", 138, 142], ["multibasic cleavage site", "DNA", 55, 79], ["furin-like enzymes", "PROTEIN", 103, 121], ["highly pathogenic viruses", "PROBLEM", 22, 47], ["a multibasic cleavage site", "PROBLEM", 53, 79], ["furin-like enzymes", "PROBLEM", 103, 121], ["highly", "OBSERVATION_MODIFIER", 22, 28], ["pathogenic", "OBSERVATION_MODIFIER", 29, 39], ["viruses", "OBSERVATION", 40, 47], ["multibasic cleavage", "OBSERVATION", 55, 74], ["many cell types", "OBSERVATION", 133, 148]]], ["Viruses of low pathogenicity become fusion-active by a protease that is secreted by respiratory cells.", [["respiratory cells", "ANATOMY", 84, 101], ["respiratory cells", "CELL", 84, 101], ["protease", "PROTEIN", 55, 63], ["respiratory cells", "CELL_TYPE", 84, 101], ["low pathogenicity", "PROBLEM", 11, 28], ["a protease", "PROBLEM", 53, 63], ["low pathogenicity", "OBSERVATION_MODIFIER", 11, 28], ["fusion", "OBSERVATION", 36, 42], ["active", "OBSERVATION_MODIFIER", 43, 49], ["respiratory cells", "OBSERVATION", 84, 101]]], ["The S protein of all IBV strains has a multibasic cleavage site and is cleaved in all cell types into the subunits S1 and S2.", [["cell", "ANATOMY", 86, 90], ["IBV", "ORGANISM", 21, 24], ["cell", "CELL", 86, 90], ["S2", "GENE_OR_GENE_PRODUCT", 122, 124], ["S protein", "PROTEIN", 4, 13], ["multibasic cleavage site", "DNA", 39, 63], ["S1", "PROTEIN", 115, 117], ["S2", "PROTEIN", 122, 124], ["IBV", "SPECIES", 21, 24], ["The S protein", "TEST", 0, 13], ["all IBV strains", "PROBLEM", 17, 32], ["a multibasic cleavage site", "PROBLEM", 37, 63], ["IBV strains", "OBSERVATION", 21, 32], ["multibasic", "OBSERVATION_MODIFIER", 39, 49], ["cleavage site", "OBSERVATION", 50, 63], ["all cell types", "OBSERVATION", 82, 96], ["subunits S1", "ANATOMY_MODIFIER", 106, 117], ["S2", "ANATOMY", 122, 124]]], ["Therefore, proteolytical activation of S is not a major determinant of the pathogenicity of IBV.", [["IBV", "ORGANISM", 92, 95], ["IBV", "SPECIES", 92, 95], ["IBV", "PROBLEM", 92, 95], ["pathogenicity", "OBSERVATION", 75, 88], ["IBV", "OBSERVATION", 92, 95]]], ["Why some IBV strains are predominantly respiratory pathogens whereas others affect other organs to cause disease, e.g. the renal system or the reproductive tract, is not known.", [["organs", "ANATOMY", 89, 95], ["renal system", "ANATOMY", 123, 135], ["reproductive tract", "ANATOMY", 143, 161], ["IBV strains", "ORGANISM", 9, 20], ["organs", "ORGAN", 89, 95], ["renal system", "MULTI-TISSUE_STRUCTURE", 123, 135], ["reproductive tract", "ORGANISM_SUBDIVISION", 143, 161], ["IBV", "SPECIES", 9, 12], ["some IBV strains", "PROBLEM", 4, 20], ["predominantly respiratory pathogens", "PROBLEM", 25, 60], ["disease", "PROBLEM", 105, 112], ["IBV strains", "OBSERVATION", 9, 20], ["predominantly", "OBSERVATION_MODIFIER", 25, 38], ["respiratory pathogens", "OBSERVATION", 39, 60], ["renal system", "ANATOMY", 123, 135], ["reproductive tract", "OBSERVATION", 143, 161], ["not known", "UNCERTAINTY", 166, 175]]], ["If there exists a second receptor for this virus as discussed above, such a protein may be responsible for the host specificity as well as the tissue or organ tropism of IBV.", [["tissue", "ANATOMY", 143, 149], ["organ", "ANATOMY", 153, 158], ["tissue", "TISSUE", 143, 149], ["organ", "ORGAN", 153, 158], ["IBV", "ORGANISM", 170, 173], ["IBV", "SPECIES", 170, 173], ["this virus", "PROBLEM", 38, 48], ["a protein", "TEST", 74, 83], ["IBV", "PROBLEM", 170, 173]]], ["Furthermore, the sialoglyconjugates used for primary attachment should be analyzed.", [["sialoglyconjugates", "CHEMICAL", 17, 35], ["sialoglyconjugates", "SIMPLE_CHEMICAL", 17, 35], ["the sialoglyconjugates", "TREATMENT", 13, 35], ["primary attachment", "TREATMENT", 45, 63]]], ["The available lectins and neuraminidases only allow a differentiation between a2,3and a2,6-linked sialic acids.", [["a2,3and a2,6-linked sialic acids", "CHEMICAL", 78, 110], ["sialic acids", "CHEMICAL", 98, 110], ["neuraminidases", "GENE_OR_GENE_PRODUCT", 26, 40], ["a2,3", "SIMPLE_CHEMICAL", 78, 82], ["a2,6-linked sialic acids", "SIMPLE_CHEMICAL", 86, 110], ["neuraminidases", "PROTEIN", 26, 40], ["a2,3and a2,6-linked sialic acids", "PROTEIN", 78, 110], ["neuraminidases", "PROBLEM", 26, 40], ["a2,3", "TEST", 78, 82], ["sialic acids", "OBSERVATION", 98, 110]]], ["Different oligosaccharides exist that contain a2,3linked sialic acid, and the sialoglycoconjugates recognized by IBV may be different from those that are preferred by avian influenza viruses.", [["sialic acid", "CHEMICAL", 57, 68], ["influenza viruses", "DISEASE", 173, 190], ["sialic acid", "CHEMICAL", 57, 68], ["a2,3linked sialic acid", "SIMPLE_CHEMICAL", 46, 68], ["sialoglycoconjugates", "SIMPLE_CHEMICAL", 78, 98], ["IBV", "ORGANISM", 113, 116], ["avian influenza viruses", "ORGANISM", 167, 190], ["avian influenza", "SPECIES", 167, 182], ["IBV", "SPECIES", 113, 116], ["Different oligosaccharides", "PROBLEM", 0, 26], ["sialic acid", "TEST", 57, 68], ["IBV", "PROBLEM", 113, 116], ["avian influenza viruses", "PROBLEM", 167, 190], ["a2", "OBSERVATION_MODIFIER", 46, 48], ["sialic", "OBSERVATION_MODIFIER", 57, 63], ["acid", "OBSERVATION_MODIFIER", 64, 68], ["IBV", "OBSERVATION", 113, 116]]], ["Such differences may also contribute to a different course of infection.", [["infection", "DISEASE", 62, 71], ["infection", "PROBLEM", 62, 71], ["may also contribute", "UNCERTAINTY", 17, 36], ["infection", "OBSERVATION", 62, 71]]], ["Expression of a2,3-linked sialic acid on epithelial cells in chickens has been analyzed for the trachea and the intestine [20, 21] .", [["epithelial cells", "ANATOMY", 41, 57], ["trachea", "ANATOMY", 96, 103], ["intestine", "ANATOMY", 112, 121], ["a2,3-linked sialic acid", "CHEMICAL", 14, 37], ["sialic acid", "CHEMICAL", 26, 37], ["a2,3-linked sialic acid", "SIMPLE_CHEMICAL", 14, 37], ["epithelial cells", "CELL", 41, 57], ["chickens", "ORGANISM", 61, 69], ["trachea", "ORGAN", 96, 103], ["intestine", "ORGAN", 112, 121], ["a2,3", "PROTEIN", 14, 18], ["epithelial cells", "CELL_TYPE", 41, 57], ["chickens", "SPECIES", 61, 69], ["chickens", "SPECIES", 61, 69], ["epithelial cells in chickens", "TREATMENT", 41, 69], ["sialic", "ANATOMY_MODIFIER", 26, 32], ["epithelial cells", "OBSERVATION", 41, 57], ["trachea", "ANATOMY", 96, 103], ["intestine", "ANATOMY", 112, 121]]], ["As far as other target organs of IBVare concerned, e.g. kidney and the reproductive system, a2,3-linked sialic acid has been shown to be present on primary kidney cells [7] .", [["organs", "ANATOMY", 23, 29], ["kidney", "ANATOMY", 56, 62], ["primary kidney cells", "ANATOMY", 148, 168], ["a2,3-linked sialic acid", "CHEMICAL", 92, 115], ["sialic acid", "CHEMICAL", 104, 115], ["organs", "ORGAN", 23, 29], ["kidney", "ORGAN", 56, 62], ["a2,3-linked sialic acid", "SIMPLE_CHEMICAL", 92, 115], ["kidney cells", "CELL", 156, 168], ["primary kidney cells", "CELL_TYPE", 148, 168], ["linked sialic acid", "PROBLEM", 97, 115], ["kidney", "ANATOMY", 56, 62], ["kidney", "ANATOMY", 156, 162]]], ["It will be interesting in the future to find out whether infection of the reproductive system is also mediated by sialic acid.", [["infection", "DISEASE", 57, 66], ["sialic acid", "CHEMICAL", 114, 125], ["sialic acid", "CHEMICAL", 114, 125], ["sialic acid", "SIMPLE_CHEMICAL", 114, 125], ["infection of the reproductive system", "PROBLEM", 57, 93], ["sialic acid", "TEST", 114, 125], ["infection", "OBSERVATION", 57, 66]]]], "08a76329625faa03777575af660b36e659dec428": [["BackgroundRecent emerging infectious diseases such as Severe Acute Respiratory Syndrome (SARS), Avian Influenza, and Middle East Respiratory Syndrome related coronavirus (MERS-CoV) continue to be a major public health concern [1] .", [["infectious diseases", "DISEASE", 26, 45], ["Acute Respiratory Syndrome", "DISEASE", 61, 87], ["SARS", "DISEASE", 89, 93], ["Avian Influenza", "DISEASE", 96, 111], ["Middle East Respiratory Syndrome", "DISEASE", 117, 149], ["Middle East Respiratory Syndrome related coronavirus", "ORGANISM", 117, 169], ["MERS-CoV", "ORGANISM", 171, 179], ["Avian Influenza", "SPECIES", 96, 111], ["Middle East Respiratory Syndrome related coronavirus", "SPECIES", 117, 169], ["MERS-CoV", "SPECIES", 171, 179], ["BackgroundRecent emerging infectious diseases", "PROBLEM", 0, 45], ["Severe Acute Respiratory Syndrome", "PROBLEM", 54, 87], ["SARS)", "PROBLEM", 89, 94], ["Avian Influenza", "PROBLEM", 96, 111], ["Middle East Respiratory Syndrome", "PROBLEM", 117, 149], ["coronavirus", "PROBLEM", 158, 169], ["infectious", "OBSERVATION", 26, 36], ["Severe", "OBSERVATION_MODIFIER", 54, 60], ["Acute", "OBSERVATION_MODIFIER", 61, 66], ["Respiratory Syndrome", "OBSERVATION", 67, 87], ["Middle", "ANATOMY_MODIFIER", 117, 123], ["Respiratory Syndrome", "OBSERVATION", 129, 149]]], ["The 2015 MERS outbreak in South Korea was the largest outbreak of MERS-CoV outside of the Middle East, resulting in 186 infected cases, 38 causalities, and 16,752 people being quarantined [2] [3] [4] .", [["MERS-CoV", "ORGANISM", 66, 74], ["people", "ORGANISM", 163, 169], ["people", "SPECIES", 163, 169], ["MERS-CoV", "SPECIES", 66, 74], ["largest", "OBSERVATION_MODIFIER", 46, 53], ["Middle East", "ANATOMY", 90, 101]]], ["The characteristics and mechanisms of MERS transmission have been well investigated since the outbreak [5] [6] [7] .", [["MERS", "GENE_OR_GENE_PRODUCT", 38, 42]]], ["Specifically, MERS deaths in Korea can be attributed to the absence of effective vaccination and treatment for MERS, weak healthcare system for epidemic control, and ill-prepared hospitals with a deficiency in professional expertise, as well as negative pressure room for isolation of MERS patients [7] [8] [9] [10] .", [["deaths", "DISEASE", 19, 25], ["MERS", "DISEASE", 285, 289], ["patients", "ORGANISM", 290, 298], ["[7] [8] [9", "SIMPLE_CHEMICAL", 299, 309], ["patients", "SPECIES", 290, 298], ["effective vaccination", "TREATMENT", 71, 92], ["treatment", "TREATMENT", 97, 106], ["MERS", "PROBLEM", 111, 115], ["epidemic control", "TREATMENT", 144, 160], ["a deficiency", "PROBLEM", 194, 206]]], ["Furthermore, increased incidences of nosocomial infection of MERS during the outbreak in 2015 elevated the fear, panic, and anger among the general public [11, 12] .BackgroundAs such, individuals exposed to risks and uncertainties tend to seek self-care measures and resort to nonconventional solutions such as complementary and alternative medicine (CAM) in order to demonstrate their autonomy, mitigate the risk, and make the situation more manageable [13] [14] [15] .", [["infection", "DISEASE", 48, 57], ["MERS", "DISEASE", 61, 65], ["panic", "DISEASE", 113, 118], ["CAM", "MULTI-TISSUE_STRUCTURE", 351, 354], ["nosocomial infection of MERS", "PROBLEM", 37, 65], ["panic", "PROBLEM", 113, 118], ["self-care measures", "TREATMENT", 244, 262], ["nonconventional solutions", "TREATMENT", 277, 302], ["alternative medicine (CAM)", "TREATMENT", 329, 355], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["nosocomial", "OBSERVATION_MODIFIER", 37, 47], ["infection", "OBSERVATION", 48, 57]]], ["Also, the usage is even greater among those with a chronic condition and report poorer health status [16] [17] [18] [19] .", [["a chronic condition", "PROBLEM", 49, 68]]], ["Thus, the use of CAM among infectious diseases patients has gained popularity over the past decades, and a growing body of literature highlights its use against the threat of new and emerging infectious diseases such as HIV/AIDS, SARS, and H1N1 [20] [21] [22] [23] [24] [25] [26] .", [["infectious diseases", "DISEASE", 27, 46], ["infectious diseases such as HIV/AIDS", "DISEASE", 192, 228], ["SARS", "DISEASE", 230, 234], ["H1N1 [20] [21] [22] [23] [24] [25] [26]", "CHEMICAL", 240, 279], ["CAM", "MULTI-TISSUE_STRUCTURE", 17, 20], ["patients", "ORGANISM", 47, 55], ["[20] [21] [22] [23] [24] [25] [26]", "SIMPLE_CHEMICAL", 245, 279], ["patients", "SPECIES", 47, 55], ["new and emerging infectious diseases", "PROBLEM", 175, 211], ["HIV/AIDS", "TEST", 220, 228], ["SARS", "PROBLEM", 230, 234], ["H1N1", "PROBLEM", 240, 244], ["infectious", "OBSERVATION", 192, 202]]], ["Furthermore, it is especially important to investigate the characteristics of CAM use in countries where the practice of traditional medicine is popular.BackgroundIn Korea, the use of CAM is widespread and culturally embedded as traditional Korean medicine (TKM) is recognized as a part of mainstream medicine in the Korean healthcare system.", [["CAM", "MULTI-TISSUE_STRUCTURE", 78, 81], ["CAM", "MULTI-TISSUE_STRUCTURE", 184, 187], ["traditional medicine", "TREATMENT", 121, 141], ["traditional Korean medicine", "TREATMENT", 229, 256]]], ["Some of its modalities, such as acupuncture, moxibustion, cupping, and herbal preparations, have been covered by the national health insurance since 1987, and patients can choose between TKM and conventional medicine based on their preferences [27] .", [["cupping", "DISEASE", 58, 65], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["acupuncture", "TREATMENT", 32, 43], ["moxibustion", "TREATMENT", 45, 56], ["cupping", "TREATMENT", 58, 65], ["herbal preparations", "TREATMENT", 71, 90]]], ["Therefore, practice and consumption of CAM modalities, including TKM, are common among Koreans to prevent and manage acute illnesses [28, 29] .BackgroundHowever, previous studies on CAM use during epidemics focus on the clinical efficacy of CAM modalities [23] [24] [25] .", [["CAM", "MULTI-TISSUE_STRUCTURE", 39, 42], ["CAM", "MULTI-TISSUE_STRUCTURE", 182, 185], ["CAM", "MULTI-TISSUE_STRUCTURE", 241, 244], ["[23] [24] [25]", "SIMPLE_CHEMICAL", 256, 270], ["CAM modalities", "TREATMENT", 39, 53], ["TKM", "TREATMENT", 65, 68], ["acute illnesses", "PROBLEM", 117, 132], ["previous studies", "TEST", 162, 178], ["CAM modalities", "TEST", 241, 255]]], ["Those provide limited information about the detailed pattern of CAM use, why specific CAM modalities were chosen, and where the patients obtained the information on CAM during the emerging infectious disease outbreak.", [["infectious disease", "DISEASE", 189, 207], ["CAM", "MULTI-TISSUE_STRUCTURE", 64, 67], ["CAM", "MULTI-TISSUE_STRUCTURE", 86, 89], ["patients", "ORGANISM", 128, 136], ["CAM", "MULTI-TISSUE_STRUCTURE", 165, 168], ["patients", "SPECIES", 128, 136], ["infectious", "OBSERVATION", 189, 199]]], ["Therefore, this study aims to examine patterns and motivations of CAM use among outpatients at a community hospital during the 2015 MERS outbreak in Korea and identify their source of information on non-conventional medicine use.Study setting and participantsA descriptive cross-sectional study was conducted among patients attending the outpatient departments at a community hospital located in Seoul, South Korea.", [["CAM", "MULTI-TISSUE_STRUCTURE", 66, 69], ["outpatients", "ORGANISM", 80, 91], ["participants", "ORGANISM", 247, 259], ["patients", "ORGANISM", 315, 323], ["participants", "SPECIES", 247, 259], ["patients", "SPECIES", 315, 323], ["this study", "TEST", 11, 21], ["A descriptive cross-sectional study", "TEST", 259, 294]]], ["All outpatients over the age of 18 were eligible to participate in the survey.", [["outpatients", "ORGANISM", 4, 15], ["outpatients", "SPECIES", 4, 15]]], ["Exclusion criteria were those who were admitted to the inpatient unit at the time of the survey, unable to speak or understand the survey questionnaire.Study sizeThe formula for sample size determination using confidence interval (CI) of proportion was used to calculate the sample size:Study sizewhere n is the required sample size, p is the estimated proportion of CAM use among the general population (0.692) calculated from previous studies [30, 31] , d is the margin of error set on 0.05, q is the proportion of people not suing CAM (1-p), and z 0.025 is 1.96 which corresponds to the confidence interval of 95%.", [["CAM", "MULTI-TISSUE_STRUCTURE", 367, 370], ["people", "ORGANISM", 517, 523], ["people", "SPECIES", 517, 523], ["Study size", "TEST", 152, 162], ["CI", "TEST", 231, 233], ["previous studies", "TEST", 428, 444], ["size", "OBSERVATION_MODIFIER", 158, 162], ["size", "OBSERVATION_MODIFIER", 282, 286], ["size", "OBSERVATION_MODIFIER", 328, 332], ["margin", "OBSERVATION_MODIFIER", 465, 471]]], ["This equation gave the minimum sample size as 328, and we distributed a total of 400 survey questionnaires assuming a 20% non-response rate.Survey instrumentThe semi-structured survey questionnaire was developed in the Korean language (See Additional file 1: Survey questionnaire).", [["This equation", "TEST", 0, 13], ["non-response rate", "TEST", 122, 139], ["Survey instrument", "TEST", 140, 157], ["The semi-structured survey questionnaire", "TEST", 157, 197], ["size", "OBSERVATION_MODIFIER", 38, 42]]], ["Because previous research tools on CAM use during emerging infectious disease outbreaks were unavailable, the survey instrument was developed based on earlier studies on CAM use [32] [33] [34] .", [["infectious disease", "DISEASE", 59, 77], ["CAM", "MULTI-TISSUE_STRUCTURE", 35, 38], ["CAM", "MULTI-TISSUE_STRUCTURE", 170, 173], ["emerging infectious disease outbreaks", "PROBLEM", 50, 87], ["the survey instrument", "TEST", 106, 127], ["infectious", "OBSERVATION_MODIFIER", 59, 69]]], ["In order to assess content and face validation of the survey instrument, the questionnaire was reviewed by three researchers to evaluate appropriateness, relevancy, clarity, adequacy, and organization of the questions.", [["the survey instrument", "TEST", 50, 71]]], ["In addition, the questionnaire was pilot-tested on a sample of 20 participants to examine length, clarity, and difficulty of the questions, and a few items were revised based on the results.Survey instrumentThe final version of the questionnaire included 36 items with both multiple-choice and open-ended questions, and respondents' perceptions and concerns regarding the MERS outbreak were measured using a 5point Likert scale.", [["participants", "SPECIES", 66, 78], ["Survey instrument", "TEST", 190, 207], ["the MERS outbreak", "PROBLEM", 368, 385], ["a 5point Likert scale", "TREATMENT", 406, 427]]], ["The survey was divided into four major sections: The first section included eight questions on health-related characteristics (smoking and drinking experience, the practice of regular exercise, and presence and perceived-severity of comorbidities) and the level of self-perceived interest in health-promoting behavior of respondents (1 = not at all, 5 = very much).", [["comorbidities", "PROBLEM", 233, 246]]], ["The second section contained 11 questions regarding respondents' perceived danger and severity of MERS outbreak (1 = not at all, 5 = very much), concerns about MERS infection (1 = not at all, 5 = very much), the opinions on the trust in government response during the MERS outbreak, and source of information about MERS outbreak.", [["MERS infection", "DISEASE", 160, 174], ["MERS infection", "PROBLEM", 160, 174]]], ["The third part consisted of seven questions on CAM use (CAM use prior to the outbreak, types of modalities used during the outbreak-the respondents who checked on any modalities were categorised as CAM users, source of information, the reason for CAM use, and intention to recommend CAM to others), and the last section had nine questions on respondents' sociodemographic characteristics such as age, gender, marital status, level of education, occupation, level of income, religion, and area of residence.Data collectionThe survey was conducted from November 26th to December 2nd, 2015.", [["CAM", "MULTI-TISSUE_STRUCTURE", 47, 50], ["CAM", "MULTI-TISSUE_STRUCTURE", 56, 59], ["CAM", "MULTI-TISSUE_STRUCTURE", 198, 201], ["CAM", "MULTI-TISSUE_STRUCTURE", 247, 250], ["modalities", "TREATMENT", 96, 106], ["Data collection", "TEST", 506, 521]]], ["Two surveyors were trained and recruited for data collection, and the information about the research was given verbally to each respondent.", [["data collection", "TEST", 45, 60]]], ["All participants were assured of their confidentiality and completed IRB-approved written informed consent before the survey.", [["participants", "SPECIES", 4, 16]]], ["A total of 400 self-completed questionnaires were distributed, but 69 participants did not return or complete the questionnaire (response rate: 82.75%); therefore, the data of 331 respondents were included in the final analysis.Statistical methodsThe collected data of 331 respondents were analyzed using the Statistical Package for Social Sciences (SPSS) version 21.0.", [["participants", "SPECIES", 70, 82], ["response rate", "TEST", 129, 142], ["the final analysis", "TEST", 209, 227], ["The collected data", "TEST", 247, 265]]], ["Pearson's Chi-square test was performed to identify differences in sociodemographic characteristics and perceptions and concerns experienced during the MERS outbreak between CAM users and non-users.", [["CAM", "MULTI-TISSUE_STRUCTURE", 174, 177], ["Pearson's Chi-square test", "TEST", 0, 25]]], ["Lastly, multivariate logistic regression analysis was conducted to determine potential predictors of CAM use during the MERS outbreak.", [["CAM", "MULTI-TISSUE_STRUCTURE", 101, 104], ["multivariate logistic regression analysis", "TEST", 8, 49], ["the MERS outbreak", "PROBLEM", 116, 133]]], ["The significant factors from previous chi-square test (gender, age, religion, marital status, occupation, smoking status, alcohol consumption, degree of concern about no treatment modality available for MERS, trust in the government response, the perceived danger of the MERS outbreak on one's health, hand washing, and refraining from physical contact with others) were subjected to the regression analysis.", [["hand", "ANATOMY", 302, 306], ["alcohol", "CHEMICAL", 122, 129], ["alcohol", "CHEMICAL", 122, 129], ["hand", "ORGANISM_SUBDIVISION", 302, 306], ["previous chi-square test", "TEST", 29, 53], ["treatment modality", "TREATMENT", 170, 188], ["MERS", "PROBLEM", 203, 207], ["hand washing", "TREATMENT", 302, 314], ["the regression analysis", "TEST", 384, 407], ["significant", "OBSERVATION_MODIFIER", 4, 15]]], ["A pvalue of less than 0.05 was considered statistically significant for all analyses.Ethical clearanceThe ethical approval of the study was obtained from the Institutional Review Board on Human Subjects Research and Ethics Committees, Hanyang University, Seoul, Korea (HYI-15-210-1).ResultsSociodemographic characteristics of study participants Table 1 presents the sociodemographic characteristics of respondents.", [["Human", "ORGANISM", 188, 193], ["Human", "SPECIES", 188, 193], ["participants", "SPECIES", 332, 344], ["A pvalue", "TEST", 0, 8], ["Ethical clearance", "TEST", 85, 102], ["the study", "TEST", 126, 135], ["HYI", "TEST", 269, 272]]], ["The majority of respondents were women (68%), married (72.5%), received undergraduate education or higher (51.1%), have monthly household income higher than approximately 4000 USD (41.4%), and used CAM prior to the outbreak (54.7%).Results76.1% of respondents have used at least one of the listed CAM modalities during the MERS outbreak, and significant differences in gender (p = 0.003), age (p = 0.001), marital status (p = 0.035), occupation (p = 0.001), religion (p = 0.006), smoking status (p = 0.003), alcohol consumption (p = 0.041), and prior use of CAM (p < 0.001) between CAM users and non-users were observedTypes of CAM modalities used during the MERS outbreakTypes of CAM modalities used by respondents during the MERS outbreak are demonstrated in Table 2 .", [["alcohol", "CHEMICAL", 508, 515], ["alcohol", "CHEMICAL", 508, 515], ["women", "ORGANISM", 33, 38], ["CAM", "MULTI-TISSUE_STRUCTURE", 297, 300], ["alcohol", "SIMPLE_CHEMICAL", 508, 515], ["CAM", "MULTI-TISSUE_STRUCTURE", 558, 561], ["CAM", "MULTI-TISSUE_STRUCTURE", 582, 585], ["CAM", "MULTI-TISSUE_STRUCTURE", 628, 631], ["CAM", "MULTI-TISSUE_STRUCTURE", 681, 684], ["women", "SPECIES", 33, 38], ["Results", "TEST", 232, 239], ["CAM (p", "TREATMENT", 558, 564], ["CAM modalities", "TREATMENT", 628, 642], ["CAM modalities", "TREATMENT", 681, 695], ["significant", "OBSERVATION_MODIFIER", 342, 353]]], ["A total of 252 CAM users were identified.", [["CAM", "ANATOMY", 15, 18], ["CAM", "MULTI-TISSUE_STRUCTURE", 15, 18]]], ["Among natural products, the prevalence of multivitamin consumption was the highest (51.2%), followed by whole grain, brown rice, and black bean (32.1%), and probiotics (31.0%).", [["grain", "ANATOMY", 110, 115], ["multivitamin", "CHEMICAL", 42, 54], ["multivitamin", "CHEMICAL", 42, 54], ["multivitamin", "SIMPLE_CHEMICAL", 42, 54], ["grain", "ORGANISM_SUBDIVISION", 110, 115], ["brown rice", "ORGANISM", 117, 127], ["black bean", "ORGANISM", 133, 143], ["rice", "SPECIES", 123, 127], ["black bean", "SPECIES", 133, 143], ["brown rice", "SPECIES", 117, 127], ["black bean", "SPECIES", 133, 143], ["multivitamin consumption", "TREATMENT", 42, 66], ["black bean", "TEST", 133, 143], ["probiotics", "TREATMENT", 157, 167]]], ["The exercise was the most practiced modality among the mind and body practices (27.8%), and traditional Korean medicine was used by 6.3% of CAM users.Source of information on CAMAs presented in Table 3 , the primary information source of CAM use was mass media (52.4%) and the internet (27.4%).", [["body", "ANATOMY", 64, 68], ["body", "ORGANISM_SUBDIVISION", 64, 68], ["CAM", "MULTI-TISSUE_STRUCTURE", 140, 143], ["CAM", "MULTI-TISSUE_STRUCTURE", 238, 241], ["traditional Korean medicine", "TREATMENT", 92, 119], ["mass media", "PROBLEM", 250, 260]]], ["The least popular source was pharmacists (2.8%).Reason for CAM use and intention to recommend CAMThe most common reason for CAM use among 252 CAM users was to improve the immune system (63.1%), followed by to prevent disease and maintain/promote health (53.2%).", [["CAM", "MULTI-TISSUE_STRUCTURE", 59, 62], ["CAM", "MULTI-TISSUE_STRUCTURE", 124, 127], ["CAM", "MULTI-TISSUE_STRUCTURE", 142, 145], ["the immune system", "TEST", 167, 184], ["disease", "PROBLEM", 217, 224], ["least", "OBSERVATION_MODIFIER", 4, 9], ["popular", "OBSERVATION_MODIFIER", 10, 17]]], ["Also, 72.6% of CAM users were willing to recommend CAM to others.", [["CAM", "MULTI-TISSUE_STRUCTURE", 15, 18], ["CAM", "MULTI-TISSUE_STRUCTURE", 51, 54]]], ["As the reason for nonuse of CAM among 79 non-CAM users, 27.8% responded that they do not believe that CAM is relevant to disease treatment, and 26.6% reported that they do not trust in the effectiveness of CAM (Table 3) .Reason for CAM use and intention to recommend CAMDifferences in perception, degree of concerns, and trust in the government response Differences in perceptions, degree of concerns, and trust in government response between CAM users and non-users are demonstrated in Table 4 .", [["CAM", "MULTI-TISSUE_STRUCTURE", 28, 31], ["CAM", "MULTI-TISSUE_STRUCTURE", 45, 48], ["CAM", "MULTI-TISSUE_STRUCTURE", 102, 105], ["CAM", "MULTI-TISSUE_STRUCTURE", 206, 209], ["CAM", "MULTI-TISSUE_STRUCTURE", 232, 235], ["CAM", "MULTI-TISSUE_STRUCTURE", 443, 446], ["disease treatment", "TREATMENT", 121, 138]]], ["Majority of respondents obtained MERS-related information through mass media (58.6%), displayed a high degree of concern about contracting the disease (49.2%), not being able to visit CAM users' concern for the lack of definitive treatment for MERS infection (p = 0.017) and self-perceived danger of the MERS outbreak (p = 0.017) was significantly greater than that of non-CAM users.", [["MERS infection", "DISEASE", 244, 258], ["MERS", "DISEASE", 304, 308], ["CAM", "MULTI-TISSUE_STRUCTURE", 184, 187], ["non-CAM", "CANCER", 369, 376], ["mass media", "TEST", 66, 76], ["the disease", "PROBLEM", 139, 150], ["definitive treatment", "TREATMENT", 219, 239], ["MERS infection", "PROBLEM", 244, 258], ["high degree", "OBSERVATION_MODIFIER", 98, 109]]], ["A more significant proportion of CAM users (48.8%) regarded government response to the MERS outbreak as inappropriate (p = 0.020), and CAM users practiced more handwashing (p = 0.011) and refrained from physical contact with others (p = 0.010) compared to the non-users.Potential predictors of CAM use during the MERS outbreakThe result of multivariate logistic regression analysis is shown inDiscussionThis research is the first attempt to understand the prevalence and determinants of CAM use among patients during the MERS outbreak in Seoul, South Korea.", [["CAM", "ANATOMY", 33, 36], ["CAM", "MULTI-TISSUE_STRUCTURE", 33, 36], ["CAM", "MULTI-TISSUE_STRUCTURE", 135, 138], ["CAM", "MULTI-TISSUE_STRUCTURE", 294, 297], ["CAM", "MULTI-TISSUE_STRUCTURE", 487, 490], ["patients", "ORGANISM", 501, 509], ["patients", "SPECIES", 501, 509], ["multivariate logistic regression analysis", "TEST", 340, 381]]], ["While the efficacy of many CAM therapies has yet to be demonstrated, previous studies reported that CAM was commonly used during the outbreak of infectious diseases, such as malaria, dengue, H1N1, SARS, and the common cold to improve health [21-23, 25, 32, 35, 36] .", [["infectious diseases", "DISEASE", 145, 164], ["malaria", "DISEASE", 174, 181], ["dengue", "DISEASE", 183, 189], ["H1N1", "DISEASE", 191, 195], ["SARS", "DISEASE", 197, 201], ["CAM", "MULTI-TISSUE_STRUCTURE", 27, 30], ["CAM", "MULTI-TISSUE_STRUCTURE", 100, 103], ["many CAM therapies", "TREATMENT", 22, 40], ["previous studies", "TEST", 69, 85], ["infectious diseases", "PROBLEM", 145, 164], ["malaria", "PROBLEM", 174, 181], ["dengue", "PROBLEM", 183, 189], ["H1N1", "PROBLEM", 191, 195], ["SARS", "PROBLEM", 197, 201], ["infectious", "OBSERVATION", 145, 155]]], ["Our findings also revealed a high utilization rate of CAM (76.1%) during the MERS outbreak, yet similar prevalence was reported during a non-epidemic period in Korea, showing an overall rise in CAM use among Koreans [30, 37, 38] .", [["CAM", "MULTI-TISSUE_STRUCTURE", 54, 57], ["CAM", "MULTI-TISSUE_STRUCTURE", 194, 197], ["a high utilization rate of CAM", "PROBLEM", 27, 57], ["the MERS outbreak", "PROBLEM", 73, 90], ["high", "OBSERVATION_MODIFIER", 29, 33], ["overall", "OBSERVATION_MODIFIER", 178, 185], ["rise", "OBSERVATION_MODIFIER", 186, 190]]], ["Furthermore, the prevalence of CAM use during the MERS outbreak was similar to that \u00aa Participants were asked to rate their degree of concern (1 = Not at all, 5 = Very much)\u00b0P articipants were asked to rate their self-perceived likelihood of contracting the disease (1 = Not at all, 5 = Very likely) 1 Participants were asked to rate their self-perceived danger of the MERS on health (1 = Not at all, 5 = Very much) * Columns do not add up to 100% due to the selection of multiple answers of cancer patients [39, 40] , yet higher than that of chronic disease patients in Korea [41] [42] [43] .DiscussionTo date, the reasons and motivations for seeking CAM during epidemics vary across studies [14, 21, 22, 32] .", [["cancer", "ANATOMY", 492, 498], ["cancer", "DISEASE", 492, 498], ["chronic disease", "DISEASE", 543, 558], ["CAM", "MULTI-TISSUE_STRUCTURE", 31, 34], ["cancer", "CANCER", 492, 498], ["patients", "ORGANISM", 499, 507], ["patients", "ORGANISM", 559, 567], ["CAM", "MULTI-TISSUE_STRUCTURE", 652, 655], ["Participants", "SPECIES", 86, 98], ["Participants", "SPECIES", 302, 314], ["patients", "SPECIES", 499, 507], ["patients", "SPECIES", 559, 567], ["contracting the disease", "PROBLEM", 242, 265], ["chronic disease", "PROBLEM", 543, 558], ["cancer", "OBSERVATION", 492, 498], ["chronic", "OBSERVATION_MODIFIER", 543, 550], ["disease", "OBSERVATION", 551, 558]]], ["However, during the MERS outbreak in Korea, the leading motivations for trying CAM were to improve the immune system and to prevent diseases.", [["immune system", "ANATOMY", 103, 116], ["CAM", "MULTI-TISSUE_STRUCTURE", 79, 82], ["trying CAM", "TREATMENT", 72, 82], ["diseases", "PROBLEM", 132, 140]]], ["During the previous outbreaks of severe influenza, it was also documented that CAM was used for direct treatment against infectious diseases in various countries [22-24, 35, 44] .", [["influenza", "DISEASE", 40, 49], ["infectious diseases", "DISEASE", 121, 140], ["CAM", "MULTI-TISSUE_STRUCTURE", 79, 82], ["severe influenza", "PROBLEM", 33, 49], ["direct treatment", "TREATMENT", 96, 112], ["infectious diseases", "PROBLEM", 121, 140], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["influenza", "OBSERVATION", 40, 49]]], ["This implies that during infectious disease outbreaks, CAM is used not only to prevent the infection through the achievement of overall well-being and enhancement of immune function, but also to cure the disease directly by combating against the virus.DiscussionAs there are multiple reasons behind the utilization of CAM, the use of CAM products differed among studies.", [["infectious disease", "DISEASE", 25, 43], ["infection", "DISEASE", 91, 100], ["CAM", "MULTI-TISSUE_STRUCTURE", 55, 58], ["CAM", "MULTI-TISSUE_STRUCTURE", 318, 321], ["CAM", "MULTI-TISSUE_STRUCTURE", 334, 337], ["infectious disease outbreaks", "PROBLEM", 25, 53], ["CAM", "TREATMENT", 55, 58], ["the infection", "PROBLEM", 87, 100], ["immune function", "PROBLEM", 166, 181], ["the disease", "PROBLEM", 200, 211], ["the virus", "PROBLEM", 242, 251], ["CAM products", "TREATMENT", 334, 346], ["infectious", "OBSERVATION_MODIFIER", 25, 35], ["infection", "OBSERVATION", 91, 100]]], ["In Korea, consumption of natural products such as a multivitamin, whole grain, and probiotics was popular during the MERS outbreak, which were the modalities that are widely used for the management and treatment of common cold and influenza-like illnesses [24] .", [["whole grain", "ANATOMY", 66, 77], ["multivitamin", "CHEMICAL", 52, 64], ["influenza-like illnesses", "DISEASE", 231, 255], ["multivitamin", "SIMPLE_CHEMICAL", 52, 64], ["natural products", "TREATMENT", 25, 41], ["a multivitamin, whole grain", "TREATMENT", 50, 77], ["probiotics", "TREATMENT", 83, 93], ["the MERS outbreak", "PROBLEM", 113, 130], ["the management", "TREATMENT", 183, 197], ["treatment", "TREATMENT", 202, 211], ["common cold", "PROBLEM", 215, 226], ["influenza", "PROBLEM", 231, 240]]], ["Such similarities in modalities used support existing findings that people's decision to use particular CAM is influenced by specific physical symptoms experienced and self-assessed health care needs [45, 46] .", [["people", "ORGANISM", 68, 74], ["CAM", "MULTI-TISSUE_STRUCTURE", 104, 107], ["people", "SPECIES", 68, 74], ["specific physical symptoms", "PROBLEM", 125, 151]]], ["Our findings also show differences in the use of self-administered modalities (multivitamin, nutritional supplements, food products, and exercise) and practitioner-administered modalities (massage, yoga, and traditional Korean medicine).", [["multivitamin", "CHEMICAL", 79, 91], ["multivitamin", "SIMPLE_CHEMICAL", 79, 91], ["self-administered modalities", "TREATMENT", 49, 77], ["multivitamin", "TREATMENT", 79, 91], ["nutritional supplements", "TREATMENT", 93, 116], ["food products", "TREATMENT", 118, 131], ["modalities (massage", "TREATMENT", 177, 196], ["yoga", "TREATMENT", 198, 202], ["traditional Korean medicine", "TREATMENT", 208, 235]]], ["Higher preference of self-administered CAM modalities in our study implies that in order to protect themselves from an outbreak event, people are more likely to rely on self-medication and minimize the risk of exposure.", [["CAM", "MULTI-TISSUE_STRUCTURE", 39, 42], ["people", "ORGANISM", 135, 141], ["people", "SPECIES", 135, 141], ["CAM modalities", "TREATMENT", 39, 53], ["our study", "TEST", 57, 66], ["self-medication", "TREATMENT", 169, 184]]], ["In fact, a high proportion of Koreans during the 2015 MERS outbreak avoided the crowded area and health facilities to prevent infection [2] .DiscussionDifferences in the method of obtaining CAM information were also observed.", [["infection", "DISEASE", 126, 135], ["CAM", "MULTI-TISSUE_STRUCTURE", 190, 193], ["infection", "PROBLEM", 126, 135], ["infection", "OBSERVATION", 126, 135]]], ["During the MERS outbreak in Korea, the most common sources were mass media (newspaper, television, radio) and the internet, which were the least popular among patients with chronic disease and non-airborne infectious disease [32, [47] [48] [49] .", [["chronic disease", "DISEASE", 173, 188], ["infectious disease", "DISEASE", 206, 224], ["patients", "ORGANISM", 159, 167], ["patients", "SPECIES", 159, 167], ["chronic disease", "PROBLEM", 173, 188], ["non-airborne infectious disease", "PROBLEM", 193, 224], ["mass", "OBSERVATION", 64, 68], ["chronic", "OBSERVATION_MODIFIER", 173, 180], ["disease", "OBSERVATION", 181, 188]]], ["Observed dependence on the mass media can be attributed to many health professionals using the mass media to provide advice on precautionary and self-care measures during the outbreak of MERS.", [["MERS", "DISEASE", 187, 191], ["the mass media", "TREATMENT", 23, 37], ["the mass media", "TREATMENT", 91, 105], ["precautionary", "TREATMENT", 127, 140], ["self-care measures", "TREATMENT", 145, 163], ["dependence", "OBSERVATION_MODIFIER", 9, 19], ["mass", "OBSERVATION", 27, 31], ["mass", "OBSERVATION", 95, 99]]], ["Furthermore, similar to the SARS epidemic in Hong Kong [50] , the majority of respondents also reported the mass media as the main source of disease-related information during the MERS outbreak in Korea.", [["SARS", "DISEASE", 28, 32], ["the mass media", "PROBLEM", 104, 118], ["disease", "PROBLEM", 141, 148], ["mass", "OBSERVATION", 108, 112], ["main", "OBSERVATION_MODIFIER", 126, 130], ["disease", "OBSERVATION", 141, 148]]], ["These findings reflect the importance of mass media accessed by the public during health emergencies, as the information provided has a critical role in the formation of risk perception and influence health behavior [51] [52] [53] .DiscussionLastly, several factors were identified as potential predictors of CAM use during the MERS outbreak.", [["CAM", "MULTI-TISSUE_STRUCTURE", 309, 312], ["mass media", "TREATMENT", 41, 51], ["mass", "OBSERVATION", 41, 45]]], ["As for sociodemographic characteristics, previous studies found female gender, younger age, and tertiary education level to be associated with CAM use among people with risk of disease development [54, 55] .", [["CAM", "MULTI-TISSUE_STRUCTURE", 143, 146], ["people", "ORGANISM", 157, 163], ["people", "SPECIES", 157, 163], ["previous studies", "TEST", 41, 57], ["disease development", "PROBLEM", 177, 196]]], ["However, on the contrary, only the higher age groups (being 40 to 49 years of age, being over 50 years of age) were more likely to use CAM in our study.", [["CAM", "MULTI-TISSUE_STRUCTURE", 135, 138], ["our study", "TEST", 142, 151]]], ["This incongruency may be due to differences in the sample size of the study and characteristics of diseases, as in the case of infectious disease outbreaks, higher perceived vulnerability among elders could influence them to engage in health-promoting behaviors [14, 56] .", [["the study", "TEST", 66, 75], ["diseases", "PROBLEM", 99, 107], ["infectious disease outbreaks", "PROBLEM", 127, 155], ["may be due to", "UNCERTAINTY", 18, 31], ["diseases", "OBSERVATION", 99, 107], ["infectious", "OBSERVATION_MODIFIER", 127, 137]]], ["In the case of health belief-related factors, those who used CAM prior to the outbreak and showed dissatisfaction with the government response to the outbreak were more likely to use CAM in the present study.", [["CAM", "MULTI-TISSUE_STRUCTURE", 61, 64], ["CAM", "MULTI-TISSUE_STRUCTURE", 183, 186], ["CAM", "TREATMENT", 61, 64], ["dissatisfaction", "PROBLEM", 98, 113], ["the present study", "TEST", 190, 207]]], ["Similarly, previous studies found distrust in the government and dissatisfaction with the conventional health care system to be associated with CAM use [16, 57] .", [["CAM", "MULTI-TISSUE_STRUCTURE", 144, 147], ["previous studies", "TEST", 11, 27]]], ["These results suggest that individuals who find the formal health care system to be unreliable resort to CAM to compensate for the lack of perceived-health care quality, to practice autonomy, and to protect themselves from health threats [16, [57] [58] [59] .", [["CAM", "MULTI-TISSUE_STRUCTURE", 105, 108]]], ["However, the findings remain inconclusive, and further research is needed to improve our understanding of the determinants of CAM use during epidemic events.DiscussionLimitations of this study include recall bias and lack of variability in research locations.", [["CAM", "MULTI-TISSUE_STRUCTURE", 126, 129], ["this study", "TEST", 182, 192]]], ["Also, the participants of the study were selected from patients visiting outpatient departments of a community hospital in Seoul; therefore, the result of the study may not fully represent those of other people in Korea.", [["patients", "ORGANISM", 55, 63], ["people", "ORGANISM", 204, 210], ["participants", "SPECIES", 10, 22], ["patients", "SPECIES", 55, 63], ["people", "SPECIES", 204, 210], ["the study", "TEST", 26, 35], ["the study", "TEST", 155, 164]]], ["Lastly, cross-sectional studies can only infer the association between CAM use and potential predictor variables.ConclusionDuring the 2015 MERS outbreak in Korea, the prevalence of CAM use was considerably high among patients with older age, prior CAM use, and dissatisfaction with the government response to the MERS outbreak.", [["CAM", "MULTI-TISSUE_STRUCTURE", 71, 74], ["CAM", "MULTI-TISSUE_STRUCTURE", 181, 184], ["patients", "ORGANISM", 217, 225], ["CAM", "MULTI-TISSUE_STRUCTURE", 248, 251], ["patients", "SPECIES", 217, 225], ["cross-sectional studies", "TEST", 8, 31], ["the MERS outbreak", "PROBLEM", 309, 326]]], ["Also, the majority of respondents reported the mass media and the internet as the main source of CAM and disease-related information.", [["CAM", "MULTI-TISSUE_STRUCTURE", 97, 100], ["the mass media", "PROBLEM", 43, 57], ["mass", "OBSERVATION", 47, 51]]], ["In the era where emerging infectious diseases continue to be a major public health concern, the effective use of mass media and information and communication technology should be considered to achieve efficient delivery of health information and to promote behavior changes in situations of vulnerability.", [["infectious diseases", "DISEASE", 26, 45], ["emerging infectious diseases", "PROBLEM", 17, 45], ["mass media", "TREATMENT", 113, 123], ["communication technology", "TREATMENT", 144, 168], ["infectious", "OBSERVATION", 26, 36]]], ["1186/s12906-020-02945-0.", [["1186/s12906-020-02945-", "CHEMICAL", 0, 22]]]], "PMC3705299": [], "PMC2288676": [["IntroductionInfluenza A virus (IV) is a highly contagious single-stranded RNA virus that infects both the upper and lower respiratory tracts of humans.", [["upper", "ANATOMY", 106, 111], ["lower respiratory tracts", "ANATOMY", 116, 140], ["Influenza A virus", "DISEASE", 12, 29], ["Influenza A virus", "ORGANISM", 12, 29], ["upper", "ORGANISM_SUBDIVISION", 106, 111], ["lower respiratory", "ORGANISM_SUBDIVISION", 116, 133], ["humans", "ORGANISM", 144, 150], ["Influenza A virus", "SPECIES", 12, 29], ["humans", "SPECIES", 144, 150], ["Influenza A virus", "SPECIES", 12, 29], ["humans", "SPECIES", 144, 150], ["IntroductionInfluenza A virus (IV)", "TREATMENT", 0, 34], ["a highly contagious single-stranded RNA virus", "PROBLEM", 38, 83], ["highly", "OBSERVATION_MODIFIER", 40, 46], ["contagious", "OBSERVATION_MODIFIER", 47, 57], ["stranded RNA virus", "OBSERVATION", 65, 83], ["upper", "ANATOMY_MODIFIER", 106, 111], ["lower", "ANATOMY_MODIFIER", 116, 121], ["respiratory tracts", "ANATOMY", 122, 140]]], ["The host innate immune Toll-like receptor 3 (TLR3) was shown previously in cells of myeloid origin to recognize the viral replicative, intermediate double-stranded RNA (dsRNA).", [["cells", "ANATOMY", 75, 80], ["myeloid", "ANATOMY", 84, 91], ["Toll-like receptor 3", "GENE_OR_GENE_PRODUCT", 23, 43], ["TLR3", "GENE_OR_GENE_PRODUCT", 45, 49], ["cells", "CELL", 75, 80], ["myeloid", "CELL", 84, 91], ["immune Toll-like receptor 3", "PROTEIN", 16, 43], ["TLR3", "PROTEIN", 45, 49], ["intermediate double-stranded RNA", "RNA", 135, 167], ["The host innate immune Toll-like receptor 3 (TLR3)", "TREATMENT", 0, 50], ["myeloid origin", "PROBLEM", 84, 98], ["the viral replicative", "PROBLEM", 112, 133], ["intermediate double-stranded RNA (dsRNA", "TREATMENT", 135, 174], ["myeloid origin", "OBSERVATION", 84, 98], ["stranded RNA", "OBSERVATION_MODIFIER", 155, 167]]], ["Thus, dsRNA is critical for the outcome of the infection and appears to be an active component of viral infection that stimulates antiviral activities.", [["infection", "DISEASE", 47, 56], ["viral infection", "DISEASE", 98, 113], ["dsRNA", "TREATMENT", 6, 11], ["the infection", "PROBLEM", 43, 56], ["viral infection", "PROBLEM", 98, 113], ["infection", "OBSERVATION", 47, 56], ["appears to be", "UNCERTAINTY", 61, 74], ["active", "OBSERVATION_MODIFIER", 78, 84], ["component", "OBSERVATION_MODIFIER", 85, 94], ["viral", "OBSERVATION_MODIFIER", 98, 103], ["infection", "OBSERVATION", 104, 113], ["antiviral activities", "OBSERVATION", 130, 150]]], ["It accumulates during the replication of many viruses [1], [2], including influenza virus.", [["influenza virus", "DISEASE", 74, 89], ["influenza virus", "ORGANISM", 74, 89], ["influenza virus", "SPECIES", 74, 89], ["many viruses", "PROBLEM", 41, 53], ["influenza virus", "PROBLEM", 74, 89], ["influenza virus", "OBSERVATION", 74, 89]]], ["Prominent sources of dsRNA include viral RNAs containing double-stranded secondary structure and dsRNA formed during viral replication [2].", [["viral RNAs", "RNA", 35, 45], ["dsRNA", "PROBLEM", 21, 26], ["viral RNAs", "PROBLEM", 35, 45], ["double-stranded secondary structure", "TREATMENT", 57, 92], ["dsRNA", "PROBLEM", 97, 102], ["viral replication", "TREATMENT", 117, 134], ["dsRNA", "OBSERVATION", 21, 26], ["viral RNAs", "OBSERVATION", 35, 45], ["double-stranded", "OBSERVATION_MODIFIER", 57, 72], ["secondary structure", "OBSERVATION", 73, 92], ["viral replication", "OBSERVATION", 117, 134]]], ["Furthermore, TLR3 contributes directly to the immune response of respiratory epithelial cells to influenza A virus and dsRNA [3], [4].", [["respiratory epithelial cells", "ANATOMY", 65, 93], ["TLR3", "GENE_OR_GENE_PRODUCT", 13, 17], ["respiratory epithelial cells", "CELL", 65, 93], ["influenza A virus", "ORGANISM", 97, 114], ["TLR3", "PROTEIN", 13, 17], ["respiratory epithelial cells", "CELL_TYPE", 65, 93], ["influenza A virus", "SPECIES", 97, 114], ["influenza A virus", "SPECIES", 97, 114], ["respiratory epithelial cells", "PROBLEM", 65, 93], ["influenza A virus", "PROBLEM", 97, 114], ["dsRNA", "TEST", 119, 124], ["respiratory epithelial cells", "OBSERVATION", 65, 93]]], ["Therefore dsRNA treatment was always used to mimic the viral infection in cell lines [5], [6], [7].", [["cell lines", "ANATOMY", 74, 84], ["viral infection", "DISEASE", 55, 70], ["cell lines", "CELL", 74, 84], ["dsRNA treatment", "TREATMENT", 10, 25], ["the viral infection in cell lines", "PROBLEM", 51, 84], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["infection", "OBSERVATION", 61, 70], ["cell lines", "OBSERVATION", 74, 84]]], ["In macrophages, dsRNA and viral infection stimulate the expression of pro-inflammatory cytokines such as IL-1alpha, IL-1beta, tumor necrosis factor, and IL-6 [1], [8], [9], [10].IntroductionCyclooxygenase (COX) is the rate-limiting enzyme in the biosynthetic pathway of prostaglandins and thromboxanes.", [["macrophages", "ANATOMY", 3, 14], ["viral infection", "DISEASE", 26, 41], ["necrosis", "DISEASE", 132, 140], ["prostaglandins", "CHEMICAL", 270, 284], ["thromboxanes", "CHEMICAL", 289, 301], ["prostaglandins", "CHEMICAL", 270, 284], ["thromboxanes", "CHEMICAL", 289, 301], ["macrophages", "CELL", 3, 14], ["IL-1alpha", "GENE_OR_GENE_PRODUCT", 105, 114], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 116, 124], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 126, 147], ["IL-6 [1]", "SIMPLE_CHEMICAL", 153, 161], ["[8]", "SIMPLE_CHEMICAL", 163, 166], ["[9]", "SIMPLE_CHEMICAL", 168, 171], ["IntroductionCyclooxygenase", "GENE_OR_GENE_PRODUCT", 178, 204], ["COX", "GENE_OR_GENE_PRODUCT", 206, 209], ["prostaglandins", "SIMPLE_CHEMICAL", 270, 284], ["thromboxanes", "SIMPLE_CHEMICAL", 289, 301], ["macrophages", "CELL_TYPE", 3, 14], ["pro-inflammatory cytokines", "PROTEIN", 70, 96], ["IL-1alpha, IL-1beta", "PROTEIN", 105, 124], ["tumor necrosis factor", "PROTEIN", 126, 147], ["IntroductionCyclooxygenase", "PROTEIN", 178, 204], ["COX", "PROTEIN", 206, 209], ["macrophages", "PROBLEM", 3, 14], ["dsRNA", "PROBLEM", 16, 21], ["viral infection", "PROBLEM", 26, 41], ["pro-inflammatory cytokines", "TEST", 70, 96], ["IL", "TEST", 105, 107], ["IL", "TEST", 116, 118], ["tumor necrosis factor", "PROBLEM", 126, 147], ["IL", "TEST", 153, 155], ["the rate", "TEST", 214, 222], ["prostaglandins", "TREATMENT", 270, 284], ["thromboxanes", "TREATMENT", 289, 301], ["macrophages", "OBSERVATION", 3, 14], ["dsRNA", "OBSERVATION_MODIFIER", 16, 21], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["infection", "OBSERVATION", 32, 41], ["pro-inflammatory cytokines", "OBSERVATION", 70, 96], ["tumor necrosis", "OBSERVATION", 126, 140]]], ["Prostaglandins play an important role in many biological processes.", [["Prostaglandins", "TREATMENT", 0, 14]]], ["Altered prostanoid production is associated with a variety of illnesses, including acute and chronic inflammation, cardiovascular disease and colon cancer [11].", [["cardiovascular", "ANATOMY", 115, 129], ["colon cancer", "ANATOMY", 142, 154], ["prostanoid", "CHEMICAL", 8, 18], ["inflammation", "DISEASE", 101, 113], ["cardiovascular disease", "DISEASE", 115, 137], ["colon cancer", "DISEASE", 142, 154], ["prostanoid", "CHEMICAL", 8, 18], ["prostanoid", "SIMPLE_CHEMICAL", 8, 18], ["colon cancer", "CANCER", 142, 154], ["Altered prostanoid production", "PROBLEM", 0, 29], ["illnesses", "PROBLEM", 62, 71], ["acute and chronic inflammation", "PROBLEM", 83, 113], ["cardiovascular disease", "PROBLEM", 115, 137], ["colon cancer", "PROBLEM", 142, 154], ["prostanoid production", "OBSERVATION", 8, 29], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["chronic", "OBSERVATION_MODIFIER", 93, 100], ["inflammation", "OBSERVATION", 101, 113], ["cardiovascular", "ANATOMY", 115, 129], ["disease", "OBSERVATION", 130, 137], ["colon", "ANATOMY", 142, 147], ["cancer", "OBSERVATION", 148, 154]]], ["Two isoforms of COX were described: COX-1 and COX-2.", [["COX", "GENE_OR_GENE_PRODUCT", 16, 19], ["COX-1", "GENE_OR_GENE_PRODUCT", 36, 41], ["COX-2", "GENE_OR_GENE_PRODUCT", 46, 51], ["COX", "PROTEIN", 16, 19], ["COX-1", "PROTEIN", 36, 41], ["COX-2", "PROTEIN", 46, 51], ["COX", "TEST", 16, 19], ["COX", "TEST", 36, 39], ["COX", "TEST", 46, 49]]], ["COX-1 is constitutively expressed in almost all tissues [12]; COX-2 is the inducible form of the enzyme, which is expressed in response to inflammatory stimuli and growth factors and is involved in mediating pain and inflammatory processes [13], [14].", [["tissues", "ANATOMY", 48, 55], ["pain", "DISEASE", 208, 212], ["COX-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["tissues", "TISSUE", 48, 55], ["COX-2", "GENE_OR_GENE_PRODUCT", 62, 67], ["COX-1", "PROTEIN", 0, 5], ["COX-2", "PROTEIN", 62, 67], ["enzyme", "PROTEIN", 97, 103], ["growth factors", "PROTEIN", 164, 178], ["COX", "TEST", 0, 3], ["COX", "TEST", 62, 65], ["the enzyme", "TEST", 93, 103], ["inflammatory stimuli", "PROBLEM", 139, 159], ["growth factors", "PROBLEM", 164, 178], ["mediating pain", "PROBLEM", 198, 212], ["inflammatory processes", "PROBLEM", 217, 239], ["inflammatory stimuli", "OBSERVATION", 139, 159], ["inflammatory", "OBSERVATION_MODIFIER", 217, 229]]], ["In our previous studies, we identified two viral proteins, the nucleoprotein and spike protein of SARS-CoV, which were involved in up-regulating COX-2 [15], [16].", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 98, 106], ["COX-2", "GENE_OR_GENE_PRODUCT", 145, 150], ["[16]", "SIMPLE_CHEMICAL", 157, 161], ["viral proteins", "PROTEIN", 43, 57], ["nucleoprotein and spike protein", "PROTEIN", 63, 94], ["SARS-CoV", "PROTEIN", 98, 106], ["COX", "PROTEIN", 145, 148], ["SARS-CoV", "SPECIES", 98, 106], ["two viral proteins", "PROBLEM", 39, 57], ["the nucleoprotein", "TEST", 59, 76], ["SARS", "PROBLEM", 98, 102], ["CoV", "TEST", 103, 106], ["COX", "TEST", 145, 148]]], ["Prostaglandin E2 (PGE2) is synthesized from PGH2 in a variety of cells, which itself is synthesized from arachidonic acid by the enzyme prostaglandin synthetase COX-2.", [["cells", "ANATOMY", 65, 70], ["Prostaglandin E2", "CHEMICAL", 0, 16], ["PGE2", "CHEMICAL", 18, 22], ["PGH2", "CHEMICAL", 44, 48], ["arachidonic acid", "CHEMICAL", 105, 121], ["prostaglandin", "CHEMICAL", 136, 149], ["Prostaglandin E2", "CHEMICAL", 0, 16], ["PGE2", "CHEMICAL", 18, 22], ["PGH2", "CHEMICAL", 44, 48], ["arachidonic acid", "CHEMICAL", 105, 121], ["prostaglandin", "CHEMICAL", 136, 149], ["Prostaglandin E2", "GENE_OR_GENE_PRODUCT", 0, 16], ["PGE2", "SIMPLE_CHEMICAL", 18, 22], ["PGH2", "SIMPLE_CHEMICAL", 44, 48], ["cells", "CELL", 65, 70], ["arachidonic acid", "SIMPLE_CHEMICAL", 105, 121], ["prostaglandin", "SIMPLE_CHEMICAL", 136, 149], ["COX-2", "GENE_OR_GENE_PRODUCT", 161, 166], ["enzyme prostaglandin synthetase COX-2", "PROTEIN", 129, 166], ["Prostaglandin E2 (PGE2)", "TREATMENT", 0, 23], ["PGH2", "PROBLEM", 44, 48], ["arachidonic acid", "TREATMENT", 105, 121], ["the enzyme prostaglandin synthetase COX", "TEST", 125, 164], ["arachidonic acid", "OBSERVATION", 105, 121]]], ["Its levels can be measured to access the COX-2 activity as described in reference [5], [6], [17], [18].IntroductionInterleukin-32 (IL-32), previously called natural killer cell transcript 4, has been recognized as a pro-inflammatory cytokine recently.", [["natural killer cell", "ANATOMY", 157, 176], ["COX-2", "GENE_OR_GENE_PRODUCT", 41, 46], ["[6]", "SIMPLE_CHEMICAL", 87, 90], ["[17]", "SIMPLE_CHEMICAL", 92, 96], ["[18]", "SIMPLE_CHEMICAL", 98, 102], ["Interleukin-32", "GENE_OR_GENE_PRODUCT", 115, 129], ["IL-32", "GENE_OR_GENE_PRODUCT", 131, 136], ["natural killer cell transcript 4", "GENE_OR_GENE_PRODUCT", 157, 189], ["COX", "PROTEIN", 41, 44], ["Interleukin-32 (IL-32", "PROTEIN", 115, 136], ["natural killer cell transcript 4", "PROTEIN", 157, 189], ["pro-inflammatory cytokine", "PROTEIN", 216, 241], ["the COX", "TEST", 37, 44], ["IntroductionInterleukin", "TEST", 103, 126]]], ["It is mainly expressed in natural killer cells, T cells, epithelial cells and blood monocytes.", [["natural killer cells", "ANATOMY", 26, 46], ["T cells", "ANATOMY", 48, 55], ["epithelial cells", "ANATOMY", 57, 73], ["blood monocytes", "ANATOMY", 78, 93], ["natural killer cells", "CELL", 26, 46], ["T cells", "CELL", 48, 55], ["epithelial cells", "CELL", 57, 73], ["blood monocytes", "CELL", 78, 93], ["natural killer cells", "CELL_TYPE", 26, 46], ["T cells", "CELL_TYPE", 48, 55], ["epithelial cells", "CELL_TYPE", 57, 73], ["blood monocytes", "CELL_TYPE", 78, 93], ["epithelial cells", "TEST", 57, 73], ["blood monocytes", "TEST", 78, 93], ["natural killer cells", "OBSERVATION", 26, 46], ["epithelial cells", "OBSERVATION", 57, 73], ["blood monocytes", "OBSERVATION", 78, 93]]], ["IL-32 can induce the pro-inflammatory cytokines TNF-\u03b1 and IL-1\u03b2 in murine peritoneal macrophages as well as in phorbol ester-differentiated human THP-1 cells [19].", [["peritoneal macrophages", "ANATOMY", 74, 96], ["THP-1 cells", "ANATOMY", 146, 157], ["phorbol ester", "CHEMICAL", 111, 124], ["phorbol ester", "CHEMICAL", 111, 124], ["IL-32", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 48, 53], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 58, 63], ["murine", "ORGANISM", 67, 73], ["peritoneal macrophages", "CELL", 74, 96], ["phorbol ester", "SIMPLE_CHEMICAL", 111, 124], ["human", "ORGANISM", 140, 145], ["THP-1 cells", "CELL", 146, 157], ["IL-32", "PROTEIN", 0, 5], ["pro-inflammatory cytokines", "PROTEIN", 21, 47], ["TNF", "PROTEIN", 48, 51], ["IL-1\u03b2", "PROTEIN", 58, 63], ["murine peritoneal macrophages", "CELL_TYPE", 67, 96], ["differentiated human THP-1 cells", "CELL_LINE", 125, 157], ["murine", "SPECIES", 67, 73], ["human", "SPECIES", 140, 145], ["human", "SPECIES", 140, 145], ["IL", "TEST", 0, 2], ["the pro-inflammatory cytokines", "TEST", 17, 47], ["TNF", "TEST", 48, 51], ["IL", "TEST", 58, 60], ["murine peritoneal macrophages", "TREATMENT", 67, 96], ["phorbol ester", "TEST", 111, 124], ["peritoneal", "ANATOMY", 74, 84], ["macrophages", "OBSERVATION", 85, 96]]], ["It plays an important role in innate and adaptive immune responses, synergism between IL-32 and other well-characterized players in innate immunity has recently been documented [20].", [["IL-32", "GENE_OR_GENE_PRODUCT", 86, 91], ["IL-32", "PROTEIN", 86, 91], ["synergism between IL", "TREATMENT", 68, 88]]], ["Furthermore, IL-32 contributes to the synovitis during rheumatoid arthritis [21].", [["synovitis", "DISEASE", 38, 47], ["rheumatoid arthritis", "DISEASE", 55, 75], ["IL-32", "GENE_OR_GENE_PRODUCT", 13, 18], ["IL-32", "PROTEIN", 13, 18], ["the synovitis", "PROBLEM", 34, 47], ["rheumatoid arthritis", "PROBLEM", 55, 75], ["synovitis", "OBSERVATION", 38, 47], ["rheumatoid arthritis", "OBSERVATION", 55, 75]]], ["It is stimulated by Mycobacterium tuberculosis[22] and it synergizes with NOD1 and NOD2 ligands to stimulate IL-1\u03b2 and IL-6 release in a caspase-1-dependent manner [23].", [["Mycobacterium tuberculosis", "DISEASE", 20, 46], ["Mycobacterium tuberculosis", "ORGANISM", 20, 46], ["NOD1", "GENE_OR_GENE_PRODUCT", 74, 78], ["NOD2", "GENE_OR_GENE_PRODUCT", 83, 87], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 109, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 119, 123], ["caspase-1", "GENE_OR_GENE_PRODUCT", 137, 146], ["NOD1", "PROTEIN", 74, 78], ["NOD2", "PROTEIN", 83, 87], ["Mycobacterium tuberculosis", "SPECIES", 20, 46], ["Mycobacterium tuberculosis", "SPECIES", 20, 46], ["Mycobacterium tuberculosis", "PROBLEM", 20, 46], ["NOD1", "TREATMENT", 74, 78], ["NOD2 ligands", "TEST", 83, 95], ["IL", "TEST", 109, 111], ["IL", "TEST", 119, 121], ["a caspase", "TEST", 135, 144], ["Mycobacterium tuberculosis", "OBSERVATION", 20, 46]]], ["Recently Proteinase 3 has been identified as a specific IL-32\u03b1 binding protein which cleaves the cytokine to enhance its activity [24].IntroductionA number of investigations demonstrated that viral infections stimulate COX-2 expression, followed by PGE2 accumulation [6], [15], [16], [25], [26].", [["viral infections", "DISEASE", 192, 208], ["PGE2", "CHEMICAL", 249, 253], ["PGE2", "CHEMICAL", 249, 253], ["Proteinase 3", "GENE_OR_GENE_PRODUCT", 9, 21], ["IL-32\u03b1", "GENE_OR_GENE_PRODUCT", 56, 62], ["COX-2", "GENE_OR_GENE_PRODUCT", 219, 224], ["PGE2", "SIMPLE_CHEMICAL", 249, 253], ["[6]", "SIMPLE_CHEMICAL", 267, 270], ["[15], [16], [25]", "SIMPLE_CHEMICAL", 272, 288], ["Proteinase 3", "PROTEIN", 9, 21], ["IL-32\u03b1 binding protein", "PROTEIN", 56, 78], ["cytokine", "PROTEIN", 97, 105], ["COX", "PROTEIN", 219, 222], ["a specific IL-32\u03b1 binding protein", "TREATMENT", 45, 78], ["investigations", "TEST", 159, 173], ["viral infections", "PROBLEM", 192, 208], ["COX", "TEST", 219, 222], ["PGE2 accumulation", "TEST", 249, 266], ["viral", "OBSERVATION_MODIFIER", 192, 197], ["infections", "OBSERVATION", 198, 208]]], ["However, the role of influenza A virus infection in the regulation of the newly described pro-inflammatory factor IL-32 expression is still unclear.", [["infection", "DISEASE", 39, 48], ["influenza A virus", "ORGANISM", 21, 38], ["IL-32", "GENE_OR_GENE_PRODUCT", 114, 119], ["pro-inflammatory factor", "PROTEIN", 90, 113], ["IL", "PROTEIN", 114, 116], ["influenza A virus", "SPECIES", 21, 38], ["influenza A virus", "SPECIES", 21, 38], ["influenza", "PROBLEM", 21, 30], ["A virus infection", "PROBLEM", 31, 48], ["pro-inflammatory factor IL", "TEST", 90, 116], ["influenza", "OBSERVATION", 21, 30], ["pro-inflammatory", "OBSERVATION_MODIFIER", 90, 106]]], ["Furthermore, since COX-2 and IL-32 are obligatory mediators of inflammation, the question arises as to whether there is an interaction between the two proteins or they act as independent effectors of host inflammatory response to viral infection.IntroductionBecause COX-2 and IL-32 gene expression are associated with inflammatory processes, the aim of this study is to investigate the role of influenza A virus infection in the regulation of IL-32 expression and to determine the molecular mechanisms responsible.", [["inflammation", "DISEASE", 63, 75], ["viral infection", "DISEASE", 230, 245], ["infection", "DISEASE", 412, 421], ["COX-2", "GENE_OR_GENE_PRODUCT", 19, 24], ["IL-32", "GENE_OR_GENE_PRODUCT", 29, 34], ["COX-2", "GENE_OR_GENE_PRODUCT", 266, 271], ["IL-32", "GENE_OR_GENE_PRODUCT", 276, 281], ["influenza A virus", "ORGANISM", 394, 411], ["IL-32", "GENE_OR_GENE_PRODUCT", 443, 448], ["COX", "PROTEIN", 19, 22], ["IL-32", "PROTEIN", 29, 34], ["COX", "PROTEIN", 266, 269], ["IL-32", "PROTEIN", 443, 448], ["influenza A virus", "SPECIES", 394, 411], ["influenza A virus", "SPECIES", 394, 411], ["COX", "TEST", 19, 22], ["IL", "TEST", 29, 31], ["inflammation", "PROBLEM", 63, 75], ["host inflammatory response", "PROBLEM", 200, 226], ["viral infection", "PROBLEM", 230, 245], ["COX", "TEST", 266, 269], ["IL-32 gene expression", "TREATMENT", 276, 297], ["inflammatory processes", "PROBLEM", 318, 340], ["this study", "TEST", 353, 363], ["influenza", "PROBLEM", 394, 403], ["A virus infection", "PROBLEM", 404, 421], ["inflammation", "OBSERVATION", 63, 75], ["inflammatory", "OBSERVATION_MODIFIER", 205, 217], ["viral", "OBSERVATION_MODIFIER", 230, 235], ["infection", "OBSERVATION", 236, 245], ["associated with", "UNCERTAINTY", 302, 317], ["inflammatory", "OBSERVATION", 318, 330], ["influenza", "OBSERVATION", 394, 403]]], ["Our results showed that influenza A virus infection or poly(IC) treatment activates COX-2 and IL-32 expression by a heretofore unrecognized mechanism, in which influenza A virus stimulates IL-32 expression through COX-2, and IL-32 feedback inhibits COX-2 expression.Patients ::: MethodsThe study examined 108 consecutive adults with influenza A virus infection (59 male, 49 female, aged 39.2\u00b113.5 yr) seropositive for influenza A antigen and 115 healthy adults (62 male, 53 female, aged 37.6\u00b111.3 yr) seronegative for influenza A antigen.", [["influenza A virus infection", "DISEASE", 24, 51], ["poly(IC", "CHEMICAL", 55, 62], ["influenza A virus infection", "DISEASE", 333, 360], ["poly(IC)", "CHEMICAL", 55, 63], ["influenza A virus", "ORGANISM", 24, 41], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 55, 63], ["COX-2", "GENE_OR_GENE_PRODUCT", 84, 89], ["IL-32", "GENE_OR_GENE_PRODUCT", 94, 99], ["influenza A virus", "ORGANISM", 160, 177], ["IL-32", "GENE_OR_GENE_PRODUCT", 189, 194], ["COX-2", "GENE_OR_GENE_PRODUCT", 214, 219], ["IL-32", "GENE_OR_GENE_PRODUCT", 225, 230], ["COX-2", "GENE_OR_GENE_PRODUCT", 249, 254], ["Patients", "ORGANISM", 266, 274], ["adults", "ORGANISM", 321, 327], ["influenza A virus", "ORGANISM", 333, 350], ["influenza A antigen", "GENE_OR_GENE_PRODUCT", 418, 437], ["influenza A antigen", "GENE_OR_GENE_PRODUCT", 518, 537], ["COX", "PROTEIN", 84, 87], ["IL-32", "PROTEIN", 189, 194], ["COX", "PROTEIN", 214, 217], ["COX", "PROTEIN", 249, 252], ["influenza A antigen", "PROTEIN", 518, 537], ["influenza A virus", "SPECIES", 24, 41], ["influenza A virus", "SPECIES", 160, 177], ["Patients", "SPECIES", 266, 274], ["influenza A virus", "SPECIES", 333, 350], ["influenza A virus", "SPECIES", 24, 41], ["influenza A virus", "SPECIES", 160, 177], ["influenza A virus", "SPECIES", 333, 350], ["influenza A virus infection", "PROBLEM", 24, 51], ["poly(IC) treatment", "TREATMENT", 55, 73], ["COX", "TEST", 84, 87], ["IL", "TEST", 94, 96], ["influenza A virus stimulates IL", "TEST", 160, 191], ["COX", "TEST", 214, 217], ["IL", "TEST", 225, 227], ["COX", "TEST", 249, 252], ["The study", "TEST", 286, 295], ["influenza A virus infection", "PROBLEM", 333, 360], ["influenza", "PROBLEM", 418, 427], ["seronegative", "PROBLEM", 501, 513], ["influenza A antigen", "PROBLEM", 518, 537], ["influenza", "OBSERVATION", 24, 33]]], ["All adults were seronegative for markers of hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis Delta virus, and HIV.", [["hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis Delta virus", "DISEASE", 44, 115], ["adults", "ORGANISM", 4, 10], ["hepatitis B virus", "ORGANISM", 44, 61], ["HBV", "ORGANISM", 63, 66], ["hepatitis C virus", "ORGANISM", 69, 86], ["HCV", "ORGANISM", 88, 91], ["hepatitis Delta virus", "ORGANISM", 94, 115], ["HIV", "ORGANISM", 121, 124], ["hepatitis B virus", "SPECIES", 44, 61], ["hepatitis C virus", "SPECIES", 69, 86], ["hepatitis Delta virus", "SPECIES", 94, 115], ["HIV", "SPECIES", 121, 124], ["hepatitis B virus", "SPECIES", 44, 61], ["HBV", "SPECIES", 63, 66], ["hepatitis C virus", "SPECIES", 69, 86], ["HCV", "SPECIES", 88, 91], ["hepatitis Delta virus", "SPECIES", 94, 115], ["HIV", "SPECIES", 121, 124], ["hepatitis B virus", "PROBLEM", 44, 61], ["HBV", "PROBLEM", 63, 66], ["hepatitis C virus (HCV)", "PROBLEM", 69, 92], ["hepatitis Delta virus", "PROBLEM", 94, 115], ["HIV", "PROBLEM", 121, 124]]], ["All of the investigated serum samples were obtained with the help from Hubei provincial Center for Disease Control and Prevention (Hubei CDC).", [["serum samples", "ANATOMY", 24, 37], ["serum samples", "ORGANISM_SUBSTANCE", 24, 37], ["serum samples", "TEST", 24, 37], ["Disease Control", "TREATMENT", 99, 114]]], ["Informed consent was obtained from each of the patients.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55]]], ["The collection of blood samples for research was approved by the Institutional Review Board of the College of Life Sciences, Wuhan University in accordance with guidelines for the protection of human subjects.Virus ::: MethodsThe influenza virus strain A/chicken/Hubei/327/2004 (H5N1) used in this study was provided by China Center for Type Culture Collection (CCTCC).", [["blood samples", "ANATOMY", 18, 31], ["blood samples", "ORGANISM_SUBSTANCE", 18, 31], ["human", "ORGANISM", 194, 199], ["Virus", "ORGANISM", 209, 214], ["influenza virus", "ORGANISM", 230, 245], ["chicken", "ORGANISM", 255, 262], ["Hubei/327/2004", "ORGANISM", 263, 277], ["H5N1", "ORGANISM", 279, 283], ["human", "SPECIES", 194, 199], ["influenza virus", "SPECIES", 230, 245], ["chicken", "SPECIES", 255, 262], ["human", "SPECIES", 194, 199], ["A/chicken/Hubei/327/2004 (H5N1", "SPECIES", 253, 283], ["blood samples", "TEST", 18, 31], ["The influenza virus strain", "PROBLEM", 226, 252], ["this study", "TEST", 293, 303], ["collection", "OBSERVATION_MODIFIER", 4, 14], ["influenza virus", "OBSERVATION", 230, 245]]], ["Stock virus was propagated in 10-day-old embryonated chicken eggs for 36 to 48 h at 37\u00b0C. The allantoic fluid was then harvested, and aliquots were stored at \u201380\u00b0C before being used.", [["eggs", "ANATOMY", 61, 65], ["allantoic fluid", "ANATOMY", 94, 109], ["Stock virus", "ORGANISM", 0, 11], ["chicken", "ORGANISM", 53, 60], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 61, 65], ["allantoic fluid", "ORGANISM_SUBSTANCE", 94, 109], ["chicken", "SPECIES", 53, 60], ["Stock virus", "SPECIES", 0, 11], ["chicken", "SPECIES", 53, 60], ["Stock virus", "PROBLEM", 0, 11], ["embryonated chicken eggs", "TREATMENT", 41, 65], ["The allantoic fluid", "TREATMENT", 90, 109], ["virus", "OBSERVATION", 6, 11], ["allantoic", "ANATOMY", 94, 103], ["fluid", "OBSERVATION", 104, 109]]], ["The final concentration of H5N1 virus infection used in this study was 1 multiplicity of infection (MOI).Plasmids, antibodies, and inhibitors ::: MethodspcDNA3.1-COX-2 was a gift from Dr. Kenneth K. Wu (University of Texas-Houston Medical School, Houston, Texas, USA).", [["H5N1 virus infection", "DISEASE", 27, 47], ["infection", "DISEASE", 89, 98], ["H5N1 virus", "ORGANISM", 27, 37], ["MethodspcDNA3.1-COX-2", "GENE_OR_GENE_PRODUCT", 146, 167], ["antibodies", "PROTEIN", 115, 125], ["MethodspcDNA3.1", "PROTEIN", 146, 161], ["COX", "PROTEIN", 162, 165], ["H5N1 virus", "SPECIES", 27, 37], ["H5N1 virus", "SPECIES", 27, 37], ["H5N1 virus infection", "PROBLEM", 27, 47], ["this study", "TEST", 56, 66], ["infection", "PROBLEM", 89, 98], ["Plasmids", "TREATMENT", 105, 113], ["H5N1 virus infection", "OBSERVATION", 27, 47], ["infection", "OBSERVATION", 89, 98]]], ["Luciferase reporter vector (pGL3) containing a COX-2 promoter region (\u2212891/+9) was constructed previously [27].", [["Luciferase reporter vector", "GENE_OR_GENE_PRODUCT", 0, 26], ["pGL3", "GENE_OR_GENE_PRODUCT", 28, 32], ["COX-2", "GENE_OR_GENE_PRODUCT", 47, 52], ["Luciferase reporter vector", "DNA", 0, 26], ["pGL3", "DNA", 28, 32], ["COX-2 promoter region", "DNA", 47, 68], ["\u2212891/+9", "DNA", 70, 77], ["a COX", "TEST", 45, 50]]], ["IL-32 promoter (\u2212746/+25) was amplified from human genomic DNA by PCR, using the following primers: 5\u2032-GTTACGCGTCCTATTTCAATATGACTGGT-3\u2032 (sense), 5\u2032- GTTAAGCTTAGGGAAAGTCCAGACTCGGG -3\u2032 (antisense); and then inserted into pGL3-Basic vector to generate IL-32 promoter and Luciferase gene fusion plasmid (pIL-32-Luc).", [["IL-32", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 45, 50], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["GTTAAGCTTAGGGAAAGTCCAGACTCGGG -3", "GENE_OR_GENE_PRODUCT", 149, 181], ["pGL3", "GENE_OR_GENE_PRODUCT", 219, 223], ["IL-32", "GENE_OR_GENE_PRODUCT", 249, 254], ["Luciferase", "GENE_OR_GENE_PRODUCT", 268, 278], ["pIL-32-Luc", "GENE_OR_GENE_PRODUCT", 300, 310], ["IL-32 promoter", "DNA", 0, 14], ["human genomic DNA", "DNA", 45, 62], ["antisense", "DNA", 184, 193], ["pGL3", "DNA", 219, 223], ["IL-32 promoter", "DNA", 249, 263], ["Luciferase gene fusion plasmid", "DNA", 268, 298], ["pIL", "DNA", 300, 303], ["Luc", "DNA", 307, 310], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 45, 50], ["GTTACGCGTCCTATTTCAATATGACTGGT", "TEST", 103, 132], ["GTTAAGCTTAGGGAAAGTCCAGACTCGGG", "TEST", 149, 178], ["IL-32 promoter", "TREATMENT", 249, 263], ["Luciferase gene fusion plasmid", "TREATMENT", 268, 298], ["pIL", "TEST", 300, 303]]], ["An IL-32 construct was created by RT-PCR amplification of the open reading frame from A549 human lung epithelial cells.", [["A549", "ANATOMY", 86, 90], ["lung epithelial cells", "ANATOMY", 97, 118], ["IL-32", "GENE_OR_GENE_PRODUCT", 3, 8], ["A549", "CELL", 86, 90], ["human", "ORGANISM", 91, 96], ["lung epithelial cells", "CELL", 97, 118], ["IL-32 construct", "DNA", 3, 18], ["open reading frame", "DNA", 62, 80], ["A549 human lung epithelial cells", "CELL_LINE", 86, 118], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["An IL-32 construct", "TREATMENT", 0, 18], ["RT-PCR amplification", "TEST", 34, 54], ["lung", "ANATOMY", 97, 101], ["epithelial cells", "OBSERVATION", 102, 118]]], ["To create IL-32-encoding vector, the IL-32 beta gene was amplified using the following primers: 5\u2032- CATGAATTCCATGTGCTTCCCGAAGG -3\u2032 (sense), 5\u2032- CTACTCGAGGTATCTTCATTTTGAGGATTG -3\u2032 (antisense); in which EcoRI and XhoI sites were introduced, respectively.", [["IL-32", "GENE_OR_GENE_PRODUCT", 10, 15], ["IL-32 beta", "GENE_OR_GENE_PRODUCT", 37, 47], ["EcoRI", "GENE_OR_GENE_PRODUCT", 201, 206], ["XhoI", "GENE_OR_GENE_PRODUCT", 211, 215], ["IL-32-encoding vector", "DNA", 10, 31], ["IL-32 beta gene", "DNA", 37, 52], ["EcoRI and XhoI sites", "DNA", 201, 221], ["the IL-32 beta gene", "TREATMENT", 33, 52], ["CATGAATTCCATGTGCTTCCCGAAGG", "TEST", 100, 126], ["CTACTCGAGGTATCTTCATTTTGAGGATTG", "TEST", 144, 174], ["EcoRI and XhoI sites", "TREATMENT", 201, 221]]], ["The PCR product was cloned into EcoRI and XhoI sites of pCMV-tag2A (Stratagene) to generate plasmid Flag2A-IL-32, in which IL-32 beta protein was tagged by FLAG.Plasmids, antibodies, and inhibitors ::: MethodsAll of the ten genes of influenza A virus H5N1 were obtained by RT-PCR from H5N1 infected A549 cells and constructed into pCMV-Flag2A vector to generate IV-gene expressing plasmids (Flag2A-HA, Flag2A-NA, Flag2A-NP, Flag2A-NS1 Flag2A-NS2, Flag2A-M1, Flag2A-M2, Flag2A-PA, Flag2A-PB1, Flag2A-PB2) using specific pairs of primers for each influenza A virus gene as follows: HA: 5\u2032- ACGGGATCCGATGGAGAAAATAGTGCTT -3\u2032 (sense), 5\u2032- ACGCTCGAGTGAACTCACAAATTTA -3\u2032 (antisense); NA: 5\u2032-GCGGAATTCTATGAATCCAAATCAGAAGATAATAAC-3\u2032 (sense), 5\u2032- AAAGGGCCCCTACTTGTCAATGGTGAATGG -3\u2032 (antisense); NP: 5\u2032- AAAGGATCCCATGGCGTCTCAAGGCACC -3\u2032 (sense), 5\u2032- ACCGAATTCTTAATTGTCATACTCC -3\u2032 (antisense); NS1: 5\u2032- ACAGGATCCGATGGATTCCAACACTGTGTC -3\u2032 (sense), 5\u2032- CTTGAATTCTCAGCCACCTTATTTC -3\u2032 (antisense); NS2: 5\u2032- ACAGGATCCGATGGATTCCAACACTGTGTC -3\u2032 (sense), 5\u2032- CTAGGGCCCATCATTAAATAAGCTGAAACGA -3\u2032 (antisense); M1: 5\u2032- TCTGAATTCGATGAGTCTTCTAAC -3\u2032 (sense), 5\u2032- TTAGGGCCCGCAACAACAAGAGGATCACT -3\u2032 (antisense); M2: 5\u2032- TCTGAATTCGATGAGTCTTCTAAC -3\u2032 (sense), 5\u2032- TTTCTCGAGGGTAGTTTTTTACTCCAAT -3\u2032 (antisense); PA: 5\u2032- AATGGATCCTATGGAAGACTTTGTGCGAC -3\u2032 (sense), 5\u2032- CAGGGGCCCTACTTCAGTGCATGTGCGAG -3\u2032 (antisense); PB1: 5\u2032- CAAACGGATCCCATGGATGTCAATCCGAC -3\u2032 (sense), 5\u2032- CAAGAAGCTTTCACTATTTCTGCCGTCTG -3\u2032 (antisense); PB2; 5\u2032- GCAAAAGCAGGTCAAATATA -3\u2032 (sense), 5\u2032- GTTTTTAAACAATTCGACACTA -3\u2032 (antisense); IL-32 siRNA plasmid was constructed by ligating the corresponding pairs of oligonucleotide to pSilencer\u2122 2.1-U6 neo (Ambion, Inc., Augstin, TX, USA) based on the sequences described previously [28].", [["A549 cells", "ANATOMY", 299, 309], ["plasmids", "ANATOMY", 381, 389], ["EcoRI", "GENE_OR_GENE_PRODUCT", 32, 37], ["XhoI", "GENE_OR_GENE_PRODUCT", 42, 46], ["pCMV-tag2A", "GENE_OR_GENE_PRODUCT", 56, 66], ["IL-32", "GENE_OR_GENE_PRODUCT", 107, 112], ["IL-32 beta", "GENE_OR_GENE_PRODUCT", 123, 133], ["FLAG", "GENE_OR_GENE_PRODUCT", 156, 160], ["influenza A virus H5N1", "ORGANISM", 233, 255], ["H5N1", "ORGANISM", 285, 289], ["A549 cells", "CELL", 299, 309], ["pCMV", "ORGANISM", 331, 335], ["Flag2A", "GENE_OR_GENE_PRODUCT", 336, 342], ["IV", "GENE_OR_GENE_PRODUCT", 362, 364], ["Flag2A-HA", "GENE_OR_GENE_PRODUCT", 391, 400], ["Flag2A-NA", "GENE_OR_GENE_PRODUCT", 402, 411], ["Flag2A-NP", "GENE_OR_GENE_PRODUCT", 413, 422], ["Flag2A-NS1 Flag2A-NS2", "GENE_OR_GENE_PRODUCT", 424, 445], ["Flag2A-M1", "GENE_OR_GENE_PRODUCT", 447, 456], ["Flag2A-M2", "GENE_OR_GENE_PRODUCT", 458, 467], ["Flag2A-PA", "GENE_OR_GENE_PRODUCT", 469, 478], ["Flag2A-PB1", "GENE_OR_GENE_PRODUCT", 480, 490], ["Flag2A-PB2", "GENE_OR_GENE_PRODUCT", 492, 502], ["influenza A virus", "ORGANISM", 545, 562], ["5\u2032- GCAAAAGCAGGTCAAATATA -3", "GENE_OR_GENE_PRODUCT", 1491, 1518], ["IL-32", "GENE_OR_GENE_PRODUCT", 1573, 1578], ["EcoRI and XhoI sites", "DNA", 32, 52], ["pCMV", "DNA", 56, 60], ["tag2A", "DNA", 61, 66], ["Stratagene", "DNA", 68, 78], ["Flag2A", "DNA", 100, 106], ["IL-32", "DNA", 107, 112], ["IL-32 beta protein", "PROTEIN", 123, 141], ["FLAG", "PROTEIN", 156, 160], ["antibodies", "PROTEIN", 171, 181], ["A549 cells", "CELL_LINE", 299, 309], ["pCMV-Flag2A vector", "DNA", 331, 349], ["IV-gene expressing plasmids", "DNA", 362, 389], ["Flag2A", "DNA", 391, 397], ["HA", "DNA", 398, 400], ["Flag2A", "DNA", 402, 408], ["NA", "DNA", 409, 411], ["Flag2A", "DNA", 413, 419], ["NP", "DNA", 420, 422], ["Flag2A", "DNA", 424, 430], ["NS1", "DNA", 431, 434], ["Flag2A", "DNA", 435, 441], ["NS2", "DNA", 442, 445], ["Flag2A", "DNA", 447, 453], ["M1", "DNA", 454, 456], ["Flag2A", "DNA", 458, 464], ["M2", "DNA", 465, 467], ["Flag2A", "DNA", 469, 475], ["PA", "DNA", 476, 478], ["Flag2A", "DNA", 480, 486], ["PB1", "DNA", 487, 490], ["Flag2A", "DNA", 492, 498], ["PB2", "DNA", 499, 502], ["influenza A virus gene", "DNA", 545, 567], ["NS1", "DNA", 882, 885], ["NS2", "DNA", 982, 985], ["PB1", "DNA", 1383, 1386], ["PB2", "DNA", 1486, 1489], ["IL-32 siRNA plasmid", "DNA", 1573, 1592], ["pSilencer\u2122 2.1", "DNA", 1667, 1681], ["U6 neo", "DNA", 1682, 1688], ["influenza A virus H5N1", "SPECIES", 233, 255], ["influenza A virus", "SPECIES", 545, 562], ["influenza A virus H5N1", "SPECIES", 233, 255], ["pCMV", "SPECIES", 331, 335], ["influenza A virus", "SPECIES", 545, 562], ["The PCR product", "TREATMENT", 0, 15], ["EcoRI and XhoI sites", "TREATMENT", 32, 52], ["pCMV", "TEST", 56, 60], ["IL", "TEST", 107, 109], ["IL", "TEST", 123, 125], ["beta protein", "TEST", 129, 141], ["Plasmids", "TREATMENT", 161, 169], ["Methods", "TREATMENT", 202, 209], ["influenza A virus H5N1", "PROBLEM", 233, 255], ["RT", "TEST", 273, 275], ["PCR", "TEST", 276, 279], ["H5N1 infected A549 cells", "PROBLEM", 285, 309], ["pCMV", "TEST", 331, 335], ["Flag2A vector", "TREATMENT", 336, 349], ["Flag2A", "TEST", 391, 397], ["HA", "PROBLEM", 398, 400], ["Flag2A", "TEST", 402, 408], ["NA", "TEST", 409, 411], ["Flag2A", "TEST", 413, 419], ["NP", "TEST", 420, 422], ["Flag2A", "TEST", 424, 430], ["Flag2A", "TEST", 435, 441], ["NS2", "TEST", 442, 445], ["Flag2A", "TEST", 447, 453], ["Flag2A", "TEST", 458, 464], ["Flag2A", "TEST", 469, 475], ["PA", "TEST", 476, 478], ["Flag2A", "TEST", 480, 486], ["PB1", "TEST", 487, 490], ["Flag2A", "TEST", 492, 498], ["specific pairs of primers", "TREATMENT", 510, 535], ["each influenza A virus gene", "PROBLEM", 540, 567], ["HA", "TEST", 580, 582], ["ACGGGATCCGATGGAGAAAATAGTGCTT", "TEST", 588, 616], ["ACGCTCGAGTGAACTCACAAATTTA", "TEST", 634, 659], ["NA", "TEST", 677, 679], ["GCGGAATTCTATGAATCCAAATCAGAAGATAATAAC", "TEST", 684, 720], ["AAAGGGCCCCTACTTGTCAATGGTGAATGG", "TEST", 737, 767], ["AAAGGATCCCATGGCGTCTCAAGGCACC", "TEST", 793, 821], ["ACCGAATTCTTAATTGTCATACTCC", "TEST", 839, 864], ["NS1", "TEST", 882, 885], ["ACAGGATCCGATGGATTCCAACACTGTGTC", "TEST", 891, 921], ["CTTGAATTCTCAGCCACCTTATTTC", "TEST", 939, 964], ["ACAGGATCCGATGGATTCCAACACTGTGTC", "TEST", 991, 1021], ["CTAGGGCCCATCATTAAATAAGCTGAAACGA", "TEST", 1039, 1070], ["TCTGAATTCGATGAGTCTTCTAAC", "TEST", 1096, 1120], ["TTAGGGCCCGCAACAACAAGAGGATCACT", "TEST", 1138, 1167], ["TCTGAATTCGATGAGTCTTCTAAC", "TEST", 1193, 1217], ["TTTCTCGAGGGTAGTTTTTTACTCCAAT", "TEST", 1235, 1263], ["AATGGATCCTATGGAAGACTTTGTGCGAC", "TEST", 1289, 1318], ["CAGGGGCCCTACTTCAGTGCATGTGCGAG", "TEST", 1336, 1365], ["PB1", "TEST", 1383, 1386], ["CAAACGGATCCCATGGATGTCAATCCGAC", "TEST", 1392, 1421], ["CAAGAAGCTTTCACTATTTCTGCCGTCTG", "TEST", 1439, 1468], ["PB2", "TEST", 1486, 1489], ["GCAAAAGCAGGTCAAATATA", "TEST", 1495, 1515], ["IL-32 siRNA plasmid", "TREATMENT", 1573, 1592], ["pSilencer\u2122", "TEST", 1667, 1677], ["U6 neo", "TREATMENT", 1682, 1688], ["A549 cells", "OBSERVATION", 299, 309]]], ["All constructs was confirmed by DNA sequencing.Plasmids, antibodies, and inhibitors ::: MethodsMonoclonal mouse antibody against human COX-2 was purchased from Cayman Chemical Company (Ann Arbor, MI, USA).", [["DNA", "CELLULAR_COMPONENT", 32, 35], ["mouse", "ORGANISM", 106, 111], ["human", "ORGANISM", 129, 134], ["COX-2", "GENE_OR_GENE_PRODUCT", 135, 140], ["antibodies", "PROTEIN", 57, 67], ["MethodsMonoclonal mouse antibody", "PROTEIN", 88, 120], ["human COX-2", "PROTEIN", 129, 140], ["mouse", "SPECIES", 106, 111], ["human", "SPECIES", 129, 134], ["mouse", "SPECIES", 106, 111], ["human", "SPECIES", 129, 134], ["DNA sequencing", "TEST", 32, 46], ["Plasmids", "TREATMENT", 47, 55], ["MethodsMonoclonal mouse antibody", "TREATMENT", 88, 120], ["human COX", "TEST", 129, 138]]], ["Polyclonal goat antibody against human IL-32 was purchased from R&D Systems, Inc. USA.", [["human", "ORGANISM", 33, 38], ["IL-32", "GENE_OR_GENE_PRODUCT", 39, 44], ["Polyclonal goat antibody", "PROTEIN", 0, 24], ["human IL-32", "PROTEIN", 33, 44], ["goat", "SPECIES", 11, 15], ["human", "SPECIES", 33, 38], ["goat", "SPECIES", 11, 15], ["human", "SPECIES", 33, 38], ["Polyclonal goat antibody", "TEST", 0, 24], ["human IL", "TEST", 33, 41]]], ["Polyclonal goat antibody specific for human \u03b2-actin (SC-1616) were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).Plasmids, antibodies, and inhibitors ::: MethodsN-(2-cyclohexylosy-4-nitrophenyl)-methanesulphonamide (NS398) (Promega, Madison, WI) was dissolved in DMSO and used as indicated concentrations according to reference [29].", [["SC-1616", "CHEMICAL", 53, 60], ["MethodsN-(2-cyclohexylosy-4-nitrophenyl)-methanesulphonamide", "CHEMICAL", 175, 235], ["NS398", "CHEMICAL", 237, 242], ["DMSO", "CHEMICAL", 284, 288], ["MethodsN-(2-cyclohexylosy-4-nitrophenyl)-methanesulphonamide", "CHEMICAL", 175, 235], ["NS398", "CHEMICAL", 237, 242], ["DMSO", "CHEMICAL", 284, 288], ["human", "ORGANISM", 38, 43], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 44, 51], ["SC-1616", "CELL", 53, 60], ["MethodsN-(2-cyclohexylosy-4-nitrophenyl)-methanesulphonamide", "SIMPLE_CHEMICAL", 175, 235], ["NS398", "SIMPLE_CHEMICAL", 237, 242], ["DMSO", "SIMPLE_CHEMICAL", 284, 288], ["Polyclonal goat antibody", "PROTEIN", 0, 24], ["human \u03b2-actin", "PROTEIN", 38, 51], ["antibodies", "PROTEIN", 144, 154], ["goat", "SPECIES", 11, 15], ["human", "SPECIES", 38, 43], ["goat", "SPECIES", 11, 15], ["human", "SPECIES", 38, 43], ["Polyclonal goat antibody", "TEST", 0, 24], ["Plasmids", "TREATMENT", 134, 142], ["MethodsN", "TREATMENT", 175, 183], ["cyclohexylosy", "TREATMENT", 187, 200], ["nitrophenyl)", "TREATMENT", 203, 215], ["methanesulphonamide (NS398) (Promega, Madison, WI)", "TREATMENT", 216, 266]]], ["Aspirin (Sigma, St. Louis, MO, USA), Synthetic polyinosinic-polycytidylic acid poly(IC) (Sigma, St. Louis, MO, USA), and recombinant human interferon-\u03b3 (IFN-\u03b3) (Peprotech, London, UK) were dissolved in PBS and used at a final concentration of 5 mM, 50 \u00b5g/ml, 150 U/ml, respectively.Cell culture ::: MethodsHEK 293T cells were cultured in DMEM (GibcoBRL, USA), human lung epithelial cells A549 were cultured in F12K media (GibcoBRL, USA), respectively.", [["Cell", "ANATOMY", 282, 286], ["293T cells", "ANATOMY", 310, 320], ["lung epithelial cells A549", "ANATOMY", 366, 392], ["Aspirin", "CHEMICAL", 0, 7], ["polyinosinic-polycytidylic acid poly", "CHEMICAL", 47, 83], ["Aspirin", "CHEMICAL", 0, 7], ["polyinosinic-polycytidylic acid poly(IC)", "CHEMICAL", 47, 87], ["Aspirin", "SIMPLE_CHEMICAL", 0, 7], ["Sigma", "SIMPLE_CHEMICAL", 9, 14], ["polyinosinic-polycytidylic acid poly", "SIMPLE_CHEMICAL", 47, 83], ["IC", "SIMPLE_CHEMICAL", 84, 86], ["St. Louis", "ORGANISM", 96, 105], ["human", "ORGANISM", 133, 138], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 139, 151], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 153, 158], ["UK", "ORGANISM", 180, 182], ["Cell", "CELL", 282, 286], ["MethodsHEK 293T cells", "CELL", 299, 320], ["human", "ORGANISM", 360, 365], ["lung epithelial cells A549", "CELL", 366, 392], ["recombinant human interferon-\u03b3", "PROTEIN", 121, 151], ["IFN", "PROTEIN", 153, 156], ["\u03b3", "PROTEIN", 157, 158], ["Peprotech", "PROTEIN", 161, 170], ["MethodsHEK 293T cells", "CELL_LINE", 299, 320], ["human lung epithelial cells A549", "CELL_LINE", 360, 392], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 360, 365], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 360, 365], ["Aspirin", "TREATMENT", 0, 7], ["Synthetic polyinosinic-polycytidylic acid poly(IC", "TREATMENT", 37, 86], ["recombinant human interferon", "TREATMENT", 121, 149], ["Cell culture", "TEST", 282, 294], ["MethodsHEK 293T cells", "TEST", 299, 320], ["human lung epithelial cells A549", "TEST", 360, 392], ["lung", "ANATOMY", 366, 370], ["epithelial cells A549", "OBSERVATION", 371, 392]]], ["All media were supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 \u00b5g/ml streptomycin sulfate and all cell cultures were maintained at 37\u00b0C in a 5% CO2 incubator.Transient transfection and Luciferase reporter gene assays ::: MethodsCells were plated at density of 4.0\u00d7105 cells per 24-well plate or 6-well plate and grown to confluence reaching about 80% at the time of transfection.", [["fetal calf serum", "ANATOMY", 37, 53], ["cell cultures", "ANATOMY", 118, 131], ["cells", "ANATOMY", 288, 293], ["penicillin", "CHEMICAL", 64, 74], ["streptomycin", "CHEMICAL", 89, 101], ["CO2", "CHEMICAL", 164, 167], ["penicillin", "CHEMICAL", 64, 74], ["streptomycin sulfate", "CHEMICAL", 89, 109], ["CO2", "CHEMICAL", 164, 167], ["fetal calf", "ORGANISM_SUBSTANCE", 37, 47], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["penicillin", "SIMPLE_CHEMICAL", 64, 74], ["streptomycin sulfate", "SIMPLE_CHEMICAL", 89, 109], ["cell cultures", "CELL", 118, 131], ["CO2", "SIMPLE_CHEMICAL", 164, 167], ["Luciferase", "GENE_OR_GENE_PRODUCT", 205, 215], ["cells", "CELL", 288, 293], ["cell cultures", "CELL_LINE", 118, 131], ["Luciferase reporter gene", "DNA", 205, 229], ["calf", "SPECIES", 43, 47], ["All media", "TREATMENT", 0, 9], ["10% fetal calf serum", "TREATMENT", 33, 53], ["penicillin", "TREATMENT", 64, 74], ["streptomycin sulfate", "TREATMENT", 89, 109], ["all cell cultures", "TEST", 114, 131], ["a 5% CO2 incubator", "TREATMENT", 159, 177], ["MethodsCells", "TEST", 241, 253], ["confluence", "OBSERVATION_MODIFIER", 341, 351], ["transfection", "OBSERVATION", 386, 398]]], ["The plasmids which express COX-2, IL-32, the pGL3-promoter plasmids, pRL-TK (Promega) were co-transfected into the cells by using Lipofectamine 2000 reagent (Invitrogen).", [["plasmids", "ANATOMY", 4, 12], ["cells", "ANATOMY", 115, 120], ["COX-2", "GENE_OR_GENE_PRODUCT", 27, 32], ["IL-32", "GENE_OR_GENE_PRODUCT", 34, 39], ["pGL3", "GENE_OR_GENE_PRODUCT", 45, 49], ["pRL-TK", "GENE_OR_GENE_PRODUCT", 69, 75], ["Promega", "GENE_OR_GENE_PRODUCT", 77, 84], ["cells", "CELL", 115, 120], ["Invitrogen", "SIMPLE_CHEMICAL", 158, 168], ["plasmids", "DNA", 4, 12], ["COX-2, IL-32", "DNA", 27, 39], ["pGL3-promoter plasmids", "DNA", 45, 67], ["pRL", "DNA", 69, 72], ["TK", "DNA", 73, 75], ["Promega", "DNA", 77, 84], ["The plasmids", "TREATMENT", 0, 12], ["COX", "TEST", 27, 30], ["IL", "TEST", 34, 36], ["the pGL3-promoter plasmids", "TREATMENT", 41, 67], ["pRL-TK (Promega)", "TREATMENT", 69, 85], ["Lipofectamine 2000 reagent", "TREATMENT", 130, 156]]], ["If necessary, poly(IC), IFN-\u03b3, NS398, and Aspirin were added into the culture media after transfection.", [["poly", "CHEMICAL", 14, 18], ["IFN-\u03b3", "CHEMICAL", 24, 29], ["NS398", "CHEMICAL", 31, 36], ["Aspirin", "CHEMICAL", 42, 49], ["poly(IC)", "CHEMICAL", 14, 22], ["NS398", "CHEMICAL", 31, 36], ["Aspirin", "CHEMICAL", 42, 49], ["poly(IC", "SIMPLE_CHEMICAL", 14, 21], ["IFN-\u03b3", "SIMPLE_CHEMICAL", 24, 29], ["NS398", "SIMPLE_CHEMICAL", 31, 36], ["Aspirin", "SIMPLE_CHEMICAL", 42, 49], ["IFN", "PROTEIN", 24, 27], ["poly(IC)", "TREATMENT", 14, 22], ["IFN", "TREATMENT", 24, 27], ["NS398", "TREATMENT", 31, 36], ["Aspirin", "TREATMENT", 42, 49], ["the culture media", "TREATMENT", 66, 83]]], ["24 h post-transfection, cells were serum-starved for another 24 h before being harvested.", [["cells", "ANATOMY", 24, 29], ["serum", "ANATOMY", 35, 40], ["cells", "CELL", 24, 29], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["serum", "TEST", 35, 40], ["harvested", "OBSERVATION", 79, 88]]], ["Luciferase activities were measured 48 h after transfection according to the manufacturer's instructions (Promega) and Renilla Luciferase activities were determined as internal control for transfection efficiency as previously described [15].", [["Luciferase", "GENE_OR_GENE_PRODUCT", 127, 137], ["Luciferase activities", "TEST", 0, 21], ["transfection", "TREATMENT", 47, 59], ["Promega)", "TREATMENT", 106, 114], ["Renilla Luciferase activities", "TREATMENT", 119, 148], ["transfection efficiency", "PROBLEM", 189, 212]]], ["Assays were performed in triplicate and expressed as means\u00b1s.d. relative to vector or mock control as 100 (RLU) or luciferase activity (LUC).Semiquantitative RT-PCR analysis ::: MethodsTotal RNA, isolated from A549 cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA), was treated with DNase I and reverse-transcribed with MLV reverse transcriptase (Promega) and random primers (Takara).", [["A549 cells", "ANATOMY", 210, 220], ["luciferase", "GENE_OR_GENE_PRODUCT", 115, 125], ["A549 cells", "CELL", 210, 220], ["DNase I", "GENE_OR_GENE_PRODUCT", 292, 299], ["luciferase", "PROTEIN", 115, 125], ["MethodsTotal RNA", "RNA", 178, 194], ["A549 cells", "CELL_LINE", 210, 220], ["DNase I", "PROTEIN", 292, 299], ["MLV reverse transcriptase", "PROTEIN", 329, 354], ["Assays", "TEST", 0, 6], ["mock control", "TREATMENT", 86, 98], ["Semiquantitative RT-PCR analysis", "TEST", 141, 173], ["MethodsTotal RNA", "PROBLEM", 178, 194], ["A549 cells", "TEST", 210, 220], ["Trizol reagent", "TREATMENT", 227, 241], ["Invitrogen", "TREATMENT", 243, 253], ["DNase I", "TREATMENT", 292, 299], ["MLV reverse transcriptase (Promega)", "TREATMENT", 329, 364], ["random primers (Takara)", "TREATMENT", 369, 392], ["A549 cells", "OBSERVATION", 210, 220]]], ["PCR was performed in 25 \u00b5l reactions with the detection primer pairs described as follows: IL-32 sense: 5\u2032- CATGAATTCCATGTGCTTCCCGAAGG-3\u2032; IL-32 antisense: 5\u2032- CTACTCGAGGTATCTTCATTTTGAGGATTG -3\u2032.", [["IL-32", "GENE_OR_GENE_PRODUCT", 91, 96], ["IL-32", "SIMPLE_CHEMICAL", 139, 144], ["PCR", "TEST", 0, 3], ["the detection primer pairs", "TEST", 42, 68], ["IL", "TEST", 91, 93], ["CATGAATTCCATGTGCTTCCCGAAGG", "TEST", 108, 134]]], ["Detection primers for COX-2, and \u03b2-actin were described previously [15]. \u03b2-actin was amplified by PCR for normalization in all reactions.", [["COX-2", "GENE_OR_GENE_PRODUCT", 22, 27], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 33, 40], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 73, 80], ["COX", "PROTEIN", 22, 25], ["\u03b2-actin", "PROTEIN", 33, 40], ["\u03b2-actin", "DNA", 73, 80], ["Detection primers", "TEST", 0, 17], ["COX", "TEST", 22, 25], ["\u03b2-actin", "TREATMENT", 33, 40], ["\u03b2-actin", "TREATMENT", 73, 80], ["all reactions", "PROBLEM", 123, 136]]], ["The primers for IL-32 were designed for detecting all known isoforms of human IL-32.", [["IL-32", "GENE_OR_GENE_PRODUCT", 16, 21], ["human", "ORGANISM", 72, 77], ["IL-32", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL", "PROTEIN", 16, 18], ["human IL-32", "PROTEIN", 72, 83], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["human IL", "TEST", 72, 80]]], ["PCR products were analyzed by electrophoresis on 1% agarose gel containing ethidium bromide.Western blot analysis ::: MethodsProtein extracts of cultured cells were prepared by suspending cells in lysis buffer (0.01% EDTA, 0.1% Triton X-100, 10% proteinase inhibitors cocktail), sonication, and centrifugation.", [["extracts", "ANATOMY", 133, 141], ["cells", "ANATOMY", 154, 159], ["cells", "ANATOMY", 188, 193], ["ethidium bromide", "CHEMICAL", 75, 91], ["Triton X-100", "CHEMICAL", 228, 240], ["ethidium bromide", "CHEMICAL", 75, 91], ["EDTA", "CHEMICAL", 217, 221], ["agarose", "SIMPLE_CHEMICAL", 52, 59], ["ethidium bromide", "SIMPLE_CHEMICAL", 75, 91], ["MethodsProtein extracts", "ORGANISM_SUBSTANCE", 118, 141], ["cells", "CELL", 154, 159], ["cells", "CELL", 188, 193], ["EDTA", "SIMPLE_CHEMICAL", 217, 221], ["Triton X-100", "SIMPLE_CHEMICAL", 228, 240], ["cultured cells", "CELL_LINE", 145, 159], ["PCR products", "TREATMENT", 0, 12], ["electrophoresis", "TEST", 30, 45], ["1% agarose gel", "TREATMENT", 49, 63], ["ethidium bromide", "TREATMENT", 75, 91], ["MethodsProtein extracts of cultured cells", "TREATMENT", 118, 159], ["lysis buffer", "TREATMENT", 197, 209], ["EDTA", "TREATMENT", 217, 221], ["10% proteinase inhibitors cocktail", "TREATMENT", 242, 276], ["sonication", "TREATMENT", 279, 289], ["centrifugation", "TREATMENT", 295, 309]]], ["Concentrations of proteins in supernatant were quantified using protein assay kit (Bio-Rad).", [["supernatant", "ANATOMY", 30, 41], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 83, 90], ["Concentrations of proteins in supernatant", "PROBLEM", 0, 41], ["protein assay kit", "TEST", 64, 81]]], ["Western blot analysis was performed using COX-2 and IL-32 antibodies and sample loading was normalized by using \u03b2-actin antibody.", [["sample", "ANATOMY", 73, 79], ["COX-2", "GENE_OR_GENE_PRODUCT", 42, 47], ["IL-32 antibodies", "GENE_OR_GENE_PRODUCT", 52, 68], ["\u03b2-actin antibody", "GENE_OR_GENE_PRODUCT", 112, 128], ["COX-2 and IL-32 antibodies", "PROTEIN", 42, 68], ["\u03b2-actin antibody", "PROTEIN", 112, 128], ["Western blot analysis", "TEST", 0, 21], ["COX", "TEST", 42, 45], ["IL", "TEST", 52, 54], ["sample loading", "TEST", 73, 87]]], ["Immunoblots were visualized with the ECL detection system (Pierce, Rockford, IL, USA).COX-2 activity ::: MethodsBecause increased PGE2 is the metabolite of COX-2 enzyme catalysis in epithelial cells, COX-2-derived PGE2 levels in the culture medium was assayed by the Biotrak Prostaglandin E2 Enzyme Immunoassay system (R & D Systems) according to the manufacturer's protocol.ELISA for IL-32 measurement ::: MethodsELISA assays were developed using IL-32 antibody and a polypeptide, H-KEELTPQKCSEPQSSK-OH, (GL Biochem Ltd.", [["epithelial cells", "ANATOMY", 182, 198], ["PGE2", "CHEMICAL", 130, 134], ["PGE2", "CHEMICAL", 214, 218], ["Prostaglandin E2", "CHEMICAL", 275, 291], ["PGE2", "CHEMICAL", 130, 134], ["PGE2", "CHEMICAL", 214, 218], ["Prostaglandin E2", "CHEMICAL", 275, 291], ["OH", "CHEMICAL", 501, 503], ["COX-2", "GENE_OR_GENE_PRODUCT", 86, 91], ["PGE2", "SIMPLE_CHEMICAL", 130, 134], ["COX-2", "GENE_OR_GENE_PRODUCT", 156, 161], ["epithelial cells", "CELL", 182, 198], ["COX-2", "GENE_OR_GENE_PRODUCT", 200, 205], ["PGE2", "SIMPLE_CHEMICAL", 214, 218], ["IL-32", "GENE_OR_GENE_PRODUCT", 385, 390], ["IL-32", "GENE_OR_GENE_PRODUCT", 448, 453], ["H-KEELTPQKCSEPQSSK-OH", "SIMPLE_CHEMICAL", 482, 503], ["COX", "PROTEIN", 86, 89], ["COX-2 enzyme", "PROTEIN", 156, 168], ["epithelial cells", "CELL_TYPE", 182, 198], ["IL", "PROTEIN", 385, 387], ["IL-32 antibody", "PROTEIN", 448, 462], ["Immunoblots", "TEST", 0, 11], ["COX", "TEST", 86, 89], ["COX", "TEST", 156, 159], ["epithelial cells", "TEST", 182, 198], ["COX", "TEST", 200, 203], ["PGE2 levels", "TEST", 214, 225], ["the culture medium", "TEST", 229, 247], ["the Biotrak Prostaglandin E2 Enzyme Immunoassay system", "TEST", 263, 317], ["the manufacturer's protocol", "TREATMENT", 347, 374], ["MethodsELISA assays", "TEST", 407, 426], ["IL", "TEST", 448, 450], ["a polypeptide", "TREATMENT", 467, 480], ["epithelial cells", "OBSERVATION", 182, 198]]], ["Shanghai China) was synthesized as an antigen for making an IL-32 protein standard curve.", [["IL-32", "GENE_OR_GENE_PRODUCT", 60, 65], ["IL", "PROTEIN", 60, 62], ["an antigen", "TEST", 35, 45], ["an IL", "TEST", 57, 62]]], ["ELISAs were prepared by coating the bottom of a 96-well plate with diluted serum samples or culture media.", [["serum samples", "ANATOMY", 75, 88], ["serum samples", "ORGANISM_SUBSTANCE", 75, 88], ["ELISAs", "TEST", 0, 6], ["diluted serum samples", "TEST", 67, 88], ["culture media", "TEST", 92, 105]]], ["50 \u00b5l of 2 \u00b5g/ml capture antibody was incubated for one hour then washed three times with TBST, followed by HRP-labeled secondary antibody incubation for 15 minutes, and finally washed six times with TBST.", [["HRP", "SIMPLE_CHEMICAL", 108, 111], ["HRP", "PROTEIN", 108, 111], ["2 \u00b5g/ml capture antibody", "TREATMENT", 9, 33], ["TBST", "TREATMENT", 90, 94], ["HRP", "TEST", 108, 111], ["secondary antibody incubation", "TREATMENT", 120, 149], ["TBST", "TREATMENT", 200, 204]]], ["ELISAs were developed with TMB (Sigma) substrate and the absorbance at double-wavelength 450 nm/630 nm was measured.", [["TMB", "CHEMICAL", 27, 30], ["TMB", "SIMPLE_CHEMICAL", 27, 30], ["ELISAs", "TEST", 0, 6], ["the absorbance", "PROBLEM", 53, 67]]], ["IL-32 concentrations were calculated from the standard curve.Statistical analysis ::: MethodsAll experiments were reproducible and were carried out in triplicate or quadruplicate.", [["IL-32", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL", "PROTEIN", 0, 2], ["IL-32 concentrations", "TREATMENT", 0, 20], ["Methods", "TREATMENT", 86, 93]]], ["Student's t test for paired samples was used to determine statistical significance.", [["Student's t test", "TEST", 0, 16], ["paired samples", "TEST", 21, 35]]], ["Differences were considered statistically significant at a value of P\u22640.05.Serum levels of PGE2 and IL-32 ::: ResultsThe serum levels of PGE2 and IL-32 were significantly higher in the cohort of patients with influenza A virus infection investigated in comparison with healthy control individuals (mean\u00b1SEM for PGE2, 808.7\u00b152.9 vs. 299.5\u00b145.4 pg/ml; for IL-32, 183.8\u00b143.6 vs. 116.2\u00b129.3 pg/ml, respectively, P<0.01 Mann Whitney-U) as described in Table 1.COX-2 and IL-32 activation in response to influenza A virus infection and dsRNA treatment in a time-dependent manner ::: ResultsIt has been reported that influenza virus can activate the expression of COX-2 in cell culture systems [26] and that dsRNA can induce the production of COX-2, followed by PGE2 release [5].", [["Serum", "ANATOMY", 75, 80], ["serum", "ANATOMY", 121, 126], ["cell culture", "ANATOMY", 665, 677], ["PGE2", "CHEMICAL", 91, 95], ["PGE2", "CHEMICAL", 137, 141], ["influenza A virus infection", "DISEASE", 209, 236], ["PGE2", "CHEMICAL", 311, 315], ["infection", "DISEASE", 515, 524], ["PGE2", "CHEMICAL", 754, 758], ["PGE2", "CHEMICAL", 91, 95], ["PGE2", "CHEMICAL", 137, 141], ["PGE2", "CHEMICAL", 311, 315], ["PGE2", "CHEMICAL", 754, 758], ["Serum", "ORGANISM_SUBSTANCE", 75, 80], ["PGE2", "SIMPLE_CHEMICAL", 91, 95], ["IL-32", "GENE_OR_GENE_PRODUCT", 100, 105], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["PGE2", "SIMPLE_CHEMICAL", 137, 141], ["IL-32", "GENE_OR_GENE_PRODUCT", 146, 151], ["patients", "ORGANISM", 195, 203], ["influenza A virus", "ORGANISM", 209, 226], ["IL-32", "GENE_OR_GENE_PRODUCT", 354, 359], ["COX-2", "GENE_OR_GENE_PRODUCT", 455, 460], ["IL-32", "GENE_OR_GENE_PRODUCT", 465, 470], ["influenza A virus", "ORGANISM", 497, 514], ["influenza virus", "ORGANISM", 609, 624], ["COX-2", "GENE_OR_GENE_PRODUCT", 656, 661], ["cell", "CELL", 665, 669], ["COX-2", "GENE_OR_GENE_PRODUCT", 735, 740], ["PGE2", "SIMPLE_CHEMICAL", 754, 758], ["PGE2", "PROTEIN", 137, 141], ["IL", "PROTEIN", 146, 148], ["COX", "PROTEIN", 455, 458], ["COX-2", "PROTEIN", 656, 661], ["COX-2", "PROTEIN", 735, 740], ["patients", "SPECIES", 195, 203], ["influenza A virus", "SPECIES", 209, 226], ["influenza A virus", "SPECIES", 497, 514], ["influenza A virus", "SPECIES", 209, 226], ["influenza A virus", "SPECIES", 497, 514], ["influenza virus", "SPECIES", 609, 624], ["Serum levels", "TEST", 75, 87], ["PGE2", "TEST", 91, 95], ["IL", "TEST", 100, 102], ["The serum levels", "TEST", 117, 133], ["PGE2", "TEST", 137, 141], ["IL", "TEST", 146, 148], ["influenza A virus infection", "PROBLEM", 209, 236], ["PGE2", "TEST", 311, 315], ["IL", "TEST", 354, 356], ["P", "TEST", 408, 409], ["COX", "TEST", 455, 458], ["IL", "TEST", 465, 467], ["influenza A virus infection", "PROBLEM", 497, 524], ["dsRNA treatment", "TREATMENT", 529, 544], ["influenza virus", "PROBLEM", 609, 624], ["COX", "TEST", 656, 659], ["cell culture systems", "TEST", 665, 685], ["dsRNA", "TREATMENT", 700, 705]]], ["Initially, we investigated whether influenza A virus infection and dsRNA plays a role, if any, in the regulation of IL-32 expression.", [["infection", "DISEASE", 53, 62], ["influenza A virus", "ORGANISM", 35, 52], ["IL-32", "GENE_OR_GENE_PRODUCT", 116, 121], ["IL", "PROTEIN", 116, 118], ["influenza A virus", "SPECIES", 35, 52], ["influenza A virus", "SPECIES", 35, 52], ["influenza A virus infection", "PROBLEM", 35, 62]]], ["A549 cells were infected with influenza A virus or treated with poly(IC)+IFN-\u03b3, results showed that A549 cells were susceptible to influenza virus infection and apparent cytopathic effect was observed after viral infection.", [["A549 cells", "ANATOMY", 0, 10], ["A549 cells", "ANATOMY", 100, 110], ["influenza A virus", "DISEASE", 30, 47], ["influenza virus infection", "DISEASE", 131, 156], ["viral infection", "DISEASE", 207, 222], ["A549 cells", "CELL", 0, 10], ["influenza A virus", "ORGANISM", 30, 47], ["poly(IC)", "SIMPLE_CHEMICAL", 64, 72], ["IFN-\u03b3", "SIMPLE_CHEMICAL", 73, 78], ["A549 cells", "CELL", 100, 110], ["influenza virus", "ORGANISM", 131, 146], ["A549 cells", "CELL_LINE", 0, 10], ["IFN", "PROTEIN", 73, 76], ["A549 cells", "CELL_LINE", 100, 110], ["influenza A virus", "SPECIES", 30, 47], ["influenza virus", "SPECIES", 131, 146], ["influenza A virus", "SPECIES", 30, 47], ["influenza virus", "SPECIES", 131, 146], ["A549 cells", "PROBLEM", 0, 10], ["influenza A virus", "PROBLEM", 30, 47], ["poly(IC)", "TREATMENT", 64, 72], ["IFN", "TEST", 73, 76], ["A549 cells", "PROBLEM", 100, 110], ["influenza virus infection", "PROBLEM", 131, 156], ["apparent cytopathic effect", "PROBLEM", 161, 187], ["viral infection", "PROBLEM", 207, 222], ["A549 cells", "OBSERVATION", 100, 110], ["influenza virus", "OBSERVATION", 131, 146], ["cytopathic", "OBSERVATION_MODIFIER", 170, 180], ["infection", "OBSERVATION", 213, 222]]], ["The culture supernatants and cell lysates were harvested at different time points after infection or induction as follows: 0 h, 6 h, 12 h, 24 h, 48 h.", [["supernatants", "ANATOMY", 12, 24], ["cell lysates", "ANATOMY", 29, 41], ["infection", "DISEASE", 88, 97], ["cell lysates", "CELL", 29, 41], ["The culture supernatants", "TEST", 0, 24], ["cell lysates", "TREATMENT", 29, 41], ["infection", "PROBLEM", 88, 97], ["cell lysates", "OBSERVATION", 29, 41], ["infection", "OBSERVATION", 88, 97]]], ["PGE2 accumulation (Fig. 1A) and IL-32 production (Fig. 1B) in culture supernatants were measured as described in materials and methods section.", [["supernatants", "ANATOMY", 70, 82], ["PGE2", "CHEMICAL", 0, 4], ["PGE2", "CHEMICAL", 0, 4], ["PGE2", "SIMPLE_CHEMICAL", 0, 4], ["IL-32", "GENE_OR_GENE_PRODUCT", 32, 37], ["PGE2", "PROTEIN", 0, 4], ["PGE2 accumulation", "TEST", 0, 17], ["IL", "TEST", 32, 34], ["culture supernatants", "TEST", 62, 82]]], ["COX-2, IL-32 mRNA (Fig. 1C) and protein (Fig. 1D) expression levels in lysated cells were examined by semiquantitative RT-PCR and western blot analyses, respectively.", [["lysated cells", "ANATOMY", 71, 84], ["COX-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-32", "GENE_OR_GENE_PRODUCT", 7, 12], ["Fig. 1C", "GENE_OR_GENE_PRODUCT", 19, 26], ["Fig. 1D", "GENE_OR_GENE_PRODUCT", 41, 48], ["lysated cells", "CELL", 71, 84], ["COX", "PROTEIN", 0, 3], ["IL-32 mRNA", "RNA", 7, 17], ["lysated cells", "CELL_TYPE", 71, 84], ["COX", "TEST", 0, 3], ["IL", "TEST", 7, 9], ["mRNA", "TEST", 13, 17], ["Fig", "TEST", 19, 22], ["1C", "TEST", 24, 26], ["protein", "TEST", 32, 39], ["Fig", "TEST", 41, 44], ["expression levels in lysated cells", "PROBLEM", 50, 84], ["semiquantitative RT-PCR", "TEST", 102, 125], ["western blot analyses", "TEST", 130, 151]]], ["These results suggested that both influenza A virus infection and dsRNA treatment could activate the expression of COX-2 and IL-32 in A549 cells in a time-dependent manner.Identification of the viral components involved in influenza A virus-stimulated COX-2 and IL-32 expression ::: ResultsTo identify the viral components which play important roles in IV-stimulated pro-inflammatory factors COX-2 and IL-32 expression, we screened all ten proteins of influenza virus: HA, NA, NP, NS1, NS2, M1, M2, PA, PB1, PB2 and poly(IC) (to mimic viral replicative intermediate dsRNA) by luciferase assays.", [["A549 cells", "ANATOMY", 134, 144], ["influenza A virus infection", "DISEASE", 34, 61], ["influenza A virus", "ORGANISM", 34, 51], ["COX-2", "GENE_OR_GENE_PRODUCT", 115, 120], ["IL-32", "GENE_OR_GENE_PRODUCT", 125, 130], ["A549 cells", "CELL", 134, 144], ["influenza A virus", "ORGANISM", 223, 240], ["COX-2", "GENE_OR_GENE_PRODUCT", 252, 257], ["IL-32", "GENE_OR_GENE_PRODUCT", 262, 267], ["IV", "GENE_OR_GENE_PRODUCT", 353, 355], ["COX-2", "GENE_OR_GENE_PRODUCT", 392, 397], ["IL-32", "GENE_OR_GENE_PRODUCT", 402, 407], ["influenza virus", "ORGANISM", 452, 467], ["HA", "GENE_OR_GENE_PRODUCT", 469, 471], ["NA", "MULTI-TISSUE_STRUCTURE", 473, 475], ["NS1", "GENE_OR_GENE_PRODUCT", 481, 484], ["NS2", "GENE_OR_GENE_PRODUCT", 486, 489], ["M1", "GENE_OR_GENE_PRODUCT", 491, 493], ["M2", "GENE_OR_GENE_PRODUCT", 495, 497], ["PA", "GENE_OR_GENE_PRODUCT", 499, 501], ["PB1", "GENE_OR_GENE_PRODUCT", 503, 506], ["PB2", "GENE_OR_GENE_PRODUCT", 508, 511], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 516, 524], ["luciferase", "GENE_OR_GENE_PRODUCT", 576, 586], ["COX-2", "PROTEIN", 115, 120], ["IL-32", "PROTEIN", 125, 130], ["A549 cells", "CELL_LINE", 134, 144], ["COX", "PROTEIN", 252, 255], ["pro-inflammatory factors", "PROTEIN", 367, 391], ["COX", "PROTEIN", 392, 395], ["IL", "PROTEIN", 402, 404], ["NS1", "PROTEIN", 481, 484], ["NS2", "PROTEIN", 486, 489], ["M1", "PROTEIN", 491, 493], ["M2", "PROTEIN", 495, 497], ["PA", "PROTEIN", 499, 501], ["PB1", "PROTEIN", 503, 506], ["PB2", "PROTEIN", 508, 511], ["poly(IC)", "PROTEIN", 516, 524], ["luciferase", "PROTEIN", 576, 586], ["influenza A virus", "SPECIES", 34, 51], ["influenza A virus", "SPECIES", 223, 240], ["influenza virus", "SPECIES", 452, 467], ["influenza A virus", "SPECIES", 34, 51], ["influenza A virus", "SPECIES", 223, 240], ["both influenza A virus infection", "PROBLEM", 29, 61], ["dsRNA treatment", "TREATMENT", 66, 81], ["COX", "TEST", 115, 118], ["IL", "TEST", 125, 127], ["the viral components", "PROBLEM", 190, 210], ["influenza A virus", "PROBLEM", 223, 240], ["COX", "TEST", 252, 255], ["the viral components", "PROBLEM", 302, 322], ["COX", "TEST", 392, 395], ["IL", "TEST", 402, 404], ["influenza virus", "PROBLEM", 452, 467], ["HA", "TEST", 469, 471], ["NA", "TEST", 473, 475], ["NP", "TEST", 477, 479], ["NS1", "TEST", 481, 484], ["NS2", "TEST", 486, 489], ["PA", "TEST", 499, 501], ["PB1", "TEST", 503, 506], ["PB2", "TEST", 508, 511], ["poly(IC", "TREATMENT", 516, 523], ["viral replicative intermediate dsRNA", "TREATMENT", 535, 571], ["luciferase assays", "TEST", 576, 593], ["both", "OBSERVATION_MODIFIER", 29, 33], ["influenza", "OBSERVATION", 34, 43], ["viral", "OBSERVATION", 194, 199], ["viral components", "OBSERVATION", 306, 322], ["M1", "ANATOMY", 491, 493], ["intermediate dsRNA", "OBSERVATION", 553, 571]]], ["Results showed that poly(IC), poly(IC)+IFN-\u03b3, and NS1 are the most important factors in the induction of either COX-2 (Fig. 2A) or IL-32 (Fig. 2B) promoter activities, which means dsRNA and NS1 are the key viral components involved in IV-triggered COX-2 and IL-32 expression during viral infection.", [["poly", "CHEMICAL", 20, 24], ["viral infection", "DISEASE", 282, 297], ["poly(IC)", "CHEMICAL", 30, 38], ["poly(IC)", "SIMPLE_CHEMICAL", 20, 28], ["poly(IC", "SIMPLE_CHEMICAL", 30, 37], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 39, 44], ["NS1", "GENE_OR_GENE_PRODUCT", 50, 53], ["COX-2", "GENE_OR_GENE_PRODUCT", 112, 117], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 119, 126], ["IL-32", "GENE_OR_GENE_PRODUCT", 131, 136], ["Fig. 2B", "GENE_OR_GENE_PRODUCT", 138, 145], ["NS1", "GENE_OR_GENE_PRODUCT", 190, 193], ["COX-2", "GENE_OR_GENE_PRODUCT", 248, 253], ["IL-32", "GENE_OR_GENE_PRODUCT", 258, 263], ["IFN", "PROTEIN", 39, 42], ["\u03b3", "PROTEIN", 43, 44], ["NS1", "PROTEIN", 50, 53], ["COX", "PROTEIN", 112, 115], ["NS1", "PROTEIN", 190, 193], ["COX", "PROTEIN", 248, 251], ["poly(IC), poly(IC)", "PROBLEM", 20, 38], ["IFN", "TEST", 39, 42], ["NS1", "PROBLEM", 50, 53], ["COX", "TEST", 112, 115], ["IL", "TEST", 131, 133], ["NS1", "TREATMENT", 190, 193], ["COX", "TEST", 248, 251], ["IL", "TREATMENT", 258, 260], ["viral infection", "PROBLEM", 282, 297], ["viral infection", "OBSERVATION", 282, 297]]], ["In this study, we focused on the function of dsRNA in inflammatory response to IV infection.DsRNA stimulates IL-32 through COX-2 pathway during inflammatory response ::: ResultsTo define the role of COX-2 in the regulation of influenza A virus induced pro-inflammatory factor IL-32, poly(IC)+IFN-\u03b3 treatment was used to mimic the influenza A virus infection in following experiments as reported previously[30].DsRNA stimulates IL-32 through COX-2 pathway during inflammatory response ::: ResultsFirst, the effects of COX-2 on the activation of IL-32 promoter were determined.", [["infection", "DISEASE", 82, 91], ["IFN-\u03b3", "CHEMICAL", 292, 297], ["influenza A virus infection", "DISEASE", 330, 357], ["DsRNA", "SIMPLE_CHEMICAL", 92, 97], ["IL-32", "GENE_OR_GENE_PRODUCT", 109, 114], ["COX-2", "GENE_OR_GENE_PRODUCT", 123, 128], ["COX-2", "GENE_OR_GENE_PRODUCT", 199, 204], ["influenza A virus", "ORGANISM", 226, 243], ["IL-32", "GENE_OR_GENE_PRODUCT", 276, 281], ["poly(IC)", "SIMPLE_CHEMICAL", 283, 291], ["IFN-\u03b3", "SIMPLE_CHEMICAL", 292, 297], ["influenza A virus", "ORGANISM", 330, 347], ["DsRNA", "SIMPLE_CHEMICAL", 410, 415], ["IL-32", "GENE_OR_GENE_PRODUCT", 427, 432], ["COX-2", "GENE_OR_GENE_PRODUCT", 441, 446], ["COX-2", "GENE_OR_GENE_PRODUCT", 517, 522], ["IL-32", "GENE_OR_GENE_PRODUCT", 544, 549], ["DsRNA", "PROTEIN", 92, 97], ["IL-32", "PROTEIN", 109, 114], ["COX", "PROTEIN", 123, 126], ["COX-2", "PROTEIN", 199, 204], ["pro-inflammatory factor IL-32", "PROTEIN", 252, 281], ["IFN", "PROTEIN", 292, 295], ["DsRNA", "PROTEIN", 410, 415], ["IL-32", "PROTEIN", 427, 432], ["COX", "PROTEIN", 441, 444], ["COX-2", "PROTEIN", 517, 522], ["IL-32 promoter", "DNA", 544, 558], ["influenza A virus", "SPECIES", 226, 243], ["influenza A virus", "SPECIES", 330, 347], ["influenza A virus", "SPECIES", 226, 243], ["influenza A virus", "SPECIES", 330, 347], ["this study", "TEST", 3, 13], ["dsRNA", "PROBLEM", 45, 50], ["inflammatory response", "PROBLEM", 54, 75], ["IV infection", "PROBLEM", 79, 91], ["DsRNA stimulates IL", "TREATMENT", 92, 111], ["COX", "TEST", 199, 202], ["influenza", "PROBLEM", 226, 235], ["pro-inflammatory factor IL", "TEST", 252, 278], ["poly(IC)", "TREATMENT", 283, 291], ["IFN", "PROBLEM", 292, 295], ["treatment", "TREATMENT", 298, 307], ["the influenza A virus infection", "PROBLEM", 326, 357], ["DsRNA stimulates IL", "TREATMENT", 410, 429], ["COX", "TEST", 517, 520], ["IL-32 promoter", "TREATMENT", 544, 558], ["inflammatory", "OBSERVATION_MODIFIER", 54, 66], ["infection", "OBSERVATION", 82, 91]]], ["A549 cells were cotransfected with the reporter plasmid pIL-32-Luc and pcDNA3.1, pcDNA3.1-COX-2 plus different concentration of NS398 as mentioned in Fig. 3A, pcDNA3.1 was used as empty vector control.", [["A549 cells", "ANATOMY", 0, 10], ["NS398", "CHEMICAL", 128, 133], ["NS398", "CHEMICAL", 128, 133], ["A549 cells", "CELL", 0, 10], ["pIL-32", "GENE_OR_GENE_PRODUCT", 56, 62], ["Luc", "GENE_OR_GENE_PRODUCT", 63, 66], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 71, 79], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 81, 87], ["COX-2", "GENE_OR_GENE_PRODUCT", 90, 95], ["NS398", "SIMPLE_CHEMICAL", 128, 133], ["3A", "GENE_OR_GENE_PRODUCT", 155, 157], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 159, 167], ["A549 cells", "CELL_LINE", 0, 10], ["reporter plasmid pIL-32", "DNA", 39, 62], ["Luc", "DNA", 63, 66], ["pcDNA3.1", "DNA", 71, 79], ["pcDNA3", "DNA", 81, 87], ["COX", "PROTEIN", 90, 93], ["pcDNA3.1", "DNA", 159, 167], ["A549 cells", "PROBLEM", 0, 10], ["the reporter plasmid pIL", "TEST", 35, 59], ["pcDNA3", "PROBLEM", 81, 87], ["COX", "TEST", 90, 93], ["different concentration of NS398", "TREATMENT", 101, 133], ["pcDNA3.1", "TREATMENT", 159, 167], ["empty vector control", "TREATMENT", 180, 200], ["NS398", "OBSERVATION", 128, 133]]], ["Results from Luciferase activity assay showed that the level of IL-32 promoter activity was increased by COX-2 over-expression and it was blocked by COX-2 inhibitor NS398 in a dose-dependent manner.DsRNA stimulates IL-32 through COX-2 pathway during inflammatory response ::: ResultsSecondly, to determine the effects of COX-2 on the activation of IL-32 mRNA level and protein expression, A549 cells were transfected with different amounts of pcDNA3.1-COX-2.", [["A549 cells", "ANATOMY", 389, 399], ["NS398", "CHEMICAL", 165, 170], ["NS398", "CHEMICAL", 165, 170], ["Luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["IL-32", "GENE_OR_GENE_PRODUCT", 64, 69], ["COX-2", "GENE_OR_GENE_PRODUCT", 105, 110], ["COX-2", "GENE_OR_GENE_PRODUCT", 149, 154], ["NS398", "SIMPLE_CHEMICAL", 165, 170], ["DsRNA", "SIMPLE_CHEMICAL", 198, 203], ["IL-32", "GENE_OR_GENE_PRODUCT", 215, 220], ["COX-2", "GENE_OR_GENE_PRODUCT", 229, 234], ["COX-2", "GENE_OR_GENE_PRODUCT", 321, 326], ["IL-32", "GENE_OR_GENE_PRODUCT", 348, 353], ["A549 cells", "CELL", 389, 399], ["pcDNA3.1-COX-2", "GENE_OR_GENE_PRODUCT", 443, 457], ["IL-32 promoter", "DNA", 64, 78], ["COX", "PROTEIN", 105, 108], ["COX", "PROTEIN", 149, 152], ["DsRNA", "PROTEIN", 198, 203], ["IL-32", "PROTEIN", 215, 220], ["COX", "PROTEIN", 229, 232], ["COX-2", "PROTEIN", 321, 326], ["IL-32 mRNA", "RNA", 348, 358], ["A549 cells", "CELL_LINE", 389, 399], ["pcDNA3.1", "DNA", 443, 451], ["COX", "PROTEIN", 452, 455], ["Luciferase activity assay", "TEST", 13, 38], ["IL", "TEST", 64, 66], ["COX", "TEST", 149, 152], ["DsRNA stimulates IL", "TREATMENT", 198, 217], ["COX", "TEST", 321, 324], ["IL", "TEST", 348, 350], ["mRNA level", "TEST", 354, 364], ["protein expression", "TEST", 369, 387], ["A549 cells", "TEST", 389, 399], ["COX", "TEST", 452, 455], ["A549 cells", "OBSERVATION", 389, 399]]], ["Results from RT-PCR using IL-32-specific, or \u03b2-actin-specific primers showed that the levels of IL-32 mRNA were increased as the amount of pcDNA3.1-COX-2 increased, but the levels of \u03b2-actin mRNA remained relatively constant (Fig. 3B).", [["IL-32", "GENE_OR_GENE_PRODUCT", 26, 31], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 45, 52], ["IL-32", "GENE_OR_GENE_PRODUCT", 96, 101], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 139, 147], ["COX-2", "GENE_OR_GENE_PRODUCT", 148, 153], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 183, 190], ["\u03b2-actin", "PROTEIN", 45, 52], ["IL-32 mRNA", "RNA", 96, 106], ["pcDNA3.1", "PROTEIN", 139, 147], ["COX", "PROTEIN", 148, 151], ["\u03b2-actin mRNA", "RNA", 183, 195], ["RT", "TEST", 13, 15], ["PCR", "TEST", 16, 19], ["IL", "TEST", 26, 28], ["specific primers", "TEST", 53, 69], ["the levels", "TEST", 82, 92], ["IL", "TEST", 96, 98], ["mRNA", "TEST", 102, 106], ["COX", "TEST", 148, 151], ["the levels", "TEST", 169, 179], ["\u03b2-actin mRNA", "PROBLEM", 183, 195]]], ["Furthermore, IL-32 production in culture supernatants was stimulated by COX-2 over-expression in a dose-dependent manner (Fig. 3C).DsRNA stimulates IL-32 through COX-2 pathway during inflammatory response ::: ResultsThirdly, results from RT-PCR analyses showed that the level of IL-32 mRNA activated by poly(IC)+IFN-\u03b3 was suppressed by COX-2-specific inhibitor NS398 in a dose dependent manner (Fig. 3D).", [["supernatants", "ANATOMY", 41, 53], ["NS398", "CHEMICAL", 361, 366], ["NS398", "CHEMICAL", 361, 366], ["IL-32", "GENE_OR_GENE_PRODUCT", 13, 18], ["COX-2", "GENE_OR_GENE_PRODUCT", 72, 77], ["DsRNA", "SIMPLE_CHEMICAL", 131, 136], ["IL-32", "GENE_OR_GENE_PRODUCT", 148, 153], ["COX-2", "GENE_OR_GENE_PRODUCT", 162, 167], ["IL-32", "GENE_OR_GENE_PRODUCT", 279, 284], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 303, 311], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 312, 317], ["COX-2", "GENE_OR_GENE_PRODUCT", 336, 341], ["NS398", "SIMPLE_CHEMICAL", 361, 366], ["IL", "PROTEIN", 13, 15], ["COX", "PROTEIN", 72, 75], ["DsRNA", "PROTEIN", 131, 136], ["IL-32", "PROTEIN", 148, 153], ["COX-2", "PROTEIN", 162, 167], ["IL-32 mRNA", "RNA", 279, 289], ["poly(IC)+IFN-\u03b3", "PROTEIN", 303, 317], ["COX", "PROTEIN", 336, 339], ["IL", "TEST", 13, 15], ["culture supernatants", "TEST", 33, 53], ["COX", "TEST", 72, 75], ["DsRNA stimulates IL", "TEST", 131, 150], ["RT", "TEST", 238, 240], ["PCR analyses", "TEST", 241, 253], ["the level", "TEST", 266, 275], ["IL", "TEST", 279, 281], ["mRNA", "TEST", 285, 289], ["poly", "TEST", 303, 307], ["IFN", "TEST", 312, 315], ["COX", "TEST", 336, 339], ["specific inhibitor NS398", "TREATMENT", 342, 366]]], ["Furthermore, IL-32 accumulation in culture supernatants stimulated by poly(IC)+IFN-\u03b3 were suppressed by 80 \u00b5M NS398 (Fig. 3E).DsRNA stimulates IL-32 through COX-2 pathway during inflammatory response ::: ResultsTaken together, these data suggest that COX-2 is an upstream regulatory factor of dsRNA-triggered IL-32 production.IL-32 feedback inhibits dsRNA-induced COX-2 expression ::: ResultsThe effect of IL-32 on the regulation of COX-2 promoter was determined.", [["supernatants", "ANATOMY", 43, 55], ["NS398", "CHEMICAL", 110, 115], ["NS398", "CHEMICAL", 110, 115], ["IL-32", "GENE_OR_GENE_PRODUCT", 13, 18], ["poly(IC)", "SIMPLE_CHEMICAL", 70, 78], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 79, 84], ["NS398", "SIMPLE_CHEMICAL", 110, 115], ["DsRNA", "SIMPLE_CHEMICAL", 126, 131], ["IL-32", "GENE_OR_GENE_PRODUCT", 143, 148], ["COX-2", "GENE_OR_GENE_PRODUCT", 157, 162], ["COX-2", "GENE_OR_GENE_PRODUCT", 251, 256], ["IL-32", "GENE_OR_GENE_PRODUCT", 309, 314], ["IL-32", "GENE_OR_GENE_PRODUCT", 326, 331], ["COX-2", "GENE_OR_GENE_PRODUCT", 364, 369], ["IL-32", "GENE_OR_GENE_PRODUCT", 406, 411], ["COX-2", "GENE_OR_GENE_PRODUCT", 433, 438], ["IL-32", "PROTEIN", 13, 18], ["IFN", "PROTEIN", 79, 82], ["DsRNA", "PROTEIN", 126, 131], ["IL-32", "PROTEIN", 143, 148], ["COX", "PROTEIN", 157, 160], ["COX", "PROTEIN", 251, 254], ["upstream regulatory factor", "PROTEIN", 263, 289], ["IL", "PROTEIN", 326, 328], ["COX", "PROTEIN", 364, 367], ["IL-32", "PROTEIN", 406, 411], ["COX-2 promoter", "DNA", 433, 447], ["IL", "TREATMENT", 13, 15], ["culture supernatants", "TEST", 35, 55], ["IFN", "TEST", 79, 82], ["DsRNA stimulates IL", "TREATMENT", 126, 145], ["these data", "TEST", 227, 237], ["COX", "TEST", 251, 254], ["dsRNA", "PROBLEM", 293, 298], ["IL", "TEST", 326, 328], ["IL", "TREATMENT", 406, 408], ["COX-2 promoter", "TREATMENT", 433, 447]]], ["A549 cells were cotransfected with the reporter plasmid pCOX-2-Luc and pCMV-Flag2A, Flag2A-IL-32.", [["A549 cells", "ANATOMY", 0, 10], ["A549 cells", "CELL", 0, 10], ["pCOX-2", "GENE_OR_GENE_PRODUCT", 56, 62], ["Luc", "GENE_OR_GENE_PRODUCT", 63, 66], ["pCMV-Flag2A", "GENE_OR_GENE_PRODUCT", 71, 82], ["Flag2A-IL-32", "GENE_OR_GENE_PRODUCT", 84, 96], ["A549 cells", "CELL_LINE", 0, 10], ["reporter plasmid pCOX-2-Luc", "DNA", 39, 66], ["pCMV", "DNA", 71, 75], ["Flag2A", "DNA", 76, 82], ["Flag2A", "DNA", 84, 90], ["IL-32", "DNA", 91, 96], ["A549 cells", "PROBLEM", 0, 10], ["the reporter plasmid pCOX", "TEST", 35, 60], ["pCMV", "TEST", 71, 75]]], ["Results from Luciferase activity assay showed that the level of COX-2 promoter activity was decreased by IL-32 over-expression (Fig. 4A).IL-32 feedback inhibits dsRNA-induced COX-2 expression ::: ResultsTo determine the effects of IL-32 on the regulation of COX-2 mRNA expression, PGE2 production, A549 cells were transfected with different amounts of Flag2A-IL-32 and treated with poly(IC)+IFN-\u03b3 as the inducer.", [["A549 cells", "ANATOMY", 298, 308], ["PGE2", "CHEMICAL", 281, 285], ["PGE2", "CHEMICAL", 281, 285], ["Luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["COX-2", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-32", "GENE_OR_GENE_PRODUCT", 105, 110], ["IL-32", "GENE_OR_GENE_PRODUCT", 137, 142], ["COX-2", "GENE_OR_GENE_PRODUCT", 175, 180], ["IL-32", "GENE_OR_GENE_PRODUCT", 231, 236], ["COX-2", "GENE_OR_GENE_PRODUCT", 258, 263], ["PGE2", "SIMPLE_CHEMICAL", 281, 285], ["A549 cells", "CELL", 298, 308], ["Flag2A-IL-32", "GENE_OR_GENE_PRODUCT", 352, 364], ["poly(IC)", "SIMPLE_CHEMICAL", 382, 390], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 391, 396], ["COX", "PROTEIN", 64, 67], ["IL", "PROTEIN", 105, 107], ["IL", "PROTEIN", 137, 139], ["COX", "PROTEIN", 175, 178], ["IL-32", "PROTEIN", 231, 236], ["COX-2 mRNA", "RNA", 258, 268], ["A549 cells", "CELL_LINE", 298, 308], ["Flag2A", "PROTEIN", 352, 358], ["IL", "PROTEIN", 359, 361], ["poly(IC)+IFN-\u03b3", "PROTEIN", 382, 396], ["Luciferase activity assay", "TEST", 13, 38], ["COX", "TEST", 64, 67], ["IL", "TEST", 137, 139], ["IL", "TEST", 231, 233], ["COX", "TEST", 258, 261], ["PGE2 production", "PROBLEM", 281, 296], ["A549 cells", "PROBLEM", 298, 308], ["Flag2A-IL", "TREATMENT", 352, 361], ["poly(IC)", "TREATMENT", 382, 390], ["IFN", "TREATMENT", 391, 394]]], ["Results from RT-PCR using COX-2-specific, or \u03b2-actin-specific primers showed that the levels of COX-2 mRNA was decreased as the amount of Flag2A-IL-32 increased, but the levels of \u03b2-actin mRNA remained relatively constant (Fig. 4B).", [["COX-2", "GENE_OR_GENE_PRODUCT", 26, 31], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 45, 52], ["COX-2", "GENE_OR_GENE_PRODUCT", 96, 101], ["Flag2A-IL-32", "GENE_OR_GENE_PRODUCT", 138, 150], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 180, 187], ["COX", "PROTEIN", 26, 29], ["\u03b2-actin", "PROTEIN", 45, 52], ["COX-2 mRNA", "RNA", 96, 106], ["Flag2A", "PROTEIN", 138, 144], ["IL", "PROTEIN", 145, 147], ["\u03b2-actin mRNA", "RNA", 180, 192], ["RT-PCR", "TEST", 13, 19], ["COX", "TEST", 26, 29], ["\u03b2-actin", "TEST", 45, 52], ["specific primers", "TEST", 53, 69], ["the levels", "TEST", 82, 92], ["COX", "TEST", 96, 99], ["mRNA", "TEST", 102, 106], ["Flag2A", "TEST", 138, 144], ["IL", "TEST", 145, 147], ["the levels", "TEST", 166, 176], ["\u03b2-actin mRNA", "PROBLEM", 180, 192]]], ["Furthermore, PGE2 production in culture supernatants was suppressed by IL-32 over-expression in a dose-dependent manner (Fig. 4C).IL-32 feedback inhibits dsRNA-induced COX-2 expression ::: ResultsTo confirm the above results, IL-32-specific siRNA was cotransfected along with reporter plasmid pCOX-2-Luc into A549 cells and treated with poly(IC)+IFN-\u03b3.", [["supernatants", "ANATOMY", 40, 52], ["A549 cells", "ANATOMY", 309, 319], ["PGE2", "CHEMICAL", 13, 17], ["PGE2", "CHEMICAL", 13, 17], ["PGE2", "SIMPLE_CHEMICAL", 13, 17], ["IL-32", "GENE_OR_GENE_PRODUCT", 71, 76], ["IL-32", "GENE_OR_GENE_PRODUCT", 130, 135], ["COX-2", "GENE_OR_GENE_PRODUCT", 168, 173], ["IL-32", "GENE_OR_GENE_PRODUCT", 226, 231], ["pCOX-2", "GENE_OR_GENE_PRODUCT", 293, 299], ["Luc", "GENE_OR_GENE_PRODUCT", 300, 303], ["A549 cells", "CELL", 309, 319], ["poly(IC)", "SIMPLE_CHEMICAL", 337, 345], ["PGE2", "PROTEIN", 13, 17], ["IL", "PROTEIN", 71, 73], ["IL", "PROTEIN", 130, 132], ["COX", "PROTEIN", 168, 171], ["IL-32", "PROTEIN", 226, 231], ["reporter plasmid pCOX-2-Luc", "DNA", 276, 303], ["A549 cells", "CELL_LINE", 309, 319], ["IFN", "PROTEIN", 346, 349], ["PGE2 production", "TEST", 13, 28], ["culture supernatants", "TEST", 32, 52], ["IL", "TEST", 71, 73], ["IL", "TEST", 130, 132], ["IL", "TEST", 226, 228], ["specific siRNA", "TREATMENT", 232, 246], ["reporter plasmid pCOX", "TEST", 276, 297], ["poly(IC)", "TREATMENT", 337, 345], ["A549 cells", "OBSERVATION", 309, 319]]], ["Results from Luciferase activity assay showed that the level of COX-2 promoter activity was increased by knocking down IL-32 (Fig. 4D).", [["Luciferase", "GENE_OR_GENE_PRODUCT", 13, 23], ["COX-2", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-32", "GENE_OR_GENE_PRODUCT", 119, 124], ["COX", "PROTEIN", 64, 67], ["IL-32", "PROTEIN", 119, 124], ["Luciferase activity assay", "TEST", 13, 38], ["COX", "TEST", 64, 67]]], ["Furthermore, PGE2 production in culture supernatants stimulated with poly(IC)+IFN-\u03b3 was enhanced by knocking down IL-32 (Fig. 4E).IL-32 feedback inhibits dsRNA-induced COX-2 expression ::: ResultsTaken together, these data suggest that IL-32 plays a very important role in the inflammatory response following an influenza A/COX-2/IL-32 dependent positive regulatory order, while a negative feedback to COX-2 biosynthesis was also first observed.Influenza A-induced PGE2 production and IL-32 expression were inhibited by NS398 and Aspirin ::: ResultsTo confirm the COX-2 and IL-32 regulatory loop, A549 cells were infected by influenza A virus and treated with or without selective COX-2 inhibitor NS398, or non-selective COX inhibitor Aspirin, a widely used anti-inflammatory drug.", [["supernatants", "ANATOMY", 40, 52], ["A549 cells", "ANATOMY", 597, 607], ["PGE2", "CHEMICAL", 13, 17], ["PGE2", "CHEMICAL", 465, 469], ["NS398", "CHEMICAL", 520, 525], ["Aspirin", "CHEMICAL", 530, 537], ["NS398", "CHEMICAL", 697, 702], ["Aspirin", "CHEMICAL", 735, 742], ["PGE2", "CHEMICAL", 13, 17], ["PGE2", "CHEMICAL", 465, 469], ["NS398", "CHEMICAL", 520, 525], ["Aspirin", "CHEMICAL", 530, 537], ["NS398", "CHEMICAL", 697, 702], ["Aspirin", "CHEMICAL", 735, 742], ["PGE2", "SIMPLE_CHEMICAL", 13, 17], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 69, 77], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 78, 83], ["IL-32", "GENE_OR_GENE_PRODUCT", 114, 119], ["Fig. 4E", "GENE_OR_GENE_PRODUCT", 121, 128], ["IL-32", "GENE_OR_GENE_PRODUCT", 130, 135], ["COX-2", "GENE_OR_GENE_PRODUCT", 168, 173], ["IL-32", "GENE_OR_GENE_PRODUCT", 236, 241], ["COX-2", "GENE_OR_GENE_PRODUCT", 324, 329], ["IL-32", "GENE_OR_GENE_PRODUCT", 330, 335], ["COX-2", "GENE_OR_GENE_PRODUCT", 402, 407], ["PGE2", "GENE_OR_GENE_PRODUCT", 465, 469], ["IL-32", "GENE_OR_GENE_PRODUCT", 485, 490], ["NS398", "SIMPLE_CHEMICAL", 520, 525], ["Aspirin", "SIMPLE_CHEMICAL", 530, 537], ["COX-2", "GENE_OR_GENE_PRODUCT", 564, 569], ["IL-32", "GENE_OR_GENE_PRODUCT", 574, 579], ["A549 cells", "CELL", 597, 607], ["influenza A virus", "ORGANISM", 625, 642], ["COX-2", "GENE_OR_GENE_PRODUCT", 681, 686], ["NS398", "SIMPLE_CHEMICAL", 697, 702], ["COX", "GENE_OR_GENE_PRODUCT", 721, 724], ["Aspirin", "SIMPLE_CHEMICAL", 735, 742], ["PGE2", "PROTEIN", 13, 17], ["poly(IC)+IFN-\u03b3", "PROTEIN", 69, 83], ["IL-32", "PROTEIN", 114, 119], ["Fig. 4E", "PROTEIN", 121, 128], ["IL", "PROTEIN", 130, 132], ["COX", "PROTEIN", 168, 171], ["IL-32", "PROTEIN", 236, 241], ["COX", "PROTEIN", 402, 405], ["COX", "PROTEIN", 564, 567], ["A549 cells", "CELL_LINE", 597, 607], ["Influenza", "SPECIES", 445, 454], ["influenza A virus", "SPECIES", 625, 642], ["influenza A virus", "SPECIES", 625, 642], ["PGE2 production", "TREATMENT", 13, 28], ["culture supernatants", "TEST", 32, 52], ["poly(IC", "TREATMENT", 69, 76], ["knocking down IL", "TEST", 100, 116], ["IL", "TEST", 130, 132], ["the inflammatory response", "PROBLEM", 273, 298], ["an influenza A/COX", "TEST", 309, 327], ["IL", "TEST", 330, 332], ["COX", "TEST", 402, 405], ["Influenza A-induced PGE2 production", "TREATMENT", 445, 480], ["IL", "TEST", 485, 487], ["Aspirin", "TREATMENT", 530, 537], ["the COX", "TEST", 560, 567], ["IL", "TEST", 574, 576], ["A549 cells", "PROBLEM", 597, 607], ["influenza A virus", "PROBLEM", 625, 642], ["selective COX", "TREATMENT", 671, 684], ["NS398", "TREATMENT", 697, 702], ["non-selective COX inhibitor Aspirin", "TREATMENT", 707, 742], ["anti-inflammatory drug", "TREATMENT", 758, 780], ["inflammatory", "OBSERVATION", 277, 289], ["A549 cells", "OBSERVATION", 597, 607], ["anti-inflammatory drug", "OBSERVATION", 758, 780]]], ["Results showed that IV-triggered PGE2 release (Fig. 5A) and IL-32 (Fig. 5B) production in the culture supernatants were inhibited by either NS398 or Aspirin, which indicated that IL-32 is an important pro-inflammatory factor downstream of COX-2 during influenza A virus infection.Influenza A-induced PGE2 production was increased by knocking down IL-32 ::: ResultsThe effect of IL-32 on the regulation of IV infection induced PGE2 production was also determined.", [["supernatants", "ANATOMY", 102, 114], ["PGE2", "CHEMICAL", 33, 37], ["NS398", "CHEMICAL", 140, 145], ["Aspirin", "CHEMICAL", 149, 156], ["influenza A virus infection", "DISEASE", 252, 279], ["Influenza", "DISEASE", 280, 289], ["PGE2", "CHEMICAL", 300, 304], ["infection", "DISEASE", 408, 417], ["PGE2", "CHEMICAL", 426, 430], ["PGE2", "CHEMICAL", 33, 37], ["NS398", "CHEMICAL", 140, 145], ["Aspirin", "CHEMICAL", 149, 156], ["PGE2", "CHEMICAL", 300, 304], ["PGE2", "CHEMICAL", 426, 430], ["PGE2", "SIMPLE_CHEMICAL", 33, 37], ["IL-32", "GENE_OR_GENE_PRODUCT", 60, 65], ["Fig. 5B", "GENE_OR_GENE_PRODUCT", 67, 74], ["NS398", "SIMPLE_CHEMICAL", 140, 145], ["Aspirin", "SIMPLE_CHEMICAL", 149, 156], ["IL-32", "GENE_OR_GENE_PRODUCT", 179, 184], ["COX-2", "GENE_OR_GENE_PRODUCT", 239, 244], ["influenza A virus", "ORGANISM", 252, 269], ["PGE2", "SIMPLE_CHEMICAL", 300, 304], ["IL-32", "GENE_OR_GENE_PRODUCT", 347, 352], ["IL-32", "GENE_OR_GENE_PRODUCT", 378, 383], ["IV", "GENE_OR_GENE_PRODUCT", 405, 407], ["PGE2", "SIMPLE_CHEMICAL", 426, 430], ["PGE2", "PROTEIN", 33, 37], ["IL-32", "PROTEIN", 179, 184], ["pro-inflammatory factor", "PROTEIN", 201, 224], ["COX-2", "PROTEIN", 239, 244], ["IL", "PROTEIN", 347, 349], ["IL-32", "PROTEIN", 378, 383], ["influenza A virus", "SPECIES", 252, 269], ["influenza A virus", "SPECIES", 252, 269], ["IV-triggered PGE2 release", "TREATMENT", 20, 45], ["IL", "TEST", 60, 62], ["the culture supernatants", "TEST", 90, 114], ["NS398", "TREATMENT", 140, 145], ["Aspirin", "TREATMENT", 149, 156], ["IL", "TEST", 179, 181], ["COX", "TEST", 239, 242], ["influenza A virus infection", "PROBLEM", 252, 279], ["Influenza A-induced PGE2 production", "TREATMENT", 280, 315], ["IL", "TREATMENT", 378, 380], ["IV infection induced PGE2 production", "TREATMENT", 405, 441]]], ["We found that PGE2 release in A549 cell culture supernatants stimulated by IV infection was increased (Fig. 5C) and IL-32 production decreased (Fig. 5D) by knocking down IL-32.Influenza A-induced PGE2 production was increased by knocking down IL-32 ::: ResultsTaken together, these data demonstrate that a novel inflammatory pathway in response to influenza A virus infection and dsRNA treatment was identified as described in Fig. 6.DiscussionOur results demonstrate that significant increase of serum COX-2-derived PGE2 and IL-32 levels were observed in influenza A infected patients compared with healthy individuals.", [["A549 cell culture supernatants", "ANATOMY", 30, 60], ["serum", "ANATOMY", 497, 502], ["PGE2", "CHEMICAL", 14, 18], ["infection", "DISEASE", 78, 87], ["Influenza", "DISEASE", 176, 185], ["PGE2", "CHEMICAL", 196, 200], ["influenza A virus infection", "DISEASE", 348, 375], ["PGE2", "CHEMICAL", 517, 521], ["influenza A infected", "DISEASE", 556, 576], ["PGE2", "CHEMICAL", 14, 18], ["PGE2", "CHEMICAL", 196, 200], ["PGE2", "CHEMICAL", 517, 521], ["PGE2", "SIMPLE_CHEMICAL", 14, 18], ["A549 cell", "CELL", 30, 39], ["IL-32", "GENE_OR_GENE_PRODUCT", 116, 121], ["IL-32", "GENE_OR_GENE_PRODUCT", 170, 175], ["PGE2", "SIMPLE_CHEMICAL", 196, 200], ["IL-32", "GENE_OR_GENE_PRODUCT", 243, 248], ["influenza A virus", "ORGANISM", 348, 365], ["serum", "ORGANISM_SUBSTANCE", 497, 502], ["COX-2", "GENE_OR_GENE_PRODUCT", 503, 508], ["PGE2", "GENE_OR_GENE_PRODUCT", 517, 521], ["IL-32", "GENE_OR_GENE_PRODUCT", 526, 531], ["influenza A", "ORGANISM", 556, 567], ["patients", "ORGANISM", 577, 585], ["A549 cell culture", "CELL_LINE", 30, 47], ["IL-32", "PROTEIN", 170, 175], ["IL", "PROTEIN", 243, 245], ["serum COX-2", "PROTEIN", 497, 508], ["influenza A virus", "SPECIES", 348, 365], ["patients", "SPECIES", 577, 585], ["influenza A virus", "SPECIES", 348, 365], ["influenza A", "SPECIES", 556, 567], ["PGE2 release", "PROBLEM", 14, 26], ["A549 cell culture supernatants", "TREATMENT", 30, 60], ["IV infection", "PROBLEM", 75, 87], ["IL", "TREATMENT", 116, 118], ["Influenza A-induced PGE2 production", "TREATMENT", 176, 211], ["these data", "TEST", 276, 286], ["a novel inflammatory pathway", "PROBLEM", 304, 332], ["influenza A virus infection", "PROBLEM", 348, 375], ["dsRNA treatment", "TREATMENT", 380, 395], ["serum COX", "TEST", 497, 506], ["PGE2", "TEST", 517, 521], ["IL", "TEST", 526, 528], ["influenza", "PROBLEM", 556, 565], ["A549 cell", "OBSERVATION", 30, 39], ["inflammatory", "OBSERVATION_MODIFIER", 312, 324], ["significant", "OBSERVATION_MODIFIER", 473, 484], ["increase", "OBSERVATION_MODIFIER", 485, 493], ["infected", "OBSERVATION", 568, 576]]], ["Viral infection resulted in 2.7-fold increase in PGE2 synthesis and 58.2% increase in IL-32 production.", [["Viral infection", "DISEASE", 0, 15], ["PGE2", "CHEMICAL", 49, 53], ["PGE2", "CHEMICAL", 49, 53], ["Viral", "ORGANISM", 0, 5], ["PGE2", "SIMPLE_CHEMICAL", 49, 53], ["IL-32", "GENE_OR_GENE_PRODUCT", 86, 91], ["IL", "PROTEIN", 86, 88], ["Viral infection", "PROBLEM", 0, 15], ["2.7-fold increase", "PROBLEM", 28, 45], ["PGE2 synthesis", "TEST", 49, 63], ["IL", "TEST", 86, 88], ["infection", "OBSERVATION", 6, 15], ["2.7-fold", "OBSERVATION_MODIFIER", 28, 36], ["increase", "OBSERVATION_MODIFIER", 37, 45], ["PGE2 synthesis", "OBSERVATION", 49, 63], ["increase", "OBSERVATION_MODIFIER", 74, 82]]], ["Both influenza A virus infection and poly(IC)+IFN-\u03b3 treatment in A549 human lung epithelial cells were able to induce COX-2/ IL-32 mRNA and protein expression as well as PGE2 and IL-32 accumulation in the cell culture supernatants.", [["A549", "ANATOMY", 65, 69], ["lung epithelial cells", "ANATOMY", 76, 97], ["cell culture supernatants", "ANATOMY", 205, 230], ["influenza A virus infection", "DISEASE", 5, 32], ["poly(IC", "CHEMICAL", 37, 44], ["IFN-\u03b3", "CHEMICAL", 46, 51], ["PGE2", "CHEMICAL", 170, 174], ["PGE2", "CHEMICAL", 170, 174], ["influenza A virus", "ORGANISM", 5, 22], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 37, 45], ["IFN-\u03b3", "SIMPLE_CHEMICAL", 46, 51], ["A549", "CELL", 65, 69], ["human", "ORGANISM", 70, 75], ["lung epithelial cells", "CELL", 76, 97], ["COX-2", "GENE_OR_GENE_PRODUCT", 118, 123], ["IL-32", "GENE_OR_GENE_PRODUCT", 125, 130], ["PGE2", "SIMPLE_CHEMICAL", 170, 174], ["IL-32", "GENE_OR_GENE_PRODUCT", 179, 184], ["cell", "CELL", 205, 209], ["IFN", "PROTEIN", 46, 49], ["A549 human lung epithelial cells", "CELL_LINE", 65, 97], ["influenza A virus", "SPECIES", 5, 22], ["human", "SPECIES", 70, 75], ["influenza A virus", "SPECIES", 5, 22], ["human", "SPECIES", 70, 75], ["Both influenza A virus infection", "PROBLEM", 0, 32], ["poly(IC)", "TREATMENT", 37, 45], ["IFN", "TREATMENT", 46, 49], ["treatment", "TREATMENT", 52, 61], ["A549 human lung epithelial cells", "TEST", 65, 97], ["COX", "TEST", 118, 121], ["IL", "TEST", 125, 127], ["protein expression", "TEST", 140, 158], ["PGE2", "TEST", 170, 174], ["IL", "TEST", 179, 181], ["the cell culture supernatants", "TEST", 201, 230], ["influenza", "OBSERVATION", 5, 14], ["virus infection", "OBSERVATION", 17, 32], ["lung", "ANATOMY", 76, 80], ["epithelial cells", "OBSERVATION", 81, 97], ["cell", "OBSERVATION", 205, 209]]], ["IL-32 was induced by influenza virus infection through COX-2-dependent mechanism.DiscussionAlthough pro-inflammatory factor COX-2 has been identified as an obligatory mediator in the airway inflammation during influenza virus infection [26], virtually little is currently known regarding the regulation of a newly identified proinfammatory factor IL-32 in influenza A virus infection or the mechanism whereby influenza A virus upregulates IL-32 expression.", [["airway", "ANATOMY", 183, 189], ["influenza virus infection", "DISEASE", 21, 46], ["airway inflammation", "DISEASE", 183, 202], ["influenza virus infection", "DISEASE", 210, 235], ["influenza A virus infection", "DISEASE", 356, 383], ["IL-32", "GENE_OR_GENE_PRODUCT", 0, 5], ["influenza virus", "ORGANISM", 21, 36], ["COX-2", "GENE_OR_GENE_PRODUCT", 55, 60], ["COX-2", "GENE_OR_GENE_PRODUCT", 124, 129], ["airway", "PATHOLOGICAL_FORMATION", 183, 189], ["influenza virus", "ORGANISM", 210, 225], ["IL-32", "GENE_OR_GENE_PRODUCT", 347, 352], ["influenza A virus", "ORGANISM", 356, 373], ["influenza A virus", "ORGANISM", 409, 426], ["IL-32", "GENE_OR_GENE_PRODUCT", 439, 444], ["IL-32", "PROTEIN", 0, 5], ["COX-2", "PROTEIN", 55, 60], ["pro-inflammatory factor COX-2", "PROTEIN", 100, 129], ["proinfammatory factor IL-32", "PROTEIN", 325, 352], ["IL-32", "PROTEIN", 439, 444], ["influenza virus", "SPECIES", 21, 36], ["influenza virus", "SPECIES", 210, 225], ["influenza A virus", "SPECIES", 356, 373], ["influenza A virus", "SPECIES", 409, 426], ["influenza virus", "SPECIES", 21, 36], ["influenza virus", "SPECIES", 210, 225], ["influenza A virus", "SPECIES", 356, 373], ["influenza A virus", "SPECIES", 409, 426], ["IL", "TREATMENT", 0, 2], ["influenza virus infection", "PROBLEM", 21, 46], ["COX", "TEST", 55, 58], ["pro-inflammatory factor COX", "PROBLEM", 100, 127], ["the airway inflammation", "PROBLEM", 179, 202], ["influenza virus infection", "PROBLEM", 210, 235], ["a newly identified proinfammatory factor IL", "PROBLEM", 306, 349], ["influenza A virus infection", "PROBLEM", 356, 383], ["influenza A virus upregulates IL", "TREATMENT", 409, 441], ["influenza virus", "OBSERVATION", 21, 36], ["airway", "ANATOMY", 183, 189], ["inflammation", "OBSERVATION", 190, 202]]], ["The present study provides considerable new information relevant to these issues.", [["The present study", "TEST", 0, 17]]], ["We identified first a COX-2/IL-32 regulatory loop in which COX-2 upregulated IL-32 expression and IL-32 feedback inhibited COX-2 expression in influenza A virus infected A549 lung epithelial cells.", [["A549 lung epithelial cells", "ANATOMY", 170, 196], ["COX-2", "GENE_OR_GENE_PRODUCT", 22, 27], ["IL-32", "GENE_OR_GENE_PRODUCT", 28, 33], ["COX-2", "GENE_OR_GENE_PRODUCT", 59, 64], ["IL-32", "GENE_OR_GENE_PRODUCT", 77, 82], ["IL-32", "GENE_OR_GENE_PRODUCT", 98, 103], ["COX-2", "GENE_OR_GENE_PRODUCT", 123, 128], ["influenza A virus", "ORGANISM", 143, 160], ["A549 lung epithelial cells", "CELL", 170, 196], ["COX", "PROTEIN", 59, 62], ["IL", "PROTEIN", 77, 79], ["COX-2", "PROTEIN", 123, 128], ["A549 lung epithelial cells", "CELL_LINE", 170, 196], ["influenza A virus", "SPECIES", 143, 160], ["influenza A virus", "SPECIES", 143, 160], ["a COX", "TEST", 20, 25], ["COX", "TEST", 59, 62], ["IL", "TEST", 77, 79], ["IL", "TEST", 98, 100], ["COX", "TEST", 123, 126], ["influenza A virus infected A549 lung epithelial cells", "PROBLEM", 143, 196], ["epithelial cells", "OBSERVATION", 180, 196]]], ["At present, a possible \u201ccross-talk\u201d between two important pro-inflammatory factors nitric oxide synthase (NOS) and COX has been extensively examined in different cell lines, tissues and under different pathophysiological conditions with conflicting results [31].", [["cell lines", "ANATOMY", 162, 172], ["tissues", "ANATOMY", 174, 181], ["nitric oxide", "CHEMICAL", 83, 95], ["nitric oxide", "CHEMICAL", 83, 95], ["nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 83, 104], ["NOS", "GENE_OR_GENE_PRODUCT", 106, 109], ["COX", "GENE_OR_GENE_PRODUCT", 115, 118], ["cell lines", "CELL", 162, 172], ["tissues", "TISSUE", 174, 181], ["pro-inflammatory factors", "PROTEIN", 58, 82], ["nitric oxide synthase", "PROTEIN", 83, 104], ["NOS", "PROTEIN", 106, 109], ["COX", "PROTEIN", 115, 118], ["cell lines", "CELL_LINE", 162, 172], ["important pro-inflammatory factors nitric oxide synthase", "TREATMENT", 48, 104], ["COX", "TREATMENT", 115, 118], ["cell lines", "OBSERVATION", 162, 172]]], ["But the relationship between COX-2 and IL-32 has not been evaluated.DiscussionComparing the IV infection induced IL-32 level in cell culture with that in human individuals, a significant difference between them was observed, over 10-fold increase in cell culture versus 58.2% in human individuals.", [["cell culture", "ANATOMY", 128, 140], ["cell culture", "ANATOMY", 250, 262], ["infection", "DISEASE", 95, 104], ["COX-2", "GENE_OR_GENE_PRODUCT", 29, 34], ["IL-32", "GENE_OR_GENE_PRODUCT", 39, 44], ["IL-32", "GENE_OR_GENE_PRODUCT", 113, 118], ["cell culture", "CELL", 128, 140], ["human", "ORGANISM", 154, 159], ["cell", "CELL", 250, 254], ["human", "ORGANISM", 279, 284], ["COX", "PROTEIN", 29, 32], ["IL-32", "PROTEIN", 39, 44], ["IL", "PROTEIN", 113, 115], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 279, 284], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 279, 284], ["COX", "TEST", 29, 32], ["IL", "TEST", 39, 41], ["the IV infection induced IL", "TREATMENT", 88, 115], ["cell culture", "TEST", 128, 140], ["cell culture", "TEST", 250, 262], ["significant", "OBSERVATION_MODIFIER", 175, 186], ["difference", "OBSERVATION_MODIFIER", 187, 197]]], ["It is likely the pro-inflammatory factor is not able to be increased sharply under physiological conditions due to complex inflammation network in which pro-inflammatory factors regulate each other.DiscussionTwo viral components, the NS1 and viral replicative intermediate dsRNA were identified to be involved in IV infection triggered COX-2 and IL-32 expression in A549 cells.", [["A549 cells", "ANATOMY", 366, 376], ["inflammation", "DISEASE", 123, 135], ["infection", "DISEASE", 316, 325], ["NS1", "GENE_OR_GENE_PRODUCT", 234, 237], ["COX-2", "GENE_OR_GENE_PRODUCT", 336, 341], ["IL-32", "GENE_OR_GENE_PRODUCT", 346, 351], ["A549 cells", "CELL", 366, 376], ["pro-inflammatory factor", "PROTEIN", 17, 40], ["pro-inflammatory factors", "PROTEIN", 153, 177], ["NS1 and viral replicative intermediate dsRNA", "DNA", 234, 278], ["COX", "PROTEIN", 336, 339], ["A549 cells", "CELL_LINE", 366, 376], ["the pro-inflammatory factor", "PROBLEM", 13, 40], ["complex inflammation network", "PROBLEM", 115, 143], ["Two viral components", "PROBLEM", 208, 228], ["the NS1", "TREATMENT", 230, 237], ["viral replicative intermediate dsRNA", "PROBLEM", 242, 278], ["IV infection", "PROBLEM", 313, 325], ["COX", "TEST", 336, 339], ["IL", "TEST", 346, 348], ["is likely", "UNCERTAINTY", 3, 12], ["pro-inflammatory", "OBSERVATION_MODIFIER", 17, 33], ["inflammation", "OBSERVATION", 123, 135], ["intermediate dsRNA", "OBSERVATION", 260, 278], ["A549 cells", "OBSERVATION", 366, 376]]], ["Because TLR3 contributes directly to the inflammatory response of respiratory epithelial cells to both influenza A virus and dsRNA, we focused on the function of dsRNA in the regulation of COX-2 and IL-32 expression in this study.", [["respiratory epithelial cells", "ANATOMY", 66, 94], ["TLR3", "GENE_OR_GENE_PRODUCT", 8, 12], ["respiratory epithelial cells", "CELL", 66, 94], ["influenza A virus", "ORGANISM", 103, 120], ["COX-2", "GENE_OR_GENE_PRODUCT", 189, 194], ["IL-32", "GENE_OR_GENE_PRODUCT", 199, 204], ["TLR3", "PROTEIN", 8, 12], ["respiratory epithelial cells", "CELL_TYPE", 66, 94], ["COX", "PROTEIN", 189, 192], ["influenza A virus", "SPECIES", 103, 120], ["influenza A virus", "SPECIES", 103, 120], ["TLR3", "PROBLEM", 8, 12], ["respiratory epithelial cells", "PROBLEM", 66, 94], ["both influenza A virus and dsRNA", "PROBLEM", 98, 130], ["dsRNA", "PROBLEM", 162, 167], ["COX", "TEST", 189, 192], ["this study", "TEST", 219, 229], ["inflammatory", "OBSERVATION_MODIFIER", 41, 53], ["respiratory epithelial cells", "OBSERVATION", 66, 94]]], ["Role of viral NS1 protein in the pro-inflammatory process need further investigation.DiscussionCyclooxygenase metabolizes arachidonic acid to prostaglandins (PGs) and thromboxane [32].", [["arachidonic acid", "CHEMICAL", 122, 138], ["prostaglandins", "CHEMICAL", 142, 156], ["PGs", "CHEMICAL", 158, 161], ["thromboxane", "CHEMICAL", 167, 178], ["arachidonic acid", "CHEMICAL", 122, 138], ["prostaglandins", "CHEMICAL", 142, 156], ["thromboxane", "CHEMICAL", 167, 178], ["NS1", "GENE_OR_GENE_PRODUCT", 14, 17], ["DiscussionCyclooxygenase", "SIMPLE_CHEMICAL", 85, 109], ["arachidonic acid", "SIMPLE_CHEMICAL", 122, 138], ["prostaglandins", "SIMPLE_CHEMICAL", 142, 156], ["PGs", "SIMPLE_CHEMICAL", 158, 161], ["thromboxane [32]", "SIMPLE_CHEMICAL", 167, 183], ["viral NS1 protein", "PROTEIN", 8, 25], ["viral NS1 protein", "TEST", 8, 25], ["further investigation", "TEST", 63, 84], ["DiscussionCyclooxygenase metabolizes arachidonic acid", "TREATMENT", 85, 138], ["prostaglandins (PGs)", "TREATMENT", 142, 162], ["thromboxane", "TREATMENT", 167, 178], ["viral NS1 protein", "OBSERVATION", 8, 25], ["pro-inflammatory process", "OBSERVATION", 33, 57]]], ["COX-2 has been elucidated to be crucial to the inflammatory response [33] and tumorigenesis [34], [35], so nonsteroidal anti-inflammatory drugs (NSAIDs) selective for its inhibition are used clinically to treat inflammatory arthropathies but always cause many side effects such as gastrointestinal (GI) mucosa damage and cardiovascular adverse events [36], [37], [38].", [["gastrointestinal", "ANATOMY", 281, 297], ["mucosa", "ANATOMY", 303, 309], ["cardiovascular", "ANATOMY", 321, 335], ["inflammatory arthropathies", "DISEASE", 211, 237], ["gastrointestinal (GI) mucosa damage", "DISEASE", 281, 316], ["cardiovascular adverse events", "DISEASE", 321, 350], ["COX-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["nonsteroidal anti-inflammatory drugs", "SIMPLE_CHEMICAL", 107, 143], ["NSAIDs", "SIMPLE_CHEMICAL", 145, 151], ["gastrointestinal", "ORGANISM_SUBDIVISION", 281, 297], ["mucosa", "MULTI-TISSUE_STRUCTURE", 303, 309], ["COX-2", "PROTEIN", 0, 5], ["COX", "TEST", 0, 3], ["tumorigenesis", "TEST", 78, 91], ["nonsteroidal anti-inflammatory drugs", "TREATMENT", 107, 143], ["NSAIDs)", "TREATMENT", 145, 152], ["its inhibition", "TREATMENT", 167, 181], ["inflammatory arthropathies", "PROBLEM", 211, 237], ["many side effects", "PROBLEM", 255, 272], ["gastrointestinal (GI) mucosa damage", "PROBLEM", 281, 316], ["cardiovascular adverse events", "PROBLEM", 321, 350], ["inflammatory", "OBSERVATION_MODIFIER", 47, 59], ["gastrointestinal", "ANATOMY", 281, 297], ["mucosa", "ANATOMY", 303, 309]]], ["Aspirin is one of the classic NSAIDs, and its anti-inflammatory activity is associated with cyclooxygenase inhibition directly or indirectly [39].", [["Aspirin", "CHEMICAL", 0, 7], ["Aspirin", "CHEMICAL", 0, 7], ["Aspirin", "SIMPLE_CHEMICAL", 0, 7], ["NSAIDs", "SIMPLE_CHEMICAL", 30, 36], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 92, 106], ["cyclooxygenase", "PROTEIN", 92, 106], ["Aspirin", "TREATMENT", 0, 7], ["the classic NSAIDs", "TREATMENT", 18, 36], ["its anti-inflammatory activity", "TREATMENT", 42, 72], ["cyclooxygenase inhibition", "PROBLEM", 92, 117]]], ["NSAID-associated GI mucosal injury is an important clinical problem and the increased knowledge of physiological roles of COX-2 enzyme in a variety of tissues, including stomach and kidney, together with the withdrawal from the clinic trials of rofecoxib and valdecoxib because of cardiovascular toxicity, have challenged the benefits of selective COX-2 inhibition [38].", [["GI mucosal", "ANATOMY", 17, 27], ["tissues", "ANATOMY", 151, 158], ["stomach", "ANATOMY", 170, 177], ["kidney", "ANATOMY", 182, 188], ["cardiovascular", "ANATOMY", 281, 295], ["GI mucosal injury", "DISEASE", 17, 34], ["rofecoxib", "CHEMICAL", 245, 254], ["valdecoxib", "CHEMICAL", 259, 269], ["cardiovascular toxicity", "DISEASE", 281, 304], ["rofecoxib", "CHEMICAL", 245, 254], ["valdecoxib", "CHEMICAL", 259, 269], ["NSAID", "SIMPLE_CHEMICAL", 0, 5], ["GI mucosal", "PATHOLOGICAL_FORMATION", 17, 27], ["COX-2", "GENE_OR_GENE_PRODUCT", 122, 127], ["tissues", "TISSUE", 151, 158], ["stomach", "ORGAN", 170, 177], ["kidney", "ORGAN", 182, 188], ["rofecoxib", "SIMPLE_CHEMICAL", 245, 254], ["valdecoxib", "SIMPLE_CHEMICAL", 259, 269], ["cardiovascular", "ANATOMICAL_SYSTEM", 281, 295], ["COX-2", "GENE_OR_GENE_PRODUCT", 348, 353], ["COX-2 enzyme", "PROTEIN", 122, 134], ["COX", "PROTEIN", 348, 351], ["NSAID", "TREATMENT", 0, 5], ["GI mucosal injury", "PROBLEM", 17, 34], ["COX", "TEST", 122, 125], ["stomach and kidney", "PROBLEM", 170, 188], ["the withdrawal", "PROBLEM", 204, 218], ["rofecoxib", "TREATMENT", 245, 254], ["valdecoxib", "TREATMENT", 259, 269], ["cardiovascular toxicity", "PROBLEM", 281, 304], ["selective COX", "TREATMENT", 338, 351], ["mucosal", "ANATOMY", 20, 27], ["injury", "OBSERVATION", 28, 34], ["stomach", "ANATOMY", 170, 177], ["kidney", "ANATOMY", 182, 188]]], ["Our study identified a novel COX-2 downstream pro-inflammatory factor IL-32 which could be a potential target for screening anti-inflammatory drugs with less adverse effects.DiscussionIn summary, these studies provide new insights into a novel model as described in Fig. 6 in which influenza A virus or poly(IC)+IFN-\u03b3 triggers pro-inflammatory factors COX-2 and IL-32 expression, COX-2-derived PGE2 production, and subsequent host inflammatory responses.", [["PGE2", "CHEMICAL", 394, 398], ["PGE2", "CHEMICAL", 394, 398], ["COX-2", "GENE_OR_GENE_PRODUCT", 29, 34], ["IL-32", "GENE_OR_GENE_PRODUCT", 70, 75], ["influenza A virus", "ORGANISM", 282, 299], ["poly(IC)", "GENE_OR_GENE_PRODUCT", 303, 311], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 312, 317], ["COX-2", "GENE_OR_GENE_PRODUCT", 352, 357], ["IL-32", "GENE_OR_GENE_PRODUCT", 362, 367], ["COX-2", "GENE_OR_GENE_PRODUCT", 380, 385], ["PGE2", "GENE_OR_GENE_PRODUCT", 394, 398], ["COX-2 downstream pro-inflammatory factor IL-32", "PROTEIN", 29, 75], ["poly(IC)+IFN-\u03b3", "PROTEIN", 303, 317], ["pro-inflammatory factors", "PROTEIN", 327, 351], ["COX", "PROTEIN", 352, 355], ["influenza A virus", "SPECIES", 282, 299], ["influenza A virus", "SPECIES", 282, 299], ["Our study", "TEST", 0, 9], ["a novel COX", "TEST", 21, 32], ["downstream pro-inflammatory factor IL", "TEST", 35, 72], ["screening anti-inflammatory drugs", "TREATMENT", 114, 147], ["these studies", "TEST", 196, 209], ["influenza A virus", "PROBLEM", 282, 299], ["poly(IC)", "TEST", 303, 311], ["IFN", "TEST", 312, 315], ["pro-inflammatory factors", "TEST", 327, 351], ["COX", "TEST", 352, 355], ["IL", "TEST", 362, 364], ["COX", "TEST", 380, 383], ["PGE2 production", "TEST", 394, 409], ["inflammatory", "OBSERVATION_MODIFIER", 431, 443]]], ["In this model, we further demonstrate that COX-2 is located up-stream of IL-32 in the positive regulatory pathway.", [["COX-2", "GENE_OR_GENE_PRODUCT", 43, 48], ["IL-32", "GENE_OR_GENE_PRODUCT", 73, 78], ["COX-2", "PROTEIN", 43, 48], ["IL-32", "PROTEIN", 73, 78], ["COX", "TEST", 43, 46], ["IL", "TEST", 73, 75]]], ["The cross-talk between the two genes is described as follows: COX-2 upregulates IL-32 production, and conversely, IL-32 attenuates COX-2 activity.", [["COX-2", "GENE_OR_GENE_PRODUCT", 62, 67], ["IL-32", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL-32", "GENE_OR_GENE_PRODUCT", 114, 119], ["COX-2", "GENE_OR_GENE_PRODUCT", 131, 136], ["COX", "PROTEIN", 62, 65], ["COX", "PROTEIN", 131, 134], ["COX", "TEST", 62, 65], ["IL", "TEST", 80, 82]]]], "1979adc54a27e3dee0ffbf2b08b583bfb9900bb4": [["INTRODUCTIONThe daily number of new cases infected by COVID-19 is currently exponentially growing for most countries affected by the virus.", [["COVID-19", "CHEMICAL", 54, 62], ["the virus", "PROBLEM", 129, 138], ["new", "OBSERVATION_MODIFIER", 32, 35]]], ["However, this exponential growth rate varies significantly for different regions over the globe.", [["this exponential growth rate", "TEST", 9, 37], ["exponential", "OBSERVATION_MODIFIER", 14, 25], ["growth", "OBSERVATION_MODIFIER", 26, 32], ["globe", "ANATOMY", 90, 95]]], ["Little information is known about this matter, while there are indications that the environmental temperature may be a factor; for instance, northern and colder US and Italian regions experienced much more incidents than others.INTRODUCTIONTypically, the evolution curve of the spread of the coronavirus initiates with a pre-exponential phase characterized by a mild logarithmic growth, followed by the outburst phase of the exponential growth.", [["coronavirus", "DISEASE", 292, 303], ["coronavirus", "ORGANISM", 292, 303], ["the environmental temperature", "PROBLEM", 80, 109], ["the coronavirus", "PROBLEM", 288, 303], ["a pre-exponential phase", "TEST", 319, 342], ["a mild logarithmic growth", "PROBLEM", 360, 385], ["coronavirus", "OBSERVATION", 292, 303], ["mild", "OBSERVATION_MODIFIER", 362, 366], ["logarithmic", "OBSERVATION_MODIFIER", 367, 378], ["growth", "OBSERVATION_MODIFIER", 379, 385]]], ["Social-distancing measures against the spread may affect the evolution curve in a way that the exponential growth slows down and starts to decay, depending though on the effectiveness and applicability of these measures.", [["distancing measures", "TREATMENT", 7, 26], ["the exponential growth", "PROBLEM", 91, 113], ["these measures", "TREATMENT", 205, 219]]], ["However, after the decay of the spread at some place, new infected cases may outburst in other places, marked with insignificant number of cases until that moment.", [["new", "OBSERVATION_MODIFIER", 54, 57], ["infected", "OBSERVATION", 58, 66]]], ["For example, Fig.1 (left) shows the evolution curve of spread for the infected cases in mainland China; clearly, we observe the whole growth\u2212decay cycle, as well as, a new re-growth phase.INTRODUCTIONSuper-strict measures, such as complete shut down and quarantines, can successfully lead to the deceleration of the exponential growth of infected cases (Giugliano, 2020) .", [["the infected cases", "PROBLEM", 66, 84], ["a new re-growth phase", "TEST", 166, 187], ["INTRODUCTIONSuper", "TREATMENT", 188, 205], ["left", "ANATOMY_MODIFIER", 20, 24], ["infected", "OBSERVATION_MODIFIER", 70, 78], ["exponential", "OBSERVATION_MODIFIER", 316, 327], ["growth", "OBSERVATION_MODIFIER", 328, 334]]], ["Inevitably, measures may be loosened during the decay phase, leading to the birth of an equally disastrous re-growth phase.", [["may be", "UNCERTAINTY", 21, 27], ["loosened", "OBSERVATION", 28, 36], ["disastrous", "OBSERVATION", 96, 106]]], ["US & Italy (right); phases (color-coded): pre-exponential (pre-exp), exponential (exp) growth, decelerated growth, decay, and possibly, a re-growth.", [["US", "TEST", 0, 2], ["exponential (exp) growth", "PROBLEM", 69, 93], ["decelerated growth", "PROBLEM", 95, 113], ["right", "ANATOMY_MODIFIER", 12, 17], ["growth", "OBSERVATION_MODIFIER", 107, 113]]], ["Day t=1 corresponds to 1/15/2020 for China, 2/20/2020 for Italy, 2/27/2020 for US.", [["US", "TEST", 79, 81]]], ["Evolution in China cases follows the whole growth-decay cycle, and a new re-growth phase.", [["a new re-growth phase", "TEST", 67, 88]]], ["Italian cases are characterized by a milder exponential rate, entered the phase of decelerated growth on March 12.", [["a milder exponential rate", "PROBLEM", 35, 60], ["decelerated growth", "PROBLEM", 83, 101]]], ["US suffers with a larger exponential rate, and it is not clear whether has entered the decelerated growth phase.", [["a larger exponential rate", "PROBLEM", 16, 41], ["the decelerated growth phase", "PROBLEM", 83, 111], ["decelerated", "OBSERVATION_MODIFIER", 87, 98], ["growth", "OBSERVATION_MODIFIER", 99, 105], ["phase", "OBSERVATION_MODIFIER", 106, 111]]], ["The exponential growth rate for China rose as high as \u03bb=0.169\u00b10.017, while for Italy and US the rates were \u03bb=0.090\u00b10.004 and 0.121\u00b10.003, respectively (with correlation coefficient > 0.99).INTRODUCTIONThe exponential growth is the most effective phase for the evolution curve of infected cases; and the most important question regarding this evolution is still open (Black et al. 2020) : What can influence the exponential growth rate, and thus, \"flatten the curve\"?", [["The exponential growth rate", "TEST", 0, 27], ["China rose", "TEST", 32, 42], ["US the rates", "TEST", 89, 101], ["infected cases", "PROBLEM", 279, 293], ["the exponential growth rate", "TEST", 407, 434], ["exponential", "OBSERVATION_MODIFIER", 4, 15], ["growth", "OBSERVATION_MODIFIER", 16, 22], ["exponential", "OBSERVATION_MODIFIER", 205, 216], ["growth", "OBSERVATION_MODIFIER", 217, 223], ["most effective phase", "OBSERVATION_MODIFIER", 231, 251], ["infected", "OBSERVATION", 279, 287]]], ["Measures, strict or not, may affect the evolution of new infected cases, by shifting the spread curve from the exponential to the decelerated growth.", [["new infected cases", "PROBLEM", 53, 71], ["the spread curve", "TEST", 85, 101], ["the decelerated growth", "PROBLEM", 126, 148], ["new", "OBSERVATION_MODIFIER", 53, 56], ["infected", "OBSERVATION", 57, 65]]], ["It should be noted though that measures do not affect the exponential growth rate itself, but only the period of time that this exponential phase applies.", [["this exponential phase applies", "TREATMENT", 123, 153]]], ["Then, what factors do affect the exponential growth rate?INTRODUCTIONThe age distribution in the place where the outburst occurs is unlikely to be a factor; indeed, the number of new cases is known to be positively correlated with age, however, the exponential growth rate (China: 0.169; US: 0.121; Italy: 0.090 -decreasing rate) appears to be negatively correlated to the age median of these countries (China: 37.4; US: 38.1; Italy: 45.5 -increasing age); hence, the age is likely irrelevant to the rate variations.INTRODUCTIONIn addition, culture in social activities may be a factor; for example, this might be contributing in the observed differences among the exponential rates in the cases of China, Italy, and US ( Fig.1) .", [["the exponential growth rate", "TEST", 29, 56], ["US", "TEST", 288, 290], ["US", "TEST", 417, 419], ["culture", "TEST", 541, 548], ["distribution", "OBSERVATION_MODIFIER", 77, 89], ["unlikely to be", "UNCERTAINTY", 132, 146], ["new", "OBSERVATION_MODIFIER", 179, 182], ["rate variations", "OBSERVATION", 500, 515]]], ["However, what is causing the major variation of exponential rates among different regions of the same culture?", [["exponential rates", "PROBLEM", 48, 65], ["the same culture", "TEST", 93, 109], ["major", "OBSERVATION_MODIFIER", 29, 34], ["variation", "OBSERVATION_MODIFIER", 35, 44], ["exponential", "OBSERVATION_MODIFIER", 48, 59]]], ["It is apparent that culture does not constitute the main factor influencing the exponential rate.", [["culture", "TEST", 20, 27], ["main", "OBSERVATION_MODIFIER", 52, 56]]], ["Figure 2 shows the regional variation of infected cases (left) and average winter temperature (right) in Italy.", [["regional", "OBSERVATION_MODIFIER", 19, 27], ["variation", "OBSERVATION_MODIFIER", 28, 37], ["infected", "OBSERVATION", 41, 49], ["left", "ANATOMY_MODIFIER", 57, 61], ["right", "ANATOMY_MODIFIER", 95, 100]]], ["The possible negative correlation, observed between regional number of infected cases and winter temperature in Italy, is an indication of the influence of temperature on the exponential growth, but it certainly does not constitute a necessary condition.", [["infected cases", "PROBLEM", 71, 85], ["possible", "UNCERTAINTY", 4, 12], ["infected", "OBSERVATION", 71, 79]]], ["The reason is that the map plots the total number of the infected cases N t , which does not depend only on the exponential rate \u03bb, but also on the initial number of cases N 0 .INTRODUCTIONIt is generally accepted that the initial infected cases in Italy were travelled directly from China; since some destinations are more favorable than others, then, the initial number of cases N 0 , as well as the current number of cases N t (which is proportional to N 0 ), should be subject of regional variation.", [["the map plots", "TEST", 19, 32], ["infected", "OBSERVATION_MODIFIER", 57, 65], ["infected", "OBSERVATION", 231, 239], ["regional variation", "OBSERVATION", 484, 502]]], ["Therefore, there is a non-negligible possibility, the observed regional variation of the number of infected cases N t to be caused by the regional distribution of the initial cases N 0 .", [["non-negligible possibility", "UNCERTAINTY", 22, 48], ["regional", "OBSERVATION_MODIFIER", 63, 71], ["variation", "OBSERVATION_MODIFIER", 72, 81], ["number", "OBSERVATION_MODIFIER", 89, 95], ["infected", "OBSERVATION", 99, 107]]], ["In such a case, main airport cities would have incredibly high number of infected cases outplaying a possible negative correlation of daily infected cases with regional average temperature T; the latter may be one of the reasons of the high numbers of cases observed in New York City and Rome.", [["high number", "OBSERVATION_MODIFIER", 58, 69]]], ["On the other hand, in their letter to the White House, members of a National Academy of Sciences committee said that \"There is some evidence to suggest that [coronavirus] may transmit less efficiently in environments with higher ambient temperature and humidity; however, given the lack of host immunity globally, this reduction in transmission efficiency may not lead to a significant reduction in disease spread without the concomitant adoption of major public health interventions\" (Relman, 2020) .INTRODUCTIONNevertheless, it has to be stressed out that there were no statistical analyses focused on the exponential growth rates of the infected cases in regions with different temperatures.", [["[coronavirus", "ORGANISM", 157, 169], ["coronavirus", "PROBLEM", 158, 169], ["higher ambient temperature", "TREATMENT", 222, 248], ["transmission efficiency", "PROBLEM", 332, 355], ["a significant reduction in disease spread", "PROBLEM", 372, 413], ["statistical analyses", "PROBLEM", 572, 592], ["the infected cases in regions", "PROBLEM", 636, 665], ["significant", "OBSERVATION_MODIFIER", 374, 385], ["reduction", "OBSERVATION_MODIFIER", 386, 395], ["disease", "OBSERVATION", 399, 406], ["infected", "OBSERVATION", 640, 648], ["different", "OBSERVATION_MODIFIER", 671, 680], ["temperatures", "OBSERVATION_MODIFIER", 681, 693]]], ["However, their analysis was performed on the number of the infected cases N t , which is subject to the randomness of the initial cases N 0 as explained above, and not to the exponential growth rate \u03bb, which is dependent on physical characteristics of the coronavirus, binding protein, and environment.", [["coronavirus", "ORGANISM", 256, 267], ["coronavirus, binding protein", "PROTEIN", 256, 284], ["their analysis", "TEST", 9, 23], ["the coronavirus", "PROBLEM", 252, 267]]], ["Analysis of regional cases can show whether the speculated negative correlation between temperature and number of infected cases is true, meaning a negative correlation between temperature and exponential growth rate.", [["exponential growth rate", "TEST", 193, 216], ["negative", "OBSERVATION", 59, 67], ["infected", "OBSERVATION", 114, 122]]], ["If the environmental temperature plays indeed a substantial role on the virus spread, then, this can provide promising results, such as, the estimation of the critical temperature that may eliminate the number of daily new cases in heavily infected regions.INTRODUCTIONThe purpose of this paper is to improve understanding of the effect of environmental temperature on the spread of COVID-19 and its exponential growth rate.", [["the virus spread", "PROBLEM", 68, 84], ["environmental temperature", "PROBLEM", 340, 365], ["COVID", "TEST", 383, 388], ["heavily", "OBSERVATION_MODIFIER", 232, 239], ["infected", "OBSERVATION", 240, 248]]], ["Then, we calculate the exponential growth rates of infected cases for US and Italian regions, derive the relationship of these rates with the environmental temperature, evaluate its statistical confidence, and determine the critical temperature that eliminates this rate.Modeling behind \"Flattening the curve\"A standard model for describing the evolution of the infected cases by viruses is given by ( ) ( )Modeling behind \"Flattening the curve\"; N t is the number of total infected cases evolved from the initial N 0 cases, N max is the maximum possible number of infected cases; \u03bb is the exponential growth rate, and becomes clear for x t <<1, where I is negligible, leading to:Modeling behind \"Flattening the curve\"The function of negative feedback I models factors that flattens the curve, such as, the measures taken against spreading.", [["this rate", "TEST", 261, 270], ["Flattening the curve", "PROBLEM", 288, 308], ["the infected cases", "PROBLEM", 358, 376], ["viruses", "PROBLEM", 380, 387], ["Flattening the curve", "PROBLEM", 424, 444], ["total infected cases", "PROBLEM", 468, 488], ["Flattening the curve", "PROBLEM", 697, 717], ["negative feedback I models factors", "PROBLEM", 734, 768], ["Flattening", "OBSERVATION_MODIFIER", 288, 298], ["infected", "OBSERVATION", 362, 370], ["infected", "OBSERVATION", 565, 573]]], ["While these factors are not affecting the exponential growth rate \u03bb, they become more effective as the number of cases increases, getting closer to N max ; exponent b controls the effectiveness of these factors; strict {loose} measures correspond to smaller {larger} values of b.", [["these factors", "PROBLEM", 197, 210]]], ["Figure 3 shows the evolution curve of the number of new (\u0394N t = N t+1 \u2212N t ) and total infected cases (N t ) and how this curve flattens for stricter measures (smaller values of b).", [["total infected cases", "PROBLEM", 81, 101], ["this curve", "TEST", 117, 127], ["stricter measures", "TEST", 141, 158]]], ["As observed in Fig.3(b) , stricter measures, nicely modeled by decreasing b, do not affect the exponential rate \u03bb but they successfully flatten the curve.", [["stricter measures", "TREATMENT", 26, 43]]], ["However, the same can be achieved by downgrading the exponential growth rate.", [["exponential", "OBSERVATION_MODIFIER", 53, 64], ["growth", "OBSERVATION_MODIFIER", 65, 71]]], ["Applied measures could be loosen and shorter!", [["loosen", "OBSERVATION", 26, 32]]], ["Model (1) originates from the logistic map family (e.g., Livadiotis, 2005; and references therein; Wu et al. 2020) ; other complicate versions, such as, the Susceptible-Infectious-Recovered models (e.g., Ciarochi, 2020) may be expressed by multi-dimensional differential or difference equations (e.g., Elaydi, 2005, and references therein; Livadiotis et al. 2016 ), but still, the curve flattening is governed by the same features.", [["the curve flattening", "PROBLEM", 377, 397], ["Infectious", "OBSERVATION", 169, 179], ["curve", "OBSERVATION_MODIFIER", 381, 386], ["flattening", "OBSERVATION", 387, 397]]], ["The two composites, the exponential growth E and the negative feedback I, are just the main and necessary conditions for reproducing the growth-decay phases of the spread curve.", [["the spread curve", "TEST", 160, 176], ["two", "OBSERVATION_MODIFIER", 4, 7], ["composites", "OBSERVATION_MODIFIER", 8, 18], ["exponential", "OBSERVATION_MODIFIER", 24, 35], ["growth", "OBSERVATION_MODIFIER", 36, 42]]], ["Their interplay shows how the spread curve can be flattened as a result of stricter measures, independently of the existent exponential rate.Modeling behind \"Flattening the curve\".", [["stricter measures", "TREATMENT", 75, 92], ["Flattening the curve\"", "PROBLEM", 158, 179]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020 . . https://doi.org/10.1101Main factors influencing the exponential growth rateWhat are the main factors that can affect the exponential growth rate \u03bb of COVID-19 spread?Main factors influencing the exponential growth rateThe rate \u03bb is expected to have positive correlation with the reproduction number R 0 (e.g., proportional to its logarithm), and negative correlation with the incubation period \u03c4 (e.g., inverse proportional) (Milligan and Barrett, 2015) .", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101Main factors", "PROTEIN", 279, 314], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the exponential growth rate", "TEST", 396, 423], ["COVID", "TEST", 429, 434], ["Main factors", "PROBLEM", 445, 457], ["the exponential growth rate", "TEST", 470, 497], ["The rate", "TEST", 497, 505], ["med", "ANATOMY", 105, 108], ["exponential", "OBSERVATION_MODIFIER", 331, 342], ["growth", "OBSERVATION_MODIFIER", 343, 349]]], ["The number R 0 is a measure of how contagious a disease is; it provides the average number of people in a susceptible population that a single infected person will spread the disease to over the course of their infection (Ciarochi, 2020) , and depends on the physical characteristics of coronavirus (Hao 2020) .", [["infection", "DISEASE", 211, 220], ["coronavirus", "DISEASE", 287, 298], ["people", "ORGANISM", 94, 100], ["coronavirus", "ORGANISM", 287, 298], ["people", "SPECIES", 94, 100], ["person", "SPECIES", 152, 158], ["the disease", "PROBLEM", 171, 182], ["their infection", "PROBLEM", 205, 220], ["coronavirus", "PROBLEM", 287, 298], ["disease", "OBSERVATION", 48, 55], ["infection", "OBSERVATION", 211, 220]]], ["The incubation period \u03c4 is the time elapsed between exposure to coronavirus and first symptoms; during this period, an infected individual cannot infect others; other characteristic periods and time intervals are the latent period between exposure and infection, and the generation time, mostly concerned with transmission process (Nishiura, 2010) .", [["infection", "DISEASE", 252, 261], ["coronavirus", "ORGANISM", 64, 75], ["coronavirus", "PROBLEM", 64, 75], ["first symptoms", "PROBLEM", 80, 94], ["infection", "PROBLEM", 252, 261], ["infected", "OBSERVATION", 119, 127], ["latent", "OBSERVATION_MODIFIER", 217, 223], ["infection", "OBSERVATION", 252, 261]]], ["Characteristic values for COVID-19 are \u03c4~5-6 days and R 0~2 -4 (Chen, 2020) .", [["Characteristic values", "TEST", 0, 21], ["COVID", "TEST", 26, 31]]], ["The rate expression can be written asMain factors influencing the exponential growth rate, and involves all the physical characteristics of the mechanisms of infection and the environmental interactions; this can be easily derived, considering difference equations (that is, iterated discrete maps) (e.g., see: Livadiotis and Elaydi, 2012; Kwessi et al., 2018; Dayeh et al, 2018) .", [["infection", "DISEASE", 158, 167], ["Main factors", "PROTEIN", 37, 49], ["the exponential growth rate", "TEST", 62, 89], ["infection", "PROBLEM", 158, 167], ["infection", "OBSERVATION", 158, 167]]], ["(2),Main factors influencing the exponential growth ratewhere the exponential rate is given by:Main factors influencing the exponential growth rateThe main factors that can affect the exponential rate \u03bb are: (a) culture in social activities, and (b) environmental temperature and/or other thermodynamic parameters.", [["the exponential growth rate", "TEST", 120, 147], ["a) culture", "TEST", 209, 219], ["other thermodynamic parameters", "TEST", 283, 313], ["main", "OBSERVATION_MODIFIER", 151, 155]]], ["As previously mentioned, measures against the virus spread do not effectively influence the exponential growth rate; e.g., they do not change the culture in social activities, which are characteristics of the particular population, but they can just cease these activities for some period of time.", [["the virus spread", "PROBLEM", 42, 58], ["the exponential growth rate", "TEST", 88, 115], ["the culture", "TEST", 142, 153], ["virus", "OBSERVATION", 46, 51]]], ["We approach this dependence by (i) a linear approximation of the phenomenological relationship between exponential rate and temperature, and (ii) the connection of reproduction number with Arrhenius behavior (with negative activation energy):Main factors influencing the exponential growth rate(i) The temperature can affect the physical properties of coronavirus, such as, the incubation time \u03c4, as well as, the reproduction number R 0 that depends on these physical properties (Hao, 2020) .", [["coronavirus", "ORGANISM", 352, 363], ["exponential rate", "TEST", 103, 119], ["Arrhenius behavior", "PROBLEM", 189, 207], ["coronavirus", "PROBLEM", 352, 363]]], ["A linear approximation absorbs the (weak) temperature dependence of any parameters involved in the exponential rate; then, Eq.(5) gives:Main factors influencing the exponential growth ratewhere we set the intercept to be given in normal conditions of atmospheric temperature and pressure (NTP) (that is, T=20 C 0 , P= 1atm).", [["NTP", "CHEMICAL", 289, 292], ["A linear approximation absorbs the (weak) temperature dependence", "PROBLEM", 0, 64], ["the exponential rate", "TEST", 95, 115], ["Main factors", "PROBLEM", 136, 148], ["atmospheric temperature", "TEST", 251, 274], ["pressure (NTP", "TREATMENT", 279, 292], ["T", "TEST", 304, 305], ["linear", "OBSERVATION_MODIFIER", 2, 8], ["approximation", "OBSERVATION_MODIFIER", 9, 22], ["absorbs", "OBSERVATION_MODIFIER", 23, 30]]], ["Then, we rewrite the exponential rate as:Main factors influencing the exponential growth rate(ii) Coronavirus uses their major surface spike protein to bind on a receptor -another protein that acts like a doorway into a human cell (Wrapp et al., 2020) .", [["surface", "ANATOMY", 127, 134], ["cell", "ANATOMY", 226, 230], ["human", "ORGANISM", 220, 225], ["cell", "CELL", 226, 230], ["major surface spike protein", "PROTEIN", 121, 148], ["human cell", "CELL_TYPE", 220, 230], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 220, 225], ["Main factors", "PROBLEM", 41, 53], ["Coronavirus", "PROBLEM", 98, 109]]], ["The whole process is a slow chemical reaction, where .", [["a slow chemical reaction", "PROBLEM", 21, 45], ["slow", "OBSERVATION_MODIFIER", 23, 27], ["chemical reaction", "OBSERVATION", 28, 45]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.21.20072405 doi: medRxiv preprint the mechanism behind can lead to rates negatively correlated with temperature, i.e., increasing rate with decreasing temperature.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 327, 334], ["decreasing temperature", "PROBLEM", 450, 472], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["This is consistent to reaction rate expressed by the Arrhenius exponential with and Benson, 1984) .", [["reaction rate", "PROBLEM", 22, 35], ["consistent to", "UNCERTAINTY", 8, 21]]], ["Then, the effective reproduction number 0 ( ) R T is expressed as a product combining the reproduction number in the absence of temperature effect, 0 R \uf0a5 , and the Arrhenius exponential rate, namely,(which was not certified by peer review)Then, Eq.", [["temperature effect", "PROBLEM", 128, 146], ["the Arrhenius exponential rate", "TEST", 160, 190]]], ["(5) gives(which was not certified by peer review)We rewrite this expression as:(which was not certified by peer review)Reactions of negative activation energy are barrier-less, relying on the capture of the molecules in a potential well.", [["negative activation energy", "PROBLEM", 132, 158], ["negative", "OBSERVATION_MODIFIER", 132, 140], ["activation energy", "OBSERVATION", 141, 158]]], ["Increasing {decreasing} the temperature leads to a reduced {gained} probability of the colliding molecules capturing one another.", [["Increasing {decreasing} the temperature", "PROBLEM", 0, 39], ["colliding molecules", "OBSERVATION", 87, 106]]], ["Exponential spread is mainly related to outdoors activities while the decelerated growth caused by effective measures is related to indoors activities.", [["Exponential spread", "PROBLEM", 0, 18], ["the decelerated growth", "PROBLEM", 66, 88]]], ["Therefore, as long as the exponential growth takes place, the environmental temperature has an effective role on the chemical reaction between virus and spike protein.", [["spike protein", "PROTEIN", 153, 166], ["the environmental temperature", "PROBLEM", 58, 87], ["the chemical reaction between virus", "PROBLEM", 113, 148], ["spike protein", "PROBLEM", 153, 166]]], ["Due to the negative activation energy, decreasing the environmental temperature reduces the probability of virus-protein reaction, thus the virus may stay inactive on air or surfaces and eventually die.", [["the negative activation energy", "PROBLEM", 7, 37], ["the environmental temperature", "PROBLEM", 50, 79], ["virus-protein reaction", "PROBLEM", 107, 129], ["the virus", "PROBLEM", 136, 145], ["activation energy", "OBSERVATION", 20, 37]]], ["It should be noted that both the models (7b) and (10b) consider that the exponential rate \u03bb, or the reproduction number R 0 , are subjects to a component influenced by the culture in social activities (intercept \u03bb 0 ) and a component mostly influenced by the temperature (slope p 2 ).", [["the exponential rate", "TEST", 69, 89], ["the culture", "TEST", 168, 179]]], ["In this way, the slope may indicate to some universal quantity involved, such as, the (negative) activation energy.(which was not certified by peer review)Next, we employ the above two expressions of exponential rate \u03bb and temperature T, Eqs.(7a,10a), in order to set the two types of statistical models for fitting (\u03a4, \u03bb) measurements for US and Italian regions.METHODWe use publicly available datasets of: (1) average enviromental temperature of US and Italian regions (e.g., see: www.ncdc.noaa.gov/data-access/land-based-station-data/land-based-datasets/climate-normals; it.climate-data.org; www.weather-atlas.com); (2) time series of the number of daily infected cases of US and Italian regions (e.g., see: www.thelancet.com; www.protezionecivile.gov.it).METHODWe analyze the datasets of regional infected cases in US and Italy, derive the relationship of the exponential growth rate of the number of cases with temperature, and evaluate its statistical confidence.", [["exponential rate", "TEST", 200, 216], ["regional", "OBSERVATION_MODIFIER", 792, 800], ["infected", "OBSERVATION", 801, 809]]], ["First, we derive the exponential growth rates of the infected cases characterizing each examined region of Italy and US; then, we plot these values against the environmental temperatures of each region, and perform the corresponding statistical analysis.", [["the corresponding statistical analysis", "TEST", 215, 253], ["infected", "OBSERVATION", 53, 61]]], ["We proceed according to the following steps:METHOD(i) Collect the time series of the current infected cases N t for all US and Italian regions.METHODFor each of the US and Italian regions, we plot log(N t ) and log(\u0394N t ) with time t, detect the time intervals of linear relationship corresponding to the phase of exponential growth, fit the datapoints within this region, and derive the slope (on linear-log scale), that is, the exponential growth rate \u03bb.", [["exponential growth", "PROBLEM", 314, 332], ["linear-log scale", "TREATMENT", 398, 414], ["the exponential growth rate", "TEST", 426, 453]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["1101 rate, \u03bb, thus the slopes resulted from the linear fits of log(N t ) and log(\u0394N t ) with time are (weighted) averaged (Fig.4) . (iii) Collect environmental temperature data and calculate the temperature averaged over the whole examined region.", [["environmental temperature data", "TEST", 146, 176], ["the temperature", "TEST", 191, 206]]], ["The incubation period \u03c4 is longer than the time scale of a single day or night, thus the temperature is averaged over the daily and nightly measurements. (iv)(which was not certified by peer review)Co-plot all the derived sample values (\u03a4\u00b1\u03b4\u03a4, \u03bb\u00b1\u03b4\u03bb), where each pair corresponds to each examined region; then, apply a linear fitting in order to derive the linear relationship between T and \u03bb, as well as evaluate the statistical confidence of this relationship; repeat the same for all US and Italian regions.(which was not certified by peer review)Determine the critical temperature T C for which the rate becomes negligible; to eliminate the uncertainties of T C as a fitting parameter, we perform the linear fitting with the statistical model(which was not certified by peer review)Repeat (iv) and (v) with pairs of (T -1 \u00b1\u03b4T -1 , \u03bb\u00b1\u03b4\u03bb); we estimate again T C by performing the linear fitting with the statistical model \u03bb=\u03bb 0 (-1+\u03a4 C /T) instead of \u03bb=p 1 +p 2 \u2022T -1 .Figure 4.Linear fitting of the number of the total N t and new \u0394N t infected cases with time (on linear-log scale) for the states of California and Illinois, where the slope reads the exponential rate \u03bb.", [["T C", "GENE_OR_GENE_PRODUCT", 660, 663], ["T C", "PROTEIN", 660, 663], ["\u00b1\u03b4T", "PROTEIN", 824, 827], ["the temperature", "TEST", 85, 100], ["Co-plot", "TEST", 198, 205], ["the derived sample values", "TEST", 210, 235], ["a linear fitting", "TREATMENT", 315, 331], ["the linear fitting", "TREATMENT", 699, 717], ["T", "TEST", 819, 820], ["\u00b1\u03b4T", "TEST", 824, 827], ["the linear fitting", "TREATMENT", 876, 894], ["the statistical model \u03bb", "TEST", 900, 923], ["\u03bb=p", "TEST", 951, 954], ["linear-log scale", "TREATMENT", 1066, 1082], ["number", "OBSERVATION_MODIFIER", 1000, 1006], ["infected", "OBSERVATION_MODIFIER", 1037, 1045]]], ["The resulted rates from the linear fitting of log(N t ) (black) and log(\u0394N t ) (red) are (weighted) averaged (blue).", [["rates", "OBSERVATION_MODIFIER", 13, 18], ["linear", "OBSERVATION_MODIFIER", 28, 34]]], ["The phases are color-coded as in Figure 1 .STATISTICAL ANALYSISThe hypothesis to be tested is that the exponential growth rate \u03bb varies linearly with temperature; (x is set to be the temperature or its inverse).", [["STATISTICAL ANALYSIS", "TEST", 43, 63], ["the exponential growth rate", "TEST", 99, 126]]], ["This is tested by examining the chi-square corresponding to the fitting of the two-parameter linear statistical model H is the \u03b1-th diagonal element of its .", [["\u03b1-th diagonal element", "DNA", 127, 148]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020.(which was not certified by peer review), \u03b1=1,2, where the derivatives are numerically derived.(which was not certified by peer review)We will use two linear statistical models, (a)(which was not certified by peer review), as given by Eqs.(7a,10a) ; both can be written with the linear expression:(which was not certified by peer review)The statistical confidence of the dependence of the exponential growth rate on the environmental average temperature may be sufficiently high for the acceptance of any of the two statistical models.", [["CC", "CHEMICAL", 0, 2], ["\u03b1=1,2", "SIMPLE_CHEMICAL", 317, 322], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["the exponential growth rate", "PROBLEM", 660, 687], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["exponential", "OBSERVATION_MODIFIER", 664, 675], ["growth", "OBSERVATION_MODIFIER", 676, 682]]], ["The goodness of the fitting of each model is evaluated using two types of statistical tests, the \"reduced chi-square\", the \"p-value of the extremes\", and their combination (e.g., Frisch et al., 2013; Schwadron et al., 2013 , Fuselier et al., 2014 , while Student's t-test is also used for evaluating the statistical confidence of the derived slopes: -Reduced Chi-Square: The goodness of a fit is estimated by the reduced chi-square value, 2 -Student's t-test: This is another test for evaluating the statistical confidence of the slope derived from the linear fitting of the temperature-rate sample points (T i \u00b1\u03b4T i , \u03bb i \u00b1\u03b4\u03bb i ) and (T i -1 \u00b1\u03b4T i -1 , \u03bb i \u00b1\u03b4\u03bb i ).", [["statistical tests", "TEST", 74, 91], ["Student's t-test", "TEST", 255, 271], ["another test", "TEST", 468, 480], ["the temperature", "TEST", 571, 586]]], ["The Student's t-test is not passed for the null hypothesis that they examined slope equals zero, when the corresponding p t -value is less than the acceptable confidence limit of 0.05; then, the null hypothesis is rejected, meaning the slope has statistically significant difference for zero.", [["Student's t-test", "DNA", 4, 20], ["The Student's t-test", "TEST", 0, 20], ["the null hypothesis", "PROBLEM", 191, 210], ["rejected", "OBSERVATION", 214, 222]]], ["In addition, we examine the slopes estimated for US with those estimated for Italian regions, by derivingRESULTSThe linear fitting of log(N t ) or log(\u0394N t ) with time t within the region of exponential growth phase, resulted to the respective rates (given by the fitted slope); their weighted averages are shown in Table 1 for US and in Table 2 for Italian regions, while plotted against the average regional temperature in Figs.", [["US", "TEST", 49, 51], ["US", "TEST", 328, 330]]], ["The method of weighted fitting for double uncertainties (x i \u00b1\u03b4x i , \u03bb i \u00b1\u03b4\u03bb i ), as described by Fasano and Vio, 1988) , is used for estimating the fitting parameters \u03bb 0 , T C , together with their statistical, propagation, and total errors.", [["The method of weighted fitting", "TREATMENT", 0, 30], ["double uncertainties", "TREATMENT", 35, 55]]], ["The fits of the linear statistical model with temperature, x i =T i , (left panels in Figs.", [["linear", "OBSERVATION_MODIFIER", 16, 22], ["left", "ANATOMY_MODIFIER", 71, 75]]], ["5, 6), as well as of the alternative statistical model with inverse temperature, (right panels in Figs.", [["inverse temperature", "PROBLEM", 60, 79], ["right", "ANATOMY_MODIFIER", 82, 87]]], ["5, 6) , are both characterized with high statistical confidence, attaining high p-values (>0.05) and reduced chi-squares 2 red \uf063 values (close to 1); also, both fits provide similar estimations of T C .", [["T C", "GENE_OR_GENE_PRODUCT", 197, 200], ["high statistical confidence", "PROBLEM", 36, 63], ["high p-values", "PROBLEM", 75, 88], ["reduced chi-squares", "PROBLEM", 101, 120], ["red \uf063 values", "TEST", 123, 135], ["high", "OBSERVATION_MODIFIER", 36, 40]]], ["The fitting results are shown in Table 3 .RESULTSWe also examine whether the sample points (T i \u00b1\u03b4T i , \u03bb i \u00b1\u03b4\u03bb i ) are subject to statistically significant concentrations or rarefactions, namely, whether possible heterogeneities within the distribution of sample points plays significant role in the fitted relationship.", [["rarefactions", "PROBLEM", 175, 187], ["significant", "OBSERVATION_MODIFIER", 145, 156], ["concentrations", "OBSERVATION", 157, 171], ["distribution", "OBSERVATION_MODIFIER", 241, 253], ["significant", "OBSERVATION_MODIFIER", 277, 288]]], ["For this, we derive the temperature-rate relationship and its statistical confidence by fitting the homogenized set of sample points, instead of the raw sample points; then, we examine whether the fitting parameters differ from those derived from fitting the raw sample points.", [["the temperature", "TEST", 20, 35], ["the fitting parameters", "PROBLEM", 193, 215]]], ["We estimate the weighted mean and error of the rates included in each bin.", [["the rates", "TEST", 43, 52]]], ["In the case of US regions we also performed a homogenization of rates, by grouping the temperaturebinned means in rate binning of \u0394\u03bb ~ 0.01 d -1 .", [["a homogenization of rates", "TREATMENT", 44, 69], ["rate binning", "TEST", 114, 126]]], ["In the case of sample points with inverse temperatures, (T i -1 \u00b1\u03b4T i -1 , \u03bb i \u00b1\u03b4\u03bb i ), the procedure is exactly the same.", [["inverse temperatures", "TEST", 34, 54], ["T i", "TEST", 57, 60], ["the procedure", "TREATMENT", 88, 101]]], ["Homogenized datasets result in a smooth relationship between the values of binned temperature and rate, as it can be observed in the plots of rate against temperature or inverse temperature (left or right lower panels, respectively), and for both US and Italy regions (Figs.", [["inverse temperature", "PROBLEM", 170, 189], ["right lower panels", "TEST", 199, 217], ["left", "ANATOMY_MODIFIER", 191, 195], ["right", "ANATOMY_MODIFIER", 199, 204], ["lower panels", "ANATOMY", 205, 217]]], ["The results are highly supportive of the negative correlation between rate and temperature.", [["rate", "TEST", 70, 74]]], ["We observe that the linear relationships of the growth rate with temperature or inverse temperature are characterized by high statistical confidence for the homogenized datasets (p-values much higher than significant limit of 0.05; 2 red \uf063 far from the significant limits of 0.1 and 10).", [["the growth rate", "TEST", 44, 59], ["inverse temperature", "PROBLEM", 80, 99], ["the homogenized datasets", "PROBLEM", 153, 177], ["p-values", "TEST", 179, 187]]], ["Therefore, the arrangement of sample points do not affect significantly the fitting results.RESULTSIn addition, as shown in Tables 3 and 4 , the linear fits of sample points (T i \u00b1\u03b4T i , \u03bb i \u00b1\u03b4\u03bb i ) and (T i -1 \u00b1\u03b4T i -1 , \u03bb i \u00b1\u03b4\u03bb i ) do not pass the Student's t-test for the null hypothesis that their slopes equals zero, i.e., the corresponding p t -values are less than the acceptable confidence limit of 0.05; therefore, the negative correlation of environmental temperature with the exponential rate is statistically significant (accepted with confidence 95%).RESULTS. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020 . . https://doi.org/10.1101 (1) The exponential growth rate and its uncertainty is the weighted averaging of the rates derived from total and new infected cases;(which was not certified by peer review)(2) the environmental temperature is averaged over the time period, from \u03c4~5 days before the appearance of the 1 st case, to 1 st April; (3) the standard deviation of temperature is given by the half difference between highest and lowest values within the examined time period, divided by \u221a2 (similar to the standard deviation for a sinusoidal function); (4) NY: The temperature refers to the New York City, instead of the whole state, which suffers from the vast majority of the state infected cases. .", [["CC", "CHEMICAL", 573, 575], ["\u221a2", "PROTEIN", 1338, 1340], ["T i", "TEST", 213, 216], ["test", "TEST", 262, 266], ["the null hypothesis", "TEST", 271, 290], ["environmental temperature", "PROBLEM", 452, 477], ["the exponential rate", "TEST", 483, 503], ["CC", "TEST", 573, 575], ["ND", "PROBLEM", 582, 584], ["The copyright holder", "TREATMENT", 774, 794], ["The exponential growth rate", "TEST", 880, 907], ["the environmental temperature", "TEST", 1053, 1082], ["NC", "ANATOMY", 579, 581], ["med", "ANATOMY", 678, 681], ["new", "OBSERVATION_MODIFIER", 990, 993], ["infected", "OBSERVATION", 994, 1002], ["infected", "OBSERVATION", 1535, 1543]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.21.20072405 doi: medRxiv preprint Figure 5 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Linear fitting of rates with (left) temperatures and (right) inverse temperatures for US regions.", [["Linear fitting of rates with (left) temperatures and (right) inverse temperatures for US regions", "PROBLEM", 0, 96], ["rates", "OBSERVATION_MODIFIER", 18, 23], ["left", "ANATOMY_MODIFIER", 30, 34], ["right", "ANATOMY_MODIFIER", 54, 59]]], ["The fitting is weighted with double uncertainties (on both the temperature and rate values).", [["double uncertainties", "PROBLEM", 29, 49], ["the temperature", "TEST", 59, 74]]], ["The analysis is first completed for the raw measurements (upper) and then repeated for the binned averages (lower).(which was not certified by peer review).", [["The analysis", "TEST", 0, 12], ["the raw measurements", "TEST", 36, 56]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.1101/2020.04.21.20072405 doi: medRxiv preprint Figure 6 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv preprint Figure", "TREATMENT", 327, 350], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["1101 In order to improve the statistics of the estimated critical temperature, we combine the sample points (T i \u00b1\u03b4T i , \u03bb i \u00b1\u03b4\u03bb i ) of US and Italian regions.", [["US", "TEST", 136, 138], ["Italian regions", "ANATOMY", 143, 158]]], ["First, we perform the Student's t-test to compare the slopes corresponding to US and Italian regions; we find high p t -values (>0.05) for both fits of x=T and x=T -1 , thus, the two populations are likely characterized by the same slope.", [["T -1", "GENE_OR_GENE_PRODUCT", 162, 166], ["the Student's t-test", "TEST", 18, 38]]], ["Tthe respective intercept \u03bb 0 does not pass the same test, i.e., the intercepts corresponding to US and Italian regions are likely different.", [["likely", "UNCERTAINTY", 124, 130], ["different", "OBSERVATION_MODIFIER", 131, 140]]], ["A universality may characterize the slopes of fits x=T or x=T -1 , i.e.,(which was not certified by peer review)Next, we perform the linear fits of the sample points (T i \u00b1\u03b4T i , \u03bb i \u00b1\u03b4\u03bb i ) and (T i -1 \u00b1\u03b4T i -1 , \u03bb i \u00b1\u03b4\u03bb i ) for the mixed set of US and Italian data, once the rates of the Italian regions are shifted by \u0394\u03bb; the optimal fitting is obtained for that shift \u0394\u03bb, for which the reduced chi-square is ~1, the p-value of the extremes is ~0.5, and the combined measure ~0 (see previous section).", [["\u0394\u03bb", "PROTEIN", 372, 374], ["the slopes of fits", "PROBLEM", 32, 50], ["T i", "TEST", 196, 199], ["T i", "TEST", 205, 208], ["US", "TEST", 247, 249], ["Italian data", "TEST", 254, 266], ["the rates", "TEST", 273, 282]]], ["(Note that the optimization is not performed for the binned datasets, since they are characterized by smaller p-values -see, Figs.", [["the optimization", "TEST", 11, 27], ["the binned datasets", "PROBLEM", 49, 68], ["smaller", "OBSERVATION_MODIFIER", 102, 109]]], ["The weighted mean is performed separately for the fitting cases of x=T and x=T -1 ; however, the weighted mean of the critical temperature is performed for all four results.Figure 7.Fitting of datasets combined for US and Italian regions, with the latter's rates shifted by \u0394\u03bb.", [["US", "TEST", 215, 217]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020 . . https://doi.org/10.1101 Figure 8 .", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 279, 302], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["med", "ANATOMY", 105, 108]]], ["Relationship of the reproduction number R 0 and its uncertainty with environmental temperature T. According to this, new affected cases cease (R 0 =1) when temperature climbs to T C~3 0 C 0 or (~86 F 0 ).DISCUSSION AND CONCLUSIONSUp-to-date there is no systematic statistical analysis of the effect of the environmental temperature T (and possibly other weather parameters) on the exponential growth rate of the cases infected by COVID-19, while a statistically confident relationship between temperature and growth rate (either with positive or negative correlation) is still unknown.DISCUSSION AND CONCLUSIONSThe presented analysis led to a statistically confident relationship of negative correlation between the exponential growth rate and the average environmental temperature, derived for US and Italian regions.", [["temperature climbs", "TEST", 156, 174], ["T C", "TEST", 178, 181], ["COVID", "TEST", 430, 435], ["growth rate", "TEST", 509, 520], ["the exponential growth rate", "TEST", 712, 739]]], ["In particular, we analyzed datasets of regional infected cases in US and Italy, derived the exponential growth rates for each of these regions and plotted them against environmental temperatures averaged within the same regions, derived the relationship of temperature -growth rate, and evaluated its statistical confidence.DISCUSSION AND CONCLUSIONS.", [["environmental temperatures", "PROBLEM", 168, 194], ["regional", "OBSERVATION_MODIFIER", 39, 47], ["infected", "OBSERVATION", 48, 56]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020. . https://doi.org/10.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["1101 The performed statistical analysis involved fitting of linear statistical models with the datasets of environmental temperature (or its inverse) and exponential growth rate, finding their relationship, and evaluating its statistical confidence.", [["statistical analysis", "TEST", 19, 39], ["linear statistical models", "PROBLEM", 60, 85]]], ["The two linear models developed and used for the statistical analysis are (a)(which was not certified by peer review)The statistical confidence of fitting was evaluated using the reduced chi-square values, the p-value of extremes, and a testing measure that combines both of these values.", [["the statistical analysis", "TEST", 45, 69], ["the reduced chi-square values", "PROBLEM", 175, 204], ["a testing measure", "TEST", 235, 252], ["two", "OBSERVATION_MODIFIER", 4, 7], ["linear", "OBSERVATION_MODIFIER", 8, 14]]], ["Also, the statistical confidence was also evaluated using the Student's t-test, where the derived slopes compared to a hypothetical zero slope.", [["the Student's t-test", "TEST", 58, 78], ["zero slope", "OBSERVATION", 132, 142]]], ["The sample points of temperature (or inverse temperature) and exponential growth rate were also tested for statistically significant concentrations or rarefactions; namely, for possible heterogeneities within the distribution of sample points that could have significant role in the results.", [["temperature", "TEST", 21, 32], ["inverse temperature", "TEST", 37, 56], ["exponential growth rate", "TEST", 62, 85], ["statistically significant concentrations", "PROBLEM", 107, 147], ["rarefactions", "PROBLEM", 151, 163], ["heterogeneities", "PROBLEM", 186, 201]]], ["The statistical analysis of the homogenized temperature-rate data points concluded that the negative correlation between temperature and exponential rate is stable, having no statistically significant variability due to concentrations or rarefactions, and it is characterized by a high statistical confidence.(which was not certified by peer review)We also performed a Student's t-test and ensured that the difference between two sample means of US and Italian regions is not statistically significant.", [["The statistical analysis", "TEST", 0, 24], ["the homogenized temperature", "TEST", 28, 55], ["temperature", "TEST", 121, 132], ["exponential rate", "TEST", 137, 153], ["statistically significant variability", "PROBLEM", 175, 212], ["concentrations", "PROBLEM", 220, 234], ["rarefactions", "PROBLEM", 238, 250], ["a Student's t-test", "TEST", 367, 385], ["stable", "OBSERVATION_MODIFIER", 157, 163], ["not statistically", "UNCERTAINTY", 472, 489], ["significant", "OBSERVATION_MODIFIER", 490, 501]]], ["A possible universality may characterize the slope of the temperature-rate relationship.", [["possible", "UNCERTAINTY", 2, 10]]], ["This verifies the modeling developed and used by this analysis, where the exponential rate \u03bb, or the reproduction number R 0 , are subjects to a component influenced by the culture in social activities (intercept \u03bb 0 ) and a component influenced by the temperature (slope p 2 ).", [["this analysis", "TEST", 49, 62], ["the exponential rate", "TEST", 70, 90], ["the culture", "TEST", 169, 180]]], ["In this way, the slope may indicate to a universal quantity involved, such as, the (negative) activation energy.(which was not certified by peer review)Since the derived slopes for US and Italian regions are characterized by no statistically confident difference, we improved the statistics of the estimated fitting parameters by combined the sample points of US and Italian regions.", [["US", "TEST", 181, 183], ["no", "UNCERTAINTY", 225, 227]]], ["From the derived relationship, among others, we were able to derive the values of the (negative) activation energy E a , and the reproduction number R 0 at normal conditions and how this depends on temperature.(which was not certified by peer review)Therefore, the results clearly showed that there is indeed statistically significant negative correlation of temperature on the exponential growth rate of the cases infected by COVID-19.", [["COVID-19", "CHEMICAL", 427, 435], ["COVID-19", "CHEMICAL", 427, 435], ["COVID", "TEST", 427, 432], ["significant", "OBSERVATION_MODIFIER", 323, 334], ["negative", "OBSERVATION", 335, 343]]], ["Figure 9 shows the anticorrelation between the mapped exponential rates and average environmental temperature of the USA regions examined by this analysis, which they are characterized by readable exponential growth phase in their evolution spread curve.", [["this analysis", "TEST", 141, 154], ["exponential", "OBSERVATION_MODIFIER", 197, 208], ["growth", "OBSERVATION_MODIFIER", 209, 215], ["phase", "OBSERVATION_MODIFIER", 216, 221]]], ["Anti-correlation between the spatial distributions of the exponential growth rates of the infected cases (left) and the average environmental temperature (right).(which was not certified by peer review).", [["spatial", "OBSERVATION_MODIFIER", 29, 36], ["distributions", "OBSERVATION_MODIFIER", 37, 50], ["exponential", "OBSERVATION_MODIFIER", 58, 69], ["growth", "OBSERVATION_MODIFIER", 70, 76], ["infected", "OBSERVATION_MODIFIER", 90, 98], ["left", "ANATOMY_MODIFIER", 106, 110], ["average", "OBSERVATION_MODIFIER", 120, 127], ["environmental", "OBSERVATION_MODIFIER", 128, 141], ["temperature", "OBSERVATION_MODIFIER", 142, 153], ["right", "ANATOMY_MODIFIER", 155, 160]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020 . . https://doi.org/10.1101 Given the negative correlation of the environmental temperature with the exponential growth rate, it was reasonable to ask for the critical temperature that eliminates the exponential rate, and thus the number of daily new cases in infected regions.", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 320, 343], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["the environmental temperature", "PROBLEM", 378, 407], ["the critical temperature", "PROBLEM", 471, 495], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["infected", "OBSERVATION", 576, 584]]], ["This was found to be T C~8 6.1 \u00b1 4.3 F 0 for US regions.", [["T C", "TEST", 21, 24], ["US regions", "TEST", 45, 55]]], ["It is straightforward to ask when the environmental temperature will climb above this critical value.", [["the environmental temperature", "TEST", 34, 63]]], ["As an example, Figure 10 plots the daily average temperatures in San Antonio, Texas, shown that will be clearly above the estimated T C threshold in the second half of May.", [["T C", "GENE_OR_GENE_PRODUCT", 132, 135]]], ["According to the statistically confident relationship between exponential growth rate of infected cases shown in Fig.8 , the critical temperature, which eliminates the exponential growth, and thus the COVID-19 spread, is T C = 86.1 \u00b1 4.3 F 0 .", [["infected cases", "PROBLEM", 89, 103], ["the critical temperature", "PROBLEM", 121, 145], ["the exponential growth", "PROBLEM", 164, 186], ["the COVID", "TEST", 197, 206], ["T C", "TEST", 221, 224], ["infected", "OBSERVATION", 89, 97], ["exponential", "OBSERVATION_MODIFIER", 168, 179], ["growth", "OBSERVATION_MODIFIER", 180, 186]]], ["The plot shows also the May-June daily, nightly, and 24h-averaged environmental temperatures in San Antonio, Texas, averaged over the last three years.", [["The plot", "TEST", 0, 8]]], ["The daily average temperatures will be clearly above the estimated T C threshold in the second half of May; thus, the plot suggests a possible date for loosening the strict measures in San Antonio, that is, May 24.(which was not certified by peer review)The resulted high statistical confidence of the negative correlation of the environmental temperature on the exponential growth rate of the cases infected by COVID-19 is certainly encouraging for loosening super-strict social-distancing measures, at least, during the summery high temperatures.", [["COVID-19", "CHEMICAL", 412, 420], ["loosening", "PROBLEM", 152, 161], ["the environmental temperature", "PROBLEM", 326, 355], ["loosening", "PROBLEM", 450, 459], ["high", "OBSERVATION_MODIFIER", 267, 271]]], ["However, we are, by no-means, recommending a return-to-work date based only on this study.", [["this study", "TEST", 79, 89]]], ["But we do think that this should be part of the decision, as well as an inspiration for repeating the same analysis in other heavily infected regions.", [["the same analysis", "TEST", 98, 115], ["infected", "OBSERVATION", 133, 141]]], ["The steps of these analyses may be followed as:(which was not certified by peer review)(i) Identify different outbreaks in regions with the same culture in social activities and different environmental temperature; (ii) Estimate the exponential growth rates for these regions from the time series of infected cases; (iii) Plot the derived rates against the environmental temperature averaged for these regions, and repeat the analysis of this study to determine the temperature-rate relationship and its statistical confidence.(which was not certified by peer review).", [["these analyses", "TEST", 13, 27], ["the same culture", "TEST", 136, 152], ["infected cases", "PROBLEM", 300, 314], ["repeat the analysis", "TEST", 415, 434], ["this study", "TEST", 438, 448], ["the temperature", "TEST", 462, 477]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 24, 2020 . . https://doi.org/10.1101", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 320, 343], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "807479d4a1f69c19270b8ffa43b38a6c4634c9ea": [["IntroductionWE'reported the excretion of rotaviruses by neonates in the nurseries of two large metropolitan hospitals in Sydney.'", [["rotaviruses", "ORGANISM", 41, 52], ["rotaviruses", "PROBLEM", 41, 52], ["rotaviruses", "OBSERVATION", 41, 52], ["large", "OBSERVATION_MODIFIER", 89, 94], ["metropolitan", "OBSERVATION_MODIFIER", 95, 107]]], ["Our studies suggested that there was a high incidence of asymptomatic infection (53% in one nursery and 26% in the other) and that the virus persisted for long periods in the nurseries.", [["infection", "DISEASE", 70, 79], ["Our studies", "TEST", 0, 11], ["asymptomatic infection", "PROBLEM", 57, 79], ["the virus", "PROBLEM", 131, 140], ["high", "OBSERVATION_MODIFIER", 39, 43], ["asymptomatic", "OBSERVATION_MODIFIER", 57, 69], ["infection", "OBSERVATION", 70, 79], ["virus", "OBSERVATION", 135, 140]]], ["Chrystie et awl. have also drawn attention to the high infection-rate and lack of symptoms in neonates in St. Thomas' Hospital, London.", [["infection", "DISEASE", 55, 64], ["neonates", "ORGANISM", 94, 102], ["the high infection", "PROBLEM", 46, 64], ["symptoms in neonates", "PROBLEM", 82, 102], ["awl", "OBSERVATION", 12, 15], ["high", "OBSERVATION_MODIFIER", 50, 54], ["infection", "OBSERVATION", 55, 64]]], ["On the other hand, Bishop et al. 3 ,4 described outbreaks of diarrhoea in hospital nurseries which they attribute to rotaviruses.IntroductionA high percentage of cases of enteritis in infants and young children has been shown to be associated with rotaviruses, and our initial interest in neonatal infections was stimulated by the finding of rotaviruses in five babies with diarrhoea who were less than 7 days old.", [["diarrhoea", "DISEASE", 61, 70], ["rotaviruses", "DISEASE", 117, 128], ["enteritis", "DISEASE", 171, 180], ["neonatal infections", "DISEASE", 289, 308], ["diarrhoea", "DISEASE", 374, 383], ["rotaviruses", "ORGANISM", 117, 128], ["infants", "ORGANISM", 184, 191], ["children", "ORGANISM", 202, 210], ["rotaviruses", "ORGANISM", 342, 353], ["babies", "ORGANISM", 362, 368], ["infants", "SPECIES", 184, 191], ["children", "SPECIES", 202, 210], ["diarrhoea", "PROBLEM", 61, 70], ["rotaviruses", "PROBLEM", 117, 128], ["enteritis", "PROBLEM", 171, 180], ["rotaviruses", "PROBLEM", 248, 259], ["neonatal infections", "PROBLEM", 289, 308], ["rotaviruses", "PROBLEM", 342, 353], ["diarrhoea", "PROBLEM", 374, 383], ["rotaviruses", "OBSERVATION", 117, 128], ["high percentage", "OBSERVATION_MODIFIER", 143, 158], ["enteritis", "OBSERVATION", 171, 180], ["infections", "OBSERVATION", 298, 308], ["rotaviruses", "OBSERVATION", 342, 353]]], ["However, the discovery that many symptomless neonates were excreting virus raised doubts about its role as a causative agent in diarrhoea in the very young and we have therefore extended our studies to six hospital nurseries in the greater metropolitan area of Sydney.Collection of SpecimensFaecal specimens were collected from all babies in a particular nursery on a given day.", [["SpecimensFaecal specimens", "ANATOMY", 282, 307], ["diarrhoea", "DISEASE", 128, 137], ["neonates", "ORGANISM", 45, 53], ["SpecimensFaecal specimens", "CANCER", 282, 307], ["babies", "ORGANISM", 332, 338], ["many symptomless neonates", "PROBLEM", 28, 53], ["excreting virus", "PROBLEM", 59, 74], ["diarrhoea", "PROBLEM", 128, 137], ["Collection of SpecimensFaecal specimens", "TEST", 268, 307], ["greater", "OBSERVATION_MODIFIER", 232, 239]]], ["5 standard public hospital nurseries in widely scattered areas of metropolitan Sydney were surveyed in this manner.", [["widely", "OBSERVATION_MODIFIER", 40, 46], ["scattered", "OBSERVATION_MODIFIER", 47, 56], ["areas", "OBSERVATION_MODIFIER", 57, 62]]], ["No baby had diarrhoea at the time of the survey.", [["diarrhoea", "DISEASE", 12, 21], ["diarrhoea", "PROBLEM", 12, 21], ["diarrhoea", "OBSERVATION", 12, 21]]], ["Specimens were subsequently collected from neonates with diarrhoea, a few with \"loose\" or \"mucousy\" stools, and from normal babies during outbreaks of diarrhoea.", [["Specimens", "ANATOMY", 0, 9], ["stools", "ANATOMY", 100, 106], ["diarrhoea", "DISEASE", 57, 66], ["diarrhoea", "DISEASE", 151, 160], ["neonates", "ORGANISM", 43, 51], ["Specimens", "TEST", 0, 9], ["diarrhoea", "PROBLEM", 57, 66], ["\"loose\" or \"mucousy\" stools", "PROBLEM", 79, 106], ["diarrhoea", "PROBLEM", 151, 160], ["diarrhoea", "OBSERVATION", 151, 160]]], ["Most of the neonates were less than 7 days old.", [["neonates", "ORGANISM", 12, 20]]], ["Specimens were transported to the laboratory within 24 h and stored at -20\u00b0C until processed.Laboratory TechniquesA 20% w/v suspension of faeces was made in Hanks' balanced salt solution without antibiotics, mixed with an equal volume of Arklone P (trichlorotrifluoroethane), and homogenised thoroughly for 5 min.", [["Specimens", "ANATOMY", 0, 9], ["faeces", "ANATOMY", 138, 144], ["Arklone P", "CHEMICAL", 238, 247], ["trichlorotrifluoroethane", "CHEMICAL", 249, 273], ["Arklone P", "CHEMICAL", 238, 247], ["trichlorotrifluoroethane", "CHEMICAL", 249, 273], ["faeces", "ORGANISM_SUBSTANCE", 138, 144], ["trichlorotrifluoroethane", "SIMPLE_CHEMICAL", 249, 273], ["Laboratory TechniquesA", "TREATMENT", 93, 115], ["v suspension of faeces", "TREATMENT", 122, 144], ["Hanks' balanced salt solution", "TREATMENT", 157, 186], ["antibiotics", "TREATMENT", 195, 206], ["Arklone P (trichlorotrifluoroethane)", "TREATMENT", 238, 274]]], ["The homogenate was then centrifuged at 7000 g for 20 min and the aqueous layer removed.", [["homogenate", "ANATOMY", 4, 14], ["aqueous layer", "ANATOMY", 65, 78], ["aqueous layer", "ORGANISM_SUBSTANCE", 65, 78], ["the aqueous layer", "TREATMENT", 61, 78], ["layer", "OBSERVATION_MODIFIER", 73, 78], ["removed", "OBSERVATION", 79, 86]]], ["A portion of this aqueous layer was then centrifuged at 240 000 g for 30 min.", [["aqueous layer", "ANATOMY", 18, 31], ["aqueous layer", "ORGANISM_SUBSTANCE", 18, 31], ["this aqueous layer", "TREATMENT", 13, 31]]], ["For electron microscopy the pellet was resuspended in a few drops of distilled water, one drop of which was placed on a carbon-coated parlodion grid, allowed to dry, and then negatively stained with 3% phosphotungstic acid at pH 6-5.", [["phosphotungstic acid", "CHEMICAL", 202, 222], ["carbon", "CHEMICAL", 120, 126], ["phosphotungstic acid", "CHEMICAL", 202, 222], ["phosphotungstic acid", "SIMPLE_CHEMICAL", 202, 222], ["electron microscopy", "TEST", 4, 23], ["a carbon-coated parlodion grid", "TREATMENT", 118, 148], ["3% phosphotungstic acid at pH", "TREATMENT", 199, 228]]], ["A Philips 201 electron microscope was used.ResultsFaecal specimens from 628 neonates were processed and examined for viruses.", [["ResultsFaecal specimens", "ANATOMY", 43, 66], ["ResultsFaecal specimens", "CANCER", 43, 66], ["neonates", "ORGANISM", 76, 84], ["A Philips 201 electron microscope", "TEST", 0, 33], ["ResultsFaecal specimens", "TEST", 43, 66], ["neonates", "TEST", 76, 84], ["viruses", "PROBLEM", 117, 124]]], ["Rotaviruses were found in 304 (49%) (table i).", [["Rotaviruses", "PROBLEM", 0, 11]]], ["The four groups of neonates (normal babies tested during surveys, normal babies tested during outbreaks of diarrhoea in the nurseries, those with diarrhoea, and those with mild gastrointestinal symptoms) gave excretion rates of 44%, 46%, 61%, and 45% respectively.", [["gastrointestinal", "ANATOMY", 177, 193], ["diarrhoea", "DISEASE", 107, 116], ["diarrhoea", "DISEASE", 146, 155], ["gastrointestinal symptoms", "DISEASE", 177, 202], ["neonates", "ORGANISM", 19, 27], ["gastrointestinal", "ORGANISM_SUBDIVISION", 177, 193], ["diarrhoea", "PROBLEM", 107, 116], ["diarrhoea", "PROBLEM", 146, 155], ["mild gastrointestinal symptoms", "PROBLEM", 172, 202], ["excretion rates", "TEST", 209, 224]]], ["Of the 6 nurseries 5 showed evidence of infection.", [["infection", "DISEASE", 40, 49], ["infection", "PROBLEM", 40, 49], ["evidence of", "UNCERTAINTY", 28, 39], ["infection", "OBSERVATION", 40, 49]]], ["In the sixth nursery no rota viruses were found during the survey or later when there were cases of diarrhoea.", [["diarrhoea", "DISEASE", 100, 109], ["rota viruses", "PROBLEM", 24, 36], ["diarrhoea", "PROBLEM", 100, 109], ["rota viruses", "OBSERVATION", 24, 36], ["diarrhoea", "OBSERVATION", 100, 109]]], ["The difference between the percentage of positive excretors in the diarrhoea group and that in the normal-baby group is statistically significant (P<0.05).ResultsVery few other viral particles were found in the deposits examined by electron microscopy.", [["diarrhoea", "DISEASE", 67, 76], ["positive excretors in the diarrhoea group", "PROBLEM", 41, 82], ["Very few other viral particles", "PROBLEM", 162, 192], ["electron microscopy", "TEST", 232, 251], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["percentage", "OBSERVATION_MODIFIER", 27, 37], ["positive", "OBSERVATION_MODIFIER", 41, 49], ["excretors", "OBSERVATION_MODIFIER", 50, 59], ["diarrhoea", "OBSERVATION_MODIFIER", 67, 76], ["normal", "OBSERVATION", 99, 105], ["statistically", "OBSERVATION_MODIFIER", 120, 133], ["significant", "OBSERVATION_MODIFIER", 134, 145], ["viral particles", "OBSERVATION", 177, 192]]], ["2 myxoviruslike particles, 2 coronavirus-like particles, a small 18 nm particle (possibly a parvovirus), 4 mycoplasma-like organisms, and a number of bacteriophages were the only other microorganisms seen.", [["parvovirus", "DISEASE", 92, 102], ["parvovirus", "ORGANISM", 92, 102], ["2 myxoviruslike particles", "PROBLEM", 0, 25], ["2 coronavirus-like particles", "PROBLEM", 27, 55], ["a small 18 nm particle", "PROBLEM", 57, 79], ["a parvovirus)", "PROBLEM", 90, 103], ["4 mycoplasma-like organisms", "PROBLEM", 105, 132], ["bacteriophages", "PROBLEM", 150, 164], ["other microorganisms", "PROBLEM", 179, 199], ["small", "OBSERVATION_MODIFIER", 59, 64], ["18 nm", "OBSERVATION_MODIFIER", 65, 70], ["particle", "OBSERVATION_MODIFIER", 71, 79], ["parvovirus", "OBSERVATION", 92, 102], ["bacteriophages", "OBSERVATION", 150, 164]]], ["Attempts to isolate viruses by standard cell-culture techniques were unsuccess- More than 100 specimens were tested but no viruses were cultivated.", [["cell", "ANATOMY", 40, 44], ["specimens", "ANATOMY", 94, 103], ["cell", "CELL", 40, 44], ["specimens", "CANCER", 94, 103], ["isolate viruses", "PROBLEM", 12, 27], ["culture techniques", "TEST", 45, 63], ["viruses", "PROBLEM", 123, 130]]], ["Likewise bacteriological investigations did not reveal any pathogens.ResultsAge of Infection Continuing Presence of Virus and Seasonal Incidence 2 nurseries were studied continuously for 9 mo and another for 11 mo.", [["Likewise bacteriological investigations", "TEST", 0, 39], ["any pathogens", "PROBLEM", 55, 68], ["Infection", "PROBLEM", 83, 92], ["Virus", "PROBLEM", 116, 121], ["pathogens", "OBSERVATION", 59, 68], ["Infection", "OBSERVATION", 83, 92]]], ["Rotaviruses were regularly found inDiscussionThese studies indicate that about half the newborn babies in the nurseries of five major metropolitan hospitals in Sydney were infected with rotaviruses before they were discharged.", [["babies", "ORGANISM", 96, 102], ["rotaviruses", "ORGANISM", 186, 197], ["Rotaviruses", "PROBLEM", 0, 11], ["These studies", "TEST", 45, 58], ["rotaviruses", "TREATMENT", 186, 197]]], ["The great majority of these infections were asymptomatic and apparently quite transient in some babies.", [["infections", "DISEASE", 28, 38], ["babies", "ORGANISM", 96, 102], ["these infections", "PROBLEM", 22, 38], ["great", "OBSERVATION_MODIFIER", 4, 9], ["majority", "OBSERVATION_MODIFIER", 10, 18], ["infections", "OBSERVATION", 28, 38]]], ["One surprising feature was the rapidity with which the neonates became infected after they entered the nursery.", [["neonates", "ORGANISM", 55, 63], ["rapidity", "OBSERVATION_MODIFIER", 31, 39], ["infected", "OBSERVATION", 71, 79]]], ["3 out of 35 babies tested were found to be excreting virus one day after birth and 24 out of 65 (35%) two days after birth.", [["babies", "ORGANISM", 12, 18]]], ["From the third day, approximately 50% were excreting virus.", [["excreting virus", "OBSERVATION", 43, 58]]], ["The neonatal gut is colonised by lactobacilli and Escherichia coli within a few days of birth and it is not unreasonable to assume that rapid infection can take place with rotavir-uses.", [["neonatal gut", "ANATOMY", 4, 16], ["infection", "DISEASE", 142, 151], ["rotavir", "CHEMICAL", 172, 179], ["rotavir", "CHEMICAL", 172, 179], ["gut", "ORGANISM_SUBDIVISION", 13, 16], ["lactobacilli", "SIMPLE_CHEMICAL", 33, 45], ["Escherichia coli", "ORGANISM", 50, 66], ["rotavir", "SIMPLE_CHEMICAL", 172, 179], ["Escherichia coli", "SPECIES", 50, 66], ["Escherichia coli", "SPECIES", 50, 66], ["lactobacilli", "PROBLEM", 33, 45], ["Escherichia coli", "PROBLEM", 50, 66], ["rapid infection", "PROBLEM", 136, 151], ["rotavir", "TREATMENT", 172, 179], ["gut", "ANATOMY", 13, 16], ["colonised", "OBSERVATION", 20, 29], ["lactobacilli", "OBSERVATION", 33, 45], ["Escherichia coli", "OBSERVATION", 50, 66], ["rapid", "OBSERVATION_MODIFIER", 136, 141], ["infection", "OBSERVATION", 142, 151]]], ["Mebus et al. have shown that bovine rotavirus will produce diarrhoea in newborn calves in 15 h after artificial inoculation.", [["diarrhoea", "DISEASE", 59, 68], ["bovine", "ORGANISM", 29, 35], ["rotavirus", "ORGANISM", 36, 45], ["calves", "ORGANISM", 80, 86], ["bovine", "SPECIES", 29, 35], ["calves", "SPECIES", 80, 86], ["bovine", "SPECIES", 29, 35], ["rotavirus", "SPECIES", 36, 45], ["bovine rotavirus", "PROBLEM", 29, 45], ["diarrhoea", "PROBLEM", 59, 68], ["artificial inoculation", "TREATMENT", 101, 123]]], ["Excretion of viruses 24-48 h after birth by the human neonate is therefore not improbable.DiscussionHow the virus is acquired is not known but the few available facts strongly suggest environmental spread within the nursery.", [["human", "ORGANISM", 48, 53], ["neonate", "ORGANISM", 54, 61], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["Excretion of viruses", "PROBLEM", 0, 20], ["viruses", "OBSERVATION", 13, 20], ["not improbable", "UNCERTAINTY", 75, 89]]], ["Adults seldom excrete rotaviruses and although a few cases of gastroenteritis and asymptomatic infection have been recorded7,8 it is unlikely that individual infection is acquired directly from mother or nurses.DiscussionIt is most likely that the virus enters the nursery through a visiting child or the rare adult excretor and then passes readily from neonate to neonate; the result is a persisting endemic infection as susceptible babies enter the nursery.DiscussionWe found no seasonal variation in the incidence of infection.", [["gastroenteritis", "DISEASE", 62, 77], ["infection", "DISEASE", 95, 104], ["infection", "DISEASE", 158, 167], ["infection", "DISEASE", 409, 418], ["infection", "DISEASE", 520, 529], ["Adults", "ORGANISM", 0, 6], ["rotaviruses", "ORGANISM", 22, 33], ["neonate", "ORGANISM", 354, 361], ["neonate", "ORGANISM", 365, 372], ["babies", "ORGANISM", 434, 440], ["Adults", "SPECIES", 0, 6], ["Adults seldom excrete rotaviruses", "PROBLEM", 0, 33], ["gastroenteritis", "PROBLEM", 62, 77], ["asymptomatic infection", "PROBLEM", 82, 104], ["individual infection", "PROBLEM", 147, 167], ["the virus", "PROBLEM", 244, 253], ["a persisting endemic infection", "PROBLEM", 388, 418], ["seasonal variation", "PROBLEM", 481, 499], ["infection", "PROBLEM", 520, 529], ["rotaviruses", "OBSERVATION", 22, 33], ["gastroenteritis", "OBSERVATION", 62, 77], ["asymptomatic", "OBSERVATION_MODIFIER", 82, 94], ["infection", "OBSERVATION", 95, 104], ["unlikely", "UNCERTAINTY", 133, 141], ["infection", "OBSERVATION", 158, 167], ["most likely", "UNCERTAINTY", 227, 238], ["virus", "OBSERVATION", 248, 253], ["persisting", "OBSERVATION_MODIFIER", 390, 400], ["endemic", "OBSERVATION_MODIFIER", 401, 408], ["infection", "OBSERVATION", 409, 418], ["no", "UNCERTAINTY", 478, 480], ["seasonal", "OBSERVATION_MODIFIER", 481, 489], ["variation", "OBSERVATION_MODIFIER", 490, 499], ["infection", "OBSERVATION", 520, 529]]], ["About half the babies in the nursery seem to be consistently excreting virus throughout the year, unlike the infants and young children in whom the prevalence of the virus increases in the late winter and early spring.9DiscussionBecause of the high infection-rate among the newborn babies without symptoms, the role of rotaviruses as a cause of enteritis is not clear.", [["infection", "DISEASE", 249, 258], ["rotaviruses", "DISEASE", 319, 330], ["enteritis", "DISEASE", 345, 354], ["babies", "ORGANISM", 15, 21], ["infants", "ORGANISM", 109, 116], ["children", "ORGANISM", 127, 135], ["babies", "ORGANISM", 282, 288], ["rotaviruses", "ORGANISM", 319, 330], ["infants", "SPECIES", 109, 116], ["children", "SPECIES", 127, 135], ["the virus", "PROBLEM", 162, 171], ["the high infection", "PROBLEM", 240, 258], ["symptoms", "PROBLEM", 297, 305], ["rotaviruses", "PROBLEM", 319, 330], ["enteritis", "PROBLEM", 345, 354], ["virus", "OBSERVATION", 71, 76], ["virus", "OBSERVATION", 166, 171], ["high", "OBSERVATION_MODIFIER", 244, 248], ["infection", "OBSERVATION", 249, 258], ["enteritis", "OBSERVATION", 345, 354]]], ["Only 84 out of 304 babies (28%) excreting virus had diarrhoea.", [["diarrhoea", "DISEASE", 52, 61], ["babies", "ORGANISM", 19, 25], ["excreting virus", "PROBLEM", 32, 47], ["diarrhoea", "PROBLEM", 52, 61], ["diarrhoea", "OBSERVATION", 52, 61]]], ["However, there were significantly more neonates with diarrhoea excreting virus than the symptom-free group (p<0.05) and in the absence of any other pathogen it seems that these viruses do in fact cause diarrhoea in some neonates.", [["diarrhoea", "DISEASE", 53, 62], ["diarrhoea", "DISEASE", 202, 211], ["neonates", "ORGANISM", 220, 228], ["significantly more neonates", "PROBLEM", 20, 47], ["diarrhoea excreting virus", "PROBLEM", 53, 78], ["any other pathogen", "PROBLEM", 138, 156], ["these viruses", "PROBLEM", 171, 184], ["diarrhoea", "PROBLEM", 202, 211], ["some neonates", "PROBLEM", 215, 228], ["viruses", "OBSERVATION", 177, 184], ["diarrhoea", "OBSERVATION", 202, 211]]], ["It was noted that viruses from some babies were coated with an antibody-like material; this feature may be an indication of the antibody level of the mother's milk or perhaps the non-antibody virus inhibitor recently described in human and cow's milk by Matthews et al.Io We did not find \"antibody\" coated viruses in cases of diarrhoea.", [["milk", "ANATOMY", 159, 163], ["diarrhoea", "DISEASE", 326, 335], ["babies", "ORGANISM", 36, 42], ["milk", "ORGANISM_SUBSTANCE", 159, 163], ["non-antibody virus", "ORGANISM", 179, 197], ["human", "ORGANISM", 230, 235], ["cow", "ORGANISM", 240, 243], ["milk", "ORGANISM_SUBSTANCE", 246, 250], ["milk", "SPECIES", 159, 163], ["human", "SPECIES", 230, 235], ["cow", "SPECIES", 240, 243], ["human", "SPECIES", 230, 235], ["cow", "SPECIES", 240, 243], ["viruses", "PROBLEM", 18, 25], ["some babies", "PROBLEM", 31, 42], ["an antibody-like material", "PROBLEM", 60, 85], ["the antibody level", "PROBLEM", 124, 142], ["the non-antibody virus inhibitor", "TREATMENT", 175, 207], ["diarrhoea", "PROBLEM", 326, 335], ["viruses", "OBSERVATION", 18, 25], ["diarrhoea", "OBSERVATION", 326, 335]]], ["The possible existence of rotavirus serotypes of differing pathogenicity could also explain the variable response to infection, but the determination of minor antigenic differences is not possible with the techniques available at present.", [["infection", "DISEASE", 117, 126], ["rotavirus", "ORGANISM", 26, 35], ["rotavirus", "SPECIES", 26, 35], ["rotavirus serotypes", "PROBLEM", 26, 45], ["differing pathogenicity", "PROBLEM", 49, 72], ["infection", "PROBLEM", 117, 126], ["minor antigenic differences", "PROBLEM", 153, 180], ["the techniques", "TEST", 202, 216], ["possible existence of", "UNCERTAINTY", 4, 25], ["rotavirus serotypes", "OBSERVATION", 26, 45], ["differing", "OBSERVATION_MODIFIER", 49, 58], ["pathogenicity", "OBSERVATION", 59, 72], ["could also explain", "UNCERTAINTY", 73, 91], ["variable", "OBSERVATION_MODIFIER", 96, 104], ["response", "OBSERVATION_MODIFIER", 105, 113], ["infection", "OBSERVATION", 117, 126], ["not possible", "UNCERTAINTY", 184, 196]]]], "PMC7457007": [["IntroductionRecently, a novel virus, SARS-CoV-2 (COVID-19) originating in China at the end of2019 has been the cause of a fatal global pandemic.", [["SARS", "DISEASE", 37, 41], ["SARS-CoV-2", "ORGANISM", 37, 47], ["COVID-19", "ORGANISM", 49, 57], ["SARS-CoV-2 (COVID-19", "SPECIES", 37, 57], ["a novel virus", "PROBLEM", 22, 35], ["SARS", "TEST", 37, 41], ["CoV", "TEST", 42, 45], ["COVID", "TEST", 49, 54], ["a fatal global pandemic", "PROBLEM", 120, 143], ["fatal", "OBSERVATION_MODIFIER", 122, 127], ["global", "OBSERVATION_MODIFIER", 128, 134], ["pandemic", "OBSERVATION", 135, 143]]], ["At the time of writing, thedeath toll from COVID-19 infection in the UK has surpassed 30,000 and represents thehighest record of national deaths in Europe.1 The overall estimates ofCOVID-19 death rate in the UK is 0.66% increasing to 7.8% in the population of over80 years of age2; higher death rates have been reported in cases with underlyinghealth conditions or those of older age.3,4 The virus spreads mainly viaclose contact and respiratory droplets that lead to a high transmission rate ingroups in close contact such as hospitalised patients.5,6IntroductionFragility hip fractures have an estimated incidence of 70,000 cases per year in theUK and are expected to reach 6.3 million world-wide by the year 2050.7,8 This injuryaffects elderly populations, necessitates hospital admission, and makes this groupparticularly prone to COVID-19 infection.", [["respiratory droplets", "ANATOMY", 434, 454], ["hip", "ANATOMY", 574, 577], ["COVID-19", "CHEMICAL", 43, 51], ["infection", "DISEASE", 52, 61], ["deaths", "DISEASE", 138, 144], ["death", "DISEASE", 190, 195], ["death", "DISEASE", 289, 294], ["Fragility hip fractures", "DISEASE", 564, 587], ["infection", "DISEASE", 844, 853], ["COVID-19", "ORGANISM", 43, 51], ["patients", "ORGANISM", 540, 548], ["patients", "SPECIES", 540, 548], ["COVID", "TEST", 43, 48], ["infection", "PROBLEM", 52, 61], ["The overall estimates ofCOVID", "TEST", 157, 186], ["death rate", "TEST", 190, 200], ["higher death rates", "PROBLEM", 282, 300], ["underlyinghealth conditions", "PROBLEM", 334, 361], ["The virus spreads", "PROBLEM", 388, 405], ["IntroductionFragility hip fractures", "PROBLEM", 552, 587], ["infection", "PROBLEM", 844, 853], ["infection", "OBSERVATION", 52, 61], ["virus", "OBSERVATION", 392, 397], ["respiratory droplets", "OBSERVATION", 434, 454], ["hip", "ANATOMY", 574, 577], ["fractures", "OBSERVATION", 578, 587], ["infection", "OBSERVATION", 844, 853]]], ["Hip fracture itself is associated withincreased mortality, and the risk of death tends to cluster in the first 30-daysafter injury, then decreases thereafter.9 The 30-day mortality rate rangesfrom 3.5%\u201310%,10,11 with the National Hip Fracture Database (NHFD) showing a UK30-day mortality rate of 7%.12 Different predictors and risk factors of hip fractures30-day mortality have been studied,13,14 however there is no publishedevidence on the effect of COVID-19 on hip fracture 30-day mortality.", [["Hip", "ANATOMY", 0, 3], ["hip", "ANATOMY", 464, 467], ["fracture", "DISEASE", 4, 12], ["death", "DISEASE", 75, 80], ["COVID-19", "CHEMICAL", 452, 460], ["fracture", "DISEASE", 468, 476], ["COVID-19", "CHEMICAL", 452, 460], ["Hip", "ORGANISM_SUBDIVISION", 0, 3], ["hip", "ORGANISM_SUBDIVISION", 464, 467], ["Hip fracture", "PROBLEM", 0, 12], ["death", "PROBLEM", 75, 80], ["mortality rate", "TEST", 171, 185], ["mortality rate", "TEST", 278, 292], ["hip fractures30", "PROBLEM", 343, 358], ["publishedevidence", "PROBLEM", 417, 434], ["COVID", "TEST", 452, 457], ["hip fracture", "PROBLEM", 464, 476], ["fracture", "OBSERVATION", 4, 12], ["Hip", "ANATOMY", 230, 233], ["Fracture", "OBSERVATION", 234, 242], ["hip", "ANATOMY", 343, 346], ["no", "UNCERTAINTY", 414, 416], ["hip", "ANATOMY", 464, 467], ["fracture", "OBSERVATION", 468, 476]]], ["The aim of thisstudy is to analyse the effect of COVID-19 infection on hip fracture 30-daymortality.MethodsWe retrospectively reviewed all adult hip fractures admitted to two units, in March2020 and April 2020.", [["hip", "ANATOMY", 71, 74], ["hip", "ANATOMY", 145, 148], ["COVID-19", "CHEMICAL", 49, 57], ["infection", "DISEASE", 58, 67], ["fracture", "DISEASE", 75, 83], ["hip fractures", "DISEASE", 145, 158], ["COVID-19", "ORGANISM", 49, 57], ["hip", "ORGANISM_SUBDIVISION", 71, 74], ["hip", "ORGANISM_SUBDIVISION", 145, 148], ["COVID-19 infection", "PROBLEM", 49, 67], ["hip fracture", "PROBLEM", 71, 83], ["all adult hip fractures", "PROBLEM", 135, 158], ["infection", "OBSERVATION", 58, 67], ["hip", "ANATOMY", 71, 74], ["fracture", "OBSERVATION", 75, 83], ["hip", "ANATOMY", 145, 148], ["fractures", "OBSERVATION", 149, 158]]], ["Patients characteristics, the Nottingham Hip Fracture Score,the Charlson comorbidity index, and place of residence were recorded.", [["Fracture", "DISEASE", 45, 53], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the Nottingham Hip Fracture Score", "PROBLEM", 26, 59], ["the Charlson comorbidity index", "TEST", 60, 90], ["Hip", "ANATOMY", 41, 44], ["Fracture", "OBSERVATION", 45, 53]]], ["COVID-19 wasdiagnosed according to the national and local guidelines using reverse transcriptasepolymerase chain reaction (SARS-CoV-2 RdRp RT-PCR) of throat swap samples.", [["throat swap samples", "ANATOMY", 150, 169], ["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5], ["reverse transcriptasepolymerase chain reaction", "TREATMENT", 75, 121], ["SARS", "TEST", 123, 127], ["CoV", "TEST", 128, 131], ["RdRp RT-PCR", "TREATMENT", 134, 145], ["throat swap samples", "TEST", 150, 169], ["throat", "ANATOMY", 150, 156]]], ["Allpatients had received low molecular weight heparin (Enoxaparin sodium fortymilligrams) daily to prevent thromboembolic events and underwent surgery when deemedsafe following multi-disciplinary consultant review by orthopaedics, Care of theElderly, and anaesthetics.MethodsThe primary outcome measure was 30-day mortality of hip fractures associated withCOVID-19 infection; secondary outcome measures were, risk factors of 30-daymortality, medical complications, surgical complications, radiological appearanceand laboratory results relating to diagnosis and treatment of COVID-19.MethodsThe hip fractures 30-day mortality associated with COVID-19 infection was assessed,but due to the small sample size, the analysis was limited to descriptive statisticsto avoid Type I error.15 Kaplan-Meier test was used to present the trend of Survivaland Cumulative hazard between groups.", [["hip", "ANATOMY", 327, 330], ["hip", "ANATOMY", 594, 597], ["heparin", "CHEMICAL", 46, 53], ["Enoxaparin sodium fortymilligrams", "CHEMICAL", 55, 88], ["thromboembolic", "DISEASE", 107, 121], ["fractures", "DISEASE", 331, 340], ["infection", "DISEASE", 365, 374], ["fractures", "DISEASE", 598, 607], ["COVID-19", "CHEMICAL", 641, 649], ["infection", "DISEASE", 650, 659], ["Enoxaparin sodium fortymilligrams", "CHEMICAL", 55, 88], ["heparin", "SIMPLE_CHEMICAL", 46, 53], ["Enoxaparin sodium fortymilligrams", "SIMPLE_CHEMICAL", 55, 88], ["hip", "ORGANISM_SUBDIVISION", 327, 330], ["hip", "ORGANISM_SUBDIVISION", 594, 597], ["low molecular weight heparin (Enoxaparin sodium fortymilligrams", "TREATMENT", 25, 88], ["thromboembolic events", "PROBLEM", 107, 128], ["surgery", "TREATMENT", 143, 150], ["anaesthetics", "TREATMENT", 255, 267], ["hip fractures", "PROBLEM", 327, 340], ["withCOVID-19 infection", "PROBLEM", 352, 374], ["secondary outcome measures", "PROBLEM", 376, 402], ["medical complications", "PROBLEM", 442, 463], ["surgical complications", "PROBLEM", 465, 487], ["treatment", "TREATMENT", 561, 570], ["COVID", "TEST", 574, 579], ["The hip fractures", "PROBLEM", 590, 607], ["COVID-19 infection", "PROBLEM", 641, 659], ["the small sample size", "PROBLEM", 684, 705], ["the analysis", "TEST", 707, 719], ["Type I error", "PROBLEM", 766, 778], ["Meier test", "TEST", 789, 799], ["thromboembolic", "OBSERVATION", 107, 121], ["hip", "ANATOMY", 327, 330], ["fractures", "OBSERVATION", 331, 340], ["infection", "OBSERVATION", 365, 374], ["hip", "ANATOMY", 594, 597], ["fractures", "OBSERVATION", 598, 607], ["infection", "OBSERVATION", 650, 659], ["small", "OBSERVATION_MODIFIER", 688, 693], ["size", "OBSERVATION_MODIFIER", 701, 705]]], ["Statistical Package for Social Sciences (SPSS,version 24.0, IBM Co., Armonk, NY, USA) was used.MethodsThe study was authorized by the local ethical committee as part of the ClinicalEffectivenessand Audit Department (registration number: 852), and was performed inaccordance with the ethical standards of the 1964 Declaration of Helsinki as revisedin 2000.ResultsSeventy-five patients presented with hip fractures during the study period (Table 1).", [["hip", "ANATOMY", 399, 402], ["fractures", "DISEASE", 403, 412], ["patients", "ORGANISM", 375, 383], ["hip", "ORGANISM_SUBDIVISION", 399, 402], ["patients", "SPECIES", 375, 383], ["hip fractures", "PROBLEM", 399, 412], ["hip", "ANATOMY", 399, 402], ["fractures", "OBSERVATION", 403, 412]]], ["The mean age was83.5 years (range 65\u201398 years), and 53 were females (70.7%); all hip fractures weredue to low velocity injury and three (4%) had associated injuries (one wrist and twohumeral fractures).", [["hip", "ANATOMY", 81, 84], ["wrist", "ANATOMY", 170, 175], ["twohumeral", "ANATOMY", 180, 190], ["fractures", "DISEASE", 85, 94], ["low velocity injury", "DISEASE", 106, 125], ["injuries", "DISEASE", 156, 164], ["fractures", "DISEASE", 191, 200], ["hip", "ORGANISM_SUBDIVISION", 81, 84], ["wrist", "ORGANISM_SUBDIVISION", 170, 175], ["females", "TEST", 60, 67], ["all hip fractures", "PROBLEM", 77, 94], ["low velocity injury", "PROBLEM", 106, 125], ["associated injuries (one wrist and twohumeral fractures", "PROBLEM", 145, 200], ["hip", "ANATOMY", 81, 84], ["fractures", "OBSERVATION", 85, 94], ["low velocity", "OBSERVATION_MODIFIER", 106, 118], ["injuries", "OBSERVATION", 156, 164], ["wrist", "ANATOMY", 170, 175], ["twohumeral", "ANATOMY", 180, 190], ["fractures", "OBSERVATION", 191, 200]]], ["Twenty patients had COVID-19 infection (26.7%).ResultsThere was a significant difference of mortality rate in the COVID-19 positive group(n = 10, 50%) compared to COVID-19 negative group (n = 4, 7.3%), with mean time todeath of 19.8 days (95% confidence interval: 17.0\u201322.5 days, Figure 1).", [["infection", "DISEASE", 29, 38], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["COVID", "TEST", 20, 25], ["19 infection", "PROBLEM", 26, 38], ["mortality rate", "TEST", 92, 106], ["the COVID", "TEST", 110, 119], ["COVID", "TEST", 163, 168], ["mean time todeath", "TEST", 207, 224], ["infection", "OBSERVATION", 29, 38], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["difference", "OBSERVATION_MODIFIER", 78, 88]]], ["The mean time from admission tosurgery was 43.1 hours and 38.3 hours in COVID-19 positive and COVID-19 negativegroups, respectively.", [["COVID", "TEST", 72, 77], ["COVID", "TEST", 94, 99]]], ["Six patients (30%) contracted the COVID-19 infection in thecommunity and 14 (70%) developed symptoms after hospital admission 13/14 were testedpositive post-operatively with mean time to confirmed infection of 12.6 days.ResultsTwo thirds of the cases had intra-capsular hip fracture and cemented hiphemiarthroplasty was the most common operation performed (Table 1); three patients were managedconservatively.", [["hip", "ANATOMY", 270, 273], ["infection", "DISEASE", 43, 52], ["infection", "DISEASE", 197, 206], ["fracture", "DISEASE", 274, 282], ["hiphemiarthroplasty", "DISEASE", 296, 315], ["patients", "ORGANISM", 4, 12], ["hip", "ORGANISM_SUBDIVISION", 270, 273], ["patients", "ORGANISM", 373, 381], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 373, 381], ["the COVID", "TEST", 30, 39], ["infection", "PROBLEM", 43, 52], ["symptoms", "PROBLEM", 92, 100], ["infection", "PROBLEM", 197, 206], ["intra-capsular hip fracture", "PROBLEM", 255, 282], ["cemented hiphemiarthroplasty", "TREATMENT", 287, 315], ["infection", "OBSERVATION", 43, 52], ["infection", "OBSERVATION", 197, 206], ["hip", "ANATOMY", 270, 273], ["fracture", "OBSERVATION", 274, 282], ["cemented hiphemiarthroplasty", "OBSERVATION", 287, 315]]], ["The mean Nottingham hip fracture score was 5.6 (range 0\u20138), and theCharlson comorbidity index had a mean of 5.2 (range 0\u20139).", [["hip", "ANATOMY", 20, 23], ["fracture", "DISEASE", 24, 32], ["The mean Nottingham hip fracture score", "TEST", 0, 38], ["theCharlson comorbidity index", "TEST", 64, 93], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["hip", "ANATOMY", 20, 23], ["fracture", "OBSERVATION", 24, 32]]], ["One patient (1.3%) in theCOVID-19 negative group had an acute myocardial infarction post-operatively whichwas the cause of death.", [["myocardial", "ANATOMY", 62, 72], ["acute myocardial infarction", "DISEASE", 56, 83], ["death", "DISEASE", 123, 128], ["patient", "ORGANISM", 4, 11], ["myocardial", "MULTI-TISSUE_STRUCTURE", 62, 72], ["patient", "SPECIES", 4, 11], ["theCOVID", "TEST", 22, 30], ["an acute myocardial infarction", "PROBLEM", 53, 83], ["death", "PROBLEM", 123, 128], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["myocardial", "ANATOMY", 62, 72], ["infarction", "OBSERVATION", 73, 83]]], ["The patient who underwent uncemented hip hemiarthroplasty(1.3%) had a periprosthetic fracture which was managed conservatively.", [["hip", "ANATOMY", 37, 40], ["fracture", "DISEASE", 85, 93], ["patient", "ORGANISM", 4, 11], ["hip", "ORGANISM_SUBDIVISION", 37, 40], ["patient", "SPECIES", 4, 11], ["uncemented hip hemiarthroplasty", "TREATMENT", 26, 57], ["a periprosthetic fracture", "PROBLEM", 68, 93], ["uncemented", "OBSERVATION_MODIFIER", 26, 36], ["hip", "ANATOMY", 37, 40], ["hemiarthroplasty", "OBSERVATION", 41, 57], ["periprosthetic", "ANATOMY", 70, 84], ["fracture", "OBSERVATION", 85, 93]]], ["Twenty-four(32%) patients were admitted from their own home and 51 (68%) case came from aninstitution.ResultsThe baseline laboratory results between the two groups are given in (Table 2); c-reactiveprotein and white cell count were higher in the COVID-19 positive group with arelative lymphopaenia.ResultsAll COVID-19 positive cases had shown symptoms of fever and cough and receivedsupplemental oxygen, and all ten who died were hypoxic; all 20 positive patients hadundergone chest x-ray or/and chest computerised tomography (CT) to assess lunginvolvement, which showed seven (35%) cases had radiological lung findings of newpulmonary infiltrates, consistent with viral pneumonitis which resulted in mortality(70% of mortality, Figure2).", [["white cell", "ANATOMY", 210, 220], ["lung", "ANATOMY", 606, 610], ["newpulmonary infiltrates", "ANATOMY", 623, 647], ["lymphopaenia", "DISEASE", 285, 297], ["fever", "DISEASE", 355, 360], ["cough", "DISEASE", 365, 370], ["oxygen", "CHEMICAL", 396, 402], ["lunginvolvement", "DISEASE", 541, 556], ["pneumonitis", "DISEASE", 671, 682], ["oxygen", "CHEMICAL", 396, 402], ["patients", "ORGANISM", 17, 25], ["c-reactiveprotein", "GENE_OR_GENE_PRODUCT", 188, 205], ["white cell", "CELL", 210, 220], ["oxygen", "SIMPLE_CHEMICAL", 396, 402], ["patients", "ORGANISM", 455, 463], ["lung", "ORGAN", 606, 610], ["newpulmonary infiltrates", "PATHOLOGICAL_FORMATION", 623, 647], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 455, 463], ["c-reactiveprotein", "TEST", 188, 205], ["white cell count", "TEST", 210, 226], ["the COVID", "TEST", 242, 251], ["arelative lymphopaenia", "PROBLEM", 275, 297], ["All COVID", "TEST", 305, 314], ["symptoms", "PROBLEM", 343, 351], ["fever", "PROBLEM", 355, 360], ["cough", "PROBLEM", 365, 370], ["receivedsupplemental oxygen", "TREATMENT", 375, 402], ["hypoxic", "PROBLEM", 430, 437], ["chest x-ray", "TEST", 477, 488], ["chest computerised tomography", "TEST", 496, 525], ["CT", "TEST", 527, 529], ["lunginvolvement", "TEST", 541, 556], ["radiological lung findings", "PROBLEM", 593, 619], ["newpulmonary infiltrates", "PROBLEM", 623, 647], ["viral pneumonitis", "PROBLEM", 665, 682], ["lymphopaenia", "OBSERVATION", 285, 297], ["fever", "OBSERVATION", 355, 360], ["cough", "OBSERVATION", 365, 370], ["chest", "ANATOMY", 477, 482], ["chest", "ANATOMY", 496, 501], ["lung", "ANATOMY", 606, 610], ["newpulmonary", "ANATOMY", 623, 635], ["infiltrates", "OBSERVATION", 636, 647], ["consistent with", "UNCERTAINTY", 649, 664], ["viral", "OBSERVATION_MODIFIER", 665, 670], ["pneumonitis", "OBSERVATION", 671, 682]]], ["None of the ten survivors had features of viral pneumonitis on imagingand 7/20 (35%) received antibacterial therapy.DiscussionThis study presents the first evidence of high (50%) 30-day mortality in fragilityhip fractures associated with COVID-19 infection.", [["pneumonitis", "DISEASE", 48, 59], ["fractures", "DISEASE", 212, 221], ["COVID-19", "CHEMICAL", 238, 246], ["infection", "DISEASE", 247, 256], ["viral pneumonitis", "PROBLEM", 42, 59], ["imagingand", "TEST", 63, 73], ["antibacterial therapy", "TREATMENT", 94, 115], ["This study", "TEST", 126, 136], ["fragilityhip fractures", "PROBLEM", 199, 221], ["COVID-19 infection", "PROBLEM", 238, 256], ["viral", "OBSERVATION_MODIFIER", 42, 47], ["pneumonitis", "OBSERVATION", 48, 59], ["high", "OBSERVATION_MODIFIER", 168, 172], ["fractures", "OBSERVATION", 212, 221], ["infection", "OBSERVATION", 247, 256]]], ["Recent estimates based on datafrom China predict an overall case fatality of 6.4% in those aged over 65 years and13.4% in over 85 years group.2 A population-based study in the UK, including more than 3.8million subjects, projects an estimate of 4.4% 1-year mortality rate in high riskgroups.16 Further findings were an expected death rate of 9.7% in over85 years of age without co-morbidities, which increases to 21.7% in those over85 years and have more than three co-morbidities.", [["death", "DISEASE", 328, 333], ["A population-based study", "TEST", 144, 168], ["mortality rate", "TEST", 257, 271], ["an expected death rate", "TEST", 316, 338], ["co-morbidities", "PROBLEM", 378, 392], ["high riskgroups", "OBSERVATION_MODIFIER", 275, 290]]], ["The average time to death fromadmission was 19.8 days in our study.", [["death", "DISEASE", 20, 25], ["our study", "TEST", 57, 66]]], ["Similar findings have been reported from theChinese mainland with mean time from disease onset to death of 17.8 days.2,17DiscussionThe COVID-19 virus causes a two-phase immune response.18 The second phase, cytokinerelease syndrome (CRS) which develops after the first week, causes immune-mediatedlung damage and/or multi-organ failure, and leads to death.", [["multi-organ", "ANATOMY", 315, 326], ["death", "DISEASE", 98, 103], ["cytokinerelease syndrome", "DISEASE", 206, 230], ["CRS", "DISEASE", 232, 235], ["multi-organ failure", "DISEASE", 315, 334], ["death", "DISEASE", 349, 354], ["COVID-19 virus", "ORGANISM", 135, 149], ["multi-organ", "ORGAN", 315, 326], ["COVID-19 virus", "SPECIES", 135, 149], ["The COVID", "TEST", 131, 140], ["cytokinerelease syndrome", "PROBLEM", 206, 230], ["CRS", "PROBLEM", 232, 235], ["immune-mediatedlung damage", "PROBLEM", 281, 307], ["multi-organ failure", "PROBLEM", 315, 334], ["death", "PROBLEM", 349, 354], ["mediatedlung damage", "OBSERVATION", 288, 307], ["multi-organ", "ANATOMY", 315, 326], ["failure", "OBSERVATION", 327, 334]]], ["CRS is mediated byleukocytes other than lymphocytes and this leads to leucocytosis associated withlymphopenia.", [["byleukocytes", "ANATOMY", 16, 28], ["lymphocytes", "ANATOMY", 40, 51], ["CRS", "DISEASE", 0, 3], ["leucocytosis", "DISEASE", 70, 82], ["withlymphopenia", "DISEASE", 94, 109], ["byleukocytes", "CELL", 16, 28], ["lymphocytes", "CELL", 40, 51], ["lymphocytes", "CELL_TYPE", 40, 51], ["CRS", "PROBLEM", 0, 3], ["mediated byleukocytes", "PROBLEM", 7, 28], ["lymphocytes", "PROBLEM", 40, 51], ["leucocytosis associated withlymphopenia", "PROBLEM", 70, 109], ["leucocytosis", "OBSERVATION", 70, 82], ["withlymphopenia", "OBSERVATION", 94, 109]]], ["In our study, COVID-19 positive patients had higher mean leukocytecounts and lower mean lymphocytes count compared to COVID-19 negative patients.Various studies have shown that surgery following trauma acts as a \u2018\u2018second hit\u2019\u2019and induces a strong proinflammatory response.19,20 We have postulated that in hipfractures associated with COVID-19 infection there are three potential hits, trauma,COVID-19 infection and surgery.", [["lymphocytes", "ANATOMY", 88, 99], ["trauma", "DISEASE", 195, 201], ["hipfractures", "DISEASE", 305, 317], ["infection", "DISEASE", 343, 352], ["trauma", "DISEASE", 385, 391], ["infection", "DISEASE", 401, 410], ["COVID-19", "GENE_OR_GENE_PRODUCT", 14, 22], ["patients", "ORGANISM", 32, 40], ["lymphocytes", "CELL", 88, 99], ["patients", "ORGANISM", 136, 144], ["hipfractures", "CANCER", 305, 317], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 136, 144], ["COVID-19", "SPECIES", 334, 342], ["our study", "TEST", 3, 12], ["COVID", "TEST", 14, 19], ["higher mean leukocytecounts", "PROBLEM", 45, 72], ["lower mean lymphocytes count", "PROBLEM", 77, 105], ["COVID", "TEST", 118, 123], ["Various studies", "TEST", 145, 160], ["surgery", "TREATMENT", 177, 184], ["a strong proinflammatory response", "PROBLEM", 238, 271], ["COVID-19 infection", "PROBLEM", 334, 352], ["trauma", "PROBLEM", 385, 391], ["COVID-19 infection", "PROBLEM", 392, 410], ["surgery", "TREATMENT", 415, 422], ["lower", "OBSERVATION_MODIFIER", 77, 82], ["mean lymphocytes count", "OBSERVATION", 83, 105], ["infection", "OBSERVATION", 343, 352], ["infection", "OBSERVATION", 401, 410]]], ["Hip fracture surgery may act as a \u2018\u2018third hit\u2019\u2019 thatboost the hyper immune state caused by COVID-19 virus which may be a major factor inthe increased mortality.", [["Hip", "ANATOMY", 0, 3], ["fracture", "DISEASE", 4, 12], ["COVID-19 virus", "CHEMICAL", 91, 105], ["COVID-19 virus", "ORGANISM", 91, 105], ["COVID-19 virus", "SPECIES", 91, 105], ["Hip fracture", "PROBLEM", 0, 12], ["surgery", "TREATMENT", 13, 20], ["the hyper immune state", "PROBLEM", 58, 80], ["COVID-19 virus", "PROBLEM", 91, 105], ["increased mortality", "PROBLEM", 140, 159], ["fracture", "OBSERVATION", 4, 12], ["increased", "OBSERVATION_MODIFIER", 140, 149], ["mortality", "OBSERVATION", 150, 159]]], ["A recently published trial involving 6425 patients hasshown that the immunosuppressant dexamethasone significantly reduced the death ratein COVID-19 positive patients,21 supporting the theory of ahyperimmune reaction leading to higher mortality rates in COVID-19 patients.DiscussionWe observed radiological evidence of viral pneumonitis in 35% of patients proven tobe COVID-19 positive, all of whom died; interestingly, all COVID-19 positivesurvivors had normal chest x-rays, suggesting that CXR findings of viral pneumonitiscould be an indicator of mortality.", [["chest", "ANATOMY", 462, 467], ["dexamethasone", "CHEMICAL", 87, 100], ["death", "DISEASE", 127, 132], ["ahyperimmune reaction", "DISEASE", 195, 216], ["viral pneumonitis", "DISEASE", 319, 336], ["viral pneumonitiscould", "DISEASE", 508, 530], ["dexamethasone", "CHEMICAL", 87, 100], ["patients", "ORGANISM", 42, 50], ["dexamethasone", "SIMPLE_CHEMICAL", 87, 100], ["COVID-19", "GENE_OR_GENE_PRODUCT", 140, 148], ["patients", "ORGANISM", 158, 166], ["patients", "ORGANISM", 263, 271], ["patients", "ORGANISM", 347, 355], ["chest", "ORGAN", 462, 467], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 158, 166], ["patients", "SPECIES", 263, 271], ["patients", "SPECIES", 347, 355], ["the immunosuppressant dexamethasone", "TREATMENT", 65, 100], ["the death ratein COVID", "TEST", 123, 145], ["ahyperimmune reaction", "PROBLEM", 195, 216], ["viral pneumonitis", "PROBLEM", 319, 336], ["all COVID", "TEST", 420, 429], ["CXR", "TEST", 492, 495], ["viral pneumonitiscould", "PROBLEM", 508, 530], ["evidence of", "UNCERTAINTY", 307, 318], ["viral", "OBSERVATION_MODIFIER", 319, 324], ["pneumonitis", "OBSERVATION", 325, 336], ["chest", "ANATOMY", 462, 467], ["viral pneumonitiscould", "OBSERVATION", 508, 530]]], ["The main presenting symptoms in our study werecough and fever.", [["fever", "DISEASE", 56, 61], ["The main presenting symptoms", "PROBLEM", 0, 28], ["our study", "TEST", 32, 41], ["fever", "PROBLEM", 56, 61], ["main", "OBSERVATION_MODIFIER", 4, 8], ["symptoms", "OBSERVATION", 20, 28], ["fever", "OBSERVATION", 56, 61]]], ["Reports from China found that cough, fever and sore throat were themost common presenting feature of COVID-19 infection.22,23 Mi et al. studied ten patientswho died due to COVID-19 associated with orthopaedic fractures, six of thempresenting with hip fractures;24 60% of their patients hadlymphopenia, similar to our findings.LimitationsThe limitations of this study include its retrospective nature, relatively smallsample size, and potential confounders for mortality.", [["hip", "ANATOMY", 247, 250], ["cough", "DISEASE", 30, 35], ["fever", "DISEASE", 37, 42], ["sore throat", "DISEASE", 47, 58], ["COVID-19", "CHEMICAL", 101, 109], ["infection", "DISEASE", 110, 119], ["COVID", "DISEASE", 172, 177], ["fractures", "DISEASE", 209, 218], ["fractures", "DISEASE", 251, 260], ["hadlymphopenia", "DISEASE", 286, 300], ["COVID-19", "CELL", 101, 109], ["hip", "ORGANISM_SUBDIVISION", 247, 250], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 277, 285], ["COVID-19", "SPECIES", 101, 109], ["cough", "PROBLEM", 30, 35], ["fever", "PROBLEM", 37, 42], ["sore throat", "PROBLEM", 47, 58], ["COVID-19 infection", "PROBLEM", 101, 119], ["Mi et al", "PROBLEM", 126, 134], ["COVID", "TEST", 172, 177], ["orthopaedic fractures", "PROBLEM", 197, 218], ["hip fractures", "PROBLEM", 247, 260], ["their patients hadlymphopenia", "PROBLEM", 271, 300], ["this study", "TEST", 356, 366], ["mortality", "PROBLEM", 460, 469], ["cough", "OBSERVATION", 30, 35], ["sore throat", "ANATOMY", 47, 58], ["infection", "OBSERVATION", 110, 119], ["fractures", "OBSERVATION", 209, 218], ["hip", "ANATOMY", 247, 250], ["fractures", "OBSERVATION", 251, 260], ["smallsample", "OBSERVATION_MODIFIER", 412, 423], ["size", "OBSERVATION_MODIFIER", 424, 428]]], ["To improve the sample size,data has been collected from two different units.", [["sample", "ANATOMY", 15, 21], ["the sample size", "TEST", 11, 26], ["size", "OBSERVATION_MODIFIER", 22, 26]]], ["Due to small sample size, we havenot used statistical tests as it may result in false positive findings.", [["small sample size", "PROBLEM", 7, 24], ["statistical tests", "TEST", 42, 59], ["false positive findings", "PROBLEM", 80, 103], ["small", "OBSERVATION_MODIFIER", 7, 12], ["sample", "OBSERVATION_MODIFIER", 13, 19], ["size", "OBSERVATION_MODIFIER", 20, 24], ["false positive", "OBSERVATION", 80, 94]]], ["However, ourstudy reported a clinically important difference in the 30-day mortality betweenCOVID-19 positive and COVID-19 negative hip fractures patients.", [["hip", "ANATOMY", 132, 135], ["fractures", "DISEASE", 136, 145], ["patients", "ORGANISM", 146, 154], ["patients", "SPECIES", 146, 154], ["mortality betweenCOVID", "TEST", 75, 97], ["COVID", "TEST", 114, 119], ["hip fractures patients", "PROBLEM", 132, 154], ["hip", "ANATOMY", 132, 135], ["fractures", "OBSERVATION", 136, 145]]], ["We have postulated a\u2018\u2018third hit\u2019\u2019 theory, however, further research will be needed to assess the immuneresponse before and after surgery in hip fractures associated with COVID-19infection.ConclusionOn the basis of our study, hip fractures associated with COVID-19 infection have ahigh 30-day mortality.", [["hip", "ANATOMY", 140, 143], ["hip", "ANATOMY", 225, 228], ["fractures", "DISEASE", 144, 153], ["COVID-19infection", "CHEMICAL", 170, 187], ["fractures", "DISEASE", 229, 238], ["COVID-19", "CHEMICAL", 255, 263], ["infection", "DISEASE", 264, 273], ["hip", "ORGANISM_SUBDIVISION", 140, 143], ["hip", "ORGANISM_SUBDIVISION", 225, 228], ["surgery", "TREATMENT", 129, 136], ["hip fractures", "PROBLEM", 140, 153], ["COVID-19infection", "PROBLEM", 170, 187], ["our study", "TEST", 214, 223], ["hip fractures", "PROBLEM", 225, 238], ["COVID-19 infection", "PROBLEM", 255, 273], ["hip", "ANATOMY", 140, 143], ["fractures", "OBSERVATION", 144, 153], ["hip", "ANATOMY", 225, 228], ["fractures", "OBSERVATION", 229, 238], ["infection", "OBSERVATION", 264, 273]]], ["Whilst we suggest that mortality is greater in the COVIDpositive group, the numbers are very small in comparison to other recent publishedworks on the topic in which over 6000 patients are included.", [["patients", "ORGANISM", 176, 184], ["patients", "SPECIES", 176, 184], ["greater", "OBSERVATION_MODIFIER", 36, 43], ["very", "OBSERVATION_MODIFIER", 88, 92], ["small", "OBSERVATION_MODIFIER", 93, 98]]], ["Our findings may justbe chance but we believe they are suggestive of a higher mortality when set againstcontemporary practices seen in the fight against the virus.", [["a higher mortality", "PROBLEM", 69, 87], ["the virus", "PROBLEM", 153, 162], ["suggestive of", "UNCERTAINTY", 55, 68], ["higher", "OBSERVATION_MODIFIER", 71, 77], ["mortality", "OBSERVATION", 78, 87], ["virus", "OBSERVATION", 157, 162]]], ["Delayed surgery orconservative treatment can be adopted to avoid the \u2018\u2018third hit\u2019\u2019.", [["Delayed surgery orconservative treatment", "TREATMENT", 0, 40]]], ["We have adopted aprotocol of COVID-19 testing and CXR, for all patients presenting with hip fracturesin our unit.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["COVID", "TEST", 29, 34], ["CXR", "TEST", 50, 53], ["hip", "ANATOMY", 88, 91]]], ["This helps in risk stratification and early planning of high-risksurgeries and allows counselling of the patients and family using realisticprognosis.", [["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["high-risksurgeries", "TREATMENT", 56, 74]]], ["This study should open a door for nation-wide studies of COVID-19 viruseffect on hip fractures.", [["hip", "ANATOMY", 81, 84], ["fractures", "DISEASE", 85, 94], ["hip", "ORGANISM_SUBDIVISION", 81, 84], ["This study", "TEST", 0, 10], ["wide studies", "TEST", 41, 53], ["COVID", "TEST", 57, 62], ["hip fractures", "PROBLEM", 81, 94], ["hip", "ANATOMY", 81, 84], ["fractures", "OBSERVATION", 85, 94]]]], "9bf5346fef8c0da9fd066c6dea9ce1d5e22c1dee": [["IntroductionOn March 11, 2020 , the World Health Organization declared that the outbreak of coronavirus disease 2019 (COVID-19) is a global pandemic.", [["coronavirus disease", "DISEASE", 92, 111], ["COVID-19", "CHEMICAL", 118, 126], ["coronavirus", "ORGANISM", 92, 103], ["coronavirus disease", "PROBLEM", 92, 111], ["COVID", "TEST", 118, 123], ["a global pandemic", "PROBLEM", 131, 148], ["coronavirus disease", "OBSERVATION", 92, 111], ["global", "OBSERVATION_MODIFIER", 133, 139], ["pandemic", "OBSERVATION", 140, 148]]], ["The decision came as a result of 120,000 COVID-19 infections and 4,300 deaths worldwide.", [["infections", "DISEASE", 50, 60], ["deaths", "DISEASE", 71, 77]]], ["Currently, there are no established treatments other than supportive therapies that treat the symptoms of COVID-19.", [["COVID", "DISEASE", 106, 111], ["COVID-19", "CHEMICAL", 106, 114], ["established treatments", "TREATMENT", 24, 46], ["supportive therapies", "TREATMENT", 58, 78], ["the symptoms", "PROBLEM", 90, 102], ["COVID", "TEST", 106, 111], ["no", "UNCERTAINTY", 21, 23]]], ["However, as COVID-19 is a viral infectious disease caused by SARS-CoV-2, 1 some antiviral agents have been used for treatment.", [["COVID-19", "CHEMICAL", 12, 20], ["viral infectious disease", "DISEASE", 26, 50], ["COVID-19", "GENE_OR_GENE_PRODUCT", 12, 20], ["SARS-CoV-2", "ORGANISM", 61, 71], ["COVID-19", "SPECIES", 12, 20], ["SARS-CoV", "SPECIES", 61, 69], ["COVID", "TEST", 12, 17], ["a viral infectious disease", "PROBLEM", 24, 50], ["SARS", "PROBLEM", 61, 65], ["CoV", "TEST", 66, 69], ["some antiviral agents", "TREATMENT", 75, 96], ["treatment", "TREATMENT", 116, 125], ["viral", "OBSERVATION_MODIFIER", 26, 31], ["infectious", "OBSERVATION", 32, 42]]], ["Antiviral agents such as lopinavir-ritonavir, chloroquine (including hydroxychloroquine), remdesivir, umifenovir, and ribavirin are being used, and clinical trials are ongoing.", [["lopinavir-ritonavir", "CHEMICAL", 25, 44], ["chloroquine", "CHEMICAL", 46, 57], ["hydroxychloroquine", "CHEMICAL", 69, 87], ["remdesivir", "CHEMICAL", 90, 100], ["umifenovir", "CHEMICAL", 102, 112], ["ribavirin", "CHEMICAL", 118, 127], ["lopinavir", "CHEMICAL", 25, 34], ["ritonavir", "CHEMICAL", 35, 44], ["chloroquine", "CHEMICAL", 46, 57], ["hydroxychloroquine", "CHEMICAL", 69, 87], ["remdesivir", "CHEMICAL", 90, 100], ["umifenovir", "CHEMICAL", 102, 112], ["ribavirin", "CHEMICAL", 118, 127], ["lopinavir", "SIMPLE_CHEMICAL", 25, 34], ["ritonavir", "SIMPLE_CHEMICAL", 35, 44], ["chloroquine", "SIMPLE_CHEMICAL", 46, 57], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 69, 87], ["remdesivir", "SIMPLE_CHEMICAL", 90, 100], ["umifenovir", "SIMPLE_CHEMICAL", 102, 112], ["ribavirin", "SIMPLE_CHEMICAL", 118, 127], ["Antiviral agents", "TREATMENT", 0, 16], ["lopinavir", "TREATMENT", 25, 34], ["ritonavir", "TREATMENT", 35, 44], ["chloroquine", "TREATMENT", 46, 57], ["hydroxychloroquine", "TREATMENT", 69, 87], ["remdesivir", "TREATMENT", 90, 100], ["umifenovir", "TREATMENT", 102, 112], ["ribavirin", "TREATMENT", 118, 127]]], ["2 However, clinical trials of lopinavir-ritonavir (a combination of the HIV protease inhibitors) in patients admitted with severe COVID-19 did not show a significant effect.", [["lopinavir-ritonavir", "CHEMICAL", 30, 49], ["lopinavir", "CHEMICAL", 30, 39], ["ritonavir", "CHEMICAL", 40, 49], ["COVID-19", "CHEMICAL", 130, 138], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 30, 49], ["HIV", "ORGANISM", 72, 75], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["HIV", "SPECIES", 72, 75], ["lopinavir", "TREATMENT", 30, 39], ["ritonavir", "TREATMENT", 40, 49], ["the HIV protease inhibitors", "TREATMENT", 68, 95], ["severe COVID", "PROBLEM", 123, 135], ["significant", "OBSERVATION_MODIFIER", 154, 165], ["effect", "OBSERVATION", 166, 172]]], ["3 In addition, ribavirin is known to have specific adverse effects such as psychiatric problems, 4 making it unsuitable as a first-choice medication.", [["ribavirin", "CHEMICAL", 15, 24], ["psychiatric", "DISEASE", 75, 86], ["ribavirin", "CHEMICAL", 15, 24], ["ribavirin", "SIMPLE_CHEMICAL", 15, 24], ["ribavirin", "TREATMENT", 15, 24], ["psychiatric problems", "PROBLEM", 75, 95], ["a first-choice medication", "TREATMENT", 123, 148], ["ribavirin", "OBSERVATION", 15, 24]]], ["Clinical trials involving remdesivir and chloroquine are still in progress.", [["remdesivir", "CHEMICAL", 26, 36], ["chloroquine", "CHEMICAL", 41, 52], ["remdesivir", "CHEMICAL", 26, 36], ["chloroquine", "CHEMICAL", 41, 52], ["remdesivir", "SIMPLE_CHEMICAL", 26, 36], ["chloroquine", "SIMPLE_CHEMICAL", 41, 52], ["Clinical trials", "TREATMENT", 0, 15], ["remdesivir", "TREATMENT", 26, 36], ["chloroquine", "TREATMENT", 41, 52]]], ["In addition to treatment with antiviral agents, interferons, steroids, intravenous immunoglobulin, antibiotics, and convalescent blood plasma are used depending on the patient's condition.", [["intravenous", "ANATOMY", 71, 82], ["blood plasma", "ANATOMY", 129, 141], ["steroids", "CHEMICAL", 61, 69], ["steroids", "CHEMICAL", 61, 69], ["steroids", "SIMPLE_CHEMICAL", 61, 69], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 71, 97], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["plasma", "ORGANISM_SUBSTANCE", 135, 141], ["patient", "ORGANISM", 168, 175], ["interferons", "PROTEIN", 48, 59], ["patient", "SPECIES", 168, 175], ["treatment", "TREATMENT", 15, 24], ["antiviral agents", "TREATMENT", 30, 46], ["interferons", "TREATMENT", 48, 59], ["steroids", "TREATMENT", 61, 69], ["intravenous immunoglobulin", "TREATMENT", 71, 97], ["antibiotics", "TREATMENT", 99, 110], ["convalescent blood plasma", "TREATMENT", 116, 141]]], ["2 There is no conclusive evidence that these antiviral agents and other treatments are effective against COVID-19.", [["these antiviral agents", "TREATMENT", 39, 61], ["other treatments", "TREATMENT", 66, 82], ["COVID", "TEST", 105, 110], ["no conclusive evidence", "UNCERTAINTY", 11, 33], ["antiviral", "OBSERVATION", 45, 54]]], ["2 Consequently, there is a need to search for candidate drugs other than conventional therapies.IntroductionIn this situation, China, the first country to experience COVID-19, has used traditional Chinese herbal medicine (TCHM) for the prevention and treatment of COVID-19 based on the experience of using TCHMs during the past epidemic of Severe Acute Respiratory Syndrome (SARS).", [["TCHM", "CHEMICAL", 222, 226], ["TCHMs", "CHEMICAL", 306, 311], ["Acute Respiratory Syndrome", "DISEASE", 347, 373], ["SARS", "DISEASE", 375, 379], ["candidate drugs", "TREATMENT", 46, 61], ["conventional therapies", "TREATMENT", 73, 95], ["COVID", "TEST", 166, 171], ["traditional Chinese herbal medicine", "TREATMENT", 185, 220], ["COVID", "TREATMENT", 264, 269], ["TCHMs", "TREATMENT", 306, 311], ["Severe Acute Respiratory Syndrome", "PROBLEM", 340, 373], ["Severe", "OBSERVATION_MODIFIER", 340, 346], ["Acute", "OBSERVATION_MODIFIER", 347, 352], ["Respiratory Syndrome", "OBSERVATION", 353, 373]]], ["5, 6 In the Chinese Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-Induced Pneumonia (7 th Edition), 7 Qingfei Paidu Tang (QPT) has been suggested as a herbal medicine that can be used regardless of the stage of the disease, along with prescriptions for herbal medicines that are stage-specific.", [["Pneumonia", "DISEASE", 105, 114], ["QPT", "CHEMICAL", 153, 156], ["Novel Coronavirus", "PROBLEM", 79, 96], ["Pneumonia", "PROBLEM", 105, 114], ["a herbal medicine", "TREATMENT", 180, 197], ["the disease", "PROBLEM", 242, 253], ["prescriptions", "TREATMENT", 266, 279], ["herbal medicines", "TREATMENT", 284, 300], ["Pneumonia", "OBSERVATION", 105, 114], ["disease", "OBSERVATION", 246, 253]]], ["Based on this guideline, herbal medicine treatment has been used in more than 50% of confirmed patients with COVID-19 in J o u r n a l P r e -p r o o f a region.", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["this guideline", "TREATMENT", 9, 23], ["herbal medicine treatment", "TREATMENT", 25, 50], ["COVID", "TEST", 109, 114], ["a region", "PROBLEM", 152, 160], ["region", "ANATOMY_MODIFIER", 154, 160]]], ["8 In a recent study aimed at evaluation of the combined effect of herbal medicine and conventional treatments, the rate of symptom loss at discharge, the rate of chest computed tomography (CT) image improvement, and the rate of clinical cure were significantly improved and the rate of disease exacerbation was significantly decreased compared with those after conventional treatments only.", [["a recent study", "TEST", 5, 19], ["evaluation", "TEST", 29, 39], ["herbal medicine", "TREATMENT", 66, 81], ["conventional treatments", "TREATMENT", 86, 109], ["symptom loss", "PROBLEM", 123, 135], ["chest computed tomography", "TEST", 162, 187], ["CT) image", "TEST", 189, 198], ["disease exacerbation", "PROBLEM", 286, 306], ["conventional treatments", "TREATMENT", 361, 384], ["chest", "ANATOMY", 162, 167], ["disease", "OBSERVATION", 286, 293], ["significantly", "OBSERVATION_MODIFIER", 311, 324], ["decreased", "OBSERVATION_MODIFIER", 325, 334]]], ["9 In addition, clinical trials of various oral medications and injections based on herbal medicine are underway in China.", [["oral", "ANATOMY", 42, 46], ["oral", "ORGANISM_SUBDIVISION", 42, 46], ["various oral medications", "TREATMENT", 34, 58], ["injections", "TREATMENT", 63, 73], ["herbal medicine", "TREATMENT", 83, 98]]], ["10 In this short narrative review, we will discuss the current clinical use and antiviral effects of Soshihotang (SSHT, Xiao Chai Hu Tang in Chinese, Shosaikoto in Japanese), which has been used in the past mainly for infectious diseases with chronic progression.", [["Soshihotang", "CHEMICAL", 101, 112], ["infectious diseases", "DISEASE", 218, 237], ["Soshihotang", "SIMPLE_CHEMICAL", 101, 112], ["Soshihotang (SSHT", "TREATMENT", 101, 118], ["Xiao", "TREATMENT", 120, 124], ["infectious diseases", "PROBLEM", 218, 237], ["chronic progression", "PROBLEM", 243, 262], ["chronic", "OBSERVATION_MODIFIER", 243, 250], ["progression", "OBSERVATION_MODIFIER", 251, 262]]], ["In addition, we suggest the possibility of utilizing SSHT as a new therapeutic option for COVID-19.MethodsFor conducting the present review, we searched electronic databases (PubMed, Scopus, Recens, Zizyphi Fructus, Glycyrrhizae Radix et Rhizoma, and antiviral effect.", [["SSHT", "CHEMICAL", 53, 57], ["Glycyrrhizae Radix et Rhizoma", "CHEMICAL", 216, 245], ["SSHT", "SIMPLE_CHEMICAL", 53, 57], ["SSHT", "TREATMENT", 53, 57], ["COVID", "TEST", 90, 95], ["Zizyphi Fructus", "TREATMENT", 199, 214], ["Glycyrrhizae Radix et Rhizoma", "TREATMENT", 216, 245], ["antiviral effect", "TREATMENT", 251, 267], ["suggest the possibility", "UNCERTAINTY", 16, 39], ["Glycyrrhizae Radix", "ANATOMY", 216, 234], ["antiviral effect", "OBSERVATION", 251, 267]]], ["There was no language restriction in the searching process.", [["language restriction", "PROBLEM", 13, 33], ["no", "UNCERTAINTY", 10, 12], ["language restriction", "OBSERVATION", 13, 33]]], ["In addition to searching for electronic databases, we also searched for materials related to topic directly from websites and published books.MethodsBased on the search results, we summarized the following items in the form of a narrative review; i) indications of SSHT in classical medicine and in symptoms of COVID-19, ii) utilization status and clinical evidence of SSHT in infectious diseases, especially viral diseases, iii) antiviral effect of SSHT in experimental studies, iv) potential role of SSHT in repurposing J o u r n a l P r e -p r o o f the treatment of COVID-19, v) SSHT variants that can be used according to various clinical symptoms, and vi) cautions when using SSHT.ResultsThrough the electronic databases search, we found articles evaluating the clinical usefulness of SSHT for infectious diseases, especially viral diseases (n=11), [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] and experimental studies (n=21) for antiviral effects of SSHT and its constituents.", [["COVID-19", "CHEMICAL", 311, 319], ["infectious diseases", "DISEASE", 377, 396], ["viral diseases", "DISEASE", 409, 423], ["SSHT", "CHEMICAL", 450, 454], ["SSHT", "CHEMICAL", 791, 795], ["infectious diseases", "DISEASE", 800, 819], ["viral diseases", "DISEASE", 832, 846], ["[11] [12] [13] [14] [15] [16] [17] [18] [19] [20", "CHEMICAL", 855, 903], ["SSHT", "CHEMICAL", 967, 971], ["COVID-19", "CHEMICAL", 311, 319], ["COVID-19", "CHEMICAL", 570, 578], ["SSHT", "CHEMICAL", 967, 971], ["SSHT", "GENE_OR_GENE_PRODUCT", 583, 587], ["[11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 855, 909], ["SSHT", "SIMPLE_CHEMICAL", 967, 971], ["electronic databases", "TEST", 29, 49], ["symptoms", "PROBLEM", 299, 307], ["COVID", "TEST", 311, 316], ["SSHT in infectious diseases", "PROBLEM", 369, 396], ["viral diseases", "PROBLEM", 409, 423], ["SSHT", "TREATMENT", 450, 454], ["SSHT", "TREATMENT", 502, 506], ["a l P r e -p", "TREATMENT", 532, 544], ["the treatment", "TREATMENT", 553, 566], ["COVID", "TEST", 570, 575], ["various clinical symptoms", "PROBLEM", 627, 652], ["infectious diseases", "PROBLEM", 800, 819], ["viral diseases", "PROBLEM", 832, 846], ["experimental studies", "TEST", 914, 934], ["antiviral effects of SSHT", "PROBLEM", 946, 971], ["infectious", "OBSERVATION", 377, 387]]], ["In addition to these, we wrote this review using articles found through direct searches on websites and published books.Indications of SSHT in classical medicine and in symptoms of COVID-19SSHT is a traditional herbal medicine prescription that consists of a total of seven herbs (Bupleuri Radix, Scutellariae Radix, Pinelliae Tuber, Ginseng Radix, Zingiberis Rhizoma Recens, Zizyphi Fructus, and Glycyrrhizae Radix et Rhizoma) ( Table 1 43 ).", [["SSHT", "CHEMICAL", 135, 139], ["COVID-19SSHT", "CHEMICAL", 181, 193], ["Bupleuri Radix, Scutellariae Radix, Pinelliae Tuber, Ginseng Radix, Zingiberis Rhizoma Recens, Zizyphi Fructus", "CHEMICAL", 281, 391], ["Bupleuri Radix", "ORGANISM", 281, 295], ["Scutellariae Radix", "ORGANISM", 297, 315], ["Pinelliae Tuber", "ORGANISM", 317, 332], ["Ginseng Radix", "ORGANISM", 334, 347], ["Ginseng", "SPECIES", 334, 341], ["Zingiberis Rhizoma", "SPECIES", 349, 367], ["Zingiberis Rhizoma Recens", "SPECIES", 349, 374], ["SSHT", "TREATMENT", 135, 139], ["symptoms", "PROBLEM", 169, 177], ["a traditional herbal medicine prescription", "TREATMENT", 197, 239], ["seven herbs", "TREATMENT", 268, 279], ["Bupleuri Radix", "TREATMENT", 281, 295], ["Scutellariae Radix", "TREATMENT", 297, 315], ["Pinelliae Tuber", "TREATMENT", 317, 332], ["Ginseng Radix", "TREATMENT", 334, 347], ["Zingiberis Rhizoma", "TREATMENT", 349, 367], ["Zizyphi Fructus", "TREATMENT", 376, 391], ["Glycyrrhizae Radix et Rhizoma", "TREATMENT", 397, 426], ["Scutellariae Radix", "ANATOMY", 297, 315]]], ["SSHT appeared first in Shanghan Zabing Lun, a classic of traditional East Asian medicine that is thought to have been published before AD 220.", [["SSHT", "DISEASE", 0, 4]]], ["44 One part of Shanghan Zabing Lun is Shanghan Lun, translated as \"Treatise on Cold-induced Diseases\"-a medical classic that contains traditional medical treatments for infectious diseases with fever.", [["infectious diseases", "DISEASE", 169, 188], ["fever", "DISEASE", 194, 199], ["traditional medical treatments", "TREATMENT", 134, 164], ["infectious diseases", "PROBLEM", 169, 188], ["fever", "PROBLEM", 194, 199]]], ["In Shanghan Lun infectious diseases are categorized as \"greater yang,\" \"lesser yang,\" \"yang brightness,\" \"greater yin,\" \"lesser yin,\" or \"reverting yin\" according to the stage of disease progression, and the text describes the indications and the prescriptions that could be used at each stage.", [["infectious diseases", "DISEASE", 16, 35], ["Lun infectious diseases", "PROBLEM", 12, 35], ["disease progression", "PROBLEM", 179, 198], ["the prescriptions", "TREATMENT", 243, 260], ["infectious", "OBSERVATION", 16, 26], ["disease", "OBSERVATION", 179, 186]]], ["45 SSHT has been classified as a representative prescription of \"lesser yang,\" but it is suggested as a prescription that can be used at almost any stage of the disease.", [["the disease", "PROBLEM", 157, 168], ["disease", "OBSERVATION", 161, 168]]], ["SSHT appears in several verses of Shanghan Lun, and the representative indications are as follows:Indications of SSHT in classical medicine and in symptoms of COVID-19-After suffering from zhong feng syndrome with cold damage for five or six days, there is alternating chills and fever, discomfort and fullness in the chest and hypochondriac region, taciturnity with no desire to eat, a sick and discomforting feeling in the stomach and easily vomiting with any of the following possible symptoms and signs; vexation in the chest and absence of vomiting, thirst, abdominal pain, fullness and hardening below the hypochondriac region, palpitation in the epigastrium and abnormal urination, absence of thirst and slight fever on the body or cough.", [["chest", "ANATOMY", 318, 323], ["hypochondriac region", "ANATOMY", 328, 348], ["stomach", "ANATOMY", 425, 432], ["chest", "ANATOMY", 524, 529], ["abdominal", "ANATOMY", 563, 572], ["hypochondriac region", "ANATOMY", 612, 632], ["epigastrium", "ANATOMY", 653, 664], ["body", "ANATOMY", 731, 735], ["SSHT", "DISEASE", 113, 117], ["zhong feng syndrome", "DISEASE", 189, 208], ["cold damage", "DISEASE", 214, 225], ["chills", "DISEASE", 269, 275], ["fever", "DISEASE", 280, 285], ["fullness", "DISEASE", 302, 310], ["taciturnity", "DISEASE", 350, 361], ["vomiting", "DISEASE", 444, 452], ["vomiting", "DISEASE", 545, 553], ["thirst", "DISEASE", 555, 561], ["abdominal pain", "DISEASE", 563, 577], ["fullness", "DISEASE", 579, 587], ["palpitation", "DISEASE", 634, 645], ["epigastrium", "DISEASE", 653, 664], ["abnormal urination", "DISEASE", 669, 687], ["absence of thirst", "DISEASE", 689, 706], ["fever", "DISEASE", 718, 723], ["cough", "DISEASE", 739, 744], ["chest", "ORGANISM_SUBDIVISION", 318, 323], ["stomach", "ORGAN", 425, 432], ["chest", "ORGANISM_SUBDIVISION", 524, 529], ["abdominal", "ORGANISM_SUBDIVISION", 563, 572], ["epigastrium", "CANCER", 653, 664], ["body", "ORGANISM_SUBDIVISION", 731, 735], ["SSHT", "TREATMENT", 113, 117], ["symptoms", "PROBLEM", 147, 155], ["COVID", "TEST", 159, 164], ["zhong feng syndrome", "PROBLEM", 189, 208], ["cold damage", "PROBLEM", 214, 225], ["alternating chills", "PROBLEM", 257, 275], ["fever", "PROBLEM", 280, 285], ["discomfort", "PROBLEM", 287, 297], ["fullness in the chest and hypochondriac region", "PROBLEM", 302, 348], ["a sick and discomforting feeling in the stomach", "PROBLEM", 385, 432], ["easily vomiting", "PROBLEM", 437, 452], ["symptoms", "PROBLEM", 488, 496], ["signs", "PROBLEM", 501, 506], ["vexation in the chest", "PROBLEM", 508, 529], ["vomiting", "PROBLEM", 545, 553], ["thirst", "PROBLEM", 555, 561], ["abdominal pain", "PROBLEM", 563, 577], ["fullness", "PROBLEM", 579, 587], ["hardening below the hypochondriac region", "PROBLEM", 592, 632], ["palpitation in the epigastrium", "PROBLEM", 634, 664], ["abnormal urination", "PROBLEM", 669, 687], ["thirst", "PROBLEM", 700, 706], ["slight fever on the body", "PROBLEM", 711, 735], ["cough", "PROBLEM", 739, 744], ["chills", "OBSERVATION", 269, 275], ["fullness", "OBSERVATION", 302, 310], ["chest", "ANATOMY", 318, 323], ["hypochondriac", "ANATOMY", 328, 341], ["region", "ANATOMY_MODIFIER", 342, 348], ["no", "UNCERTAINTY", 367, 369], ["stomach", "ANATOMY", 425, 432], ["chest", "ANATOMY", 524, 529], ["abdominal", "ANATOMY", 563, 572], ["pain", "OBSERVATION", 573, 577], ["fullness", "OBSERVATION", 579, 587], ["hypochondriac", "ANATOMY", 612, 625], ["region", "ANATOMY_MODIFIER", 626, 632], ["palpitation", "OBSERVATION", 634, 645], ["epigastrium", "ANATOMY", 653, 664], ["abnormal", "OBSERVATION_MODIFIER", 669, 677], ["urination", "OBSERVATION", 678, 687], ["slight", "OBSERVATION_MODIFIER", 711, 717], ["fever", "OBSERVATION", 718, 723], ["cough", "OBSERVATION", 739, 744]]], ["SSHT should be prescribed.", [["SSHT", "CHEMICAL", 0, 4], ["SSHT", "SIMPLE_CHEMICAL", 0, 4], ["SSHT", "TREATMENT", 0, 4]]], ["14 -In yang brightness disease, when there is tidal fever, loose stool, normal urination, and fullness in the chest and costal/hypochondriac region that has not abated, SSHT might be prescribed.", [["stool", "ANATOMY", 65, 70], ["chest", "ANATOMY", 110, 115], ["costal", "ANATOMY", 120, 126], ["fever", "DISEASE", 52, 57], ["stool", "ORGANISM_SUBSTANCE", 65, 70], ["chest", "ORGANISM_SUBDIVISION", 110, 115], ["costal", "ORGAN", 120, 126], ["yang brightness disease", "PROBLEM", 7, 30], ["tidal fever", "PROBLEM", 46, 57], ["loose stool", "PROBLEM", 59, 70], ["fullness in the chest and costal/hypochondriac region", "PROBLEM", 94, 147], ["SSHT", "TREATMENT", 169, 173], ["loose stool", "OBSERVATION", 59, 70], ["normal urination", "OBSERVATION", 72, 88], ["fullness", "OBSERVATION", 94, 102], ["chest", "ANATOMY", 110, 115], ["costal", "ANATOMY", 120, 126], ["hypochondriac", "ANATOMY", 127, 140], ["region", "ANATOMY_MODIFIER", 141, 147], ["not", "UNCERTAINTY", 157, 160], ["abated", "OBSERVATION_MODIFIER", 161, 167]]], ["46 -In zhong feng syndrome of yang brightness disease, there are wiry, floating and big pulses, shortness of breath, fullness in the abdomen, pain in the epigastric region and costal/hypochondriac region, a sense of qi blockage under prolonged pressure, a dry nose, the absence of sweating somnolence, yellow coloration all over the body and the eyes, difficult urination, tidal fever, hiccup at times, and swelling in front of and behind the ears.", [["abdomen", "ANATOMY", 133, 140], ["epigastric region", "ANATOMY", 154, 171], ["costal/hypochondriac region", "ANATOMY", 176, 203], ["body", "ANATOMY", 333, 337], ["eyes", "ANATOMY", 346, 350], ["ears", "ANATOMY", 443, 447], ["yang brightness disease", "DISEASE", 30, 53], ["shortness of breath", "DISEASE", 96, 115], ["pain", "DISEASE", 142, 146], ["dry nose", "DISEASE", 256, 264], ["sweating somnolence", "DISEASE", 281, 300], ["urination", "DISEASE", 362, 371], ["fever", "DISEASE", 379, 384], ["hiccup", "DISEASE", 386, 392], ["swelling", "DISEASE", 407, 415], ["abdomen", "ORGANISM_SUBDIVISION", 133, 140], ["epigastric", "ORGANISM_SUBDIVISION", 154, 164], ["costal", "ORGAN", 176, 182], ["nose", "ORGANISM_SUBDIVISION", 260, 264], ["body", "ORGANISM_SUBDIVISION", 333, 337], ["eyes", "ORGAN", 346, 350], ["ears", "ORGAN", 443, 447], ["yang brightness disease", "PROBLEM", 30, 53], ["big pulses", "PROBLEM", 84, 94], ["shortness of breath", "PROBLEM", 96, 115], ["fullness in the abdomen", "PROBLEM", 117, 140], ["pain in the epigastric region and costal/hypochondriac region", "PROBLEM", 142, 203], ["qi blockage", "PROBLEM", 216, 227], ["prolonged pressure", "PROBLEM", 234, 252], ["a dry nose", "PROBLEM", 254, 264], ["sweating somnolence", "PROBLEM", 281, 300], ["yellow coloration", "PROBLEM", 302, 319], ["difficult urination", "PROBLEM", 352, 371], ["tidal fever", "PROBLEM", 373, 384], ["hiccup", "PROBLEM", 386, 392], ["swelling", "PROBLEM", 407, 415], ["yang brightness", "OBSERVATION", 30, 45], ["floating", "OBSERVATION_MODIFIER", 71, 79], ["fullness", "OBSERVATION", 117, 125], ["abdomen", "ANATOMY", 133, 140], ["pain", "OBSERVATION", 142, 146], ["epigastric", "ANATOMY", 154, 164], ["region", "ANATOMY_MODIFIER", 165, 171], ["costal", "ANATOMY", 176, 182], ["hypochondriac", "ANATOMY", 183, 196], ["region", "ANATOMY_MODIFIER", 197, 203], ["blockage", "OBSERVATION", 219, 227], ["prolonged", "OBSERVATION_MODIFIER", 234, 243], ["pressure", "OBSERVATION_MODIFIER", 244, 252], ["yellow coloration", "OBSERVATION", 302, 319], ["body", "ANATOMY", 333, 337], ["eyes", "ANATOMY", 346, 350], ["tidal fever", "OBSERVATION", 373, 384], ["swelling", "OBSERVATION", 407, 415], ["ears", "ANATOMY", 443, 447]]], ["The condition is slightly better after needling, but the exterior syndrome remains unchanged.", [["needling", "TREATMENT", 39, 47], ["the exterior syndrome", "PROBLEM", 53, 74], ["slightly", "OBSERVATION_MODIFIER", 17, 25], ["better", "OBSERVATION_MODIFIER", 26, 32], ["exterior", "OBSERVATION_MODIFIER", 57, 65], ["syndrome", "OBSERVATION", 66, 74], ["unchanged", "OBSERVATION_MODIFIER", 83, 92]]], ["If the disease has lasted for more than ten days and the pulse is still floating, SSHT might be prescribed.", [["the disease", "PROBLEM", 3, 14], ["the pulse", "TEST", 53, 62], ["SSHT", "TREATMENT", 82, 86], ["disease", "OBSERVATION", 7, 14]]], ["46 Considering the indications above, 46 SSHT should be prescribed when there are symptoms in fever and chest discomfort along with the symptoms of digestive tract (loss of appetite, nausea, vomiting, diarrhea, or constipation, etc.) after initial onset or within 7 days of the occurrence of infectious diseases.", [["chest", "ANATOMY", 104, 109], ["digestive tract", "ANATOMY", 148, 163], ["fever", "DISEASE", 94, 99], ["chest discomfort", "DISEASE", 104, 120], ["digestive tract", "DISEASE", 148, 163], ["loss of appetite", "DISEASE", 165, 181], ["nausea", "DISEASE", 183, 189], ["vomiting", "DISEASE", 191, 199], ["diarrhea", "DISEASE", 201, 209], ["constipation", "DISEASE", 214, 226], ["infectious diseases", "DISEASE", 292, 311], ["chest", "ORGANISM_SUBDIVISION", 104, 109], ["digestive tract", "ORGANISM_SUBDIVISION", 148, 163], ["symptoms", "PROBLEM", 82, 90], ["fever", "PROBLEM", 94, 99], ["chest discomfort", "PROBLEM", 104, 120], ["the symptoms", "PROBLEM", 132, 144], ["digestive tract (loss of appetite", "PROBLEM", 148, 181], ["nausea", "PROBLEM", 183, 189], ["vomiting", "PROBLEM", 191, 199], ["diarrhea", "PROBLEM", 201, 209], ["constipation", "PROBLEM", 214, 226], ["infectious diseases", "PROBLEM", 292, 311], ["chest", "ANATOMY", 104, 109], ["digestive tract", "ANATOMY", 148, 163], ["infectious", "OBSERVATION", 292, 302]]], ["Based on the indications and recommendations in the Shanghan Lun, SSHT has been used for various infectious diseases, especially respiratory, gastrointestinal, and liver diseases with or without fever.Indications of SSHT in classical medicine and in symptoms of COVID-19The typical clinical symptoms of COVID-19 are lower respiratory symptoms (including dry cough), high fever, and difficulty breathing.", [["respiratory", "ANATOMY", 129, 140], ["gastrointestinal", "ANATOMY", 142, 158], ["liver", "ANATOMY", 164, 169], ["respiratory", "ANATOMY", 322, 333], ["SSHT", "CHEMICAL", 66, 70], ["infectious diseases", "DISEASE", 97, 116], ["respiratory, gastrointestinal, and liver diseases", "DISEASE", 129, 178], ["fever", "DISEASE", 195, 200], ["SSHT", "DISEASE", 216, 220], ["COVID", "DISEASE", 303, 308], ["respiratory symptoms", "DISEASE", 322, 342], ["dry cough", "DISEASE", 354, 363], ["fever", "DISEASE", 371, 376], ["difficulty breathing", "DISEASE", 382, 402], ["gastrointestinal", "ORGAN", 142, 158], ["liver", "ORGAN", 164, 169], ["SSHT", "TREATMENT", 66, 70], ["various infectious diseases", "PROBLEM", 89, 116], ["respiratory, gastrointestinal, and liver diseases", "PROBLEM", 129, 178], ["fever", "PROBLEM", 195, 200], ["SSHT", "TREATMENT", 216, 220], ["symptoms", "PROBLEM", 250, 258], ["COVID", "TEST", 262, 267], ["The typical clinical symptoms", "PROBLEM", 270, 299], ["COVID", "TEST", 303, 308], ["lower respiratory symptoms", "PROBLEM", 316, 342], ["dry cough", "PROBLEM", 354, 363], ["high fever", "PROBLEM", 366, 376], ["difficulty breathing", "PROBLEM", 382, 402], ["gastrointestinal", "ANATOMY", 142, 158], ["liver", "ANATOMY", 164, 169], ["diseases", "OBSERVATION", 170, 178], ["high", "OBSERVATION_MODIFIER", 366, 370], ["fever", "OBSERVATION", 371, 376]]], ["In a Chinese study of 72,314 diagnosed COVID-19 cases, 47 approximately 14% revealed severe dyspnea (oxygen saturation of 93% or less, lung infiltration 24%), and 5% showed fatal symptoms such as respiratory failure, organ J o u r n a l P r e -p r o o f failure, dysfunction, and septic shock.", [["lung", "ANATOMY", 135, 139], ["respiratory", "ANATOMY", 196, 207], ["organ", "ANATOMY", 217, 222], ["COVID", "DISEASE", 39, 44], ["dyspnea", "DISEASE", 92, 99], ["oxygen", "CHEMICAL", 101, 107], ["lung infiltration", "DISEASE", 135, 152], ["respiratory failure", "DISEASE", 196, 215], ["septic shock", "DISEASE", 280, 292], ["oxygen", "CHEMICAL", 101, 107], ["oxygen", "SIMPLE_CHEMICAL", 101, 107], ["lung", "ORGAN", 135, 139], ["organ", "ORGAN", 217, 222], ["a Chinese study", "TEST", 3, 18], ["COVID", "TEST", 39, 44], ["severe dyspnea", "PROBLEM", 85, 99], ["oxygen saturation", "TEST", 101, 118], ["lung infiltration", "TEST", 135, 152], ["fatal symptoms", "PROBLEM", 173, 187], ["respiratory failure", "PROBLEM", 196, 215], ["failure", "PROBLEM", 254, 261], ["dysfunction", "PROBLEM", 263, 274], ["septic shock", "PROBLEM", 280, 292], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["dyspnea", "OBSERVATION", 92, 99], ["lung", "ANATOMY", 135, 139], ["infiltration", "OBSERVATION", 140, 152], ["respiratory failure", "OBSERVATION", 196, 215], ["failure", "OBSERVATION", 254, 261], ["dysfunction", "OBSERVATION", 263, 274], ["septic shock", "OBSERVATION", 280, 292]]], ["There have also been reports of accompanying gastrointestinal symptoms such as nausea, vomiting, and abdominal discomfort (although the frequency is low) after the initial respiratory symptoms.", [["gastrointestinal", "ANATOMY", 45, 61], ["abdominal", "ANATOMY", 101, 110], ["respiratory", "ANATOMY", 172, 183], ["nausea", "DISEASE", 79, 85], ["vomiting", "DISEASE", 87, 95], ["abdominal discomfort", "DISEASE", 101, 121], ["gastrointestinal", "ORGAN", 45, 61], ["abdominal", "ORGANISM_SUBDIVISION", 101, 110], ["accompanying gastrointestinal symptoms", "PROBLEM", 32, 70], ["nausea", "PROBLEM", 79, 85], ["vomiting", "PROBLEM", 87, 95], ["abdominal discomfort", "PROBLEM", 101, 121], ["the initial respiratory symptoms", "PROBLEM", 160, 192], ["gastrointestinal", "ANATOMY", 45, 61], ["symptoms", "OBSERVATION", 62, 70], ["abdominal", "ANATOMY", 101, 110], ["discomfort", "OBSERVATION", 111, 121]]], ["48 In another investigation in Wuhan, Hubei, the most commonly reported clinical manifestations were fever (91.7%), cough (75.0%), fatigue (75.0%), and gastrointestinal symptoms (39.6%).", [["gastrointestinal", "ANATOMY", 152, 168], ["fever", "DISEASE", 101, 106], ["cough", "DISEASE", 116, 121], ["fatigue", "DISEASE", 131, 138], ["gastrointestinal symptoms", "DISEASE", 152, 177], ["gastrointestinal", "ORGAN", 152, 168], ["clinical manifestations", "PROBLEM", 72, 95], ["fever", "PROBLEM", 101, 106], ["cough", "PROBLEM", 116, 121], ["fatigue", "PROBLEM", 131, 138], ["gastrointestinal symptoms", "PROBLEM", 152, 177], ["gastrointestinal", "ANATOMY", 152, 168]]], ["49 In addition, there have been some cases that have shown only gastrointestinal symptoms from the onset.", [["gastrointestinal", "ANATOMY", 64, 80], ["gastrointestinal", "ORGAN", 64, 80], ["gastrointestinal symptoms", "PROBLEM", 64, 89], ["gastrointestinal", "ANATOMY", 64, 80], ["symptoms", "OBSERVATION", 81, 89]]], ["50 This patient was hospitalized with nausea and vomiting on the second day of onset and was confirmed as a COVID-19 case after the symptom of loose stool was observed on the second day of hospitalization.Indications of SSHT in classical medicine and in symptoms of COVID-19The clinical appearance of COVID-19, which is accompanied by fever, respiratory and gastrointestinal symptoms at a relatively early stage, is similar to the indications of SSHT described in the medical classic, Shanghan Lun.Utilization status and clinical evidence of SSHT in infectious diseases, especially viral diseasesSSHT has been used to treat infectious diseases caused by various bacteria and, particularly, viruses.", [["stool", "ANATOMY", 149, 154], ["respiratory", "ANATOMY", 342, 353], ["gastrointestinal", "ANATOMY", 358, 374], ["nausea", "DISEASE", 38, 44], ["vomiting", "DISEASE", 49, 57], ["SSHT", "DISEASE", 220, 224], ["COVID-19", "CHEMICAL", 266, 274], ["COVID-19", "CHEMICAL", 301, 309], ["fever", "DISEASE", 335, 340], ["respiratory and gastrointestinal symptoms", "DISEASE", 342, 383], ["SSHT", "DISEASE", 446, 450], ["SSHT", "DISEASE", 542, 546], ["infectious diseases", "DISEASE", 550, 569], ["viral diseasesSSHT", "DISEASE", 582, 600], ["infectious diseases", "DISEASE", 624, 643], ["COVID-19", "CHEMICAL", 266, 274], ["patient", "ORGANISM", 8, 15], ["stool", "ORGANISM_SUBSTANCE", 149, 154], ["gastrointestinal", "ORGAN", 358, 374], ["SSHT", "CANCER", 446, 450], ["patient", "SPECIES", 8, 15], ["nausea", "PROBLEM", 38, 44], ["vomiting", "PROBLEM", 49, 57], ["loose stool", "PROBLEM", 143, 154], ["SSHT", "TREATMENT", 220, 224], ["symptoms", "PROBLEM", 254, 262], ["COVID", "TEST", 266, 271], ["COVID", "TEST", 301, 306], ["fever", "PROBLEM", 335, 340], ["respiratory and gastrointestinal symptoms", "PROBLEM", 342, 383], ["SSHT", "TREATMENT", 446, 450], ["SSHT in infectious diseases", "PROBLEM", 542, 569], ["viral diseasesSSHT", "PROBLEM", 582, 600], ["infectious diseases", "PROBLEM", 624, 643], ["various bacteria", "PROBLEM", 654, 670], ["loose stool", "OBSERVATION", 143, 154], ["fever", "OBSERVATION", 335, 340], ["respiratory", "ANATOMY", 342, 353], ["gastrointestinal", "ANATOMY", 358, 374], ["infectious", "OBSERVATION", 550, 560], ["various", "OBSERVATION_MODIFIER", 654, 661], ["bacteria", "OBSERVATION", 662, 670]]], ["With respiratory system infections, in particular, there have been reports of SSHT used to treat viral infections such as influenza or the common cold.", [["respiratory system", "ANATOMY", 5, 23], ["respiratory system infections", "DISEASE", 5, 34], ["SSHT", "CHEMICAL", 78, 82], ["viral infections", "DISEASE", 97, 113], ["influenza", "DISEASE", 122, 131], ["SSHT", "SIMPLE_CHEMICAL", 78, 82], ["respiratory system infections", "PROBLEM", 5, 34], ["SSHT", "TREATMENT", 78, 82], ["viral infections", "PROBLEM", 97, 113], ["influenza", "PROBLEM", 122, 131], ["the common cold", "PROBLEM", 135, 150], ["respiratory system", "ANATOMY", 5, 23], ["infections", "OBSERVATION", 24, 34]]], ["In a study comparing the effects of oseltamivir in patients with influenza A, 11 SSHT treatment had an antipyretic effect equivalent to that of oseltamivir.", [["oseltamivir", "CHEMICAL", 36, 47], ["influenza A", "DISEASE", 65, 76], ["SSHT", "CHEMICAL", 81, 85], ["oseltamivir", "CHEMICAL", 144, 155], ["oseltamivir", "CHEMICAL", 36, 47], ["oseltamivir", "CHEMICAL", 144, 155], ["oseltamivir", "SIMPLE_CHEMICAL", 36, 47], ["patients", "ORGANISM", 51, 59], ["oseltamivir", "SIMPLE_CHEMICAL", 144, 155], ["patients", "SPECIES", 51, 59], ["a study", "TEST", 3, 10], ["oseltamivir", "TREATMENT", 36, 47], ["influenza A", "TREATMENT", 65, 76], ["11 SSHT treatment", "TREATMENT", 78, 95], ["an antipyretic effect", "TREATMENT", 100, 121], ["oseltamivir", "TREATMENT", 144, 155]]], ["The time required for the antipyretic effect was evaluated according to the treatment: oseltamivir (n = 8 participants), Mahwangtang (MHT, Ma Huang Tang in Chinese, Maoto in Japanese; n = 6), or SSHT (n = 6).", [["oseltamivir", "CHEMICAL", 87, 98], ["Mahwangtang", "CHEMICAL", 121, 132], ["MHT", "CHEMICAL", 134, 137], ["SSHT", "DISEASE", 195, 199], ["oseltamivir", "CHEMICAL", 87, 98], ["oseltamivir", "SIMPLE_CHEMICAL", 87, 98], ["participants", "SPECIES", 106, 118], ["the antipyretic effect", "TREATMENT", 22, 44], ["oseltamivir", "TREATMENT", 87, 98]]], ["The oseltamivir group required 2.0 \u00b1 0.6 days for antipyretic effect, and both the MHT and SSHT groups showed antipyretic effect after 2.3 \u00b1 1.0 days, with no significant difference between the two groups.", [["oseltamivir", "CHEMICAL", 4, 15], ["oseltamivir", "CHEMICAL", 4, 15], ["oseltamivir", "SIMPLE_CHEMICAL", 4, 15], ["The oseltamivir group", "TREATMENT", 0, 21], ["antipyretic effect", "PROBLEM", 50, 68], ["the MHT and SSHT groups", "TREATMENT", 79, 102], ["antipyretic effect", "PROBLEM", 110, 128], ["no", "UNCERTAINTY", 156, 158], ["significant", "OBSERVATION_MODIFIER", 159, 170], ["difference", "OBSERVATION", 171, 181]]], ["SSHT has J o u r n a l P r e -p r o o f also been reported to be a treatment for the common cold with more than five days progress.", [["a treatment", "TREATMENT", 65, 76]]], ["12 SSHT (n = 131) or placebo (n = 119) was administered to patients (25 to 75 years old) with colds more than 5 days after the onset of illness, accompanied by oral discomfort, anorexia, and tiredness.", [["oral", "ANATOMY", 160, 164], ["SSHT", "CHEMICAL", 3, 7], ["colds", "DISEASE", 94, 99], ["illness", "DISEASE", 136, 143], ["oral discomfort", "DISEASE", 160, 175], ["anorexia", "DISEASE", 177, 185], ["tiredness", "DISEASE", 191, 200], ["patients", "ORGANISM", 59, 67], ["oral", "ORGANISM_SUBDIVISION", 160, 164], ["patients", "SPECIES", 59, 67], ["placebo", "TREATMENT", 21, 28], ["colds", "PROBLEM", 94, 99], ["illness", "PROBLEM", 136, 143], ["oral discomfort", "PROBLEM", 160, 175], ["anorexia", "PROBLEM", 177, 185], ["tiredness", "PROBLEM", 191, 200], ["oral", "ANATOMY", 160, 164], ["discomfort", "OBSERVATION", 165, 175], ["anorexia", "OBSERVATION", 177, 185]]], ["Within one week (7 days) after treatment, SSHT group showed better results than placebo in the overall improvement (total effective rate: 64.1% vs 43.7%, SSHT vs placebo).", [["SSHT", "SIMPLE_CHEMICAL", 42, 46], ["treatment", "TREATMENT", 31, 40], ["total effective rate", "TEST", 116, 136], ["SSHT", "TEST", 154, 158], ["placebo", "TREATMENT", 162, 169]]], ["The SSHT group showed significant improvement in the symptoms of sore throat and tiredness in 3 to 4 days compared with the placebo group.", [["sore throat", "DISEASE", 65, 76], ["tiredness", "DISEASE", 81, 90], ["SSHT", "CANCER", 4, 8], ["the symptoms", "PROBLEM", 49, 61], ["sore throat", "PROBLEM", 65, 76], ["tiredness", "PROBLEM", 81, 90], ["the placebo group", "TREATMENT", 120, 137], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["improvement", "OBSERVATION_MODIFIER", 34, 45], ["sore throat", "ANATOMY", 65, 76]]], ["After the final SSHT administration, appetite, arthralgia, and muscle pain were significantly improved compared with placebo administration.", [["muscle", "ANATOMY", 63, 69], ["arthralgia", "DISEASE", 47, 57], ["muscle pain", "DISEASE", 63, 74], ["muscle", "ORGAN", 63, 69], ["the final SSHT administration", "TREATMENT", 6, 35], ["arthralgia", "PROBLEM", 47, 57], ["muscle pain", "PROBLEM", 63, 74], ["placebo administration", "TREATMENT", 117, 139], ["arthralgia", "OBSERVATION", 47, 57], ["muscle", "ANATOMY", 63, 69]]], ["This result suggests that SSHT might be an effective treatment of the common cold with delayed progress.Utilization status and clinical evidence of SSHT in infectious diseases, especially viral diseasesIn a report of a non-viral infection, pulmonary tuberculosis, 13 SSHT has also been used in the treatment of idiopathic interstitial pneumonia.", [["pulmonary", "ANATOMY", 240, 249], ["interstitial", "ANATOMY", 322, 334], ["SSHT", "CHEMICAL", 26, 30], ["SSHT", "DISEASE", 148, 152], ["infectious diseases", "DISEASE", 156, 175], ["viral diseases", "DISEASE", 188, 202], ["non-viral infection", "DISEASE", 219, 238], ["pulmonary tuberculosis", "DISEASE", 240, 262], ["SSHT", "CHEMICAL", 267, 271], ["idiopathic interstitial pneumonia", "DISEASE", 311, 344], ["SSHT", "SIMPLE_CHEMICAL", 26, 30], ["pulmonary", "ORGAN", 240, 249], ["an effective treatment", "TREATMENT", 40, 62], ["SSHT in infectious diseases", "PROBLEM", 148, 175], ["viral diseases", "PROBLEM", 188, 202], ["a non-viral infection", "PROBLEM", 217, 238], ["pulmonary tuberculosis", "PROBLEM", 240, 262], ["idiopathic interstitial pneumonia", "PROBLEM", 311, 344], ["infectious", "OBSERVATION", 156, 166], ["non-viral", "OBSERVATION_MODIFIER", 219, 228], ["infection", "OBSERVATION", 229, 238], ["pulmonary", "ANATOMY", 240, 249], ["tuberculosis", "OBSERVATION", 250, 262], ["idiopathic", "OBSERVATION_MODIFIER", 311, 321], ["interstitial", "ANATOMY_MODIFIER", 322, 334], ["pneumonia", "OBSERVATION", 335, 344]]], ["Tanaka et al. 14 divided idiopathic interstitial pneumonia patients into a control group (n = 20) without additional medication administration and a treatment group (n = 9) administered SSHT and compared the treatment results after more than 10 months.", [["interstitial", "ANATOMY", 36, 48], ["interstitial pneumonia", "DISEASE", 36, 58], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["idiopathic interstitial pneumonia", "PROBLEM", 25, 58], ["additional medication administration", "TREATMENT", 106, 142], ["a treatment group (n", "TREATMENT", 147, 167], ["SSHT", "TREATMENT", 186, 190], ["idiopathic", "OBSERVATION_MODIFIER", 25, 35], ["interstitial", "OBSERVATION_MODIFIER", 36, 48], ["pneumonia", "OBSERVATION", 49, 58]]], ["Improvement was shown in 11.1%Utilization status and clinical evidence of SSHT in infectious diseases, especially viral diseases(1/9) of the patients in the treatment group and slight improvement (33.3%, 3 of 9 patients) was shown in the n treatment group.Utilization status and clinical evidence of SSHT in infectious diseases, especially viral diseasesJ o u r n a l P r e -p r o o f SSHT has attracted much more attention for its antiviral effect in chronic hepatitis B and C.Utilization status and clinical evidence of SSHT in infectious diseases, especially viral diseasesAlthough the Shanghan Lun did not intend for SSHT to be used in liver disease, SSHT has been used for this purpose based on indicative phrases in the text such as \"yellow coloration all over the body and the eyes\" and \"discomfort and fullness in the chest and hypochondriac region\".", [["liver", "ANATOMY", 640, 645], ["body", "ANATOMY", 771, 775], ["eyes", "ANATOMY", 784, 788], ["chest", "ANATOMY", 826, 831], ["SSHT", "DISEASE", 74, 78], ["infectious diseases", "DISEASE", 82, 101], ["viral diseases", "DISEASE", 114, 128], ["SSHT", "DISEASE", 300, 304], ["infectious diseases", "DISEASE", 308, 327], ["SSHT", "CHEMICAL", 385, 389], ["chronic hepatitis B", "DISEASE", 452, 471], ["SSHT", "CHEMICAL", 522, 526], ["infectious diseases", "DISEASE", 530, 549], ["viral diseases", "DISEASE", 562, 576], ["liver disease", "DISEASE", 640, 653], ["fullness", "DISEASE", 810, 818], ["SSHT", "PATHOLOGICAL_FORMATION", 74, 78], ["patients", "ORGANISM", 141, 149], ["patients", "ORGANISM", 211, 219], ["SSHT", "SIMPLE_CHEMICAL", 522, 526], ["SSHT", "SIMPLE_CHEMICAL", 621, 625], ["liver", "ORGAN", 640, 645], ["body", "ORGANISM_SUBDIVISION", 771, 775], ["eyes", "ORGAN", 784, 788], ["chest", "ORGANISM_SUBDIVISION", 826, 831], ["SSHT", "DNA", 385, 389], ["SSHT", "PROTEIN", 621, 625], ["patients", "SPECIES", 141, 149], ["patients", "SPECIES", 211, 219], ["SSHT in infectious diseases", "PROBLEM", 74, 101], ["viral diseases", "PROBLEM", 114, 128], ["SSHT in infectious diseases", "PROBLEM", 300, 327], ["SSHT", "TREATMENT", 385, 389], ["its antiviral effect", "TREATMENT", 428, 448], ["chronic hepatitis B", "PROBLEM", 452, 471], ["SSHT in infectious diseases", "PROBLEM", 522, 549], ["viral diseases", "PROBLEM", 562, 576], ["SSHT", "TREATMENT", 621, 625], ["liver disease", "PROBLEM", 640, 653], ["SSHT", "TREATMENT", 655, 659], ["yellow coloration", "PROBLEM", 740, 757], ["\"discomfort", "PROBLEM", 794, 805], ["fullness in the chest and hypochondriac region\"", "PROBLEM", 810, 857], ["infectious", "OBSERVATION", 82, 92], ["slight", "OBSERVATION_MODIFIER", 177, 183], ["improvement", "OBSERVATION_MODIFIER", 184, 195], ["infectious", "OBSERVATION", 308, 318], ["chronic", "OBSERVATION_MODIFIER", 452, 459], ["hepatitis", "OBSERVATION", 460, 469], ["infectious", "OBSERVATION", 530, 540], ["liver", "ANATOMY", 640, 645], ["disease", "OBSERVATION", 646, 653], ["eyes", "ANATOMY", 784, 788], ["fullness", "OBSERVATION", 810, 818], ["chest", "ANATOMY", 826, 831]]], ["In cases of hepatitis C, it was confirmed that fever, alopecia, and leukocyte levels were significantly improved following the combination therapy of SSHT and interferon compared with those following interferon monotherapy.", [["leukocyte", "ANATOMY", 68, 77], ["hepatitis C", "DISEASE", 12, 23], ["fever", "DISEASE", 47, 52], ["alopecia", "DISEASE", 54, 62], ["SSHT", "CHEMICAL", 150, 154], ["interferon", "CHEMICAL", 200, 210], ["hepatitis C", "ORGANISM", 12, 23], ["leukocyte", "CELL", 68, 77], ["SSHT", "SIMPLE_CHEMICAL", 150, 154], ["interferon", "GENE_OR_GENE_PRODUCT", 159, 169], ["interferon", "GENE_OR_GENE_PRODUCT", 200, 210], ["SSHT", "PROTEIN", 150, 154], ["interferon", "PROTEIN", 159, 169], ["interferon", "PROTEIN", 200, 210], ["hepatitis C", "PROBLEM", 12, 23], ["fever", "PROBLEM", 47, 52], ["alopecia", "PROBLEM", 54, 62], ["leukocyte levels", "TEST", 68, 84], ["the combination therapy", "TREATMENT", 123, 146], ["SSHT", "TREATMENT", 150, 154], ["interferon", "TREATMENT", 159, 169], ["interferon monotherapy", "TREATMENT", 200, 222], ["hepatitis", "OBSERVATION", 12, 21]]], ["15 Improvements in the levels of aspartate transaminase (AST), alanine transferase (ALT), and Knodell's histology activity index, in 38% (9/24 patients) were evident when patients were administered SSHT for 12 months.", [["aspartate", "CHEMICAL", 33, 42], ["alanine", "CHEMICAL", 63, 70], ["aspartate", "CHEMICAL", 33, 42], ["alanine", "CHEMICAL", 63, 70], ["SSHT", "CHEMICAL", 198, 202], ["aspartate transaminase", "GENE_OR_GENE_PRODUCT", 33, 55], ["AST", "SIMPLE_CHEMICAL", 57, 60], ["alanine transferase", "GENE_OR_GENE_PRODUCT", 63, 82], ["ALT", "SIMPLE_CHEMICAL", 84, 87], ["patients", "ORGANISM", 143, 151], ["patients", "ORGANISM", 171, 179], ["aspartate transaminase", "PROTEIN", 33, 55], ["AST", "PROTEIN", 57, 60], ["alanine transferase", "PROTEIN", 63, 82], ["ALT", "PROTEIN", 84, 87], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 171, 179], ["the levels", "TEST", 19, 29], ["aspartate transaminase", "TEST", 33, 55], ["AST", "TEST", 57, 60], ["alanine transferase", "TEST", 63, 82], ["ALT", "TEST", 84, 87], ["Knodell's histology activity index", "TEST", 94, 128], ["SSHT", "TREATMENT", 198, 202]]], ["16 In another study, SSHT was administered for three years, and fibrosis markers were regularly followed (n = 93).", [["SSHT", "CHEMICAL", 21, 25], ["fibrosis", "DISEASE", 64, 72], ["SSHT", "SIMPLE_CHEMICAL", 21, 25], ["another study", "TEST", 6, 19], ["SSHT", "TREATMENT", 21, 25], ["fibrosis markers", "TEST", 64, 80], ["fibrosis", "OBSERVATION", 64, 72]]], ["As a result, ALT levels were reduced in both chronic active hepatitis and chronic persistent hepatitis (CPH) patients.", [["chronic active hepatitis", "DISEASE", 45, 69], ["chronic persistent hepatitis", "DISEASE", 74, 102], ["CPH", "DISEASE", 104, 107], ["ALT", "SIMPLE_CHEMICAL", 13, 16], ["patients", "ORGANISM", 109, 117], ["ALT", "PROTEIN", 13, 16], ["patients", "SPECIES", 109, 117], ["ALT levels", "TEST", 13, 23], ["both chronic active hepatitis", "PROBLEM", 40, 69], ["chronic persistent hepatitis (CPH)", "PROBLEM", 74, 108], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["active", "OBSERVATION_MODIFIER", 53, 59], ["hepatitis", "OBSERVATION", 60, 69], ["chronic", "OBSERVATION_MODIFIER", 74, 81], ["persistent", "OBSERVATION_MODIFIER", 82, 92], ["hepatitis", "OBSERVATION", 93, 102]]], ["In addition, in CPH, procollagen III peptide (PIIIP) was normalized in 69% of cases and 7S collagen in 92% of cases, which suggests a liver fibrosis suppressive effect of SSHT in chronic hepatitis C. 17 There are an increasing number of reports of the use of SSHT in the treatment of chronic hepatitis B. In most of these studies, patients are given combination therapy of SSHT with interferon-based chemotherapy.", [["liver", "ANATOMY", 134, 139], ["CPH", "DISEASE", 16, 19], ["fibrosis", "DISEASE", 140, 148], ["SSHT", "CHEMICAL", 171, 175], ["chronic hepatitis", "DISEASE", 179, 196], ["SSHT", "CHEMICAL", 259, 263], ["chronic hepatitis B.", "DISEASE", 284, 304], ["interferon", "CHEMICAL", 383, 393], ["procollagen III peptide", "GENE_OR_GENE_PRODUCT", 21, 44], ["PIIIP", "GENE_OR_GENE_PRODUCT", 46, 51], ["7S collagen", "GENE_OR_GENE_PRODUCT", 88, 99], ["liver", "ORGAN", 134, 139], ["SSHT", "SIMPLE_CHEMICAL", 171, 175], ["SSHT", "SIMPLE_CHEMICAL", 259, 263], ["patients", "ORGANISM", 331, 339], ["SSHT", "SIMPLE_CHEMICAL", 373, 377], ["interferon", "SIMPLE_CHEMICAL", 383, 393], ["procollagen III", "PROTEIN", 21, 36], ["7S collagen", "PROTEIN", 88, 99], ["interferon", "PROTEIN", 383, 393], ["patients", "SPECIES", 331, 339], ["CPH, procollagen III peptide", "TEST", 16, 44], ["PIIIP", "TEST", 46, 51], ["cases", "TEST", 78, 83], ["7S collagen", "TEST", 88, 99], ["a liver fibrosis", "PROBLEM", 132, 148], ["chronic hepatitis C.", "PROBLEM", 179, 199], ["SSHT", "TREATMENT", 259, 263], ["chronic hepatitis B.", "PROBLEM", 284, 304], ["these studies", "TEST", 316, 329], ["combination therapy", "TREATMENT", 350, 369], ["SSHT", "TREATMENT", 373, 377], ["interferon", "TREATMENT", 383, 393], ["based chemotherapy", "TREATMENT", 394, 412], ["liver", "ANATOMY", 134, 139], ["fibrosis", "OBSERVATION", 140, 148], ["chronic", "OBSERVATION_MODIFIER", 179, 186], ["hepatitis", "OBSERVATION", 187, 196], ["increasing", "OBSERVATION_MODIFIER", 216, 226], ["number", "OBSERVATION_MODIFIER", 227, 233], ["chronic", "OBSERVATION_MODIFIER", 284, 291], ["hepatitis", "OBSERVATION", 292, 301]]], ["Although there was a slight difference in the results of each study, the adjunctive or single administration treatment using SSHT showed a tendency to improve liver function, partial HBeAg negative, and reduced viral load in patients with hepatitis B compared with chemotherapy alone or placebo.", [["liver", "ANATOMY", 159, 164], ["SSHT", "CHEMICAL", 125, 129], ["HBeAg", "CHEMICAL", 183, 188], ["hepatitis B", "DISEASE", 239, 250], ["liver", "ORGAN", 159, 164], ["HBeAg", "GENE_OR_GENE_PRODUCT", 183, 188], ["patients", "ORGANISM", 225, 233], ["hepatitis B", "ORGANISM", 239, 250], ["patients", "SPECIES", 225, 233], ["each study", "TEST", 57, 67], ["the adjunctive", "TREATMENT", 69, 83], ["single administration treatment", "TREATMENT", 87, 118], ["SSHT", "TREATMENT", 125, 129], ["a tendency", "PROBLEM", 137, 147], ["liver function", "TEST", 159, 173], ["partial HBeAg", "TEST", 175, 188], ["reduced viral load", "PROBLEM", 203, 221], ["hepatitis B", "PROBLEM", 239, 250], ["chemotherapy alone", "TREATMENT", 265, 283], ["placebo", "TREATMENT", 287, 294], ["slight", "OBSERVATION_MODIFIER", 21, 27], ["difference", "OBSERVATION_MODIFIER", 28, 38], ["liver", "ANATOMY", 159, 164], ["viral load", "OBSERVATION", 211, 221]]], ["[18] [19] [20] [21] These results suggest that SSHT has an antiviral effect against the chronic hepatitis virus.Utilization status and clinical evidence of SSHT in infectious diseases, especially viral diseasesJ o u r n a l P r e -p r o o fAntiviral effect of SSHT in experimental studiesAs described above, SSHT has been applied to the treatment of viral diseases of the respiratory system and hepatobiliary system.", [["respiratory system", "ANATOMY", 372, 390], ["hepatobiliary system", "ANATOMY", 395, 415], ["SSHT", "CHEMICAL", 47, 51], ["chronic hepatitis virus", "DISEASE", 88, 111], ["SSHT", "DISEASE", 156, 160], ["infectious diseases", "DISEASE", 164, 183], ["SSHT", "CHEMICAL", 260, 264], ["SSHT", "CHEMICAL", 308, 312], ["viral diseases of the respiratory system", "DISEASE", 350, 390], ["SSHT", "CHEMICAL", 47, 51], ["[18] [19] [20] [21]", "SIMPLE_CHEMICAL", 0, 19], ["SSHT", "SIMPLE_CHEMICAL", 47, 51], ["chronic hepatitis virus", "ORGANISM", 88, 111], ["hepatobiliary", "ANATOMICAL_SYSTEM", 395, 408], ["system", "ANATOMICAL_SYSTEM", 409, 415], ["SSHT", "PROTEIN", 308, 312], ["hepatitis virus", "SPECIES", 96, 111], ["an antiviral effect", "TREATMENT", 56, 75], ["the chronic hepatitis virus", "PROBLEM", 84, 111], ["SSHT in infectious diseases", "PROBLEM", 156, 183], ["SSHT", "TREATMENT", 260, 264], ["experimental studies", "TEST", 268, 288], ["SSHT", "TREATMENT", 308, 312], ["viral diseases of the respiratory system and hepatobiliary system", "PROBLEM", 350, 415], ["antiviral", "OBSERVATION", 59, 68], ["chronic", "OBSERVATION_MODIFIER", 88, 95], ["hepatitis", "OBSERVATION", 96, 105], ["infectious", "OBSERVATION", 164, 174], ["viral", "OBSERVATION", 350, 355], ["respiratory system", "ANATOMY", 372, 390], ["hepatobiliary system", "ANATOMY", 395, 415]]], ["The clinical results of SSHT treatment can be explained by the antiviral effects of SSHT itself and the effects of each constituent herb.Antiviral effect of SSHT in experimental studiesSSHT has been shown to inhibit coxsackievirus B1 infection by inducing the expression of type I interferons 22, 23 and has been reported to inhibit antigen production through chemical promoters against Epstein-Barr virus.", [["SSHT", "CHEMICAL", 24, 28], ["SSHT", "CHEMICAL", 84, 88], ["SSHT", "CHEMICAL", 157, 161], ["SSHT", "CHEMICAL", 185, 189], ["coxsackievirus B1 infection", "DISEASE", 216, 243], ["SSHT", "CHEMICAL", 24, 28], ["SSHT", "SIMPLE_CHEMICAL", 24, 28], ["SSHT", "SIMPLE_CHEMICAL", 84, 88], ["SSHT", "SIMPLE_CHEMICAL", 157, 161], ["SSHT", "SIMPLE_CHEMICAL", 185, 189], ["coxsackievirus B1", "ORGANISM", 216, 233], ["type I interferons 22", "GENE_OR_GENE_PRODUCT", 274, 295], ["antigen", "GENE_OR_GENE_PRODUCT", 333, 340], ["Epstein-Barr virus", "ORGANISM", 387, 405], ["SSHT", "PROTEIN", 157, 161], ["type I interferons 22, 23", "PROTEIN", 274, 299], ["chemical promoters", "DNA", 360, 378], ["coxsackievirus B1", "SPECIES", 216, 233], ["Epstein-Barr virus", "SPECIES", 387, 405], ["SSHT treatment", "TREATMENT", 24, 38], ["SSHT itself", "TREATMENT", 84, 95], ["Antiviral effect of SSHT", "TREATMENT", 137, 161], ["coxsackievirus B1 infection", "PROBLEM", 216, 243], ["type I interferons", "PROBLEM", 274, 292], ["Epstein-Barr virus", "PROBLEM", 387, 405], ["infection", "OBSERVATION", 234, 243], ["Barr virus", "OBSERVATION", 395, 405]]], ["24 It has also been reported that SSHT could prevent hepatitis C virus (HCV) disease progression by promoting interleukin-10 and -12 production.", [["SSHT", "CHEMICAL", 34, 38], ["hepatitis C virus (HCV) disease", "DISEASE", 53, 84], ["SSHT", "SIMPLE_CHEMICAL", 34, 38], ["hepatitis C virus", "ORGANISM", 53, 70], ["HCV", "ORGANISM", 72, 75], ["interleukin-10", "GENE_OR_GENE_PRODUCT", 110, 124], ["-12", "GENE_OR_GENE_PRODUCT", 129, 132], ["interleukin", "PROTEIN", 110, 121], ["hepatitis C virus", "SPECIES", 53, 70], ["hepatitis C virus", "SPECIES", 53, 70], ["HCV", "SPECIES", 72, 75], ["SSHT", "TREATMENT", 34, 38], ["hepatitis C virus (HCV) disease progression", "PROBLEM", 53, 96], ["interleukin", "TEST", 110, 121], ["hepatitis", "OBSERVATION", 53, 62]]], ["25 Experimental research has shown that each constituent herb in SSHT has antiviral effects.", [["SSHT", "CHEMICAL", 65, 69], ["SSHT", "SIMPLE_CHEMICAL", 65, 69], ["antiviral effects", "TREATMENT", 74, 91]]], ["In particular, saikosaponin, a major component of Bupleuri Radix, has been reported to have antiviral activity against HCoV-22E9, a coronavirus similar to COVID-19.", [["HCoV-22E9", "ANATOMY", 119, 128], ["saikosaponin", "CHEMICAL", 15, 27], ["Bupleuri Radix", "CHEMICAL", 50, 64], ["coronavirus", "DISEASE", 132, 143], ["saikosaponin", "CHEMICAL", 15, 27], ["saikosaponin", "SIMPLE_CHEMICAL", 15, 27], ["Bupleuri Radix", "ORGANISM", 50, 64], ["HCoV-22E9", "CELL", 119, 128], ["coronavirus", "ORGANISM", 132, 143], ["COVID-19", "CELL", 155, 163], ["HCoV-22E9", "SPECIES", 119, 128], ["saikosaponin", "TREATMENT", 15, 27], ["Bupleuri Radix", "PROBLEM", 50, 64], ["antiviral activity", "TEST", 92, 110], ["HCoV", "TEST", 119, 123], ["a coronavirus", "PROBLEM", 130, 143], ["COVID", "TEST", 155, 160], ["saikosaponin", "OBSERVATION_MODIFIER", 15, 27]]], ["22 In addition, saikosaponin A inhibits influenza A replication.", [["saikosaponin A", "CHEMICAL", 16, 30], ["saikosaponin A", "CHEMICAL", 16, 30], ["saikosaponin A", "SIMPLE_CHEMICAL", 16, 30], ["influenza A", "ORGANISM", 40, 51], ["influenza A", "SPECIES", 40, 51], ["saikosaponin A inhibits influenza A replication", "PROBLEM", 16, 63]]], ["26 It has been found that ginsenoside Rb1, a major component of ginseng, can remove cytoprotective macrophages found in human immunodeficiency virus type 1 (HIV-1) infection by inhibiting the AKT pathway.", [["macrophages", "ANATOMY", 99, 110], ["ginsenoside Rb1", "CHEMICAL", 26, 41], ["human immunodeficiency virus", "DISEASE", 120, 148], ["infection", "DISEASE", 164, 173], ["ginsenoside Rb1", "CHEMICAL", 26, 41], ["ginsenoside Rb1", "SIMPLE_CHEMICAL", 26, 41], ["ginseng", "ORGANISM", 64, 71], ["macrophages", "CELL", 99, 110], ["human immunodeficiency virus type 1", "ORGANISM", 120, 155], ["HIV-1", "ORGANISM", 157, 162], ["AKT", "GENE_OR_GENE_PRODUCT", 192, 195], ["cytoprotective macrophages", "CELL_TYPE", 84, 110], ["AKT", "PROTEIN", 192, 195], ["human immunodeficiency virus type 1", "SPECIES", 120, 155], ["HIV-1", "SPECIES", 157, 162], ["human immunodeficiency virus type 1", "SPECIES", 120, 155], ["HIV-1", "SPECIES", 157, 162], ["ginsenoside Rb1", "PROBLEM", 26, 41], ["cytoprotective macrophages", "PROBLEM", 84, 110], ["human immunodeficiency virus type", "PROBLEM", 120, 153], ["HIV", "PROBLEM", 157, 160], ["infection", "PROBLEM", 164, 173], ["ginsenoside Rb1", "OBSERVATION", 26, 41], ["cytoprotective macrophages", "OBSERVATION", 84, 110], ["human immunodeficiency", "OBSERVATION_MODIFIER", 120, 142]]], ["27 The most extensively studied antiviral herb is Scutellariae Radix.", [["Scutellariae Radix", "CHEMICAL", 50, 68], ["Scutellariae Radix", "ORGANISM", 50, 68], ["antiviral herb", "OBSERVATION", 32, 46], ["Scutellariae Radix", "OBSERVATION", 50, 68]]], ["The major component of Scutellariae Radix, baicalin, is known to have antiviral activity against influenza A, 28,29 HIV-1, 30, 31 respiratory syncytial virus (RSV), 32 dengue, 33 chikungunya, 34 duck hepatitis virus (DHV), 35, 36 enterovirus, 37 and HBV.", [["Scutellariae Radix", "CHEMICAL", 23, 41], ["baicalin", "CHEMICAL", 43, 51], ["influenza A", "DISEASE", 97, 108], ["respiratory syncytial virus (RSV)", "DISEASE", 130, 163], ["dengue", "DISEASE", 168, 174], ["chikungunya", "DISEASE", 179, 190], ["duck hepatitis virus", "DISEASE", 195, 215], ["baicalin", "CHEMICAL", 43, 51], ["Scutellariae Radix", "ORGANISM", 23, 41], ["baicalin", "SIMPLE_CHEMICAL", 43, 51], ["influenza A", "ORGANISM", 97, 108], ["28,29 HIV-1, 30", "ORGANISM", 110, 125], ["31 respiratory syncytial virus", "ORGANISM", 127, 157], ["RSV", "ORGANISM", 159, 162], ["duck hepatitis virus", "ORGANISM", 195, 215], ["DHV", "CANCER", 217, 220], ["HBV", "ORGANISM", 250, 253], ["HIV-1", "SPECIES", 116, 121], ["respiratory syncytial virus (RSV", "SPECIES", 130, 162], ["duck hepatitis virus", "SPECIES", 195, 215], ["influenza A", "SPECIES", 97, 108], ["HIV-1", "SPECIES", 116, 121], ["respiratory syncytial virus", "SPECIES", 130, 157], ["RSV", "SPECIES", 159, 162], ["dengue", "SPECIES", 168, 174], ["duck hepatitis virus", "SPECIES", 195, 215], ["DHV", "SPECIES", 217, 220], ["HBV", "SPECIES", 250, 253], ["Scutellariae Radix", "TREATMENT", 23, 41], ["baicalin", "TREATMENT", 43, 51], ["antiviral activity", "TEST", 70, 88], ["influenza", "PROBLEM", 97, 106], ["HIV", "TEST", 116, 119], ["31 respiratory syncytial virus", "PROBLEM", 127, 157], ["RSV", "TEST", 159, 162], ["32 dengue", "PROBLEM", 165, 174], ["chikungunya", "PROBLEM", 179, 190], ["34 duck hepatitis virus", "PROBLEM", 192, 215], ["DHV", "TEST", 217, 220], ["enterovirus", "TEST", 230, 241], ["HBV", "PROBLEM", 250, 253], ["major", "OBSERVATION_MODIFIER", 4, 9], ["component", "OBSERVATION_MODIFIER", 10, 19], ["Scutellariae Radix", "OBSERVATION", 23, 41], ["respiratory", "ANATOMY", 130, 141], ["syncytial virus", "OBSERVATION", 142, 157]]], ["38 Another component of Scutellariae Radix, wogonin, also has an antiviral effect against the influenza virus 39 and HBV.", [["Scutellariae Radix", "CHEMICAL", 24, 42], ["wogonin", "CHEMICAL", 44, 51], ["influenza virus", "DISEASE", 94, 109], ["wogonin", "CHEMICAL", 44, 51], ["Scutellariae Radix", "ORGANISM", 24, 42], ["wogonin", "SIMPLE_CHEMICAL", 44, 51], ["influenza virus 39", "ORGANISM", 94, 112], ["HBV", "ORGANISM", 117, 120], ["influenza virus", "SPECIES", 94, 109], ["influenza virus 39", "SPECIES", 94, 112], ["HBV", "SPECIES", 117, 120], ["Scutellariae Radix", "TREATMENT", 24, 42], ["wogonin", "TREATMENT", 44, 51], ["an antiviral effect", "TREATMENT", 62, 81], ["the influenza virus", "PROBLEM", 90, 109], ["HBV", "PROBLEM", 117, 120], ["Scutellariae Radix", "OBSERVATION_MODIFIER", 24, 42], ["antiviral effect", "OBSERVATION", 65, 81]]], ["40 Lastly, Glycyrrhizae Radix et Rhizoma and its components have been reported to have antiviral activity against HCV, coxsackievirus B3, DHV, influenza, rotavirus, RSV, and herpes simplex virus 41, 42 (Table 2 21Potential role of SSHT in repurposing the treatment of COVID-19In China, which saw the first manifestation of COVID-19 and experienced local epidemics, treatment for the disease included TCHMs in combination with conventional therapies.", [["Glycyrrhizae Radix et Rhizoma", "CHEMICAL", 11, 40], ["HCV, coxsackievirus B3", "DISEASE", 114, 136], ["influenza", "DISEASE", 143, 152], ["rotavirus, RSV", "DISEASE", 154, 168], ["herpes simplex virus", "DISEASE", 174, 194], ["SSHT", "CHEMICAL", 231, 235], ["COVID-19In China", "CHEMICAL", 268, 284], ["TCHMs", "DISEASE", 400, 405], ["HCV", "ORGANISM", 114, 117], ["coxsackievirus B3", "ORGANISM", 119, 136], ["DHV", "ORGANISM", 138, 141], ["influenza", "ORGANISM", 143, 152], ["rotavirus", "ORGANISM", 154, 163], ["RSV", "ORGANISM", 165, 168], ["herpes simplex virus 41", "ORGANISM", 174, 197], ["coxsackievirus B3", "SPECIES", 119, 136], ["rotavirus", "SPECIES", 154, 163], ["RSV", "SPECIES", 165, 168], ["herpes simplex virus", "SPECIES", 174, 194], ["HCV", "SPECIES", 114, 117], ["coxsackievirus B3", "SPECIES", 119, 136], ["DHV", "SPECIES", 138, 141], ["rotavirus", "SPECIES", 154, 163], ["RSV", "SPECIES", 165, 168], ["herpes simplex virus 41", "SPECIES", 174, 197], ["Glycyrrhizae Radix et Rhizoma", "TREATMENT", 11, 40], ["antiviral activity", "PROBLEM", 87, 105], ["HCV", "PROBLEM", 114, 117], ["coxsackievirus B3", "PROBLEM", 119, 136], ["DHV", "PROBLEM", 138, 141], ["influenza", "PROBLEM", 143, 152], ["rotavirus", "PROBLEM", 154, 163], ["RSV", "PROBLEM", 165, 168], ["herpes simplex virus", "PROBLEM", 174, 194], ["SSHT", "TREATMENT", 231, 235], ["COVID", "TEST", 323, 328], ["treatment", "TREATMENT", 365, 374], ["the disease", "PROBLEM", 379, 390], ["TCHMs", "TREATMENT", 400, 405], ["conventional therapies", "TREATMENT", 426, 448]]], ["5, 6 In the Chinese Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-Induced Pneumonia (7 th Edition), 7 QPT has been suggested as a general treatment regimen forJ o u r n a l P r e -p r o o fThe results of a network pharmacology analysis of the effect of SSHT on COVID-19 also suggested that SSHT may be effective for early COVID-19 prevention and treatment.", [["Pneumonia", "DISEASE", 105, 114], ["SSHT", "CHEMICAL", 321, 325], ["SSHT", "SIMPLE_CHEMICAL", 284, 288], ["SSHT", "SIMPLE_CHEMICAL", 321, 325], ["Novel Coronavirus", "PROBLEM", 79, 96], ["Pneumonia", "PROBLEM", 105, 114], ["a general treatment regimen", "TREATMENT", 159, 186], ["SSHT", "TREATMENT", 284, 288], ["COVID", "TEST", 292, 297], ["SSHT", "TREATMENT", 321, 325], ["early COVID-19 prevention", "TREATMENT", 347, 372], ["treatment", "TREATMENT", 377, 386], ["Pneumonia", "OBSERVATION", 105, 114]]], ["57 The authors investigated 12 components of SSHT that show anti-SARS-CoV-2 activity (baicalein, beta-carotene, coptisine, formononetin, glycyrrhizic acid, kaempferol, moupinamide, quercetin, saikosaponin A, saikosaponin B2, saikosaponin D, and 7-methoxy-2-methyl isoflavone) could be effective for pneumonia treatment and immunoregulation by acting on a total of 95 key targets (IL-6, NOS2, ESR1, etc.).", [["baicalein", "CHEMICAL", 86, 95], ["beta-carotene", "CHEMICAL", 97, 110], ["coptisine", "CHEMICAL", 112, 121], ["formononetin", "CHEMICAL", 123, 135], ["glycyrrhizic acid", "CHEMICAL", 137, 154], ["kaempferol", "CHEMICAL", 156, 166], ["moupinamide", "CHEMICAL", 168, 179], ["quercetin", "CHEMICAL", 181, 190], ["saikosaponin A", "CHEMICAL", 192, 206], ["saikosaponin B2, saikosaponin D", "CHEMICAL", 208, 239], ["7-methoxy-2-methyl isoflavone", "CHEMICAL", 245, 274], ["pneumonia", "DISEASE", 299, 308], ["baicalein", "CHEMICAL", 86, 95], ["beta-carotene", "CHEMICAL", 97, 110], ["coptisine", "CHEMICAL", 112, 121], ["formononetin", "CHEMICAL", 123, 135], ["glycyrrhizic acid", "CHEMICAL", 137, 154], ["kaempferol", "CHEMICAL", 156, 166], ["moupinamide", "CHEMICAL", 168, 179], ["quercetin", "CHEMICAL", 181, 190], ["saikosaponin A", "CHEMICAL", 192, 206], ["saikosaponin B2", "CHEMICAL", 208, 223], ["saikosaponin D", "CHEMICAL", 225, 239], ["7-methoxy-2-methyl isoflavone", "CHEMICAL", 245, 274], ["SSHT", "SIMPLE_CHEMICAL", 45, 49], ["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 60, 75], ["baicalein", "SIMPLE_CHEMICAL", 86, 95], ["beta-carotene", "SIMPLE_CHEMICAL", 97, 110], ["coptisine", "SIMPLE_CHEMICAL", 112, 121], ["formononetin", "SIMPLE_CHEMICAL", 123, 135], ["glycyrrhizic acid", "SIMPLE_CHEMICAL", 137, 154], ["kaempferol", "SIMPLE_CHEMICAL", 156, 166], ["moupinamide", "SIMPLE_CHEMICAL", 168, 179], ["quercetin", "SIMPLE_CHEMICAL", 181, 190], ["saikosaponin A", "SIMPLE_CHEMICAL", 192, 206], ["saikosaponin B2", "SIMPLE_CHEMICAL", 208, 223], ["saikosaponin D", "SIMPLE_CHEMICAL", 225, 239], ["7-methoxy-2-methyl isoflavone", "SIMPLE_CHEMICAL", 245, 274], ["IL-6", "GENE_OR_GENE_PRODUCT", 380, 384], ["NOS2", "GENE_OR_GENE_PRODUCT", 386, 390], ["ESR1", "GENE_OR_GENE_PRODUCT", 392, 396], ["IL-6", "PROTEIN", 380, 384], ["NOS2", "PROTEIN", 386, 390], ["ESR1", "PROTEIN", 392, 396], ["SSHT", "TREATMENT", 45, 49], ["anti-SARS", "TEST", 60, 69], ["CoV", "TEST", 70, 73], ["baicalein", "TREATMENT", 86, 95], ["beta-carotene", "TREATMENT", 97, 110], ["coptisine", "TREATMENT", 112, 121], ["formononetin", "TREATMENT", 123, 135], ["glycyrrhizic acid", "TREATMENT", 137, 154], ["kaempferol", "TREATMENT", 156, 166], ["moupinamide", "TREATMENT", 168, 179], ["quercetin", "TREATMENT", 181, 190], ["saikosaponin A", "TREATMENT", 192, 206], ["saikosaponin B2", "TREATMENT", 208, 223], ["saikosaponin D", "TREATMENT", 225, 239], ["methoxy", "TREATMENT", 247, 254], ["methyl isoflavone", "TREATMENT", 257, 274], ["pneumonia treatment", "TREATMENT", 299, 318], ["IL", "TEST", 380, 382], ["pneumonia", "OBSERVATION", 299, 308]]], ["Based on these results, it was assumed that SSHT could have effects such as inhibition of SARS-CoV2 activity, blocking of SARS-CoV2invasion pathway, and suppression of cytokine storm expression.", [["SSHT", "CHEMICAL", 44, 48], ["SSHT", "SIMPLE_CHEMICAL", 44, 48], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 90, 99], ["SARS-CoV2invasion", "GENE_OR_GENE_PRODUCT", 122, 139], ["CoV2", "PROTEIN", 95, 99], ["cytokine", "PROTEIN", 168, 176], ["SARS", "PROBLEM", 90, 94], ["SARS-CoV2invasion pathway", "TREATMENT", 122, 147], ["cytokine storm expression", "PROBLEM", 168, 193], ["cytokine storm", "OBSERVATION", 168, 182]]], ["This phenomenon demonstrates multi-target and multi-directional activity, which is an advantage of herbal medicine composed of various herbs (Table 3) .J o u r n a l P r e -p r o o fFurthermore, it is necessary to pay special attention to the immunomodulatory effect of SSHT.J o u r n a l P r e -p r o o fIn an experimental study using a cyclophosphamide-induced immunosuppression animal model, 58 SSHT was shown to exert an immunomodulatory effect that increases lymphocytes only in the immunosuppressive model (and is invalid in the normal animal model).", [["lymphocytes", "ANATOMY", 464, 475], ["cyclophosphamide", "CHEMICAL", 338, 354], ["SSHT", "CHEMICAL", 398, 402], ["cyclophosphamide", "CHEMICAL", 338, 354], ["cyclophosphamide", "SIMPLE_CHEMICAL", 338, 354], ["lymphocytes", "CELL", 464, 475], ["lymphocytes", "CELL_TYPE", 464, 475], ["herbal medicine", "TREATMENT", 99, 114], ["fFurthermore", "PROBLEM", 181, 193], ["SSHT", "TEST", 270, 274], ["an experimental study", "TEST", 308, 329], ["a cyclophosphamide", "TREATMENT", 336, 354], ["an immunomodulatory effect", "PROBLEM", 422, 448], ["lymphocytes", "PROBLEM", 464, 475], ["the immunosuppressive model", "TREATMENT", 484, 511], ["multi-target", "OBSERVATION_MODIFIER", 29, 41], ["multi-directional activity", "OBSERVATION", 46, 72], ["immunomodulatory effect", "OBSERVATION", 425, 448], ["increases", "OBSERVATION_MODIFIER", 454, 463], ["lymphocytes", "OBSERVATION", 464, 475]]], ["In an observational study of 21 patients with COVID-19, 59 early lymphocyte degradation was observed to be a characteristic observation in the patients, suggesting that early lymphocyte degradation would have diagnostic value.", [["lymphocyte", "ANATOMY", 65, 75], ["lymphocyte", "ANATOMY", 175, 185], ["patients", "ORGANISM", 32, 40], ["lymphocyte", "CELL", 65, 75], ["patients", "ORGANISM", 143, 151], ["lymphocyte", "CELL", 175, 185], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 143, 151], ["an observational study", "TEST", 3, 25], ["COVID", "TEST", 46, 51], ["early lymphocyte degradation", "PROBLEM", 59, 87], ["early lymphocyte degradation", "PROBLEM", 169, 197], ["diagnostic value", "TEST", 209, 225], ["early", "OBSERVATION_MODIFIER", 169, 174], ["lymphocyte degradation", "OBSERVATION", 175, 197]]], ["Considering these serologic abnormalities associated with early COVID-19 and the immunomodulatory effect of SSHT, it is possible that the use of SSHT in the early to mid-term stages of the disease could be helpful (Table 3) .", [["SSHT", "CHEMICAL", 145, 149], ["SSHT", "SIMPLE_CHEMICAL", 108, 112], ["SSHT", "GENE_OR_GENE_PRODUCT", 145, 149], ["these serologic abnormalities", "PROBLEM", 12, 41], ["early COVID", "TEST", 58, 69], ["SSHT", "TREATMENT", 108, 112], ["SSHT", "TREATMENT", 145, 149], ["the disease", "PROBLEM", 185, 196], ["disease", "OBSERVATION", 189, 196]]], ["Most minor liver injuries will recover without special treatment, but severe liver injuries will result in significant disease burden.", [["liver", "ANATOMY", 11, 16], ["liver", "ANATOMY", 77, 82], ["liver injuries", "DISEASE", 11, 25], ["liver injuries", "DISEASE", 77, 91], ["liver", "ORGAN", 11, 16], ["liver", "ORGAN", 77, 82], ["Most minor liver injuries", "PROBLEM", 0, 25], ["special treatment", "TREATMENT", 47, 64], ["severe liver injuries", "PROBLEM", 70, 91], ["significant disease burden", "PROBLEM", 107, 133], ["liver", "ANATOMY", 11, 16], ["injuries", "OBSERVATION", 17, 25], ["severe", "OBSERVATION_MODIFIER", 70, 76], ["liver", "ANATOMY", 77, 82], ["injuries", "OBSERVATION", 83, 91], ["significant", "OBSERVATION_MODIFIER", 107, 118], ["disease", "OBSERVATION", 119, 126]]], ["As mentioned earlier, SSHT has been utilized in patients with HBV or HCV infection and has shown significant antiviral and hepato-protective effects.", [["SSHT", "CHEMICAL", 22, 26], ["HCV infection", "DISEASE", 69, 82], ["SSHT", "GENE_OR_GENE_PRODUCT", 22, 26], ["patients", "ORGANISM", 48, 56], ["HBV", "ORGANISM", 62, 65], ["HCV", "ORGANISM", 69, 72], ["SSHT", "PROTEIN", 22, 26], ["patients", "SPECIES", 48, 56], ["HBV", "SPECIES", 62, 65], ["HCV", "SPECIES", 69, 72], ["SSHT", "TREATMENT", 22, 26], ["HBV", "PROBLEM", 62, 65], ["HCV infection", "PROBLEM", 69, 82], ["hepato-protective effects", "TREATMENT", 123, 148], ["HCV", "OBSERVATION", 69, 72], ["significant", "OBSERVATION_MODIFIER", 97, 108], ["antiviral", "OBSERVATION", 109, 118]]], ["[15] [16] [17] [18] [19] [20] [21] 25 These clinical and pharmacological evidences of SSHT will be expected to play a role in the management of liver injury in patients with COVID-19 (Table 3) .SSHT variants that can be used according to various clinical symptomsTraditionally, SSHT has been used in combination with various prescriptions depending on the symptoms accompanying various infectious diseases.", [["liver", "ANATOMY", 144, 149], ["SSHT", "CHEMICAL", 86, 90], ["liver injury", "DISEASE", 144, 156], ["SSHT", "CHEMICAL", 278, 282], ["infectious diseases", "DISEASE", 386, 405], ["COVID-19", "CHEMICAL", 174, 182], ["[15] [16] [17] [18] [19] [20] [21] 25", "SIMPLE_CHEMICAL", 0, 37], ["SSHT", "SIMPLE_CHEMICAL", 86, 90], ["liver", "ORGAN", 144, 149], ["patients", "ORGANISM", 160, 168], ["SSHT", "GENE_OR_GENE_PRODUCT", 194, 198], ["SSHT", "SIMPLE_CHEMICAL", 278, 282], ["patients", "SPECIES", 160, 168], ["liver injury", "PROBLEM", 144, 156], ["COVID", "TEST", 174, 179], ["SSHT variants", "TREATMENT", 194, 207], ["various clinical symptoms", "PROBLEM", 238, 263], ["SSHT", "TREATMENT", 278, 282], ["various prescriptions", "TREATMENT", 317, 338], ["the symptoms", "PROBLEM", 352, 364], ["various infectious diseases", "PROBLEM", 378, 405], ["liver", "ANATOMY", 144, 149], ["injury", "OBSERVATION", 150, 156], ["infectious", "OBSERVATION", 386, 396]]], ["An example is given in Table 4 .SSHT variants that can be used according to various clinical symptomsAs we discussed earlier, SSHT (as part of QPT) has been utilized in the COVID-19 epidemic as a basic prescription that can be used at various stages.", [["SSHT", "GENE_OR_GENE_PRODUCT", 32, 36], ["SSHT", "SIMPLE_CHEMICAL", 126, 130], ["SSHT", "PROTEIN", 126, 130], ["SSHT variants", "TREATMENT", 32, 45], ["various clinical symptoms", "PROBLEM", 76, 101], ["a basic prescription", "TREATMENT", 194, 214]]], ["7, 56 This history of SSHT use suggests that each prescription for each patient can be modified according to symptoms and that the antiviral action of SSHT can also form the basis of prescription.Cautions when using SSHTSSHT should be used with caution.", [["SSHT", "CHEMICAL", 151, 155], ["patient", "ORGANISM", 72, 79], ["SSHT", "SIMPLE_CHEMICAL", 151, 155], ["patient", "SPECIES", 72, 79], ["symptoms", "PROBLEM", 109, 117], ["the antiviral action of SSHT", "TREATMENT", 127, 155], ["SSHTSSHT", "TREATMENT", 216, 224]]], ["The Korean Ministry of Food and Drug Safety permits the use of SSHT, except in the following contraindications (Table 1) : 43 patients receiving interferon; patients with liver cirrhosis and liver cancer (use of SSHT can lead to interstitial pneumonia, which can further cause serious consequences such as death); patients with platelet counts of less than 100,000/mm 3 owing to liver dysfunction.Cautions when using SSHTIt is known that administering SSHT in the above situations may cause interstitial pneumonia; therefore, use of SSHT in these situations should be avoided.", [["liver cirrhosis", "ANATOMY", 171, 186], ["liver cancer", "ANATOMY", 191, 203], ["interstitial", "ANATOMY", 229, 241], ["platelet", "ANATOMY", 328, 336], ["liver", "ANATOMY", 379, 384], ["interstitial", "ANATOMY", 491, 503], ["liver cirrhosis", "DISEASE", 171, 186], ["liver cancer", "DISEASE", 191, 203], ["SSHT", "CHEMICAL", 212, 216], ["interstitial pneumonia", "DISEASE", 229, 251], ["death", "DISEASE", 306, 311], ["liver dysfunction", "DISEASE", 379, 396], ["SSHT", "CHEMICAL", 452, 456], ["interstitial pneumonia", "DISEASE", 491, 513], ["SSHT", "CHEMICAL", 533, 537], ["patients", "ORGANISM", 126, 134], ["interferon", "GENE_OR_GENE_PRODUCT", 145, 155], ["patients", "ORGANISM", 157, 165], ["liver", "ORGAN", 171, 176], ["liver cancer", "CANCER", 191, 203], ["patients", "ORGANISM", 314, 322], ["platelet", "CELL", 328, 336], ["liver", "ORGAN", 379, 384], ["interferon", "PROTEIN", 145, 155], ["patients", "SPECIES", 126, 134], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 314, 322], ["SSHT", "TREATMENT", 63, 67], ["interferon", "TREATMENT", 145, 155], ["liver cirrhosis", "PROBLEM", 171, 186], ["liver cancer", "PROBLEM", 191, 203], ["SSHT", "TREATMENT", 212, 216], ["interstitial pneumonia", "PROBLEM", 229, 251], ["death", "PROBLEM", 306, 311], ["platelet counts", "TEST", 328, 343], ["liver dysfunction", "PROBLEM", 379, 396], ["SSHT", "TREATMENT", 452, 456], ["interstitial pneumonia", "PROBLEM", 491, 513], ["SSHT", "TREATMENT", 533, 537], ["liver", "ANATOMY", 171, 176], ["cirrhosis", "OBSERVATION", 177, 186], ["liver", "ANATOMY", 191, 196], ["cancer", "OBSERVATION", 197, 203], ["interstitial", "ANATOMY_MODIFIER", 229, 241], ["pneumonia", "OBSERVATION", 242, 251], ["liver", "ANATOMY", 379, 384], ["dysfunction", "OBSERVATION", 385, 396], ["interstitial", "ANATOMY_MODIFIER", 491, 503], ["pneumonia", "OBSERVATION", 504, 513]]], ["In particular, because of the risk of interstitial pneumonia, using SSHT requires caution with combination with interferon.J o u r n a l P r e -p r o o fAccording to the COVID-19 treatment guideline of Korean Association of Internal Medicine, use of type I interferon as monotherapy is not recommended, but use of combined therapy is recommended.", [["interstitial", "ANATOMY", 38, 50], ["interstitial pneumonia", "DISEASE", 38, 60], ["type I interferon", "CHEMICAL", 250, 267], ["interferon", "GENE_OR_GENE_PRODUCT", 112, 122], ["type I interferon", "GENE_OR_GENE_PRODUCT", 250, 267], ["interferon", "PROTEIN", 112, 122], ["type I interferon", "PROTEIN", 250, 267], ["interstitial pneumonia", "PROBLEM", 38, 60], ["SSHT", "TREATMENT", 68, 72], ["interferon", "TREATMENT", 112, 122], ["fAccording", "TREATMENT", 152, 162], ["the COVID", "TREATMENT", 166, 175], ["Internal Medicine", "TREATMENT", 224, 241], ["type I interferon", "TREATMENT", 250, 267], ["monotherapy", "TREATMENT", 271, 282], ["combined therapy", "TREATMENT", 314, 330], ["interstitial", "ANATOMY_MODIFIER", 38, 50], ["pneumonia", "OBSERVATION", 51, 60]]], ["61 Therefore, when considering the use of SSHT in clinical practice, it is necessary to confirm whether interferon is used or not.", [["interferon", "GENE_OR_GENE_PRODUCT", 104, 114], ["interferon", "PROTEIN", 104, 114], ["SSHT", "TREATMENT", 42, 46], ["interferon", "TREATMENT", 104, 114]]], ["Moreover, there have also been case reports of pulmonary edema occurring after SSHT was used for liver dysfunction of unknown etiology.", [["pulmonary", "ANATOMY", 47, 56], ["liver", "ANATOMY", 97, 102], ["pulmonary edema", "DISEASE", 47, 62], ["SSHT", "CHEMICAL", 79, 83], ["liver dysfunction", "DISEASE", 97, 114], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 47, 62], ["liver", "ORGAN", 97, 102], ["pulmonary edema", "PROBLEM", 47, 62], ["SSHT", "TREATMENT", 79, 83], ["liver dysfunction", "PROBLEM", 97, 114], ["pulmonary", "ANATOMY", 47, 56], ["edema", "OBSERVATION", 57, 62], ["liver", "ANATOMY", 97, 102], ["dysfunction", "OBSERVATION", 103, 114]]], ["62, 63 Therefore, it is necessary to pay attention to the use of SSHT when there is a liver dysfunction of unknown cause.ConclusionsSSHT has been used for infectious diseases for perhaps the last 1,900 years, and its efficacy in infectious diseases has been scientifically established.", [["liver", "ANATOMY", 86, 91], ["liver dysfunction", "DISEASE", 86, 103], ["SSHT", "CHEMICAL", 132, 136], ["infectious diseases", "DISEASE", 155, 174], ["infectious diseases", "DISEASE", 229, 248], ["SSHT", "CANCER", 65, 69], ["liver", "ORGAN", 86, 91], ["SSHT", "TREATMENT", 65, 69], ["a liver dysfunction", "PROBLEM", 84, 103], ["infectious diseases", "PROBLEM", 155, 174], ["infectious diseases", "PROBLEM", 229, 248], ["liver", "ANATOMY", 86, 91], ["dysfunction", "OBSERVATION", 92, 103], ["infectious", "OBSERVATION", 229, 239]]], ["[11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] In particular, SSHT has been used in various viral diseases based on its antiviral effect and-if contraindications are dully considered-it can be regarded as a relatively safe medication given its long history of use.", [["[11] [12] [13] [14] [15] [16] [17] [18] [19] [20", "CHEMICAL", 0, 48], ["SSHT", "CHEMICAL", 70, 74], ["viral diseases", "DISEASE", 100, 114], ["[11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 0, 54], ["SSHT", "SIMPLE_CHEMICAL", 70, 74], ["various viral diseases", "PROBLEM", 92, 114], ["a relatively safe medication", "TREATMENT", 213, 241], ["viral diseases", "OBSERVATION", 100, 114]]], ["In addition, considering the indications of SSHT, and the scope of its previous usage, we think that SSHT could be prescribed for COVID-19 patients with persistent fever, respiratory symptoms such as cough or sputum, and liver injury caused by conventional therapies.ConclusionsBased on the evidence so far, it is believed that SSHT is likely to be a repurposing medication for COVID-19.", [["respiratory", "ANATOMY", 171, 182], ["sputum", "ANATOMY", 209, 215], ["liver", "ANATOMY", 221, 226], ["SSHT", "CHEMICAL", 101, 105], ["fever", "DISEASE", 164, 169], ["respiratory symptoms", "DISEASE", 171, 191], ["cough", "DISEASE", 200, 205], ["liver injury", "DISEASE", 221, 233], ["COVID-19", "CHEMICAL", 378, 386], ["SSHT", "SIMPLE_CHEMICAL", 101, 105], ["patients", "ORGANISM", 139, 147], ["liver", "ORGAN", 221, 226], ["SSHT", "SIMPLE_CHEMICAL", 328, 332], ["patients", "SPECIES", 139, 147], ["SSHT", "TREATMENT", 44, 48], ["SSHT", "TREATMENT", 101, 105], ["persistent fever", "PROBLEM", 153, 169], ["respiratory symptoms", "PROBLEM", 171, 191], ["cough", "PROBLEM", 200, 205], ["sputum", "PROBLEM", 209, 215], ["liver injury", "PROBLEM", 221, 233], ["conventional therapies", "TREATMENT", 244, 266], ["a repurposing medication", "TREATMENT", 349, 373], ["COVID", "TEST", 378, 383], ["persistent", "OBSERVATION_MODIFIER", 153, 163], ["fever", "OBSERVATION", 164, 169], ["liver", "ANATOMY", 221, 226], ["injury", "OBSERVATION", 227, 233], ["likely to be", "UNCERTAINTY", 336, 348]]], ["Conducting further studies might provide improved understanding regarding the use of SSHT in treating COVID-19.Conflicts of InterestThe authors declare that there is no conflict of interest regarding the publication of this paper.Ethical StatementNot applicable.Data availabilityData will be made available upon request.", [["SSHT", "CHEMICAL", 85, 89], ["COVID-19", "CHEMICAL", 102, 110], ["SSHT", "SIMPLE_CHEMICAL", 85, 89], ["Conducting further studies", "TEST", 0, 26], ["SSHT", "TREATMENT", 85, 89], ["COVID", "TEST", 102, 107]]], ["All data used for this study are from previous studies which are included in References.Funding StatementThe authors declare that no funding was received in relation to this study.", [["this study", "TEST", 18, 28], ["previous studies", "TEST", 38, 54], ["this study", "TEST", 169, 179]]], ["2) Patients with liver cirrhosis and liver cancer (interstitial pneumonia can occur, which can lead to serious consequences such as death)Funding Statement3) Patients with platelet counts less than 100,000/mm 3 because of liver dysfunction J o u r n a l P r e -p r o o f Table 2 .", [["liver cirrhosis", "ANATOMY", 17, 32], ["liver cancer", "ANATOMY", 37, 49], ["interstitial", "ANATOMY", 51, 63], ["platelet", "ANATOMY", 172, 180], ["liver", "ANATOMY", 222, 227], ["liver cirrhosis", "DISEASE", 17, 32], ["liver cancer", "DISEASE", 37, 49], ["interstitial pneumonia", "DISEASE", 51, 73], ["death", "DISEASE", 132, 137], ["liver dysfunction", "DISEASE", 222, 239], ["Patients", "ORGANISM", 3, 11], ["liver", "ORGAN", 17, 22], ["liver cancer", "CANCER", 37, 49], ["Patients", "ORGANISM", 158, 166], ["platelet", "CELL", 172, 180], ["liver", "ORGAN", 222, 227], ["Patients", "SPECIES", 3, 11], ["Patients", "SPECIES", 158, 166], ["liver cirrhosis", "PROBLEM", 17, 32], ["liver cancer", "PROBLEM", 37, 49], ["interstitial pneumonia", "PROBLEM", 51, 73], ["platelet counts", "TEST", 172, 187], ["liver dysfunction", "PROBLEM", 222, 239], ["liver", "ANATOMY", 17, 22], ["cirrhosis", "OBSERVATION", 23, 32], ["liver", "ANATOMY", 37, 42], ["cancer", "OBSERVATION", 43, 49], ["interstitial", "ANATOMY_MODIFIER", 51, 63], ["pneumonia", "OBSERVATION", 64, 73], ["liver", "ANATOMY", 222, 227], ["dysfunction", "OBSERVATION", 228, 239]]], ["Antiviral effect of Soshihotang as observed in experimental studies Tonsillitis and peritonsillitis.", [["Soshihotang", "CHEMICAL", 20, 31], ["peritonsillitis", "DISEASE", 84, 99], ["Soshihotang", "SIMPLE_CHEMICAL", 20, 31], ["Antiviral effect of Soshihotang", "PROBLEM", 0, 31], ["Tonsillitis", "PROBLEM", 68, 79], ["peritonsillitis", "PROBLEM", 84, 99], ["Tonsillitis", "OBSERVATION", 68, 79], ["peritonsillitis", "OBSERVATION", 84, 99]]], ["These conditions accompanied by sore throat:Funding StatementSSHT; Soshihotang * The indications are based on drug approvals from Korea and Japan.", [["sore throat", "DISEASE", 32, 43], ["sore throat", "PROBLEM", 32, 43], ["sore", "OBSERVATION", 32, 36]]]], "PMC4773259": [["INTRODUCTIONMiddle East respiratory syndrome (MERS) is a viral respiratory disease caused by a novel coronavirus (MERS-CoV) that was first identified in Saudi Arabia in 2012 [1].", [["respiratory", "ANATOMY", 63, 74], ["INTRODUCTIONMiddle East respiratory syndrome", "DISEASE", 0, 44], ["MERS", "DISEASE", 46, 50], ["viral respiratory disease", "DISEASE", 57, 82], ["MERS-CoV", "ORGANISM", 114, 122], ["MERS-CoV", "SPECIES", 114, 122], ["East respiratory syndrome", "PROBLEM", 19, 44], ["a viral respiratory disease", "PROBLEM", 55, 82], ["a novel coronavirus", "PROBLEM", 93, 112], ["respiratory syndrome", "OBSERVATION", 24, 44], ["viral", "OBSERVATION_MODIFIER", 57, 62], ["respiratory disease", "OBSERVATION", 63, 82]]], ["No MERS cases were reported in Korea until May 20, 2015 when the first Korean MERS case was identified in a 68-yr-old man returning from the Middle East.", [["man", "ORGANISM", 118, 121], ["man", "SPECIES", 118, 121], ["MERS cases", "PROBLEM", 3, 13], ["MERS", "OBSERVATION", 3, 7], ["Middle", "ANATOMY_MODIFIER", 141, 147]]], ["Since then a total of 186 confirmed cases have been reported in Korea as of Oct 2, 2015 [23].INTRODUCTIONOn June 3, 2015, the Korean Society for Laboratory Medicine (KSLM) launched a MERS-CoV Laboratory Response Task Force (LR-TF) to facilitate clinical laboratories to set up the diagnosis of MERS-CoV infection.", [["MERS-CoV infection", "DISEASE", 294, 312], ["MERS-CoV", "ORGANISM", 294, 302], ["MERS-CoV", "SPECIES", 294, 302], ["LR-TF)", "TREATMENT", 224, 230], ["clinical laboratories", "TEST", 245, 266], ["MERS", "PROBLEM", 294, 298], ["CoV infection", "PROBLEM", 299, 312], ["CoV infection", "OBSERVATION", 299, 312]]], ["Although laboratory guidelines or resources for the molecular diagnosis of MERS-CoV had been provided by several international authoritative bodies [45], the Korean version of guideline was required in the unexperienced situation of the nationwide outbreak, which developed rapidly by intra-hospital and inter-hospital spread of an imported deadly virus.", [["MERS-CoV", "ORGANISM", 75, 83], ["MERS-CoV", "SPECIES", 75, 83], ["MERS", "PROBLEM", 75, 79], ["CoV", "PROBLEM", 80, 83], ["an imported deadly virus", "PROBLEM", 329, 353]]], ["This outbreak was beyond national capacity of laboratory preparedness for emerging infectious diseases.", [["infectious diseases", "DISEASE", 83, 102], ["emerging infectious diseases", "PROBLEM", 74, 102], ["infectious", "OBSERVATION", 83, 93]]], ["Therefore, the KSLM MERS-CoV LR-TF decided to provide the clinical laboratories with the laboratory practice guidelines of national standard for the molecular diagnosis of MERS-CoV.", [["MERS-CoV", "ORGANISM", 172, 180], ["KSLM MERS-CoV LR", "DNA", 15, 31], ["TF", "PROTEIN", 32, 34], ["MERS-CoV", "SPECIES", 172, 180], ["CoV LR", "TREATMENT", 25, 31]]], ["On behalf of the Central MERS-CoV Control Office in Korea, organized by the Korean Ministry of Health and Welfare (KMHW), the first version of the KSLM laboratory practice guidelines was issued on June 12, 2015.INTRODUCTIONThis updated version of the KSLM laboratory practice guidelines for the molecular diagnosis of MERS-CoV is based on interim recommendations for MERS-CoV laboratory testing by the WHO [4], the laboratory testing guidelines for MERS-CoV by the Centers for Disease Control and Prevention of United States (US CDC) [5], and other available resources [678].INTRODUCTIONThe guidelines provided here focus on the molecular diagnosis of MERS-CoV from case definition to interpretation and reporting as well as laboratory safety.Confirmed case ::: CASE DEFINITION OF MERS-CoV INFECTIONA person with laboratory confirmation of MERS-CoV infection by KCDC is regarded as a confirmed case irrespective of clinical signs and symptoms.", [["MERS-CoV infection", "DISEASE", 840, 858], ["MERS-CoV", "ORGANISM", 318, 326], ["MERS-CoV", "ORGANISM", 652, 660], ["MERS-CoV", "ORGANISM", 840, 848], ["person", "SPECIES", 801, 807], ["MERS-CoV", "SPECIES", 318, 326], ["MERS-CoV", "SPECIES", 367, 375], ["MERS-CoV", "SPECIES", 449, 457], ["MERS-CoV", "SPECIES", 652, 660], ["MERS-CoV", "SPECIES", 840, 848], ["MERS", "PROBLEM", 318, 322], ["CoV laboratory testing", "TEST", 372, 394], ["the laboratory testing", "TEST", 411, 433], ["Disease Control", "TREATMENT", 477, 492], ["laboratory confirmation", "TEST", 813, 836], ["MERS", "PROBLEM", 840, 844], ["CoV infection", "PROBLEM", 845, 858], ["clinical signs", "PROBLEM", 915, 929], ["symptoms", "PROBLEM", 934, 942]]], ["Detection of viral nucleic acid by real-time reverse transcription polymerase chain reaction (rRT-PCR) is the method of choice for laboratory confirmation.", [["nucleic acid", "CHEMICAL", 19, 31], ["viral nucleic acid", "TEST", 13, 31], ["reverse transcription polymerase chain reaction", "PROBLEM", 45, 92], ["laboratory confirmation", "TEST", 131, 154], ["viral nucleic acid", "OBSERVATION", 13, 31]]], ["Detailed protocols for rRT-PCR and interpretation of the results are described later in these guidelines.", [["rRT", "DNA", 23, 26], ["rRT-PCR", "TEST", 23, 30]]], ["Although seroconversion assays were not used in the 2015 Korean outbreak, serological confirmation of a case requires the demonstration of seroconversion in two serum samples, ideally taken at least 14 days apart, on the basis of enzyme immunoassay or immunofluorescent assay as a screening and a neutralization assay.Suspect case ::: CASE DEFINITION OF MERS-CoV INFECTIONA person with febrile acute respiratory illness of any severity plus either a history of travel to the Middle East or a direct epidemiological link with a confirmed MERS-CoV case within 14 days before symptom onset is regarded as a MERS-CoV suspect case.", [["serum samples", "ANATOMY", 161, 174], ["respiratory", "ANATOMY", 400, 411], ["febrile acute respiratory illness", "DISEASE", 386, 419], ["serum samples", "ORGANISM_SUBSTANCE", 161, 174], ["MERS-CoV", "ORGANISM", 537, 545], ["person", "SPECIES", 374, 380], ["MERS-CoV", "SPECIES", 537, 545], ["MERS-CoV", "SPECIES", 604, 612], ["seroconversion assays", "TEST", 9, 30], ["serological confirmation", "TEST", 74, 98], ["seroconversion", "PROBLEM", 139, 153], ["two serum samples", "TEST", 157, 174], ["enzyme immunoassay", "TEST", 230, 248], ["immunofluorescent assay", "TEST", 252, 275], ["a screening", "TEST", 279, 290], ["a neutralization assay", "TEST", 295, 317], ["febrile acute respiratory illness", "PROBLEM", 386, 419]]], ["The Middle East countries include Bahrain, Iraq, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Syria, the United Arab Emirates (UAE), and Yemen.", [["Middle", "ANATOMY_MODIFIER", 4, 10]]], ["A direct epidemiological link with a confirmed MERS-CoV case showing relevant symptoms includes: with or without adequate personal protective equipment (PPE) plus one of 1) staying or living in the same room with a confirmed case; 2) healthcare-associated exposure that includes providing care for MERS-CoV cases; 3) working with healthcare workers infected with MERS-CoV; and/or 4) direct contact with the respiratory secretion of confirmed cases.Probable case ::: CASE DEFINITION OF MERS-CoV INFECTIONIn addition to the case definitions of confirmed and suspect cases, the KSLM MERS-CoV LR-TF members agree that a case definition for a \"probable case\" is needed.", [["respiratory", "ANATOMY", 407, 418], ["MERS-CoV", "ORGANISM", 363, 371], ["KSLM MERS-CoV LR-TF members", "DNA", 575, 602], ["MERS-CoV", "SPECIES", 47, 55], ["MERS-CoV", "SPECIES", 298, 306], ["MERS-CoV", "SPECIES", 363, 371], ["relevant symptoms", "PROBLEM", 69, 86], ["the respiratory secretion", "TEST", 403, 428], ["MERS-CoV", "OBSERVATION", 485, 493]]], ["A probable case can be defined as a suspect case with negative, indeterminate, or equivocal rRT-PCR results.", [["indeterminate", "OBSERVATION_MODIFIER", 64, 77]]], ["In addition, an individual with preliminary positive rRT-PCR results from clinical laboratories but without confirmed results by KCDC can be defined as a probable case.", [["rRT", "DNA", 53, 56], ["clinical laboratories", "TEST", 74, 95]]], ["Repeat testing for MERS-CoV is recommended for probable cases.INDICATIONS FOR TESTINGThe KMHW approved the emergency use of rRT-PCR assays for MERS-CoV diagnosis in clinical laboratories with KSLM guarantee of good laboratory practice from June 6, 2015 to the end of the outbreak.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["MERS-CoV", "ORGANISM", 143, 151], ["MERS-CoV", "SPECIES", 19, 27], ["MERS-CoV", "SPECIES", 143, 151], ["Repeat testing", "TEST", 0, 14], ["MERS-CoV", "TEST", 19, 27], ["rRT", "TREATMENT", 124, 127], ["PCR assays", "TEST", 128, 138], ["MERS", "PROBLEM", 143, 147], ["clinical laboratories", "TEST", 165, 186]]], ["The KMHW defined the following indications to go for a MERS-CoV rRT-PCR test: 1) confirmation of a suspect case, 2) screening for a case with a direct epidemiological link, 3) differential diagnosis of a patient with fever and community-acquired pneumonia or acute respiratory distress syndrome, and/or 4) criteria for releasing confirmed cases from quarantine.", [["respiratory", "ANATOMY", 265, 276], ["fever", "DISEASE", 217, 222], ["pneumonia", "DISEASE", 246, 255], ["acute respiratory distress syndrome", "DISEASE", 259, 294], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 204, 211], ["a MERS", "TEST", 53, 59], ["CoV rRT", "TEST", 60, 67], ["fever", "PROBLEM", 217, 222], ["community-acquired pneumonia", "PROBLEM", 227, 255], ["acute respiratory distress syndrome", "PROBLEM", 259, 294], ["pneumonia", "OBSERVATION", 246, 255], ["acute", "OBSERVATION_MODIFIER", 259, 264], ["respiratory distress", "OBSERVATION", 265, 285]]], ["The KSLM recommends the testing for other respiratory pathogens such as influenza viruses, parainfluenza viruses, and respiratory syncytial virus, but emphasizes that there should not be any delay in testing for MERS-CoV because of those testing [4].SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTIONLower respiratory specimens such as sputum, tracheal aspirates, and bronchoalveolar lavage are preferred for the detection of MERS-CoV; however, collection of upper respiratory specimens is recommended in addition to lower respiratory specimens whenever possible (Table 1).", [["respiratory specimens", "ANATOMY", 307, 328], ["sputum", "ANATOMY", 337, 343], ["tracheal aspirates", "ANATOMY", 345, 363], ["bronchoalveolar lavage", "ANATOMY", 369, 391], ["upper respiratory specimens", "ANATOMY", 460, 487], ["respiratory specimens", "ANATOMY", 524, 545], ["influenza viruses", "DISEASE", 72, 89], ["parainfluenza viruses", "DISEASE", 91, 112], ["respiratory syncytial virus", "DISEASE", 118, 145], ["influenza viruses", "ORGANISM", 72, 89], ["parainfluenza viruses", "ORGANISM", 91, 112], ["respiratory syncytial virus", "ORGANISM", 118, 145], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 212, 220], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 345, 363], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 369, 391], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 427, 435], ["parainfluenza", "SPECIES", 91, 104], ["respiratory syncytial virus", "SPECIES", 118, 145], ["parainfluenza viruses", "SPECIES", 91, 112], ["respiratory syncytial virus", "SPECIES", 118, 145], ["MERS-CoV", "SPECIES", 212, 220], ["MERS-CoV", "SPECIES", 427, 435], ["the testing", "TEST", 20, 31], ["other respiratory pathogens", "PROBLEM", 36, 63], ["influenza viruses", "PROBLEM", 72, 89], ["parainfluenza viruses", "PROBLEM", 91, 112], ["respiratory syncytial virus", "PROBLEM", 118, 145], ["testing", "TEST", 200, 207], ["MERS", "PROBLEM", 212, 216], ["those testing", "TEST", 232, 245], ["PROTOCOLS", "TEST", 268, 277], ["SPECIMEN COLLECTIONLower respiratory specimens", "TEST", 282, 328], ["sputum", "TEST", 337, 343], ["tracheal aspirates", "TEST", 345, 363], ["bronchoalveolar lavage", "TEST", 369, 391], ["the detection", "TEST", 410, 423], ["MERS", "PROBLEM", 427, 431], ["CoV", "PROBLEM", 432, 435], ["collection of upper respiratory specimens", "TEST", 446, 487], ["lower respiratory specimens", "TEST", 518, 545], ["respiratory syncytial virus", "OBSERVATION", 118, 145], ["tracheal", "ANATOMY", 345, 353], ["aspirates", "OBSERVATION", 354, 363], ["bronchoalveolar lavage", "OBSERVATION", 369, 391], ["upper", "ANATOMY_MODIFIER", 460, 465], ["respiratory", "ANATOMY", 466, 477]]], ["Specimen collection is guided that nasopharyngeal and oropharyngeal swabs are collected from the nasopharyngeal and oropharyngeal walls, respectively, not just from the nostril or mouth.", [["nasopharyngeal", "ANATOMY", 35, 49], ["oropharyngeal swabs", "ANATOMY", 54, 73], ["nasopharyngeal", "ANATOMY", 97, 111], ["oropharyngeal walls", "ANATOMY", 116, 135], ["nostril", "ANATOMY", 169, 176], ["mouth", "ANATOMY", 180, 185], ["nasopharyngeal", "CANCER", 35, 49], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 54, 73], ["nasopharyngeal", "ORGAN", 97, 111], ["oropharyngeal walls", "MULTI-TISSUE_STRUCTURE", 116, 135], ["nostril", "ORGANISM_SUBDIVISION", 169, 176], ["mouth", "ORGANISM_SUBDIVISION", 180, 185], ["Specimen collection", "TEST", 0, 19], ["nasopharyngeal and oropharyngeal swabs", "TEST", 35, 73], ["collection", "OBSERVATION", 9, 19], ["nasopharyngeal", "ANATOMY", 35, 49], ["oropharyngeal swabs", "ANATOMY", 54, 73], ["nasopharyngeal", "ANATOMY", 97, 111], ["oropharyngeal walls", "ANATOMY", 116, 135], ["nostril", "ANATOMY", 169, 176], ["mouth", "ANATOMY", 180, 185]]], ["Nasopharyngeal and oropharyngeal swabs could be placed in the same viral transport medium.", [["Nasopharyngeal", "ANATOMY", 0, 14], ["oropharyngeal swabs", "ANATOMY", 19, 38], ["Nasopharyngeal", "CANCER", 0, 14], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 19, 38], ["Nasopharyngeal and oropharyngeal swabs", "TREATMENT", 0, 38], ["oropharyngeal", "ANATOMY", 19, 32], ["swabs", "OBSERVATION", 33, 38]]], ["Synthetic fiber flocked swabs with plastic shafts should be used to increase virus yield.", [["swabs", "ANATOMY", 24, 29], ["Synthetic fiber flocked swabs", "TREATMENT", 0, 29], ["plastic shafts", "TREATMENT", 35, 49]]], ["Calcium alginate swabs or swabs with wooden shafts are not recommended because they may contain substances that inactivate some viruses and inhibit PCR reactions.", [["swabs", "ANATOMY", 26, 31], ["Calcium", "CHEMICAL", 0, 7], ["Calcium", "CHEMICAL", 0, 7], ["Calcium", "SIMPLE_CHEMICAL", 0, 7], ["Calcium alginate swabs", "TREATMENT", 0, 22], ["swabs with wooden shafts", "TEST", 26, 50], ["some viruses", "PROBLEM", 123, 135], ["PCR reactions", "PROBLEM", 148, 161]]], ["In asymptomatic individuals, induced sputum or forced coughing may help collect lower respiratory tract specimens.", [["sputum", "ANATOMY", 37, 43], ["lower respiratory tract specimens", "ANATOMY", 80, 113], ["asymptomatic individuals", "PROBLEM", 3, 27], ["induced sputum", "PROBLEM", 29, 43], ["forced coughing", "PROBLEM", 47, 62], ["lower respiratory tract specimens", "PROBLEM", 80, 113], ["respiratory tract", "ANATOMY", 86, 103]]], ["The rRT-PCR of serum samples can be helpful for detecting MERS-CoV, but these assays are not recommended for the routine diagnostic process in MERS-CoV outbreaks.SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTIONWhile serological testing is impractical for clinical purposes during MERS-CoV outbreaks, it has incomparable importance for epidemiologic investigations.", [["serum samples", "ANATOMY", 15, 28], ["serum samples", "ORGANISM_SUBSTANCE", 15, 28], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 58, 66], ["MERS-CoV", "ORGANISM", 143, 151], ["MERS-CoV", "ORGANISM", 283, 291], ["rRT", "DNA", 4, 7], ["MERS-CoV", "SPECIES", 58, 66], ["MERS-CoV", "SPECIES", 143, 151], ["MERS-CoV", "SPECIES", 283, 291], ["The rRT-PCR of serum samples", "TEST", 0, 28], ["CoV", "PROBLEM", 63, 66], ["these assays", "TEST", 72, 84], ["SPECIMEN COLLECTIONWhile serological testing", "TEST", 194, 238], ["epidemiologic investigations", "TEST", 338, 366]]], ["On the basis of WHO interim recommendations [4], serological testing for MERS-CoV can be used to identify confirmed MERS cases that can be reported under the International Health Regulations, to survey population-based seroprevalence and to investigate past exposures.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 73, 81], ["MERS-CoV", "SPECIES", 73, 81], ["serological testing", "TEST", 49, 68]]], ["Because a total of 16,693 people were self-quarantined owing to contact history with confirmed MERS-CoV cases, investigation of seroprevalence in this population is necessary in order to understand the epidemiology and pathophysiology of MERS-CoV infection [2].", [["MERS-CoV infection", "DISEASE", 238, 256], ["people", "ORGANISM", 26, 32], ["MERS-CoV", "ORGANISM", 95, 103], ["MERS-CoV", "ORGANISM", 238, 246], ["people", "SPECIES", 26, 32], ["MERS-CoV", "SPECIES", 95, 103], ["MERS-CoV", "SPECIES", 238, 246], ["CoV infection", "PROBLEM", 243, 256]]], ["It is recommended that serum samples be collected during the acute stage of the disease, preferably during the first week after illness onset and again during convalescence, at least 14 to 21 days after the acute stage sample was collected.", [["serum samples", "ANATOMY", 23, 36], ["illness", "DISEASE", 128, 135], ["serum samples", "ORGANISM_SUBSTANCE", 23, 36], ["serum samples", "TEST", 23, 36], ["the disease", "PROBLEM", 76, 87], ["illness", "PROBLEM", 128, 135], ["the acute stage sample", "PROBLEM", 203, 225], ["disease", "OBSERVATION", 80, 87], ["acute", "OBSERVATION_MODIFIER", 207, 212]]], ["If the acute stage sampling is missed, it should be collected at least 14 days after the onset of symptoms [411].SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTIONAll specimen types for routine testing from symptomatic confirmed/ suspect/probable cases should be collected by trained healthcare workers wearing PPE.", [["the acute stage sampling", "PROBLEM", 3, 27], ["symptoms", "PROBLEM", 98, 106], ["SPECIMEN COLLECTIONAll specimen types", "TEST", 145, 182], ["routine testing", "TEST", 187, 202], ["acute", "OBSERVATION_MODIFIER", 7, 12]]], ["In addition, further precautions for infection control and prevention in hospitals should be followed when exposure to aerosols such as tracheal intubation, bronchoalveolar lavage, and expectoration is expected as below.SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTION1.", [["tracheal", "ANATOMY", 136, 144], ["bronchoalveolar lavage", "ANATOMY", 157, 179], ["infection", "DISEASE", 37, 46], ["expectoration", "DISEASE", 185, 198], ["tracheal", "MULTI-TISSUE_STRUCTURE", 136, 144], ["further precautions", "TREATMENT", 13, 32], ["infection control", "TREATMENT", 37, 54], ["aerosols", "TREATMENT", 119, 127], ["tracheal intubation", "TREATMENT", 136, 155], ["bronchoalveolar lavage", "TEST", 157, 179], ["expectoration", "PROBLEM", 185, 198], ["SPECIMEN COLLECTION1", "TEST", 252, 272], ["tracheal", "ANATOMY", 136, 144], ["intubation", "OBSERVATION", 145, 155], ["bronchoalveolar lavage", "OBSERVATION", 157, 179]]], ["Indications for additional precautions: expectoration of sputum, tracheal aspiration, bronchoscopy, intubation, and extubation.SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTION2.", [["sputum", "ANATOMY", 57, 63], ["tracheal", "ANATOMY", 65, 73], ["tracheal", "MULTI-TISSUE_STRUCTURE", 65, 73], ["additional precautions", "TREATMENT", 16, 38], ["expectoration of sputum", "PROBLEM", 40, 63], ["tracheal aspiration", "TREATMENT", 65, 84], ["bronchoscopy", "TREATMENT", 86, 98], ["intubation", "TREATMENT", 100, 110], ["extubation", "TREATMENT", 116, 126], ["SPECIMEN COLLECTION2", "TEST", 159, 179], ["tracheal", "ANATOMY", 65, 73], ["aspiration", "OBSERVATION", 74, 84]]], ["Personal protectionSPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTION- Restrict the number of healthcare workers in the room to avoid unnecessary exposure.SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTION- All healthcare workers should wear PPE, including N95 masks, gloves, long-sleeved gowns, and eye protection equipment such as goggles or face shields.SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTION- Use hand hygiene before and after patient contact and after PPE removal.SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTION3.", [["eye", "ANATOMY", 302, 305], ["hand", "ANATOMY", 416, 420], ["eye", "ORGAN", 302, 305], ["hand", "ORGANISM_SUBDIVISION", 416, 420], ["patient", "ORGANISM", 446, 453], ["patient", "SPECIES", 446, 453], ["SPECIMEN COLLECTION", "TEST", 51, 70], ["SPECIMEN COLLECTION", "TEST", 188, 207], ["PPE", "TREATMENT", 244, 247], ["N95 masks", "TREATMENT", 259, 268], ["gloves", "TREATMENT", 270, 276], ["long-sleeved gowns", "TREATMENT", 278, 296], ["eye protection equipment", "TREATMENT", 302, 326], ["SPECIMEN COLLECTION", "TEST", 391, 410], ["hand hygiene", "TREATMENT", 416, 428], ["PPE removal", "TREATMENT", 472, 483], ["SPECIMEN COLLECTION3", "TEST", 516, 536], ["eye", "ANATOMY", 302, 305]]], ["Environmental controlSPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTION- An isolation room with a ventilation system that generates negative pressure is recommended.", [["SPECIMEN COLLECTION", "TEST", 53, 72], ["a ventilation system", "TREATMENT", 97, 117]]], ["If unavailable, a single room ventilated with 6 to 12 air changes per hour (through forced ventilation duct system) can be used.SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTION- After procedures, the room should be cleaned and evacuated for 30 minutes (in the case of 12 air changes).SPECIMEN TYPE AND PROTOCOLS FOR SPECIMEN COLLECTION- Access to the room during procedures should be minimized.SPECIMEN PACKING AND TRANSPORTDouble package systems can be used for transportation within an institution.", [["duct", "MULTI-TISSUE_STRUCTURE", 103, 107], ["a single room ventilated", "TREATMENT", 16, 40], ["forced ventilation duct system", "TREATMENT", 84, 114], ["SPECIMEN COLLECTION", "TEST", 160, 179], ["SPECIMEN COLLECTION", "TEST", 319, 338], ["procedures", "TREATMENT", 366, 376], ["SPECIMEN PACKING", "TREATMENT", 397, 413], ["TRANSPORTDouble package systems", "TREATMENT", 418, 449], ["PACKING", "OBSERVATION_MODIFIER", 406, 413]]], ["All specimens must be packaged in a leak-proof plastic primary container with a screw cap.", [["specimens", "ANATOMY", 4, 13], ["All specimens", "TREATMENT", 0, 13], ["a leak-proof plastic primary container", "TREATMENT", 34, 72], ["a screw cap", "TREATMENT", 78, 89], ["leak", "OBSERVATION", 36, 40], ["plastic", "OBSERVATION_MODIFIER", 47, 54], ["primary container", "OBSERVATION", 55, 72], ["screw cap", "OBSERVATION", 80, 89]]], ["Primary containers that are decontaminated with 70% alcohol swabs and placed in a clear re-sealable zipper bag with absorbents must be packaged with a secondary container for transfer.", [["alcohol", "CHEMICAL", 52, 59], ["alcohol", "CHEMICAL", 52, 59], ["alcohol", "ORGANISM", 52, 59], ["Primary containers", "TREATMENT", 0, 18], ["70% alcohol swabs", "TREATMENT", 48, 65], ["a clear re-sealable zipper bag", "TREATMENT", 80, 110], ["absorbents", "TREATMENT", 116, 126], ["a secondary container", "TREATMENT", 149, 170]]], ["Accurate labeling or the attachment of barcodes, including at least two patient identifiers on all specimens as well as on the package, is essential to avoid specimen mix-ups and contamination.SPECIMEN PACKING AND TRANSPORTFor transportation outside an institution, triple package systems must be used according to the KCDC guidelines [12].", [["specimens", "ANATOMY", 99, 108], ["specimen", "ANATOMY", 158, 166], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["triple package systems", "TREATMENT", 266, 288], ["PACKING", "OBSERVATION_MODIFIER", 202, 209]]], ["Similar to within-an-institution transfer, all specimens must be packed in double containers.", [["specimens", "ANATOMY", 47, 56], ["all specimens", "TREATMENT", 43, 56]]], ["The secondary containers are packed with the associated information sheets such as request forms or information forms in the tertiary container, which is consistent with infectious substance shipping guidance by KCDC [15].SPECIMEN HANDLING AND NUCLEIC ACID EXTRACTIONAll specimens should be stored at 2\u20138\u2103 up to 72 hr before nucleic acid extraction.", [["specimens", "ANATOMY", 271, 280], ["nucleic acid", "CHEMICAL", 325, 337], ["nucleic acid", "SIMPLE_CHEMICAL", 325, 337], ["NUCLEIC ACID EXTRACTIONAll specimens", "TEST", 244, 280], ["nucleic acid extraction", "TREATMENT", 325, 348], ["secondary containers", "OBSERVATION", 4, 24], ["packed", "OBSERVATION_MODIFIER", 29, 35], ["consistent with", "UNCERTAINTY", 154, 169], ["infectious", "OBSERVATION", 170, 180]]], ["If nucleic acid extraction cannot be performed within 72 hr after collection, specimens should be stored at -70\u2103 or lower as soon as possible after collection.", [["specimens", "ANATOMY", 78, 87], ["nucleic acid", "CHEMICAL", 3, 15], ["nucleic acid", "SIMPLE_CHEMICAL", 3, 15], ["nucleic acid extraction", "TREATMENT", 3, 26], ["collection", "TEST", 66, 76], ["specimens", "TEST", 78, 87]]], ["MERS-CoV RNA should be extracted by using appropriate manual or automated nucleic acid extraction methods.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV RNA", "RNA", 0, 12], ["CoV RNA", "TREATMENT", 5, 12], ["automated nucleic acid extraction methods", "TREATMENT", 64, 105]]], ["For example, the QIAamp DSP Viral RNA Mini kit (QIAGEN GmbH, Hilden, Germany) is one of the most widely used manual extraction methods, and the NucliSENS easyMAG (bioM\u00e9rieux, Durham, NC, USA), MagNA Pure 96 System (Roche, Basel, Switzerland), and QIAcube (QIAGEN) are commonly used automated nucleic extraction methods.", [["the QIAamp DSP", "TEST", 13, 27], ["manual extraction methods", "TREATMENT", 109, 134], ["QIAcube (QIAGEN", "TREATMENT", 247, 262], ["automated nucleic extraction methods", "TREATMENT", 282, 318]]], ["Nucleic acid extraction from sputum, tracheal aspirates, bronchoalveolar lavage, nasopharyngeal or oropharyngeal swabs, or blood should be performed according to the manufacturers' instructions.", [["sputum", "ANATOMY", 29, 35], ["tracheal aspirates", "ANATOMY", 37, 55], ["bronchoalveolar lavage", "ANATOMY", 57, 79], ["nasopharyngeal", "ANATOMY", 81, 95], ["oropharyngeal swabs", "ANATOMY", 99, 118], ["blood", "ANATOMY", 123, 128], ["Nucleic acid", "CHEMICAL", 0, 12], ["Nucleic acid", "SIMPLE_CHEMICAL", 0, 12], ["sputum", "ORGANISM_SUBSTANCE", 29, 35], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 37, 55], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 57, 79], ["nasopharyngeal", "CANCER", 81, 95], ["oropharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 99, 118], ["blood", "ORGANISM_SUBSTANCE", 123, 128], ["Nucleic acid extraction", "TEST", 0, 23], ["sputum", "TEST", 29, 35], ["tracheal aspirates", "TEST", 37, 55], ["bronchoalveolar lavage", "TEST", 57, 79], ["nasopharyngeal or oropharyngeal swabs", "PROBLEM", 81, 118], ["acid", "OBSERVATION_MODIFIER", 8, 12], ["tracheal", "ANATOMY", 37, 45], ["aspirates", "OBSERVATION", 46, 55], ["bronchoalveolar lavage", "OBSERVATION", 57, 79], ["nasopharyngeal", "ANATOMY", 81, 95], ["oropharyngeal", "ANATOMY", 99, 112]]], ["RNA samples should be stored at -70\u2103 or lower.MOLECULAR DETECTION OF MERS-CoV RNArRT-PCR is recommended for the molecular detection of MERS-CoV RNA.", [["samples", "ANATOMY", 4, 11], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 135, 143], ["OF MERS-CoV RNArRT-PCR", "DNA", 66, 88], ["MERS-CoV RNA", "RNA", 135, 147], ["MERS-CoV", "SPECIES", 135, 143], ["RNA samples", "TEST", 0, 11], ["CoV RNArRT-PCR", "TEST", 74, 88], ["the molecular detection", "TEST", 108, 131], ["CoV RNA", "PROBLEM", 140, 147]]], ["Laboratory confirmation of MERS-CoV infection requires either a positive rRT-PCR result for at least two specific genomic targets or a single positive target with sequencing of a second target.", [["infection", "DISEASE", 36, 45], ["MERS-CoV", "ORGANISM", 27, 35], ["rRT", "DNA", 73, 76], ["genomic targets", "DNA", 114, 129], ["MERS-CoV", "SPECIES", 27, 35], ["Laboratory confirmation", "TEST", 0, 23], ["MERS", "PROBLEM", 27, 31], ["CoV infection", "PROBLEM", 32, 45], ["a positive rRT-PCR", "TEST", 62, 80], ["infection", "OBSERVATION", 36, 45]]], ["The upstream of the E protein gene (upE), open reading frame 1a (ORF1a), open reading frame 1b (ORF1b), and N genes are common targets for rRT-PCR, while RNA-dependent RNA polymerase (RdRp), ORF1b, and N genes are targets for sequencing.MOLECULAR DETECTION OF MERS-CoV RNAPractically, rRT-PCR assays targeting upE are recommended for screening (Fig. 1).", [["E protein", "GENE_OR_GENE_PRODUCT", 20, 29], ["upE", "GENE_OR_GENE_PRODUCT", 36, 39], ["open reading frame 1a", "GENE_OR_GENE_PRODUCT", 42, 63], ["ORF1a", "GENE_OR_GENE_PRODUCT", 65, 70], ["open reading frame 1b", "GENE_OR_GENE_PRODUCT", 73, 94], ["ORF1b", "GENE_OR_GENE_PRODUCT", 96, 101], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 154, 182], ["RdRp", "GENE_OR_GENE_PRODUCT", 184, 188], ["ORF1b", "GENE_OR_GENE_PRODUCT", 191, 196], ["upE", "GENE_OR_GENE_PRODUCT", 310, 313], ["E protein gene", "DNA", 20, 34], ["upE", "DNA", 36, 39], ["open reading frame 1a", "DNA", 42, 63], ["ORF1a", "DNA", 65, 70], ["open reading frame 1b", "DNA", 73, 94], ["ORF1b", "DNA", 96, 101], ["N genes", "DNA", 108, 115], ["rRT", "DNA", 139, 142], ["RNA-dependent RNA polymerase (RdRp), ORF1b, and N genes", "DNA", 154, 209], ["rRT", "DNA", 285, 288], ["upE", "DNA", 310, 313], ["open reading frame", "TEST", 73, 91], ["rRT", "TEST", 139, 142], ["PCR", "TEST", 143, 146], ["RNA", "TEST", 154, 157], ["dependent RNA polymerase", "PROBLEM", 158, 182], ["RdRp", "TEST", 184, 188], ["ORF1b", "TEST", 191, 196], ["MERS", "PROBLEM", 260, 264], ["CoV RNAPractically", "TEST", 265, 283], ["rRT-PCR assays", "TEST", 285, 299], ["screening", "TEST", 334, 343]]], ["If the upE screening assay is positive, an independent, confirmatory rRT-PCR assay targeting ORF1a should be performed.", [["ORF1a", "GENE_OR_GENE_PRODUCT", 93, 98], ["ORF1a", "PROTEIN", 93, 98], ["the upE screening assay", "TEST", 3, 26], ["confirmatory rRT-PCR assay", "TEST", 56, 82], ["ORF1a", "TEST", 93, 98]]], ["Laboratory developed tests and commercial kits for rRT-PCR assay should be used with provision of positive control and validation by LR-TF.MOLECULAR DETECTION OF MERS-CoV RNAA heterologous internal control to identify possible rRT-PCR inhibition and to confirm the integrity of the reagents of the kit is essential.", [["MERS-CoV RNAA", "ORGANISM", 162, 175], ["rRT", "GENE_OR_GENE_PRODUCT", 227, 230], ["rRT", "DNA", 227, 230], ["tests", "TEST", 21, 26], ["commercial kits", "TEST", 31, 46], ["rRT", "TREATMENT", 51, 54], ["PCR assay", "TEST", 55, 64], ["positive control", "TREATMENT", 98, 114], ["CoV RNAA heterologous internal control", "TREATMENT", 167, 205], ["rRT-PCR inhibition", "TEST", 227, 245]]], ["Each run of rRT-PCR reaction should include both positive and negative controls in parallel.", [["rRT", "DNA", 12, 15], ["rRT", "TREATMENT", 12, 15], ["PCR reaction", "PROBLEM", 16, 28], ["negative", "OBSERVATION", 62, 70]]], ["It is mandatory for all clinical laboratories to participate in the external quality control assessment organized by the KSLM LR-TF.RESULTS INTERPRETATION AND REPORTINGThe first step of interpretation of MERS-CoV rRT-PCR is verification of the internal control (Fig. 1).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 204, 212], ["MERS-CoV rRT", "DNA", 204, 216], ["all clinical laboratories", "TEST", 20, 45], ["the external quality control assessment", "TEST", 64, 103], ["MERS", "TEST", 204, 208], ["CoV rRT", "TREATMENT", 209, 216], ["PCR", "TEST", 217, 220]]], ["Negative reactions in the internal control indicate a failure of the amplification process owing to either the presence of PCR inhibitors or other reasons.", [["a failure", "PROBLEM", 52, 61], ["the amplification process", "PROBLEM", 65, 90], ["PCR inhibitors", "TREATMENT", 123, 137], ["failure", "OBSERVATION", 54, 61]]], ["In this case, retesting the same sample is required after processing it to eliminate the inhibitory effect, including re-extraction of the nucleic acids or dilution of the extracted nucleic acids.", [["nucleic acids", "CHEMICAL", 139, 152], ["nucleic acids", "CHEMICAL", 182, 195], ["nucleic acids", "SIMPLE_CHEMICAL", 182, 195], ["the nucleic acids", "TREATMENT", 135, 152], ["the extracted nucleic acids", "TREATMENT", 168, 195], ["nucleic acids", "OBSERVATION", 182, 195]]], ["When the internal control is properly amplified, the results can be classified as screen-negative, -indeterminate, or -positive according to the cycle threshold (Ct) values and whether the upE gene was amplified.", [["upE", "GENE_OR_GENE_PRODUCT", 189, 192], ["upE gene", "DNA", 189, 197], ["screen", "TEST", 82, 88], ["the cycle threshold", "TEST", 141, 160], ["Ct) values", "TEST", 162, 172], ["the upE gene", "TEST", 185, 197], ["indeterminate", "OBSERVATION_MODIFIER", 100, 113]]], ["Screen-positive specimens should be confirmed by amplification of ORF1a or other targets.", [["specimens", "ANATOMY", 16, 25], ["ORF1a", "GENE_OR_GENE_PRODUCT", 66, 71], ["ORF1a", "PROTEIN", 66, 71], ["Screen", "TEST", 0, 6]]], ["When indeterminate or equivocal results are obtained in suspect cases, the results should be reported immediately to infection control units in each hospital.RESULTS INTERPRETATION AND REPORTINGA series of negative results in the cases which have definite contact history should not rule out MERS-CoV infection, and factors that can cause false negatives such as poor specimen quality, too early or late stage specimens, inappropriate handling or specimen transport, and inherent testing problems should be investigated by obtaining an additional specimen (especially a lower respiratory specimen), by the verification of an internal control, or by retesting the sample at another facility for confirmation.LABORATORY SAFETYDiagnostic laboratory work and rRT-PCR analysis on clinical specimens from suspect, confirmed, or probable cases of MERS-CoV should be conducted in clinical laboratories with BSL-2 facilities [1314].", [["specimen", "ANATOMY", 368, 376], ["specimens", "ANATOMY", 410, 419], ["specimen", "ANATOMY", 447, 455], ["specimen", "ANATOMY", 547, 555], ["respiratory specimen", "ANATOMY", 576, 596], ["specimens", "ANATOMY", 784, 793], ["infection", "DISEASE", 117, 126], ["infection", "DISEASE", 301, 310], ["MERS-CoV", "ORGANISM", 292, 300], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 840, 848], ["MERS-CoV", "SPECIES", 292, 300], ["MERS-CoV", "SPECIES", 840, 848], ["MERS", "PROBLEM", 292, 296], ["CoV infection", "PROBLEM", 297, 310], ["false negatives", "PROBLEM", 339, 354], ["poor specimen quality", "PROBLEM", 363, 384], ["late stage specimens", "PROBLEM", 399, 419], ["specimen transport", "TEST", 447, 465], ["inherent testing problems", "PROBLEM", 471, 496], ["an additional specimen", "TEST", 533, 555], ["a lower respiratory specimen", "TEST", 568, 596], ["an internal control", "TREATMENT", 622, 641], ["rRT", "TEST", 755, 758], ["PCR analysis", "TEST", 759, 771], ["clinical specimens", "TEST", 775, 793], ["MERS", "PROBLEM", 840, 844], ["CoV", "PROBLEM", 845, 848], ["indeterminate", "OBSERVATION_MODIFIER", 5, 18], ["infection", "OBSERVATION", 301, 310]]], ["Appropriate PPE should be worn, and all technical procedures should be performed in a way that minimizes the formation of aerosols and droplets in class II biosafety cabinets with current certification.", [["Appropriate PPE", "TREATMENT", 0, 15], ["all technical procedures", "TREATMENT", 36, 60]]], ["After completion of daily work, the workspace is cleaned with 70% alcohol, and all PPEs are removed.", [["alcohol", "CHEMICAL", 66, 73], ["alcohol", "CHEMICAL", 66, 73], ["alcohol", "SIMPLE_CHEMICAL", 66, 73], ["PPEs", "SIMPLE_CHEMICAL", 83, 87], ["all PPEs", "TREATMENT", 79, 87], ["removed", "OBSERVATION", 92, 99]]], ["Hand hygiene is necessary whenever PPEs are removed and before exit from laboratories.", [["Hand hygiene", "TREATMENT", 0, 12], ["PPEs", "TREATMENT", 35, 39], ["hygiene", "OBSERVATION", 5, 12]]], ["All wastes and remaining specimens should be discarded by legislative regulation of medical wastes, but clinical specimens positive for MERS-CoV rRT-PCR should be discarded after sterilization such as autoclaving.", [["specimens", "ANATOMY", 25, 34], ["specimens", "ANATOMY", 113, 122], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 136, 144], ["MERS-CoV", "SPECIES", 136, 144], ["All wastes", "TREATMENT", 0, 10], ["remaining specimens", "TREATMENT", 15, 34], ["medical wastes", "TREATMENT", 84, 98], ["clinical specimens", "TEST", 104, 122], ["MERS", "PROBLEM", 136, 140], ["CoV rRT", "TREATMENT", 141, 148], ["PCR", "TREATMENT", 149, 152], ["sterilization", "TREATMENT", 179, 192], ["autoclaving", "TREATMENT", 201, 212], ["wastes", "OBSERVATION", 4, 10]]], ["The dilution or aliquot procedures of the potentially infectious substances, including the procedures for bacterial or fungal cultures, should be performed within a biological safety cabinet.CONCLUSIONSThese guidelines reflect our current understanding of MERS-CoV at the time of publication and the unique situation of the Korean MERS-CoV outbreak.", [["cultures", "ANATOMY", 126, 134], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 256, 264], ["MERS-CoV", "ORGANISM", 331, 339], ["MERS-CoV", "SPECIES", 256, 264], ["Korean MERS-CoV", "SPECIES", 324, 339], ["The dilution", "TREATMENT", 0, 12], ["aliquot procedures", "TREATMENT", 16, 34], ["the potentially infectious substances", "PROBLEM", 38, 75], ["the procedures", "TEST", 87, 101], ["bacterial or fungal cultures", "PROBLEM", 106, 134], ["CoV outbreak", "PROBLEM", 336, 348], ["infectious", "OBSERVATION_MODIFIER", 54, 64]]], ["When a clinical laboratory is to perform molecular testing for MERS-CoV, each laboratory should prepare its own protocols according to these guidelines and other available resources.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 63, 71], ["MERS-CoV", "SPECIES", 63, 71], ["molecular testing", "TEST", 41, 58], ["MERS", "PROBLEM", 63, 67], ["its own protocols", "TREATMENT", 104, 121]]], ["In addition, laboratory layouts and facilities that are not covered in these guidelines should be checked in order to prevent contamination during PCR procedures and also to provide a safe environment for all laboratory staff.CONCLUSIONSIn conclusion, KSLM has established the practice guidelines for the molecular diagnosis of MERS-CoV during an outbreak in Korea in 2015.", [["MERS-CoV", "ORGANISM", 328, 336], ["MERS-CoV", "SPECIES", 328, 336], ["PCR procedures", "TREATMENT", 147, 161], ["MERS", "PROBLEM", 328, 332], ["CoV", "PROBLEM", 333, 336]]], ["To prepare laboratory response to prevent and control public health crisis by emerging infectious diseases in future, practice guidelines for laboratory diagnosis of other possible agents should be prepared with preemptive risk assessment in cooperation with public and private sectors.", [["infectious diseases", "DISEASE", 87, 106], ["laboratory diagnosis", "TEST", 142, 162], ["agents", "TREATMENT", 181, 187], ["preemptive risk assessment", "TEST", 212, 238]]]]}